

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 15/12, 5/10, C12P 21/02, C07K 14/47</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/58467</b> <b>(43) International Publication Date:</b> 5 October 2000 (05.10.00)
<b>(21) International Application Number:</b> PCT/US00/07505 <b>(22) International Filing Date:</b> 22 March 2000 (22.03.00)  <b>(30) Priority Data:</b> 60/126,502 26 March 1999 (26.03.99) US 60/172,410 17 December 1999 (17.12.99) US  <b>(71) Applicant (for all designated States except US):</b> HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Laytonsville, MD 20882 (US). KOMAT-SOULIS, George [US/US]; 9518 Garwood Street, Silver Spring, MD 20901 (US).  <b>(74) Agents:</b> HOOVER, Kenley, K. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).	<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> 50 HUMAN SECRETED PROTEINS		
<b>(57) Abstract</b>  The present invention relates to 50 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## 50 Human Secreted Proteins

### *Field of the Invention*

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and their production.

### *Background of the Invention*

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins include the commercially valuable human insulin, interferon, Factor VIII, human

growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent  
5 medical diseases, disorders, and/or conditions by using secreted proteins or the genes that encode them.

### *Summary of the Invention*

The present invention relates to novel polynucleotides and the encoded  
10 polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant and synthetic methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting diseases, disorders, and/or conditions related to the polypeptides and polynucleotides, and therapeutic methods for treating such diseases, disorders, and/or conditions. The  
15 invention further relates to screening methods for identifying binding partners of the polypeptides.

### *Detailed Description*

#### Definitions

20 The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated  
25 polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term "isolated" does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by  
30 electrophoresis and transferred onto blots), sheared whole cell genomic DNA



preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide/sequences of the present invention.

In the present invention, a "secreted" protein refers to those proteins capable  
5 of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many  
10 mechanisms, including exocytosis and proteolytic cleavage.

In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment,  
15 polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain  
20 the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the  
25 nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the  
30 polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

10 A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65 degree C.

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH<sub>2</sub>PO<sub>4</sub>; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 ug/ml salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

30 Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress

background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above,  
5 due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid  
10 molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of  
15 single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of  
20 triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces  
25 chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as  
30 posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more

detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar

to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

Many proteins (and translated DNA sequences) contain regions where the amino acid composition is highly biased toward a small subset of the available residues. For example, membrane spanning domains and signal peptides (which are also membrane spanning) typically contain long stretches where Leucine (L), Valine (V), Alanine (A), and Isoleucine (I) predominate. Poly-Adenosine tracts (polyA) at the end of cDNAs appear in forward translations as poly-Lysine (poly-K) and poly-Phenylalanine (poly-F) when the reverse complement is translated. These regions are often referred to as "low complexity" regions.

Such regions can cause database similarity search programs such as BLAST to find high-scoring sequence matches that do not imply true homology. The problem is exacerbated by the fact that most weight matrices (used to score the alignments generated by BLAST) give a match between any of a group of hydrophobic amino acids (L,V and I) that are commonly found in certain low complexity regions almost as high a score as for exact matches.

In order to compensate for this, BLASTX.2 (version 2.0a5MP-WashU) employs two filters ("seg" and "xnu") which "mask" the low complexity regions in a particular sequence. These filters parse the sequence for such regions, and create a new sequence in which the amino acids in the low complexity region have been replaced with the character "X". This is then used as the input sequence (sometimes referred to herein as "Query" and/or "Q") to the BLASTX program. While this regime helps to ensure that high-scoring matches represent true homology, there is a negative consequence in that the BLASTX program uses the query sequence that has been masked by the filters to draw alignments.

Thus, a stretch of "X"s in an alignment shown in the following application does not necessarily indicate that either the underlying DNA sequence or the translated protein sequence is unknown or uncertain. Nor is the presence of such

stretches meant to indicate that the sequence is identical or not identical to the sequence disclosed in the alignment of the present invention. Such stretches may simply indicate that the BLASTX program masked amino acids in that region due to the detection of a low complexity region, as defined above. In all cases, the reference sequence(s) (sometimes referred to herein as "Subject", "Sbjct", and/or "S") indicated in the specification, sequence table (Table 1), and/or the deposited clone is (are) the definitive embodiment(s) of the present invention, and should not be construed as limiting the present invention to the partial sequence shown in an alignment, unless specifically noted otherwise herein.

10

### Polynucleotides and Polypeptides of the Invention

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 1

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil3323607 (all information available through the recited accession number is incorporated herein by reference, for example, J. Biol. Chem. 273 (29), 18325-18331 (1998)) which is described therein as "cain [Rattus norvegicus]". A partial alignment demonstrating the observed homology is shown immediately below. Drawing upon information in Sun, et. al (1998) Immunity 8(6):703-711 (which is hereby incorporated by reference herein), we predict that this protein will inhibit cacineurin-mediated signal transduction in T-lymphocytes.

```

25  >gi|3323607 (AF061947) cain [Rattus norvegicus] >sp|O88480|O88480 CAIN.
      Length = 2182

      Plus Strand HSPs:

30  Score = 1349 (474.9 bits), Expect = 4.1e-136, P = 4.1e-136
      Identities = 270/314 (85%), Positives = 281/314 (89%), Frame = +3

35  Q:   369 MIRIAALNASSTIEDDHEGSFKSHKTQTKEAQEAFAFYHKALDLQKHDRFEESAKAYH 548
      MIRIAALNASSTIEDDHEGSFKSHK QTKEAQEAFAFYHKALDLQKHDRFEESAKAYH
      S:    1 MIRIAALNASSTIEDDHEGSFKSHKIQTKEAQEAFAFYHKALDLQKHDRFEESAKAYH 60

      Q:   549 ELLEASLLREAVSSGDEKEGLKHPGLILKYSTYKNLAQLAAQREDLETAMEFYLEAVMLD 728
      ELLEA LLREAVSSGDEKEGLKHPGLILKYSTYKNLAQLAAQREDLETAMEFYLEAVMLD
      S:    61 ELLEARLLREAVSSGDEKEGLKHPGLILKYSTYKNLAQLAAQREDLETAMEFYLEAVMLD 120

```

5 Q: 729 STDVNLWKIGHVALRLIRIPLARHAFEGLRCNPDHWPCLDNLITVLYTSLSDYTTCLYF 908  
 STDVNLWKIGHVALRLIR+PLARHAFEGLRCNPDHWPCLDNLITVLYTSLSDYTTCLYF  
 S: 121 STDVNLWKIGHVALRLIRLPLARHAFEGLRCNPDHWPCLDNLITVLYTSLSDYTTCLYF 180  
 10 Q: 909 ICKALEKDCRYSGKGLVLKEKIFEEQPCLRKDSLRLMFLKCDMSIHDSVSAEQAIVDEA 1088  
 ICKALEKDCRYSGKGLVLKEKIFEEQPCLRKDSLRLMFLKCDMS+H+VSV+AAEQAIVDEA  
 S: 181 ICKALEKDCRYSGKGLVLKEKIFEEQPCLRKDSLRLMFLKCDMSVHEVSVNAEQAIVDEA 240  
 15 Q: 1263 GLICRTTRTPASLLSP 1310  
 + + P+ LL+P  
 S: 297 RIDLSDYQDPSQLLAP 312

The segment of gil3323607 that is shown as "S" above is set out in the  
 sequence listing as SEQ ID NO. 111. Based on the structural similarity these  
 20 homologous polypeptides are expected to share at least some biological activities.  
 Such activities are known in the art, some of which are described elsewhere herein.  
 Assays for determining such activities are also known in the art, some of which have  
 been described elsewhere herein. Preferred polypeptides of the invention comprise a  
 polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID  
 25 NO. 112 which corresponds to the "Q" sequence in the alignment shown above (gaps  
 introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following  
 tissues/cDNA libraries: Stratagene neuroepithelium NT2RAMI 937234; Pancreas  
 Islet Cell Tumor and to a lesser extent in Smooth muscle, IL1b induced; Human  
 30 Osteoblasts II; NCI\_CGAP\_Kid3 and NCI\_CGAP\_Pr25.

Based on similarity to known sequences, the protein encoded by the disclosed  
 cDNA is believed to be involved in the repression of signalling in T-lymphocytes. As  
 such it could be useful as a moderator of immune activity, either by direct use in, for  
 example, autoimmune disorders, organ rejection, etc. Alternatively, pharmacologic  
 35 agents or antibodies could be directed against this gene to up-regulate T-cell  
 signalling in cases of immune suppression such as AIDS, etc.

The gene encoding the disclosed cDNA is believed to reside on chromosome  
 22. Accordingly, polynucleotides related to this invention are useful as a marker in  
 linkage analysis for chromosome 22.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 61 as residues: Pro-20 to His-27.

The tissue distribution in neuroepithelium, combined with the homology to the cain protein suggests the protein product of this clone is useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain suggests it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival.

The protein is useful in modulating signal transduction pathways which may show utility the treatment of particular diseases and/or disorders. Moreover, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). The protein is also useful in modulating the immune response, particularly to immune-rejections in transplants. The polynucleotides of the invention may be used in gene therapy using methods known in the art, and described elsewhere herein Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:11 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence



would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1585 of SEQ ID NO:11, b is an integer of 15 to 1599, where both a and b correspond to the positions of  
 5 nucleotide residues shown in SEQ ID NO:11, and where b is greater than or equal to a + 14.

## FEATURES OF PROTEIN ENCODED BY GENE NO: 2

The computer algorithm BLASTX has been used to determine that the  
 10 translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil4105505 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "multiple inositol polyphosphate phosphatase [Homo sapiens]". A partial alignment demonstrating the  
 15 observed homology is shown immediately below.

```

>gi|4105505 (AF046914) multiple inositol polyphosphate phosphatase [Homo
  sapiens] >sp|G4105505|G4105505 MULTIPLE INOSITOL POLYPHOSPHATE
  PHOSPHATASE.
  Length = 487
20

  Minus Strand HSPs:

  Score = 1639 (577.0 bits), Expect = 1.7e-249, Sum P(2) = 1.7e-249
  Identities = 310/311 (99%), Positives = 310/311 (99%), Frame = -2
25

  Q: 1896 LRLITSSKHRCMDSSAAFLQGLWQHYPGLPPXDVADMEFGPPTVNDKLMRFFDHCEKFL 1717
      LRLITSSKHRCMDSSAAFLQGLWQHYPGLPP DVADMEFGPPTVNDKLMRFFDHCEKFL
  S: 177 LRLITSSKHRCMDSSAAFLQGLWQHYPGLPPPDVADMEFGPPTVNDKLMRFFDHCEKFL 236
30

  Q: 1716 TEVEKNATALYHVEAFKTGPEMQNILKKVAATLQVPVNDLNADLIQVAFFTC SFDLAIKG 1537
      TEVEKNATALYHVEAFKTGPEMQNILKKVAATLQVPVNDLNADLIQVAFFTC SFDLAIKG
  S: 237 TEVEKNATALYHVEAFKTGPEMQNILKKVAATLQVPVNDLNADLIQVAFFTC SFDLAIKG 296

  Q: 1536 VKSPWCDVFDIDDAKVLEYLNDLKQYWKRGYGYTINSRSSCTLFQDIFQHLDKAVEQKQR 1357
      VKSPWCDVFDIDDAKVLEYLNDLKQYWKRGYGYTINSRSSCTLFQDIFQHLDKAVEQKQR
  S: 297 VKSPWCDVFDIDDAKVLEYLNDLKQYWKRGYGYTINSRSSCTLFQDIFQHLDKAVEQKQR 356
35

  Q: 1356 SQPISSPVILQFGHAETLLP LLSLMGYFKDKEPLTAYNYKKQMRKFRSGLIVPYASNLI 1177
      SQPISSPVILQFGHAETLLP LLSLMGYFKDKEPLTAYNYKKQMRKFRSGLIVPYASNLI
  S: 357 SQPISSPVILQFGHAETLLP LLSLMGYFKDKEPLTAYNYKKQMRKFRSGLIVPYASNLI 416
40

  Q: 1176 FVLYHCENAKTPKEQFRVQMLLNEKVLPLAYSQETVSFYEDLKNHYKDILQSCQTSEECE 997
      FVLYHCENAKTPKEQFRVQMLLNEKVLPLAYSQETVSFYEDLKNHYKDILQSCQTSEECE
  S: 417 FVLYHCENAKTPKEQFRVQMLLNEKVLPLAYSQETVSFYEDLKNHYKDILQSCQTSEECE 476
45

  Q: 996 LARANSTSDEL 964
      LARANSTSDEL
  
```

S: 477 LARANSTSDEL 487

Score = 794 (279.5 bits), Expect = 1.7e-249, Sum P(2) = 1.7e-249  
Identities = 152/176 (86%), Positives = 153/176 (86%), Frame = -3

5 Q: 2423 MLRAPGCLLRTSVXXXXXXXXXXXXXXXXXXXXEPRDPVASSLSPYFGTKTRYEDVNPVL 2244  
MLRAPGCLLRTSV EPRDPVASSLSPYFGTKTRYEDVNPVL  
S: 1 MLRAPGCLLRTSVAPAAALAAALLSSLARCSLLEPRDPVASSLSPYFGTKTRYEDVNPVL 60

10 Q: 2243 LSGPEAPWRDPELLEGTCTFPVQLVALIRHGTRYPTVKQIRKLRLHGLLQARGSRDGGAS 2064  
LSGPEAPWRDPELLEGTCTFPVQLVALIRHGTRYPTVKQIRKLRLHGLLQ RGSRDGGAS  
S: 61 LSGPEAPWRDPELLEGTCTFPVQLVALIRHGTRYPTVKQIRKLRLHGLLQPRGSRDGGAS 120

15 Q: 2063 STGSRDLGAALADWPLWYADWMDGQLVEKGRQDMRQLALRLASLFPALFSRENYGR 1896  
STGSRDLGAAL DWPLWYADWMDGQLVEKGRQDMR +ALRLASLFPALFSRENYGR  
S: 121 STGSRDLGAALRDWPLWYADWMDGQLVEKGRQDMRHALRLASLFPALFSRENYGR 176

The segments of gil4105505 that are shown as "S" above are set out in the sequence listing as SEQ ID NO. 113 and SEQ ID NO. 115. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 114 and/or SEQ ID NO. 116 which correspond to the "Q" sequences in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Placenta and to a lesser extent in Soares infant brain

30 INIB; Stratagene pancreas (#937208); Human 8 Week Whole Embryo; Primary Dendritic Cells, lib 1; Morton Fetal Cochlea; HSC172 cells; Myeloid Progenitor Cell Line; Jurkat T-Cell, S phase; Brain Frontal Cortex, re-excision; Soares\_senescent\_fibroblasts\_NbHSF; normalized infant brain cDNA; Mo7e Cell Line GM-CSF treated (1ng/ml); Human Ovarian Cancer Reexcision; Pancreas Islet

35 Cell Tumor; Gessler Wilms tumor; NCI\_CGAP\_Co8; NCI\_CGAP\_HN4; PC3 Prostate cell line; Soares melanocyte 2NbHM; Human Testes, Reexcision; Human Adult Pulmonary, re-excision; Endothelial-induced; Human Endometrial Tumor; Keratinocyte; Soares\_parathyroid\_tumor\_NbHPA; Nine Week Old Early Stage Human and Soares placenta Nb2HP.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 62 as residues: Glu-34 to Val-39, Phe-47 to Asp-55, Glu-65 to Leu-73, His-89 to Thr-95, Arg-112 to Ala-119, Lys-149 to Arg-155, Ser-170 to Gly-178, Pro-193 to Ser-200, Arg-207 to Gln-212.

5       The tissue distribution within placenta and infant brain, combined with the homology to the multiple inositol polyphosphate phosphatase protein suggests this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, cancer, and other proliferative conditions. Similarly, developmental tissues rely on  
10 decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the  
15 polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in  
20 modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues, particularly of the brain and in developing tissues. The protein is useful, either directly or indirectly, in modulating signal transduction pathways which may be useful in treating proliferative conditions.

Moreover, the protein is useful in the detection, treatment, and/or prevention  
25 of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Protein, as well as,  
30 antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:12 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2441 of SEQ ID NO:12, b is an integer of 15 to 2455, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:12, and where b is greater than or equal to a + 14.

### FEATURES OF PROTEIN ENCODED BY GENE NO: 3

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gnl|PID|d1014095 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "S.cerevisiae hypothetical protein L3111 [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

```

>gnl|PID|d1014095 Similar to S.cerevisiae hypothetical protein L3111
(S59316)
(Homo sapiens) >sp|Q92564|Q92564 MYELOBLAST KIAA0276
(FRAGMENT).
Length = 309

Plus Strand HSPs:
Score = 648 (228.1 bits), Expect = 7.2e-63, P = 7.2e-63
Identities = 136/238 (57%), Positives = 164/238 (68%), Frame = +3

Q: 294 MPVKKRRKSPGVAAVAEDGGLKKCKISSYCRSQPPARLISGEEHFSSKKCLAWFYEYAG 473
MP +KKR+ P A +D KK + S R R+ + EE FSSK+CL WFYEYAG
S: 78 MPPRKKRR-P----ASGDDLAKKSRHDSMYRKYDSTRIKTEEEAFSSKRCLEWIFYEYAG 132

Q: 474 PDEVVGPEGMEKFCEDIGVGT*KYYYVSFSVEIGG*NMGIF-YQGRMV*RE*LHYSVTAQ 650
D+VVGPEGMEKFCEDIGV + + ++ NMG F Q + L T
S: 133 TDDVVGPEGMEKFCEDIGVEPENVMVLVLAWKLDQNMGYFTLQEWLKGMTSLQCDTT-- 190

Q: 651 KSYKTNLTFCQAQQLNDISSFKNIYRYAFDFARDKDQRLDIDTAKSMLALLLGRTWPLFS 830
+ + L + LND ++FK IYRYAFDFAR+KDQRLDI+TAK ML LLLG+ WPLF

```

S: 191 EKLRLTLDYLRSLNDSTNFKLIYRYAFDFAREKDQRSILDINTAKCMLGLLLGKIWPLFP 250  
 Q: 831 VFYQYLEQSKYRVMNKDQWYNVLEFSRTVHADLSNYDEDGAWPVLLDEFVWQKVRQTS 1007  
 VF+Q+LEQSKY+V+NKDQW NVLEFSRT++ DLSNYDEDGAWPVLLDEFVW K +Q S  
 5 S: 251 VFHQFLEQSKYKVINKDQWCNVLEFSRTINLDLSNYDEDGAWPVLLDEFVWYKDKQMS 309

The segment of gnlIPID1014095 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 117. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities.

- 10 Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 118 which corresponds to the "Q" sequence in the alignment shown above (gaps  
 15 introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares\_fetal\_heart\_NbHH19W; pBMC stimulated w/ poly I/C; HL-60, PMA 4H, re-excision; Stratagene HeLa cell s3 937216; Keratinocyte and to a lesser extent in Larynx Carcinoma; Normal Ovary, Premenopausal; K562 + PMA  
 20 (36 hrs),re-excision; Human Aortic Endothelium; Smooth Muscle Serum Treated, Norm; HEL cell line; Human Osteoclastoma, re-excision; Jurkat T-Cell, S phase; Human Chronic Synovitis; Fetal Liver, subtraction II; T-Cell PHA 16 hrs; HUMAN JURKAT MEMBRANE BOUND POLYSOMES; Merkel Cells; Rejected Kidney, lib 4; Colon Tumor; 12 Week Old Early Stage Human; Early Stage Human Brain;  
 25 Dendritic cells, pooled; Endothelial-induced; Soares\_fetal\_lung\_NbHL19W; CD34 depleted Buffy Coat (Cord Blood), re-excision; HUMAN B CELL LYMPHOMA; Human Endometrial Tumor; Stratagene colon (#937204) and Soares infant brain INIB.

- The gene encoding the disclosed cDNA is believed to reside on chromosome  
 30 11. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 11.

The tissue distribution in keratinocytes suggests the protein product of this clone is useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots,

hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, 5 uticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, 10 boils, cellulitis, erysipelas, impetigo, tinea, athletes foot, and ringworm).

Moreover, the protein product of this clone may also be useful for the treatment or diagnosis of various connective tissue disorders such as arthritis, trauma, tendonitis, chondromalacia and inflammation, autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, 15 spinal deformation, and specific joint abnormalities as well as chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Moreover, the protein is useful for the detection, treatment, and/or prevention of developmental diseases and/or disorders, including congenital defects, metabolic conditions, and cardiovascular 20 disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:13 and may have been publicly available prior to conception of 25 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1284 of SEQ ID NO:13, b 30 is an integer of 15 to 1298, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:13, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 4**

5 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Merkel Cells; Pancreas Islet Cell Tumor.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:14 and may have been publicly available prior to conception of  
10 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2110 of SEQ ID NO:14, b  
15 is an integer of 15 to 2124, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:14, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 5**

20 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in Soares placenta Nb2HP; Soares\_fetal\_heart\_NbHH19W; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Soares\_pregnant\_uterus\_NbHPU; Soares\_NFL\_T\_GBC\_S1; Stratagene placenta (#937225);  
25 Soares\_fetal\_heart\_NbHH19W; Soares\_pregnant\_uterus\_NbHPU; Soares\_NhHMPu\_S1; Human Fetal Kidney, Reexcision; Human Synovial Sarcoma; NCI\_CGAP\_GCB1; Soares\_senescent\_fibroblasts\_NbHSF; Soares\_testis\_NHT; Soares\_fetal\_heart\_NbHH19W; Soares\_total\_fetus\_Nb2HF8\_9w; Soares ovary tumor NbHOT; Soares retina N2b4HR; Soares adult brain N2b4HB55Y;  
30 Soares\_total\_fetus\_Nb2HF8\_9w; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Hemangiopericytoma; Human Adrenal Gland Tumor; Soares breast 3NbHBst;

Human fetal heart, Lambda ZAP Express; Soares\_parathyroid\_tumor\_NbHPA;  
 NCI\_CGAP\_Kid3; Activated T-cell(12h)/Thiouridine-re-excision; Stratagene colon  
 (#937204); Primary Dendritic Cells, lib 1; Human Umbilical Vein Endothelial Cells,  
 fract. B; Human Lung Cancer, subtracted; WI 38 cells; prostate-edited; Human Fetal  
 5 Spleen; Human Fetal Bone; Human T-cell lymphoma,re-excision; NTERA2  
 teratocarcinoma cell line+retinoic acid (14 days); Human Epididymus; Smooth  
 muscle, IL1b induced; Breast Cancer cell line, MDA 36; NTERA2 + retinoic acid, 14  
 days; Soares\_multiple\_sclerosis\_2NbHMSP; Human Fetal Epithelium (Skin);  
 Soares\_fetal\_lung\_NbHL19W; H. Kidney Cortex, subtracted; Prostate BPH; Human  
 10 Fetal Dura Mater; Human Uterine Cancer; T-Cell PHA 24 hrs; Liver HepG2 cell  
 line.; Human Activated T-Cells, re-excision; Ulcerative Colitis; Human Thymus;  
 Macrophage (GM-CSF treated); Pancreas Islet Cell Tumor; PC3 Prostate cell line;  
 Fetal Heart; Gessler Wilms tumor; NCI\_CGAP\_Lu5; Soares\_NbHFB;  
 Soares\_NSF\_F8\_9W\_OT\_PA\_P\_S1; Soares\_fetal\_liver\_spleen\_INFLS\_S1; Primary  
 15 Dendritic cells,frac 2; Human Fetal Lung III; Human Placenta; Human Fetal Heart;  
 NCI\_CGAP\_Ew1; NCI\_CGAP\_Lu5; NCI\_CGAP\_Pr22; NCI\_CGAP\_Sch1;  
 Keratinocyte; Human 8 Week Whole Embryo; Nine Week Old Early Stage Human;  
 Human Cerebellum and Soares\_senescent\_fibroblasts\_NbHSF.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.  
 20 65 as residues: Pro-31 to Pro-37.

Many polynucleotide sequences, such as EST sequences, are publicly  
 available and accessible through sequence databases. Some of these sequences are  
 related to SEQ ID NO:15 and may have been publicly available prior to conception of  
 the present invention. Preferably, such related polynucleotides are specifically  
 25 excluded from the scope of the present invention. To list every related sequence  
 would be cumbersome. Accordingly, preferably excluded from the present invention  
 are one or more polynucleotides comprising a nucleotide sequence described by the  
 general formula of a-b, where a is any integer between 1 to 2298 of SEQ ID NO:15, b  
 is an integer of 15 to 2312, where both a and b correspond to the positions of  
 30 nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a  
 + 14.



**FEATURES OF PROTEIN ENCODED BY GENE NO: 6**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gill872200 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "alternatively spliced product using exon 13A [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

10

```
>gi|1872200 alternatively spliced product using exon 13A [Homo sapiens]
      Length = 666
```

15

```
      Plus Strand HSPs:
```

```
      Score = 125 (44.0 bits), Expect = 2.9e-11, Sum P(3) = 2.9e-11
      Identities = 28/51 (54%), Positives = 34/51 (66%), Frame = +1
```

20

```
Q:   217 FIFLXQMELCHIFQDGLELLTSRDQPTSASQSAGITGMGHRVQPG-SFSIR 366
      F FL +   H+ Q GLELLTS D P SASQSA ITG+ HR +P S+ +R
S:   608 FEFLVETGFLHVGQAGLELLTSGDLPASASQSARITGVSHRARPEYSYKLR 658
```

The segment of gill872200 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 119. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 120 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Pancreas Islet Cell Tumor; HUMAN B CELL LYMPHOMA.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:16 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1044 of SEQ ID NO:16, b  
 5 is an integer of 15 to 1058, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 7**

10 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in normalized infant brain cDNA; NCI\_CGAP\_GCB1; Human T-cell lymphoma, re-excision; Soares retina N2b4HR; Stromal cell TF274; Soares\_total\_fetus\_Nb2HF8\_9w; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Human T-  
 15 Cell Lymphoma; Soares breast 3NbHBst; HUMAN B CELL LYMPHOMA; Human Cerebellum; HUMAN STOMACH; NCI\_CGAP\_GCB1; Human Tonsils, Lib 2; Jurkat T-cell G1 phase; Human Ovary; Human Heart; Hemangiopericytoma; Stratagene lung (#937210); Hepatocellular Tumor, re-excision; Stratagene liver (#937224); Pancreas Islet Cell Tumor; Human Placenta; Adipocytes; Human Testes  
 20 Tumor; Dendritic cells, pooled; Monocyte activated; Spleen, Chronic lymphocytic leukemia; Human Testes; Human fetal heart, Lambda ZAP Express; NCI\_CGAP\_Lu5; Soares\_testis\_NHT; Hodgkin's Lymphoma II; Human 8 Week Whole Embryo; Soares\_fetal\_heart\_NbHH19W; Soares\_parathyroid\_tumor\_NbHPA; Soares\_fetal\_liver\_spleen\_1NFLS\_S1 and Soares infant brain 1NIB.

25 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:17 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
 30 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 358 of SEQ ID NO:17, b is an integer of 15 to 372, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14.

5

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 8

It has been discovered that this gene is expressed primarily in Pancreas Islet Cell Tumor.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:18 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2029 of SEQ ID NO:18, b is an integer of 15 to 2043, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14.

20

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 9

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain 1NIB and to a lesser extent in Soares\_placenta\_8to9weeks\_2NbHP8to9W; Stratagene HeLa cell s3 937216; Spinal Cord, re-excision; Soares adult brain N2b5HB55Y; Pancreas Islet Cell Tumor; Adipocytes; Soares fetal liver spleen 1NFLS; Soares retina N2b5HR; Human Quadriceps; Human Prostate Cancer, Stage C fraction; Stratagene corneal stroma (#937222); H. Kidney Cortex, subtracted; Brain Frontal Cortex, re-excision; Macrophage-oxLDL; Human Hypothalamus, Schizophrenia; Human Whole Six Week Old Embryo; Normal colon; Smooth muscle, control; Human Bone Marrow, treated; Spleen, Chronic lymphocytic leukemia and Osteoblasts.

30

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:19 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1543 of SEQ ID NO:19, b is an integer of 15 to 1557, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 10

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gill710216 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "Homo sapiens protein". A partial alignment demonstrating the observed homology is shown immediately below.

```

>gi|1710216 unknown [Homo sapiens]
      Length = 139

25      Minus Strand HSPs:

      Score = 237 (83.4 bits), Expect = 3.6e-21, Sum P(2) = 3.6e-21
      Identities = 48/72 (66%), Positives = 53/72 (73%), Frame = -2

30      Q: 1219 YIF*TESRFVARL*CSSMILAHCNLCLLGSSNSPASASQVAGTRGMRHHTQLIFVLLVET 1040
          + F T+S V RL CS I AHCNLCL GSSNSPASAS+VAGT G QLIFV L E
      S: 51 FFFETQSHSVTRLECSGTISAHCNLCLPGSSNSPASASRVAGTAGTCRRAQLIFVFLAEM 110

35      Q: 1039 GFHHVGQDGLNL 1004
          GFHHVG+DGL+L
      S: 111 GFHHVGRDGLDL 122

      Score = 48 (16.9 bits), Expect = 3.6e-21, Sum P(2) = 3.6e-21
      Identities = 10/16 (62%), Positives = 12/16 (75%), Frame = -1

40      Q: 1001 DLMIRLPRPPKMLGLQ 954
          +L+I PR PK LGLQ

```

S: 123 NLVIHPPRSPKALGLQ 138

The segments of gil1710216 that are shown as "S" above are set out in the sequence listing as SEQ ID NO. 121 and SEQ ID NO. 123. Based on the structural  
5 similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the  
10 sequence listing as SEQ ID NO. 122 and/or SEQ ID NO. 124 which correspond to the "Q" sequences in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares breast 3NbHBst and to a lesser extent in Healing  
15 Abdomen wound, 70&90 min post incision; H. Epididymus, caput & corpus; Human T-cell lymphoma, re-excision; Human Hypothalamus, schizophrenia, re-excision; Jurkat T-cell G1 phase; Stratagene HeLa cell s3 937216; Myeloid Progenitor Cell Line; Apoptotic T-cell; Stromal cell TF274; Human Neutrophil, Activated; Human Bone Marrow, treated; T cell helper II; Human 8 Week Whole Embryo; Human  
20 Cerebellum; Primary Dendritic Cells, lib 1 and Soares infant brain 1NIB.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:20 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
25 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1782 of SEQ ID NO:20, b is an integer of 15 to 1796, where both a and b correspond to the positions of  
30 nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 11**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Jurkat T-cell G1 phase; human tonsils.

- 5 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 71 as residues: Met-19 to Asp-26.

- Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:21 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1314 of SEQ ID NO:21, b is an integer of 15 to 1328, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a + 14.
- 10  
15

**FEATURES OF PROTEIN ENCODED BY GENE NO: 12**

- 20 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Jurkat T-cell G1 phase and to a lesser extent in Human colon carcinoma (HCC) cell line, remake; Human Lung; NTERA2 teratocarcinoma cell line+retinoic acid (14 days); Human Prostate; Stromal cell TF274; Synovial Fibroblasts (control); Colon Carcinoma; NCI\_CGAP\_GCB1; Human Placenta; Adipocytes; Soares melanocyte 2NbHM; Endothelial-induced; neutrophils control; Osteoblasts; Human 8 Week Whole Embryo; Primary Dendritic Cells, lib 1 and Soares infant brain INIB.
- 25

- The translation product of this gene shares sequence homology with Ring-H2 (see, e.g., Genbank accession CAB40413). Based on the sequence similarity, the translation product of this clone is expected to share at least some biological activities
- 30

with RING finger proteins. Such activities are known in the art, some of which are described elsewhere herein.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:22 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1218 of SEQ ID NO:22, b is an integer of 15 to 1232, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.

#### 15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 13**

It has been discovered that this gene is expressed primarily in Jurkat T-cell G1 phase.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 73 as residues: Arg-22 to Tyr-28.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:23 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 543 of SEQ ID NO:23, b is an integer of 15 to 557, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:23, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 14**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

- 5   gil3702846 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "RNA polymerase II termination factor [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

```

10   >gi|3702846 (AF073771) RNA polymerase II termination factor [Homo sapiens]
      >sp|O75921|O75921 RNA POLYMERASE II TERMINATION FACTOR.
      Length = 1162

      Minus Strand HSPs:
15   Score = 483 (170.0 bits), Expect = 1.5e-89, Sum P(2) = 1.5e-89
      Identities = 101/110 (91%), Positives = 101/110 (91%), Frame = -1

      Q: 1257 ELVDP-PGCRNSARGTFFKMELFEGMRESTKISSLLAELEAIQRNSASQKSVIVSQWTNM 1081
18   EL D P S GTFFKMELFEGMRESTKISSLLAELEAIQRNSASQKSVIVSQWTNM
      S: 962 ELRDSEPSSTVSLNGTFFKMELFEGMRESTKISSLLAELEAIQRNSASQKSVIVSQWTNM 1021

      Q: 1080 LKVVALHLKKHGLTYATIDGSVNPQRMDLVEAFNHSRGPQVMLISLLAG 931
22   LKVVALHLKKHGLTYATIDGSVNPQRMDLVEAFNHSRGPQVMLISLLAG
      S: 1022 LKVVALHLKKHGLTYATIDGSVNPQRMDLVEAFNHSRGPQVMLISLLAG 1071
25

```

The segment of gil3702846 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 125. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities.

- 30   Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 126 which corresponds to the "Q" sequence in the alignment shown above (gaps
- 35   introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Colon Tumor II and to a lesser extent in Prostate; Human Lung; Jurkat T-cell G1 phase; Human umbilical vein endothelial cells, IL-4 induced; Human T-Cell Lymphoma; Primary Dendritic cells, frac 2; Spleen, Chronic



lymphocytic leukemia; Soares\_placenta\_8to9weeks\_2NbHP8to9W; T cell helper II and Soares fetal liver spleen INFLS.

The tissue distribution in colon tumor tissue, combined with the homology to the RNA polymerase II termination factor suggests this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, cancer, and other proliferative conditions. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. Moreover, the protein is useful in treating proliferative conditions, particularly through its use as an antagonist, or agonist for specific biochemical pathways (i.e. DNA repair, activated transcription, basal transcription, carcinogenic insults, etc.). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:24 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1306 of SEQ ID NO:24, b

is an integer of 15 to 1320, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 15

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gnllPIDle1346030 (all information available through the recited accession number is  
10 incorporated herein by reference) which is described therein as "phosphatases and kinases of *Caenorhabditis elegans*". A partial alignment demonstrating the observed homology is shown immediately below.

```

15 >gnl|PID|e1346030 Similarity to some phosphatases and kinases; cDNA EST
    EMBL:Z14643 comes from this gene [Caenorhabditis elegans]
    >sp|Q93566|Q93566 F25H2.2 PROTEIN.
    Length = 578

20 Plus Strand HSPs:

    Score = 441 (155.2 bits), Expect = 7.7e-69, Sum P(2) = 7.7e-69
    Identities = 80/168 (47%), Positives = 124/168 (73%), Frame = +3

25 Q: 12 LTVLSVPPEADNLDPSSDLSGQSFYDYTEKQAVPISVPRYKHVEQNGEFVVYNVYMAG 191
    + V+SV + D D ++S +DY+E +++P+++P Y V+ + E++ V+N++MAG
    S: 136 MIVISVEDPDMDFDYGEESMAYGHDYSENRLPVTIPSINTVQDSLERYTVFNIMAG 195

30 Q: 192 RQLCSKRYREFAILHQNLKREFANFTFRLPGKWPFSLSEQQLDARRRGLEEYLEKVC SI 371
    RQL S+RY EF LH LK+ F ++ FP+LPGKWPF LSEQQLD+RRRGLE+YLEK+C+I
    S: 196 RQLGSRRYSEFVELHLALKKHFDYCFQPLPGKWPFKLSEQQLDSRRRGLEQYLEKICTI 255

35 Q: 372 RVIGESDIMQEFLSESDENYNGVSDVELRVALPDGTTVTVRVKKNSTT 515
    RVI ES+++Q+FL E D + +VE+R+ LPDG+ +T+R +++ T+
    S: 256 RVIAESELVQKFLMECDP---MCEVEIRLMLPDGSPITIRRSITS 299

```

The segment of gnllPIDle1346030 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 127. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein.  
40 Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID

NO. 128 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares\_multiple\_sclerosis\_2NbHMSP and to a lesser extent in H. Leukocytes, control; Human Adult Retina; Human Colon, re-excision; Jurkat T-cell G1 phase; Human Thymus; Human Uterine Cancer; Macrophage-oxLDL; Human Adrenal Gland Tumor; Pancreas Islet Cell Tumor; Soares\_total\_fetus\_Nb2HF8\_9w; Human Synovial Sarcoma; Monocyte activated and Soares fetal liver spleen 1NFLS.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:25 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1257 of SEQ ID NO:25, b is an integer of 15 to 1271, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:25, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 16**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Stratagene colon (#937204) and to a lesser extent in Spleen, Chronic lymphocytic leukemia; Bone Marrow Cell Line (RS4,11); Soares fetal liver spleen 1NFLS; Larynx carcinoma III; HSA 172 Cells; Jurkat T-Cell, S phase; Osteoblasts; Kidney Pyramids; Larynx carcinoma IV; Osteoclastoma-normalized A; Human B Cell 8866; Human epithelioid sarcoma; Human (HCC) cell line liver (mouse) metastasis, remake; Human Aortic Endothelium; Smooth Muscle Serum Treated, Norm; Resting T-Cell, re-excision; Messangial cell, frac 2; Pancreas Tumor PCA4 Tu; Human endometrial stromal cells-treated with estradiol; Synovial IL-1/TNF stimulated; Breast Cancer cell line, MDA 36; human corpus colosum; LNCAP

prostate cell line; Human Osteoclastoma, re-excision; T-Cell PHA 16 hrs; Apoptotic T-cell; Human Fetal Dura Mater; Human Primary Breast Cancer Reexcision; Stromal cell TF274; Macrophage-oxLDL; PERM TF274; H Macrophage (GM-CSF treated), re-excision; Endothelial-induced; Hodgkin's Lymphoma II and T cell helper II.

5           Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:26 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
10           would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 573 of SEQ ID NO:26, b is an integer of 15 to 587, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a  
15           + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 17

It has been discovered that this gene is expressed primarily in Jurkat T-Cell, S phase.

20           Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:27 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
25           would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1055 of SEQ ID NO:27, b is an integer of 15 to 1069, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a  
30           + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 18**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

- 5   gil2854044 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "Strabismus [Drosophila melanogaster]". A partial alignment demonstrating the observed homology is shown immediately below.

```

10   >gi|2854044 (AF044208) Strabismus [Drosophila melanogaster]
      Length = 584

      Plus Strand HSPs:

15   Score = 428 (150.7 bits), Expect = 4.7e-53, Sum P(2) = 4.7e-53
      Identities = 88/167 (52%), Positives = 119/167 (71%), Frame = +2

      Q:  464 KQRLVVAVEEAFIHIQRLQAEQQKAPGEVMDPREAAQAIFPSMARALQKYLRITRQQNY 643
          + RL+ A EEAF HI+R+ E   AP   +DP+EAA A+FPSMARALQKYLR+TRQQ
20   S:  421 RARLITAAEEAFTHIKRIHNEP---APALPLDPQEASAVFPSMARALQKYLRVTRQQPR 477

      Q:  644 HSMESILQHLAFCITNGMTPKAFLERYLSAGPTLQYDKDR-WLSTQWRLVSDEAVTNGLR 820
          H+ ESIL+HLA C+ + ++P+AFLE YL+ P +Q +K+R W+ + W L+ DE V+ +
25   S:  478 HTFESILKHLAHLKHDLSPRAFLEPYLTESFVMQSEKERRWQS-WSLICDEIVSRPIG 536

      Q:  821 DGIVFVLKCLDFSLVNVKKIPFIILSEEFIDPKSHKFVLRQLQSETSV 964
          + F L  D SL+V V K+P L+EE +DPKS+KFVL+L SETSV
      S:  537 NECTFQLIQNDVSLMVTVHKLPHFNLAEEVVDPKSNKFVLKLNSETSV 584

```

- 30       The segment of gil2854044 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 129. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have
- 35   been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 130 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

- It has been discovered that this gene is expressed primarily in the following
- 40   tissues/cDNA libraries: Human Endometrial Tumor; Soares fetal liver spleen 1NFLS and to a lesser extent in Human Osteoclastoma Stromal Cells - unamplified; Jurkat T-

Cell, S phase; Human Pancreas Tumor; Human Thymus; Human Testes Tumor;  
Human Fetal Heart and Human 8 Week Whole Embryo.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:28 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 995 of SEQ ID NO:28, b is an integer of 15 to 1009, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.

#### 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 19

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human endometrial stromal cells-treated with progesterone; Anergic T-cell.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 79 as residues: Pro-19 to Lys-25.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:29 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 589 of SEQ ID NO:29, b is an integer of 15 to 603, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 20**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human endometrial stromal cells-treated with progesterone;

5 Nine Week Old Early Stage Human.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:30 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
10 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 389 of SEQ ID NO:30, b is an integer of 15 to 403, where both a and b correspond to the positions of  
15 nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 21**

The computer algorithm BLASTX has been used to determine that the  
20 translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil3649657 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "dynactin subunit [Homo sapiens]". A partial alignment demonstrating the observed homology is shown  
25 immediately below.

```
>gi|3649657 (AF082513) dynactin subunit [Homo sapiens] >sp|075935|075935
      DYNACTIN SUBUNIT.
      Length = 186
30
      Plus Strand HSPs:
      Score = 472 (166.2 bits), Expect = 3.6e-44, P = 3.6e-44
      Identities = 95/95 (100%), Positives = 95/95 (100%), Frame = +2
35
      Q:      2 QFILSQVALLEQVNALVPMLDSAHIKAVPEHAARLQRLAQIHQQDQCVEITEESKALL 181
```

QFILSQVALLEQVNALVPM LDSAHIKAVPEHAARLQRLAQIHQQDQCVEITEESKALL  
 S: 92 QFILSQVALLEQVNALVPM LDSAHIKAVPEHAARLQRLAQIHQQDQCVEITEESKALL 151  
 5 Q: 182 EEYNKTTMLLSKQFVQWDELLCQLEAATQVKPAEE 286  
 EEYNKTTMLLSKQFVQWDELLCQLEAATQVKPAEE  
 S: 152 EEYNKTTMLLSKQFVQWDELLCQLEAATQVKPAEE 186

The segment of gil3649657 that is shown as "S" above is set out in the  
 sequence listing as SEQ ID NO. 131. Based on the structural similarity these  
 10 homologous polypeptides are expected to share at least some biological activities.  
 Such activities are known in the art, some of which are described elsewhere herein.  
 Assays for determining such activities are also known in the art, some of which have  
 been described elsewhere herein. Preferred polypeptides of the invention comprise a  
 polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID  
 15 NO. 132 which corresponds to the "Q" sequence in the alignment shown above (gaps  
 introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following  
 tissues/cDNA libraries: Early Stage Human Brain and to a lesser extent in Soares fetal  
 liver spleen 1NFLS; Soares\_pregnant\_uterus\_NbHPU; H. Whole Brain #2, re-  
 20 excision; wilm's tumor; Soares\_fetal\_heart\_NbHH19W; NCI\_CGAP\_GCB1; H.  
 Epididymus, cauda; Soares\_placenta\_8to9weeks\_2NbHP8to9W; Stratagene  
 endothelial cell 937223; Human Umbilical Vein Endothelial Cells, uninduced;  
 Human Rhabdomyosarcoma; Soares adult brain N2b5HB55Y;  
 Soares\_total\_fetus\_Nb2HF8\_9w; Macrophage (GM-CSF treated); Human Gall  
 25 Bladder; Stratagene ovarian cancer (#937219); Soares\_senescent\_fibroblasts\_NbHSF;  
 Endothelial-induced; Human Amygdala; Human Pituitary, subtracted VIII; Thyroid  
 Tumour; WI 38 cells; Human Cardiomyopathy, subtracted; Smooth muscle, control,  
 re-excision; Smooth muscle-ILb induced; H. Epididymus, caput & corpus; Breast  
 Lymph node cDNA library; Soares retina N2b4HR; Soares\_pineal\_gland\_N3HPG;  
 30 CHME Cell Line,untreated; Human Synovium; Synovial IL-1/TNF stimulated;  
 Synovial hypoxia-RSF subtracted; Human Stomach,re-excision; Human endometrial  
 stromal cells-treated with progesterone; Synovial hypoxia; Human Colon, re-excision;  
 Jurkat T-cell G1 phase; H. Lymph node breast Cancer; Breast Cancer Cell line,  
 angiogenic; HUMAN JURKAT MEMBRANE BOUND POLYSOMES;



Soares\_fetal\_lung\_NbHL19W; Human Fetal Dura Mater; Epithelial-TNF $\alpha$  and INF induced; Human Thymus; Rejected Kidney, lib 4; H. Frontal cortex,epileptic,re-excision; Soares\_placenta\_8to9weeks\_2NbHP8to9W; Dendritic cells, pooled; Human Synovial Sarcoma; Human Neutrophil, Activated; Anergic T-cell; Human Bone Marrow, treated; Spleen, Chronic lymphocytic leukemia; Human Testes; Osteoblasts; Keratinocyte; Nine Week Old Early Stage Human and Human Cerebellum.

The gene encoding the disclosed cDNA is believed to reside on chromosome 9. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 9.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 81 as residues: Pro-26 to Val-36, Ser-46 to Arg-52, Pro-58 to Ser-63.

The tissue distribution in human brain suggests the protein product of this clone is useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain suggests it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells suggests this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, cancer, and other proliferative conditions. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers,

or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:31 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 644 of SEQ ID NO:31, b is an integer of 15 to 658, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 22**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares placenta Nb2HP and to a lesser extent in STRIATUM

DEPRESSION; HUMAN TONSILS, FRACTION 2; Human endometrial stromal cells-treated with progesterone; Human Colon, re-excision; Soares\_parathyroid\_tumor\_NbHPA; Soares\_senescent\_fibroblasts\_NbHSF; Human Adrenal Gland Tumor; Soares\_pregnant\_uterus\_NbHPU and Human Microvascular Endothelial Cells, fract. A.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 82 as residues: Asn-11 to Ser-17.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:32 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 619 of SEQ ID NO:32, b is an integer of 15 to 633, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a + 14.

## 20 FEATURES OF PROTEIN ENCODED BY GENE NO: 23

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Bone Marrow Stromal Cell, untreated and to a lesser extent in Stratagene placenta (#937225); Soares\_pregnant\_uterus\_NbHPU; Human osteoarthritic, fraction II; Soares\_senescent\_fibroblasts\_NbHSF; Human Adipose; Epithelial-TNF $\alpha$  and INF induced; Soares melanocyte 2NbHM; Soares infant brain INIB; Soares ovary tumor NbHOT; Human osteoarthritis, fraction I; Human Synovium; Healing groin wound, 7.5 hours post incision; Synovial hypoxia; Human Infant Brain; Human Pancreas Tumor, Reexcision; Soares\_placenta\_8to9weeks\_2NbHP8to9W; Human Activated T-Cells, re-excision; Adipocytes; Soares\_placenta\_8to9weeks\_2NbHP8to9W; NCI\_CGAP\_Kid5; Human Microvascular Endothelial Cells, fract. A; Human Hippocampus; H Kidney Cortex,

- subtracted III; Human Bone Marrow; Larynx Carcinoma; HM3; Human adult (K.Okubo); NCI\_CGAP\_Pr22; Human Pre-Differentiated Adipocytes; Human epithelioid sarcoma; Smooth muscle, control, re-excision; H. Epididymus, caput & corpus; Human adult small intestine, re-excision; Human Lung Cancer, re-excision;
- 5 Healing groin wound - zero hr post-incision (control); Hepatocellular Tumor, re-excision; Synovial hypoxia-RSF subtracted; Human endometrial stromal cells-treated with progesterone; Soares\_fetal\_heart\_NbHH19W;
- Soares\_senescent\_fibroblasts\_NbHSF; Soares\_senescent\_fibroblasts\_NbHSF; H. Kidney Medulla, re-excision; Human Brain, Striatum; Human Adult Testes, Large
- 10 Inserts, Reexcision; Liver, Hepatoma; Soares\_pineal\_gland\_N3HPG; Human Rhabdomyosarcoma; Soares\_testis\_NHT; Human Thymus Stromal Cells; Rejected Kidney, lib 4; Human Liver, normal; Human Placenta; Human Fetal Lung III; Bone marrow; Endothelial-induced; Endothelial cells-control; NCI\_CGAP\_Co3; NCI\_CGAP\_Co9; NCI\_CGAP\_Lu1; NCI\_CGAP\_Brn23; Colon Normal III; Smooth
- 15 muscle, control and Nine Week Old Early Stage Human.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:33 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

20 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 261 of SEQ ID NO:33, b is an integer of 15 to 275, where both a and b correspond to the positions of

25 nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 24

It has been discovered that this gene is expressed primarily in Human

30 endometrial stromal cells-treated with progesterone..

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:34 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
5 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1425 of SEQ ID NO:34, b is an integer of 15 to 1439, where both a and b correspond to the positions of  
10 nucleotide residues shown in SEQ ID NO:34, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 25**

It has been discovered that this gene is expressed primarily in the following  
15 tissues/cDNA libraries: Human endometrial stromal cells-treated with progesterone; Synovial Fibroblasts (control).

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:35 and may have been publicly available prior to conception of  
20 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1006 of SEQ ID NO:35, b  
25 is an integer of 15 to 1020, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:35, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 26**

30 The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting

example, the sequence accessible through the following database accession no. gil288145 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "put. ORF [Homo sapiens]". A partial alignment demonstrating the observed homology is shown  
 5 immediately below.

```

    >gi|288145 put. ORF [Homo sapiens] >pir|I38022|I38022 hypothetical protein
    -
    human >sp|Q29976|Q29976 MAHLAVU HEPATOCELLULAR CARCINOMA HHC(M)
10  DNA.
        Length = 196

        Plus Strand HSPs:

15      Score = 172 (60.5 bits), Expect = 6.0e-16, Sum P(2) = 6.0e-16
        Identities = 33/50 (66%), Positives = 38/50 (76%), Frame = +3

        Q:  681 GGVCL*SQLLGRRLRRENHNLGGGGCSETRSRHCTPTWVTQRDSVSKKKR 830
            GG CL SQLL RLR+ENHLN GG GCSE +S C P WVT+ DSVSK+ +
20      S:  31 GGRCLQSQLRLRLRQENHLNSGGRGCSEPKSHLCIPAWVTEGDSVSKQNK 80

        Score = 56 (19.7 bits), Expect = 6.0e-16, Sum P(2) = 6.0e-16
        Identities = 16/33 (48%), Positives = 18/33 (54%), Frame = +2

25      Q:  608 HLRSGVDDQPGNTAR-PRLYK-HSL---GGWCM 691
            HLRSGV D PG + P L K L GG C+
        S:  3 HLRSGVQDYPGQHGKIPSLKIQELAGHGGRCL 35
  
```

The segments of gil288145 that are shown as "S" above are set out in the  
 30 sequence listing as SEQ ID NO. 133 and SEQ ID NO. 135. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the  
 35 invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 134 and/or SEQ ID NO. 136 which correspond to the "Q" sequences in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in HUMAN  
 40 JURKAT MEMBRANE BOUND POLYSOMES..

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 86 as residues: Gln-17 to Leu-23.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:36 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1062 of SEQ ID NO:36, b is an integer of 15 to 1076, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:36, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 27

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gi11947129 (all information available through the recited accession number is incorporated herein by reference) which is described therein "CCAAT/enhancer-binding protein [*Caenorhabditis elegans*]". A partial alignment demonstrating the observed homology is shown immediately below.

```

>gi|1947129 (AF000262) similar to CCAAT/enhancer-binding protein
[Caenorhabditis elegans] >sp|O02080|O02080 SIMILAR TO
CCAAT/ENHANCER-BINDING PROTEIN.
Length = 417

Plus Strand HSPs:

Score = 127 (44.7 bits), Expect = 5.0e-10, Sum P(2) = 5.0e-10
Identities = 36/107 (33%), Positives = 49/107 (45%), Frame = +3

Q: 501 YVPPRLVPVHYDETXXXXXXXXXXXXXXXXXXXXVIRELKEQYSDAPEEIRDARHPHVTR 680
YV PR+ V Y+E +I ELK QYSDAPEEIR+ +
S: 259 YVAPRIRAVRYEEDEAPNKQKEKAKRRAMQSS-LIMELKNQYSDAPEEIREMSE---K 313

Q: 681 QSQEDQHRINYEESMMVRLSVSKREKGRKRANVMSSQLHSLTHFSD 821
+ Q D+ R YEE R+ ++K +K R ++ S L L F D
S: 314 KYQYDRERERYEEDNFTRIRLNKDQKRSEQLG-RSETLDDLLSFGD 359

```

The segment of gil1947129 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 137. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein.

5 Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 138 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

10 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Stratagene ovary (#937217); Soares\_NhHMPu\_S1; Human Prostate; Soares fetal liver spleen 1NFLS and to a lesser extent in Neuroblastoma; H. Striatum Depression, subtracted; Human Prostate, subtracted; Human Gall Bladder, fraction II; Human (HCC) cell line liver (mouse) metastasis, remake; Smooth Muscle  
15 Serum Treated, Norm; Human endometrial stromal cells-treated with estradiol; Synovial hypoxia-RSF subtracted; HUMAN JURKAT MEMBRANE BOUND POLYSOMES; Soares\_placenta\_8to9weeks\_2NbHP8to9W; T-Cell PHA 24 hrs; Ulcerative Colitis; Human Thymus Stromal Cells; Epithelial-TNF $\alpha$  and INF induced; Rejected Kidney, lib 4; Human T-Cell Lymphoma; Colon Normal II; Adipocytes;  
20 Colon Tumor II; human tonsils; Human Amygdala; T Cell helper I; Human Bone Marrow, treated; Bone Marrow Cell Line (RS4,11); Keratinocyte and Human 8 Week Whole Embryo.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 87 as residues: Arg-75 to Lys-82, Ser-98 to Asn-111, Leu-116 to Ser-138, Tyr-156 to  
25 Ala-175, Leu-184 to Ala-198, Thr-204 to Gln-211, Ser-227 to Arg-236, Asp-264 to Arg-290.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:37 and may have been publicly available prior to conception of  
30 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence



would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1095 of SEQ ID NO:37, b is an integer of 15 to 1109, where both a and b correspond to the positions of  
 5 nucleotide residues shown in SEQ ID NO:37, and where b is greater than or equal to a + 14.

### FEATURES OF PROTEIN ENCODED BY GENE NO: 28

The computer algorithm BLASTX has been used to determine that the  
 10 translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. pirlJC5909|JC5909 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "AE33 protein - fruit fly (*Drosophila melanogaster*)". A partial alignment demonstrating the observed  
 15 homology is shown immediately below.

```

>pir|JC5909|JC5909 AE33 protein - fruit fly (Drosophila melanogaster)
      Length = 425

20      Minus Strand HSPs:

      Score = 158 (55.6 bits), Expect = 2.2e-08, P = 2.2e-08
      Identities = 38/90 (42%), Positives = 52/90 (57%), Frame = -1

25      Q:   793 KDLIYNKVTPTFHWWKIDDKFGLTFQSPADARAfDRGIRRAIEDISQG-----CP 641
           +DL Y KV PTFHHW+  ++ GLTFQ+ ADARAfD+G+ RA  ++ G          CP
      S:   75  RDLKYYKVMPPTFHWRAGKQRNGLTFQTAADARAfDKGVLRAYNELIDGLAKSNPTIICP 134

30      Q:   640 E-SKNEAEGADD--LQANEEDSSSSSLVKDH 560
           +K ++ G DD  +  +   S SL K H
      S:   135 PLTKYDSVGEDDVFMtLDLPVESESLOKIh 164
  
```

The segment of pirlJC5909|JC5909 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 139. Based on the structural similarity these  
 35 homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID

NO. 140 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Stratagene fetal spleen (#937205); Human Osteoblasts II;

5 HUMAN JURKAT MEMBRANE BOUND POLYSOMES; H. Frontal cortex,epileptic,re-excision; Monocyte activated; Primary Dendritic Cells, lib 1.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:38 and may have been publicly available prior to conception of  
10 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 794 of SEQ ID NO:38, b  
15 is an integer of 15 to 808, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:38, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 29

20 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares retina N2b4HR and to a lesser extent in Activated T-cells, 24 hrs,re-excision; Keratinocyte; Activated T-Cells,12 hrs,re-excision; Human Activated T-Cells; Activated T-cell(12h)/Thiouridine-re-excision; Human Neutrophil, Activated; Activated T-Cell (12hs)/Thiouridine labelledEco; Epithelial-TNF $\alpha$  and  
25 INF induced; Soares retina N2b5HR; Human Neutrophils, Activated, re-excision; HUMAN JURKAT MEMBRANE BOUND POLYSOMES; Human Pancreas Tumor; Human Cerebellum; Human Pancreas Tumor, Reexcision; Human Adult Pulmonary,re-excision; Activated T-Cells, 12 hrs, subtracted; Soares\_pregnant\_uterus\_NbHPU; Rejected Kidney, lib 4; Osteoblasts; Human  
30 osteoarthritic,fraction II; Human Neutrophil; Bone Marrow Stromal Cell, untreated; Stratagene colon (#937204); Human Bone Marrow, treated; Soares infant brain 1NIB;

Activated T-Cells, 24 hrs.; Human osteoarthritis, fraction I; Brain Frontal Cortex, re-  
 excision; NCI\_CGAP\_GCB1; Human Thymus Stromal Cells; Soares\_NhHMPu\_S1;  
 Adipocytes; Endothelial-induced; Human Microvascular Endothelial Cells, fract. A;  
 Soares\_NhHMPu\_S1; NCI\_CGAP\_Kid3; Activated T-Cells, 12hrs, differentially  
 5 expressed; Soares\_testis\_NHT; Soares ovary tumor NbHOT; Activated T-Cells, 8 hrs,  
 subtracted; Activated T-Cells, 12 hrs.; H. Epididymus, cauda; Ovarian Tumor 10-3-  
 95; HL-60, PMA 4H, re-excision; H. Meningioma, M1; Human Infant Brain; T-Cell  
 PHA 16 hrs; TF-1 Cell Line GM-CSF Treated; NCI\_CGAP\_Co10;  
 NCI\_CGAP\_Pr25; Human Heart; Soares\_NhHMPu\_S1; Soares\_NFL\_T\_GBC\_S1;  
 10 Stratagene lung carcinoma 937218; normalized infant brain cDNA; Human Adipose;  
 Human Activated T-Cells, re-excision; Stratagene NT2 neuronal precursor 937230;  
 Human Testes Tumor, re-excision; Soares\_NhHMPu\_S1; Smooth muscle, serum  
 induced, re-exc; Pancreas Islet Cell Tumor; Colon Tumor; Colon Tumor II;  
 Endothelial cells-control; Smooth muscle, control; Monocyte activated; Spleen,  
 15 Chronic lymphocytic leukemia; neutrophils control; T cell helper II; HeLa cell line;  
 Human Osteoarthritic Cartilage Fraction IV; Human Normal Cartilage Fraction III;  
 Larynx normal #10 261-273; human caudate nucleus; Larynx carcinoma II; Tongue  
 carcinoma; Human Normal Cartilage Fraction IV; Human Normal Cartilage, Fraction  
 I; Human Normal Cartilage Fraction II; Human B Cell 8866; Activated T-Cells, 8  
 20 hrs., ligation 2; Ku 812F Basophils Line; Human Hippocampus, subtracted; K562 +  
 PMA (36 hrs), re-excision; Saos2, Dexamethosome Treated; Human Gall Bladder,  
 fraction II; Human OB HOS control fraction I; Human OB MG63 treated (10 nM E2)  
 fraction I; Human (HCC) cell line liver (mouse) metastasis, remake; Human White  
 Adipose; Human Cardiomyopathy, subtracted; Human Pancreatic Carcinoma; Human  
 25 Pituitary, subtracted; Smooth muscle, control, re-excision; Smooth muscle-ILb  
 induced; H. cerebellum, Enzyme subtracted; Human Lung; Human Quadriceps;  
 HTC DL1; NCI\_CGAP\_Pr25; Raji Cells, cyclohexamide treated; Healing groin  
 wound - zero hr post-incision (control); HEL cell line; Pancreas Tumor PCA4 Tu;  
 pBMC stimulated w/ poly I/C; Smooth muscle, IL1b induced; NTERA2 + retinoic  
 30 acid, 14 days; Synovial hypoxia-RSF subtracted; Human Adipose Tissue, re-excision;  
 Jurkat T-cell G1 phase; Myeloid Progenitor Cell Line; Prostate BPH; Human Adult

Small Intestine; Human Umbilical Vein, Reexcision; NCI\_CGAP\_Co3; Monocyte activated, re-excision; L428; NCI\_CGAP\_AA1; NCI\_CGAP\_Co9; NCI\_CGAP\_GC2; NCI\_CGAP\_GC4; NCI\_CGAP\_Lu1; NCI\_CGAP\_Pr22; NCI\_CGAP\_Pr24; Human Umbilical Vein Endothelial Cells, uninduced; Human

5 Uterine Cancer; Human Primary Breast Cancer Reexcision; Human Hypothalamus, Schizophrenia; HTC DL1; Human pancreatic islet; Soares\_total\_fetus\_Nb2HF8\_9w; Soares\_parathyroid\_tumor\_NbHPA; Human Hippocampus; Human Activated Monocytes; Hemangiopericytoma; Human Gall Bladder; Soares\_NhHMPu\_S1; Resting T-Cell Library, II; Colon Carcinoma; Smooth

10 muscle, serum treated; Human Placenta; Human Testes Tumor; Soares melanocyte 2NbHM; Human Fetal Lung III; Neutrophils control, re-excision; Stratagene HeLa cell s3 937216; CD34 depleted Buffy Coat (Cord Blood), re-excision; T Cell helper I; Neutrophils IL-1 and LPS induced; Bone Marrow Cell Line (RS4,11); Hodgkin's Lymphoma II; Human retina cDNA randomly primed sublibrary; NCI\_CGAP\_GC4;

15 NCI\_CGAP\_Kid3; NCI\_CGAP\_Kid6; NCI\_CGAP\_Brn23 and NCI\_CGAP\_Brn25.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:39 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

20 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1022 of SEQ ID NO:39, b is an integer of 15 to 1036, where both a and b correspond to the positions of

25 nucleotide residues shown in SEQ ID NO:39, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 30**

It has been discovered that this gene is expressed primarily in the following

30 tissues/cDNA libraries: Soares infant brain 1NIB and to a lesser extent in Human Normal Breast; Human Adrenal Gland Tumor; Human T-Cell Lymphoma; Human

- Colon, subtraction; Supt Cells, cyclohexamide treated; Aorta endothelial cells + TNF-  
 a; Human Skin Tumor; Amniotic Cells - Primary Culture; Jurkat T-cell G1 phase;  
 Human Chronic Synovitis; Human Thymus; HUMAN JURKAT MEMBRANE  
 BOUND POLYSOMES; Epithelial-TNF $\alpha$  and INF induced; NTERA2, control;  
 5 Smooth muscle, serum treated; Soares melanocyte 2NbHM; Human Placenta; Bone  
 marrow; human tonsils; Human Neutrophil, Activated; Human Adult Pulmonary, re-  
 excision; Activated T-cell(12h)/Thiouridine-re-excision and Hodgkin's Lymphoma II.

Many polynucleotide sequences, such as EST sequences, are publicly  
 available and accessible through sequence databases. Some of these sequences are  
 10 related to SEQ ID NO:40 and may have been publicly available prior to conception of  
 the present invention. Preferably, such related polynucleotides are specifically  
 excluded from the scope of the present invention. To list every related sequence  
 would be cumbersome. Accordingly, preferably excluded from the present invention  
 are one or more polynucleotides comprising a nucleotide sequence described by the  
 15 general formula of a-b, where a is any integer between 1 to 975 of SEQ ID NO:40, b  
 is an integer of 15 to 989, where both a and b correspond to the positions of  
 nucleotide residues shown in SEQ ID NO:40, and where b is greater than or equal to a  
 + 14.

## 20 FEATURES OF PROTEIN ENCODED BY GENE NO: 31

It has been discovered that this gene is expressed primarily in HUMAN  
 JURKAT MEMBRANE BOUND POLYSOMES..

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.  
 91 as residues: Tyr-28 to Ser-33.

25 Many polynucleotide sequences, such as EST sequences, are publicly  
 available and accessible through sequence databases. Some of these sequences are  
 related to SEQ ID NO:41 and may have been publicly available prior to conception of  
 the present invention. Preferably, such related polynucleotides are specifically  
 excluded from the scope of the present invention. To list every related sequence  
 30 would be cumbersome. Accordingly, preferably excluded from the present invention  
 are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 1030 of SEQ ID NO:41, b is an integer of 15 to 1044, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a + 14.

5

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 32

It has been discovered that this gene is expressed primarily in HUMAN JURKAT MEMBRANE BOUND POLYSOMES..

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:42 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 888 of SEQ ID NO:42, b is an integer of 15 to 902, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:42, and where b is greater than or equal to a + 14.

15  
20

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 33

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

pir|I46078|I46078 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "endothelin converting enzyme-2 - bovine (fragment)". A partial alignment demonstrating the observed homology is shown immediately below.

25  
30

```
>pir|I46078|I46078 endothelin converting enzyme-2 - bovine (fragment)
>gi|1101009 endothelin converting enzyme-2 [Bos taurus] (SUB
39-825)
Length = 825
```

## Plus Strand HSPs:

5      Score = 248 (87.3 bits), Expect = 6.2e-21, Sum P(2) = 6.2e-21  
       Identities = 50/65 (76%), Positives = 52/65 (80%), Frame = +1

      Q: 112 DRILVLGCGNSALSVELFLGGFPNVTSDYSSVVVAAMQARYAHVPQLRWGDHGCAEAGL 291  
           DRILVLGCGNSALSVELFLGGFP+VTSVDYSSVVVAAM+ARYAHVP LRW G  
       S: 2 DRILVLGCGNSALSVELFLGGFPDVTSDYSSVVVAAMRARYAHVPTLRWETMDVRALGF 61

10      Q: 292 PQCF 306  
           P F  
       S: 62 PSGSF 66

15      Score = 225 (79.2 bits), Expect = 6.6e-17, P = 6.6e-17  
       Identities = 44/51 (86%), Positives = 46/51 (90%), Frame = +2

      Q: 263 ETMDVRKLDFPSASFDVLEKGTLDALLAGERDPWTVSPEGVHTVDQVLSE 415  
           ETMDVR L FPS SFDVLEKGTLDALL GE+DPWTVS EGVHTVDQVL+E  
       S: 52 ETMDVRALGFPSGFDVLEKGTLDALLTGEQDPWTVSSEGVHTVDQVLNE 102

20      Score = 40 (14.1 bits), Expect = 6.2e-21, Sum P(2) = 6.2e-21  
       Identities = 8/29 (27%), Positives = 16/29 (55%), Frame = +2

25      Q: 356 RDPWTVSPEGVHTVDQVLSEVSRVLVPGG 442  
           RD W+++P+ V+ L + ++ P G  
       S: 610 RDQWSMTPQTVNAY--YLPKNEIVFPAG 636

30      The segments of pirl46078II46078 that are shown as "S" above are set out in  
       the sequence listing as SEQ ID NO. 141, SEQ ID NO. 143 and SEQ ID NO. 145.  
       Based on the structural similarity these homologous polypeptides are expected to  
       share at least some biological activities. Such activities are known in the art, some of  
       which are described elsewhere herein. Assays for determining such activities are also  
       known in the art, some of which have been described elsewhere herein. Preferred  
       35      polypeptides of the invention comprise a polypeptide having the amino acid sequence  
       set out in the sequence listing as SEQ ID NO. 142, SEQ ID NO. 144 and/or SEQ ID  
       NO. 146 which correspond to the "Q" sequences in the alignment shown above (gaps  
       introduced in a sequence by the computer are, of course, removed).

40      It has been discovered that this gene is expressed primarily in the following  
       tissues/cDNA libraries: Activated T-Cell (12hs)/Thiouridine labelledEco and to a  
       lesser extent in Human Umbilical Vein Endothelial Cells, fract. A; Human  
       endometrial stromal cells-treated with estradiol; Myeloid Progenitor Cell Line;  
       Human Primary Breast Cancer Reexcision; Human T-Cell Lymphoma and  
       Keratinocyte.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 93 as residues: His-69 to Tyr-80, Gln-131 to Glu-136.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:43 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 891 of SEQ ID NO:43, b is an integer of 15 to 905, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14.

#### 15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 34**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain 1NIB and to a lesser extent in Soares\_parathyroid\_tumor\_NbHPA; Soares\_NhHMPu\_S1; Human Prostate Cancer, Stage B2; Human Prostate; Human Adrenal Gland Tumor; Human Bone Marrow, treated; NCI\_CGAP\_Co10; NCI\_CGAP\_Kid5; Hodgkin's Lymphoma II and Keratinocyte.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:44 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1973 of SEQ ID NO:44, b is an integer of 15 to 1987, where both a and b correspond to the positions of



nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 35

5 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares\_fetal\_heart\_NbHH19W and to a lesser extent in Human Adult Small Intestine; Human Chondrosarcoma; H. Epididymus, caput & corpus; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Soares\_fetal\_lung\_NbHL19W; Spleen, Chronic lymphocytic leukemia; Soares\_fetal\_lung\_NbHL19W; H. Adipose  
10 Tissue; Human Colon Cancer, subtracted; Weizmann Olfactory Epithelium; H. Epididymus, cauda; Breast Lymph node cDNA library; Healing groin wound - zero hr post-incision (control); Human Fetal Epithelium (Skin); Synovial hypoxia; Soares\_parathyroid\_tumor\_NbHPA; Human Ovary; wilm's tumor; Soares\_parathyroid\_tumor\_NbHPA; Human Bone Marrow, re-excision; Human  
15 Uterine Cancer; Hemangiopericytoma; Resting T-Cell Library,II; breast lymph node CDNA library; Dendritic cells, pooled; Bone marrow; Monocyte activated; Hodgkin's Lymphoma II and Keratinocyte.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 95 as residues: Glu-1 to Gly-11, Met-18 to Thr-24.

20 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:45 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
25 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 892 of SEQ ID NO:45, b is an integer of 15 to 906, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a  
30 + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 36**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares melanocyte 2NbHM;

Soares\_pregnant\_uterus\_NbHPU; Soares\_parathyroid\_tumor\_NbHPA;

- 5 Soares\_senescent\_fibroblasts\_NbHSF and to a lesser extent in Early Stage Human Lung, subtracted; Human Stomach, re-excision; Keratinocyte and Primary Dendritic Cells, lib 1.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
10 related to SEQ ID NO:46 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the  
15 general formula of a-b, where a is any integer between 1 to 1428 of SEQ ID NO:46, b is an integer of 15 to 1442, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14.

20 **FEATURES OF PROTEIN ENCODED BY GENE NO: 37**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gnl|PID|d1035466 (all information available through the recited accession number is  
25 incorporated herein by reference) which is described therein as "KIAA0765 protein [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

30 >gnl|PID|d1035466 (AB018308) KIAA0765 protein [Homo sapiens]  
>sp|D1035466|D1035466 KIAA0765 PROTEIN (FRAGMENT).  
>gnl|PID|d1035777 (AB015336) HRIHFB2091 [Homo sapiens] (SUB  
219-594)  
Length = 594

## Plus Strand HSPs:

Score = 439 (154.5 bits), Expect = 4.4e-47, Sum P(2) = 4.4e-47  
 Identities = 86/86 (100%), Positives = 86/86 (100%), Frame = +1

5

Q: 451 ASSSGKPGPTVIKVNMPFTVSIIDEILDFYGYQVIPGSVCLKYNEKGMPTGEAMVAFES 630  
 ASSSGKPGPTVIKVNMPFTVSIIDEILDFYGYQVIPGSVCLKYNEKGMPTGEAMVAFES  
 S: 509 ASSSGKPGPTVIKVNMPFTVSIIDEILDFYGYQVIPGSVCLKYNEKGMPTGEAMVAFES 568

10

Q: 631 RDEATAAVIDLNDRPIGSRKVKLVLG 708  
 RDEATAAVIDLNDRPIGSRKVKLVLG  
 S: 569 RDEATAAVIDLNDRPIGSRKVKLVLG 594

15

Score = 84 (29.6 bits), Expect = 9.2, P = 1.0  
 Identities = 17/72 (23%), Positives = 37/72 (51%), Frame = +1

20

Q: 484 IKVNMPFTVSIIDEILDFYGYQVIPGSVCLKYNEKGMPTGEAMVAFESRDEATAAVIDL 663  
 + ++ +PF ++DFF ++ S + Y G TGE V F + + AA+  
 S: 94 VYLKGLPF EAENKHVIDFFKKLDIVEDSIYIAYGPNKATGEGFVEFRNEADYKAALCR- 152  
 Q: 664 NDRPIGSRKVKL 699  
 + + +G+R +++  
 S: 153 HKQYMGNRFIQV 164

25

The segments of gnlPIDId1035466 that are shown as "S" above are set out in the sequence listing as SEQ ID NO. 147 and SEQ ID NO. 149. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 148 and/or SEQ ID NO. 150 which correspond to the "Q" sequences in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

35

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Primary Dendritic Cells, lib 1 and to a lesser extent in Soares\_total\_fetus\_Nb2HF8\_9w; Stratagene placenta (#937225); Human Osteoclastoma Stromal Cells - unamplified; Soares\_pregnant\_uterus\_NbHPU; Human Adult Heart, re-excision; Human Pineal Gland; Human Colon Cancer, re-excision; Synovial IL-1/TNF stimulated; pBMC stimulated w/ poly I/C; Human Pituitary, subt IX; Soares\_fetal\_lung\_NbHL19W; H. Kidney Medulla, re-excision; Human Bone Marrow, re-excision; T-Cell PHA 24 hrs; Ulcerative Colitis; Resting T-Cell Library, II; 12 Week Old Early Stage Human; Human T-Cell Lymphoma; Human

40

Substantia Nigra; Human Placenta; Endothelial-induced; Anergic T-cell; Stratagene corneal stroma (#937222); Monocyte activated; Human Endometrial Tumor; Osteoblasts; Keratinocyte; Human 8 Week Whole Embryo; Human Cerebellum and Soares infant brain INIB.

- 5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:47 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
10 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1214 of SEQ ID NO:47, b is an integer of 15 to 1228, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a  
15 + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 38

- The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting  
20 example, the sequence accessible through the following database accession no. gnl|PID|e1253290 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "acyl-CoA dehydrogenase [*Mycobacterium tuberculosis*]". A partial alignment demonstrating the observed homology is shown immediately below.

25

```

>gnl|PID|e1253290 (AL021958) acyl-CoA dehydrogenase [Mycobacterium
tuberculosis] >gnl|PID|e1253290 (AL021958) fadE9
[Mycobacterium
30 tuberculosis]
Length = 390

Plus Strand HSPs:

Score = 1018 (358.4 bits), Expect = 4.1e-102, P = 4.1e-102
35 Identities = 198/378 (52%), Positives = 262/378 (69%), Frame = +1

Q: 160 LNEEQKEFQKVAFDFAAREMAPNMAEWDQKELFPVDVMRKAAQLGFGGVYIQTDTVGGSGL 339
LN++++ + A FA + +AP+ EWD + FPVDV+R+AA+LG +Y + DVGGSGL

```

S: 4 LNDDERVIVETAAAFAGKRLAPHALEWDAAKHFPVDVLR EAAELGMAAIYCRDDVGGSGSL 63  
 Q: 340 SRLDTSVIFEALATGCTSTTAYISIHNMCAWMIDSFGNEEQRHKFCPPLCTMEKFASYCL 519  
 RLD IFE LA T A++SIHNMCAWMIDSFG +EQR + P L TM ASYCL  
 5 S: 64 RRLDGVRIFEQLAIADPVTAAFLSIHNMCAWMIDSFGTDEQRKDWPRLATMGVIASYCL 123  
 Q: 520 TEPGSGSDAASLLTSAKKQGD---HYILNGSKAFISGAGESDIYVVMCRTGGPGPKGIS 687  
 TEPG+GSDA +L T A + G Y+L+G K FISGA SD+YVVM RTG GP+G+S  
 10 S: 124 TEPGAGSDAGALSTRAVRHSGKGGDYVLDGVKQFISGAAASDVYVVMARTGAEGFRGVS 183  
 Q: 688 CIVVEKGT PGLSFGKKEKKVGWNSQPTRAVIFEDCAVPVANRIGS---EGQGFLIAVRGL 858  
 +VEKGT PGLSFG E K+GW++QPT V+ + VP +G EG GF IA+ GL  
 S: 184 AFIVEKGT PGLSFGAPEAKMGWHAQPTAQVVLDGVRVPAEAMLGADGEGAGFGIAMSGL 243  
 15 Q: 859 NGGRINIASCSLGAHAHSVILTRDHLNVRKQFGEPLASNQYLQFTLADMATRLVAARLMV 1038  
 NGGR+NIA+CSLG A A++ ++ R+ FG L ++FTLADMAT L +R+++  
 S: 244 NGGRLNIAACSLGGAQAADFKAAYVRDRQAFGGSLLEPTVRFTLADMATGLQTSRMLL 303  
 Q: 1039 RNAAVALQEERKDAVALCSMAKLFATDECFAICNQALQMHGGYGYLKDYAVQYVRDSRV 1218  
 AA AL ++ D V LC+MAK + TD CF + +QALQ+HGGYGYL++Y +++ VRD RV  
 20 S: 304 WRAASALDDDDADKVELCAMAKRYVTDTCFEVADQALQLHGGYGYLREYGLEKIVRDLRV 363  
 Q: 1219 HQILEGSNEVMRILISRS 1272  
 H+ILEG+NE+MR++I R+  
 25 S: 364 HRILEGTNEIMRLVIGRA 381

The segment of gnlIPIDle1253290 that is shown as "S" above is set out in the  
 sequence listing as SEQ ID NO. 151. Based on the structural similarity these  
 homologous polypeptides are expected to share at least some biological activities.

30 Such activities are known in the art, some of which are described elsewhere herein.  
 Assays for determining such activities are also known in the art, some of which have  
 been described elsewhere herein. Preferred polypeptides of the invention comprise a  
 polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID  
 NO. 152 which corresponds to the "Q" sequence in the alignment shown above (gaps  
 35 introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following  
 tissues/cDNA libraries: NCI\_CGAP\_GCB1 and to a lesser extent in Spleen/normal;  
 Colon Normal; H. cerebellum, Enzyme subtracted; Human Manic Depression Tissue;  
 Ulcerative Colitis; Human Fetal Heart; Monocyte activated; Activated T-  
 40 cell(12h)/Thiouridine-re-excision; Keratinocyte; Soares\_total\_fetus\_Nb2HF8\_9w;  
 Stratagene schizo brain S11; Primary Dendritic Cells, lib 1 and Soares infant brain  
 INIB.

Many polynucleotide sequences, such as EST sequences, are publicly  
 available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:48 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2227 of SEQ ID NO:48, b is an integer of 15 to 2241, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 39

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gill1872200 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "alternatively spliced product using exon 13A [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

```

20  >gi|1872200 alternatively spliced product using exon 13A [Homo sapiens]
    >sp|P78525|P78525 MYB PROTO-ONCOGENE PROTEIN (C-MYB).
    Length = 666

    Minus Strand HSPs:
25  Score = 304 (107.0 bits), Expect = 1.2e-23, P = 1.2e-23
    Identities = 62/91 (68%), Positives = 67/91 (73%), Frame = -2

30  Q: 1360 AQAGVQWHDLSLQPPPPGFKQ-CCLSLPSSWNYGCVPPHPAFLYFLVETGFHHVGQAGL 1184
    A  GVQWHD SLQP PPGFK+ CLSLP SW+Y PP PA FLVETGF HVGQAGL
    S: 565 APTGVQWHDGSLQLPPGFKRFSCLSLPRSWDYRHPPRPANFEFLVETGFLHVGQAGL 624

    Q: 1183 ELLALGNPPALASQSAGITGVSHCARPALAF 1091
    ELL G+ PA ASQSA ITGVSH ARP ++
35  S: 625 ELLTSGDLPASASQSARITGVSHRARPEYSY 655
  
```

The segment of gill1872200 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 153. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities.

Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 154 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Activated Monocytes and to a lesser extent in Neutrophils IL-1 and LPS induced; Synovial hypoxia; Endothelial-induced; Keratinocyte; Frontal Lobe, Dementia; pBMC stimulated w/ poly I/C; Spinal Cord, re-excision; Human Activated T-Cells; Human pancreatic islet; Endothelial cells-control; Hodgkin's Lymphoma II and Primary Dendritic Cells, lib 1.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 99 as residues: Glu-83 to Leu-89, Phe-96 to Phe-103.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:49 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1563 of SEQ ID NO:49, b is an integer of 15 to 1577, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 40

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil912755 (all information available through the recited accession number is

incorporated herein by reference) which is described therein as "No definition line found [Caenorhabditis elegans]". A partial alignment demonstrating the observed homology is shown immediately below.

```

5   >gi|912755 No definition line found [Caenorhabditis elegans]
      Length = 717

      Minus Strand HSPs:
10   Score = 239 (84.1 bits), Expect = 7.3e-26, Sum P(2) = 7.3e-26
      Identities = 57/109 (52%), Positives = 71/109 (65%), Frame = -1

      Q: 1741 MIIEFALKSWLSKTLPEICDADPSALAKYVLALVKK-DKSEKELKALCIDQLDVFLQK 1565
          M I+N +AL WLS L PI DADP+ALAKYVLALVKK DK ELKA +QL+VFL
15   S: 1 MHIDNEDALFDWLSDELSPTDADPNALAKYVLALVKKPDKGHDELKAFTNEQLNVFLTD 60

      Q: 1564 ETQIFVEKLFDAVNTKSYLPPPEQPSSGSLKVEFFPHQEKDIKKEEIHTE 1415
          T FV+K+F+A+ +KSY+P P+S S P D+KKE+ E
20   S: 61 HTAPFVDKVFELTSKSYMPASTAPTASATA---P-----DLKKEKAPAE 103

```

The segment of gi912755 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 155. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 156 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Testes, Reexcision and to a lesser extent in Pharynx carcinoma; Soares\_pregnant\_uterus\_NbHPU; H. Meningima, M1; Human Infant Brain; TF-1 Cell Line GM-CSF Treated; L428; HUMAN JURKAT MEMBRANE BOUND POLYSOMES; Soares\_NFL\_T\_GBC\_S1; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Colon Normal II; Pancreatic Islet; Soares melanocyte 2NbHM; Endothelial-induced; Anergetic T-cell; Human Testes; Keratinocyte and Human 8 Week Whole Embryo.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 100 as residues: Leu-19 to Gln-29.



Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:50 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1787 of SEQ ID NO:50, b is an integer of 15 to 1801, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:50, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 41**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: 12 Week Old Early Stage Human, II; Soares fetal liver spleen INFLS and to a lesser extent in NCI\_CGAP\_GCB1; Human Primary Breast Cancer; Stratagene NT2 neuronal precursor 937230; NCI\_CGAP\_Co9; Soares placenta Nb2HP; Human colon cancer, metatized to liver, subtraction; Sinus piniformis Tumour; Pharynx Carcinoma; Human Infant Adrenal Gland; Human Pre-Differentiated Adipocytes; human colon cancer; Human Epididymus; Human Synovium; Healing groin wound, 6.5 hours post incision; Synovial hypoxia; Stratagene fetal spleen (#937205); Human fetal brain S. Meier-Ewert; Human fetal heart, Lambda ZAP Express; NCI\_CGAP\_Co11; NCI\_CGAP\_Kid6; Human Umbilical Vein Endothelial Cells, uninduced; NTERA2, control; Colon Carcinoma; Adipocytes; Human Testes Tumor; Human Fetal Lung III; Soares\_parathyroid\_tumor\_NbHPA; Endothelial cells-control; Keratinocyte; Human 8 Week Whole Embryo and Nine Week Old Early Stage Human.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:51 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1259 of SEQ ID NO:51, b  
 5 is an integer of 15 to 1273, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:51, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 42

10 The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gnllPID|d1035465 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "KIAA0764 protein  
 15 [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

```

20 >gnl|PID|d1035465 (AB018307) KIAA0764 protein [Homo sapiens]
    >sp|D1035465|D1035465 KIAA0764 PROTEIN.
    Length = 414

    Plus Strand HSPs:

25 Score = 1751 (616.4 bits), Expect = 1.0e-179, P = 1.0e-179
    Identities = 346/404 (85%), Positives = 348/404 (86%), Frame = +1

    Q: 19 RVRGEIPISSSQTNRSSFDLLPREFRLVEVHDPPLHQPSANKPKPPTMLDIPSEPCSLTI 198
        R GEIPISSSQTNRSSFDLLPREFRLVEVHDPPLHQPSANKPKPPTMLDIPSEPCSLTI
    S: 5 RYWGEIPISSSQTNRSSFDLLPREFRLVEVHDPPLHQPSANKPKPPTMLDIPSEPCSLTI 64

30 Q: 199 HTIQLIQHNRRRLRNLIXXXXXXXXXXEGVKTXXXXXXXXXXXXXXXXXXXXCKNPN 378
        HTIQLIQHNRRRLRNLI EGVKT CKNPN
    S: 65 HTIQLIQHNRRRLRNLIATAQAQNQQQTEGVKTESEPLPSCPGSPPLPDDLPLDCKNPN 124

35 Q: 379 APFQIRHSDPESDFYRGKGEPVTELSWHSCRQLLYQAVATILAHAGFDCANESVLET LTD 558
        APFQIRHSDPESDFYRGKGEPVTELSWHSCRQLLYQAVATILAHAGFDCANESVLET LTD
    S: 125 APFQIRHSDPESDFYRGKGEPVTELSWHSCRQLLYQAVATILAHAGFDCANESVLET LTD 184

40 Q: 559 VAHEYCLKFTKLLRFAVDREARLGQTPFPPLNGKEQGFHEVGIGSVLSLQKFWQHRIKDYH 738
        VAHEYCLKFTKLLRFAVDREARLGQTPFP + EQ FHEVGIGSVLSLQKFWQHRIKDYH
    S: 185 VAHEYCLKFTKLLRFAVDREARLGQTPFP - DVMEQVFHEVGIGSVLSLQKFWQHRIKDYH 243

45 Q: 739 SYMLQISKQLSEEEYERIVNPEKATEDAKPVKIKEEPVSDITFPVSEELADLASGDQSLP 918
        SYMLQISKQLSEEEYERIVNPEKATEDAKPVKIKEEPVSDITFPVSEELADLASGDQSLP
    S: 244 SYMLQISKQLSEEEYERIVNPEKATEDAKPVKIKEEPVSDITFPVSEELADLASGDQSLP 303

    Q: 919 MGVLGAQSERFPSNLEVEASPOASSAEVNASPLWNLAHVMEQSEEGNVSGHVLGSD 1098
  
```

```

      MGVLGAQSERFPSNLEVEAS PQASSAEVNASPLWNLAHVKMEPQESEEGNVSGHGVLGSD
S:   304 MGVLGAQSERFPSNLEVEAS PQASSAEVNASPLWNLAHVKMEPQESEEGNVSGHGVLGSD 363

      VFEEPISGMSEAGIPQXXXXXXXXXXXXXXXXXLMGSSPVFNQRC 1230
Q:   1099 VFEEPISGMSEAGIPQXXXXXXXXXXXXXXXXXLMGSSPVFNQRC 1230
      VFEEP+SGMSEAGIPQ LMGSSPVFNQRC
S:   364 VFEEPMSEAGIPQSPDDSDSSYSGSHSTDSLMGSSPVFNQRC 407

```

The segment of gnl|PID|d1035465 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 157. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 158 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in Human Endometrial Tumor; Keratinocyte; Human 8 Week Whole Embryo; H. cerebellum, Enzyme subtracted; Raji Cells, cyclohexamide treated; Human Osteosarcoma; Soares\_testis\_NHT; Soares\_NhHMPu\_S1; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Human Placenta; Human Amygdala; Smooth muscle, control; NCI\_CGAP\_Kid5; Stratagene colon (#937204); Human Cerebellum; Primary Dendritic Cells, lib 1; NCI\_CGAP\_GCB1; Lung Mesothelium; Human Leukocytes; Human (Caco-2) cell line, adenocarcinoma, colon, remake; Human OB MG63 treated (10 nM E2) fraction I; Soares retina N2b4HR; B Cell lymphoma; HEL cell line; Human Epididymus; Stratagene placenta (#937225); KMH2; Apoptotic T-cell; Soares\_NhHMPu\_S1; Human Heart; Human Adrenal Gland Tumor; Macrophage-oxLDL, re-excision; PC3 Prostate cell line; Atrium cDNA library Human heart; Fetal Heart; Colon Tumor; Neutrophils IL-1 and LPS induced; Smooth muscle, serum treated; Soares\_NhHMPu\_S1; Human Synovial Sarcoma; Anergic T-cell; T Cell helper I; Human fetal heart, Lambda ZAP Express; NCI\_CGAP\_GCB1; Human Bone Marrow, treated; Osteoblasts; Nine Week Old Early Stage Human and Soares\_fetal\_lung\_NbHL19W.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:52 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
5 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1454 of SEQ ID NO:52, b is an integer of 15 to 1468, where both a and b correspond to the positions of  
10 nucleotide residues shown in SEQ ID NO:52, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 43**

It has been discovered that this gene is expressed primarily in Human Colon  
15 Cancer, subtracted.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:53 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
20 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1162 of SEQ ID NO:53, b is an integer of 15 to 1176, where both a and b correspond to the positions of  
25 nucleotide residues shown in SEQ ID NO:53, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 44**

The computer algorithm BLASTX has been used to determine that the  
30 translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

gil1389766 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "Homo sapiens protein". A partial alignment demonstrating the observed homology is shown immediately below.

```

5      >gil1389766 unknown [Homo sapiens]
          Length = 118

10      Plus Strand HSPs:
          Score = 268 (94.3 bits), Expect = 6.9e-22, P = 6.9e-22
          Identities = 56/76 (73%), Positives = 60/76 (78%), Frame = +3

15      Q: 1470 QAGRSGSRL*SQHFGRPRQVDHLRSGV*DQPGQHGETPSLLKNTKISWAWWRAPVILATQ 1649
          QAGR GSRL HFGRPR+ D+LR GV DQ GQ GE+PSLLKNTKISWAWW PVI A +
          S: 47 QAGRCGSRL--HFGRPRRADYLRIGVPDQRGQGESPSLLKNTKISWAWW-VPVIPAIR 102

          Q: 1650 EAEAGESLEPGRWWLQ 1697
          E EAGESLEPGR LQ
20      S: 103 EGEAGESLEPGRQRLQ 118

```

The segment of gil1389766 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 159. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities.

Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 160 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

When tested against U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in Soares melanocyte 2NbHM; Monocyte activated; Human Cerebellum, differentially expressed; K562 + PMA (36 hrs); Human Membrane Bound Polysomes- Enzyme  
5 Subtraction; prostate-edited; H. Epididymus, caput & corpus; HSA 172 Cells; Human adult small intestine, re-excision; Human Osteoclastoma, re-excision; Jurkat T-Cell, S phase; Human Manic Depression Tissue; L428; Human Fetal Dura Mater; Macrophage-oxLDL; Human Activated Monocytes; Soares breast 2NbHBst; Pancreas Islet Cell Tumor; Resting T-Cell Library, II; Dendritic cells, pooled; Endothelial cells-  
10 control; Human Amygdala; Osteoblasts and Primary Dendritic Cells, lib 1.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:54 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
15 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1765 of SEQ ID NO:54, b is an integer of 15 to 1779, where both a and b correspond to the positions of  
20 nucleotide residues shown in SEQ ID NO:54, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 45**

It has been discovered that this gene is expressed primarily in the following  
25 tissues/cDNA libraries: K562 + PMA (36 hrs), re-excision; Primary Dendritic Cells, lib 1.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:55 and may have been publicly available prior to conception of  
30 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence

would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1459 of SEQ ID NO:55, b is an integer of 15 to 1473, where both a and b correspond to the positions of  
 5 nucleotide residues shown in SEQ ID NO:55, and where b is greater than or equal to a + 14.

### FEATURES OF PROTEIN ENCODED BY GENE NO: 46

The computer algorithm BLASTX has been used to determine that the  
 10 translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil4097898 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "transcriptional repressor NOT4Hp [Homo sapiens]". A partial alignment demonstrating the observed  
 15 homology is shown immediately below.

```

    >gi|4097898 potential transcriptional repressor NOT4Hp [Homo sapiens]
    >sp|G4097898|G4097898 POTENTIAL TRANSCRIPTIONAL REPRESSOR
  20 NOT4HP.
      Length = 642

      Plus Strand HSPs:

      Score = 704 (247.8 bits), Expect = 8.9e-69, P = 8.9e-69
  25 Identities = 133/150 (88%), Positives = 133/150 (88%), Frame = +2

      Q:      2 GQAARYPWMAFPRNSIMHLNHTANPTSNSNFLDLNLPPQHNTGLGGIPVAGIPASSGNSL 181
          GQAARYPWMAFPRNSIMHLNHTANPTSNSNFLDLNLPPQHNTGLGGIPVAGIPASSGNSL
      S:    493 GQAARYPWMAFPRNSIMHLNHTANPTSNSNFLDLNLPPQHNTGLGGIPVAGIPASSGNSL 552

  30 Q:    182 DSLQDDNPPHWLKSQALTEMDGPSAAPSQTHHSAPFSXQIPLHRASWNXXXXXXXXXXXX 361
          DSLQDDNPPHWLKSQALTEMDGPSAAPSQTHHSAPFS QIPLHRASWN
      S:    553 DSLQDDNPPHWLKSQALTEMDGPSAAPSQTHHSAPFSTQIPLHRASWNYPYPPSPNPSSF 612

  35 Q:    362 XXXXXGFQTAFRPPSKTPTDLLQSSTLDRH 451
          GFQTAFRPPSKTPTDLLQSSTLDRH
      S:    613 HSPPPGFQTAFRPPSKTPTDLLQSSTLDRH 642
  
```

The segment of gil4097898 that is shown as "S" above is set out in the  
 40 sequence listing as SEQ ID NO. 161. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein.

Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 162 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: NCI\_CGAP\_GCB1; Soares fetal liver spleen 1NFLS and to a lesser extent in Soares\_fetal\_heart\_NbHH19W; Soares melanocyte 2NbHM; Soares\_NFL\_T\_GBC\_S1; Soares ovary tumor NbHOT;

10 Soares\_NSF\_F8\_9W\_OT\_PA\_P\_S1; Soares\_parathyroid\_tumor\_NbHPA; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; NCI\_CGAP\_GC4; NCI\_CGAP\_Brn23; Saos2, Dexamethosome Treated; Human Adult Spleen; Smooth Muscle Serum Treated, Norm; Human Osteoclastoma Stromal Cells - unamplified; Salivary Gland, Lib 2; Prostate BPH; Mo7e Cell Line GM-CSF treated (1ng/ml); Stromal cell TF274;

15 Pancreas Islet Cell Tumor; Human Testes, Reexcision; Human Amygdala; Spleen, Chronic lymphocytic leukemia; Nine Week Old Early Stage Human and Soares placenta Nb2HP.

The tissue distribution in fetal liver/spleen suggests the protein product of this clone is useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex- vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders

20 such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells suggests this protein may play a role in the

25 regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, cancer, and other

30



proliferative conditions. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in  
5 acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection,  
10 treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

15 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:56 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
20 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2718 of SEQ ID NO:56, b is an integer of 15 to 2732, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56, and where b is greater than or equal to a  
25 + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 47

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting  
30 example, the sequence accessible through the following database accession no. gil2507637 (all information available through the recited accession number is

incorporated herein by reference, for example, DNA Cell Biol. 18 (2), 141-145 (1999)) which is described therein as "SNARE protein Ykt6 [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

```

5      >gi|2507637 SNARE protein Ykt6 [Homo sapiens]
          Length = 198

          Plus Strand HSPs:

10     Score = 920 (323.9 bits), Expect = 1.0e-91, P = 1.0e-91
          Identities = 183/198 (92%), Positives = 183/198 (92%), Frame = +1

      Q:   127 MKLYSLSVLYKGEAKVLLKAAYDXXXXXXXXXXXXXXXXMTFTSQLIVERSSSKGTRASVK 306
          MKLYSLSVLYKGEAKVLLKAAYD                      MTFTSQLIVERSSSKGTRASVK
15     S:    1 MKLYSLSVLYKGEAKVLLKAAYDVSSFSFFQRSSVQEFMTFTSQLIVERSSSKGTRASVK 60

      Q:   307 EQDYLCVYVRNDSLAVGVVIADNEYPSRVAFTLLEKVLDEFKQVDRIDWPVGSPTIHY 486
          EQDYLCVYVRNDSLAVGVVIADNEYPSRVAFTLLEKVLDEFKQVDRIDWPVGSPTIHY
20     S:    61 EQDYLCVYVRNDSLAVGVVIADNEYPSRVAFTLLEKVLDEFKQVDRIDWPVGSPTIHY 120

      Q:   487 PALDGHLSRYQNPREADPMTKVQAEDETKEILHNTMESLLERGEKLDDLVSKEVLGTQ 666
          PALDGHLSRYQNPREADPMTKVQAEDETKEILHNTMESLLERGEKLDDLVSKEVLGTQ
25     S:   121 PALDGHLSRYQNPREADPMTKVQAEDETKEILHNTMESLLERGEKLDDLVSKEVLGTQ 180

      Q:   667 SKAFYKTARKQNSCCAIM 720
          SKAFYKTARKQNSCCAIM
      S:   181 SKAFYKTARKQNSCCAIM 198

```

The segment of gil2507637 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 163. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 164 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares adult brain N2b5HB55Y and to a lesser extent in Soares adult brain N2b4HB55Y; Soares\_fetal\_heart\_NbHH19W; Soares infant brain 1NIB; Keratinocyte; Human Cerebellum; Soares fetal liver spleen 1NFLS; Primary Dendritic Cells, lib 1; Soares\_total\_fetus\_Nb2HF8\_9w; Pharynx carcinoma; Soares retina N2b5HR; Human Primary Breast Cancer, re-excision;

- Soares\_fetal\_heart\_NbHH19W; Cem cells cyclohexamide treated; Raji Cells, cyclohexamide treated; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; KMH2; T-Cell PHA 16 hrs; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Soares\_senescent\_fibroblasts\_NbHSF; Stratagene hNT neuron (#937233); Human adult testis, large inserts; Colon
- 5 Carcinoma; Soares breast 3NbHBst; Human Fetal Lung III; Endothelial-induced; Stratagene colon (#937204); Osteoblasts; Soares\_NhHMPu\_S1; Soares\_pregnant\_uterus\_NbHPU; Human Prostate Cancer, Stage C; H. Kidney Medulla, subtracted; Human Infant Adrenal Gland, Subtracted; Cheek Carcinoma; Frontal Lobe, Dementia; Human OB HOS treated (10 nM E2) fraction I; Human
- 10 Aortic Endothelium; Human Umbilical Vein Endothelial Cells, fract. A; Human Neutrophils, Activated, re-excision; Smooth Muscle Serum Treated, Norm; H. cerebellum, Enzyme subtracted; Human Lung; Soares retina N2b4HR; Apoptotic T-cell, re-excision; Human Synovium; Human Prostate Cancer, Stage C fraction; NTERA2 + retinoic acid, 14 days; Human Fetal Epithelium (Skin); Ovarian Tumor
- 15 10-3-95; Synovial hypoxia; Jurkat T-Cell, S phase; Synovial Fibroblasts (II1/TNF), subt; Soares\_NhHMPu\_S1; Human Brain, Striatum; L428; Human Umbilical Vein Endothelial Cells, uninduced; Human Fetal Dura Mater; Human Pancreas Tumor; Macrophage-oxLDL; Human Hypothalamus, Schizophrenia; Human umbilical vein endothelial cells, IL-4 induced; Human Adipose; Rejected Kidney, lib 4; Human
- 20 Whole Six Week Old Embryo; Resting T-Cell Library, II; H. Frontal cortex, epileptic, re-excision; breast lymph node CDNA library; Adipocytes; Dendritic cells, pooled; Normal colon; Human Synovial Sarcoma; Primary Dendritic cells, frac 2; Human Neutrophil, Activated; Human Adult Pulmonary, re-excision; Endothelial cells-control; Monocyte activated; Soares\_NhHMPu\_S1; Spleen, Chronic
- 25 lymphocytic leukemia; Hodgkin's Lymphoma II; Stratagene hNT neuron (#937233); T cell helper II; Stratagene pancreas (#937208); Stratagene neuroepithelium (#937231); Nine Week Old Early Stage Human and Soares placenta Nb2HP.

The gene encoding the disclosed cDNA is believed to reside on chromosome 6. Accordingly, polynucleotides related to this invention are useful as a marker in

30 linkage analysis for chromosome 6.

The tissue distribution in adult and infant brain suggests the protein product of this clone is useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain suggests it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival.

Moreover, the expression within infant tissue and other cellular sources marked by proliferating cells suggests this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, cancer, and other proliferative conditions. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. Protein, as well as,

antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:57 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2763 of SEQ ID NO:57, b is an integer of 15 to 2777, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:57, and where b is greater than or equal to a + 14.

#### 15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 48**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in Soares\_fetal\_liver\_spleen\_1NFLS\_S1; NCI\_CGAP\_GCB1; NCI\_CGAP\_GCB1; Stratagene lung (#937210); Human Synovial Sarcoma; Soares placenta Nb2HP; Soares\_NhHMPu\_S1; Stratagene colon (#937204); Human Thymus Stromal Cells; T Cell helper I; Soares\_pregnant\_uterus\_NbHPU; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Primary Dendritic Cells, lib 1; Soares infant brain 1NIB; H. Kidney Pyramid, subtracted; Human Infant Adrenal Gland, Subtracted; Soares ovary tumor NbHOT; Dermatofibrosarcoma Protuberance; A1-CELL LINE; Human Thyroid; Human Epididymus; Breast Cancer cell line, MDA 36; Synovial hypoxia-RSF subtracted; Human endometrial stromal cells-treated with progesterone; Human Osteoclastoma, re-excision; wilm's tumor; Human Fetal Dura Mater; Human Hippocampus; Liver, Hepatoma; Stratagene lung carcinoma 937218; Human umbilical vein endothelial cells, IL-4 induced; Human Adipose; Ulcerative Colitis; Human Thymus; Macrophage-oxLDL, re-excision; Human heart cDNA (YNakamura); Human fetal heart, Lambda ZAP Express; NCI\_CGAP\_Pr25; PC3

Prostate cell line; Human Testes Tumor; Dendritic cells, pooled; Endothelial cells-control; NCI\_CGAP\_Co2; NCI\_CGAP\_Co3; NCI\_CGAP\_GC2; NCI\_CGAP\_GC4; NCI\_CGAP\_Lu5; NCI\_CGAP\_Co10; NCI\_CGAP\_Brn25; NCI\_CGAP\_Pr4.1; Colon Normal III; T cell helper II and Keratinocyte.

5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:58 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
10 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 651 of SEQ ID NO:58, b is an integer of 15 to 665, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:58, and where b is greater than or equal to a  
15 + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 49

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting  
20 example, the sequence accessible through the following database accession no. gil204362 (all information available through the recited accession number is incorporated herein by reference, for example J. Biol. Chem. 266, 18792-18796 (1991)) which is described therein as "pot. glutaminase (EC 3.5.1.2); putative [Rattus norvegicus]". A partial alignment demonstrating the observed homology is shown  
25 immediately below.

```
>gil204362 pot. glutaminase (EC 3.5.1.2); putative [Rattus norvegicus]
      Length = 326
```

30 Minus Strand HSPs:

```
Score = 687 (241.8 bits), Expect = 5.9e-67, P = 5.9e-67
Identities = 126/127 (99%), Positives = 126/127 (99%), Frame = -3
```

35 Q: 3019 CESASVMAATLANGGFCPITGERVLSPEAVRNTLSLMHSCGMYDFSGQFAFHVGLPAKSG 2840  
CESASVMAATLANGGFCPITGERVLSPEAVRNTLSLMHSCGMYDFSGQFAFHVGLPAKSG

S: 81 CESASVMAATLANGGFCPTIGERVLSPEAVRNTLSLMHSCGMYDFSGQFAFHVGLPAKSG 140  
 Q: 2839 VAGGILLVVPNVMMGMCWXPPLDKMGNSVKGIFHCHDLVSLCNFHNNDNLRHFAKKLDPR 2660  
 VAGGILLVVPNVMMGMCW PPLDKMGNSVKGIFHCHDLVSLCNFHNNDNLRHFAKKLDPR  
 5 S: 141 VAGGILLVVPNVMMGMCWSPPLDKMGNSVKGIFHCHDLVSLCNFHNNDNLRHFAKKLDPR 200  
 Q: 2659 REGGDQR 2639  
 REGGDQR  
 S: 201 REGGDQR 207  
 10

The segment of gil204362 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 165. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein. Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 166 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: NCI\_CGAP\_GCB1 and to a lesser extent in T-Cell PHA 24 hrs; 12 Week Old Early Stage Human; Hodgkin's Lymphoma II; Human 8 Week Whole Embryo; Soares placenta Nb2HP; Primary Dendritic Cells, lib 1; Mo7e Cell Line GM-CSF treated (1ng/ml); Human Eosinophils; Colon Carcinoma; 12 Week Early Stage Human II, Reexcision; Human T-cell lymphoma, re-excision; Stratagene endothelial cell 937223; Stratagene NT2 neuronal precursor 937230; Bone Marrow Stromal Cell, untreated; Stratagene lung (#937210); Soares\_pregnant\_uterus\_NbHPU; Human Endometrial Tumor; Human fetal heart, Lambda ZAP Express; Osteoblasts; Human Cerebellum; C7MCF7 cell line, estrogen treated; Soares\_placenta\_8to9weeks\_2NbHP8to9W; Bone Marrow Stroma, TNF&LPS ind; Larynx Normal; Activated T-Cells, 8 hrs, subtracted; Human Microvascular Endothelial Cells, fract. B; Thymus; Dermatofibrosarcoma Protuberance; Human Umbilical Vein Endothelial Cells, fract. A; Human Pancreatic Carcinoma; Human Thyroid; B Cell lymphoma; Human Synovium; pBMC stimulated w/ poly I/C; Healing groin wound, 7.5 hours post incision; Synovial hypoxia-RSF subtracted; NCI\_CGAP\_GCB1; Human endometrial stromal cells-treated with

- progesterone; Healing groin wound, 6.5 hours post incision; Ovarian Tumor 10-3-95; Soares\_pregnant\_uterus\_NbHPU; Human Osteoclastoma, re-excision; Jurkat T-cell G1 phase; Synovial Fibroblasts (II1/TNF), subt; KMH2; Human Chronic Synovitis; Human Umbilical Vein, Reexcision; Soares\_fetal\_heart\_NbHH19W; Human Bone
- 5 Marrow, re-excision; TF-1 Cell Line GM-CSF Treated; human ovarian cancer; 12 Week Old Early Stage Human, II; Human Umbilical Vein Endothelial Cells, uninduced; Soares\_placenta\_8to9weeks\_2NbHP8to9W; Human umbilical vein endothelial cells, IL-4 induced; Human Activated Monocytes; Human fetal heart, Lambda ZAP Express; Human retina cDNA randomly primed sublibrary;
- 10 NCI\_CGAP\_GCB1; Human Testes Tumor, re-excision; Human Adrenal Gland Tumor; Rejected Kidney, lib 4; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; NTERA2, control; Gessler Wilms tumor; Liver HepG2 cell line.; PC3 Prostate cell line; Resting T-Cell Library,II; Human T-Cell Lymphoma; NCI\_CGAP\_GCB1; Human Substantia Nigra; Colon Tumor II; Human fetal lung; Human Placenta; Human Fetal Heart;
- 15 Human Neutrophil, Activated; Endothelial-induced; Anergic T-cell; HUMAN B CELL LYMPHOMA; Human Bone Marrow, treated; NCI\_CGAP\_Sch1 and Nine Week Old Early Stage Human.

The tissue distribution in Expression within embryonic tissue and other cellular sources marked by proliferating cells suggests this protein may play a role in

20 the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, cancer, and other proliferative conditions. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of

25 some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein

30 may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases.



The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:59 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
10 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3007 of SEQ ID NO:59, b is an integer of 15 to 3021, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:59, and where b is greater than or equal to a  
15 + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 50

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Monocyte activated and to a lesser extent in Weizmann  
20 Olfactory Epithelium; Human Aortic Endothelium; Human Normal Breast; Human Bone Marrow, re-excision; Soares breast 2NbHBst; NCI\_CGAP\_GCB1; Keratinocyte and Soares fetal liver spleen 1NFLS.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 110 as residues: Ala-4 to Gly-10.

25 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:60 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
30 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 544 of SEQ ID NO:60, b is an integer of 15 to 558, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:60, and where b is greater than or equal to a + 14.

Table 1

Gene No.	cDNA Clone ID	ATCC Deposit NO:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HISEJ52	203957 4/26/99	pSport1	11	1599	1	1599	128	128	61	1	17	18	27
2	HJBCG74	203957 4/26/99	pBluescript SK-	12	2455	12	2428	33	33	62	1	30	31	224
3	HJPBE39	203957 4/26/99	Uni-ZAP XR	13	1298	69	1298		170	63	1			18
4	HISAN63	203957 4/26/99	pSport1	14	2124	1	2124	597	597	64	1	22	23	38
5	HISAT78	203957 4/26/99	pSport1	15	2312	835	2287	967	967	65	1	30	31	66
6	HISBA38	203957 4/26/99	pSport1	16	1058	1	1058	169	169	66	1	32	33	36
7	HISCJ20	203957 4/26/99	pSport1	17	372	1	372	257	257	67	1	24	25	38
8	HISCK41	203957 4/26/99	pSport1	18	2043	1	2043	82	82	68	1	28	29	33
9	HISCO45	203957 4/26/99	pSport1	19	1557	116	1541	315	315	69	1			32

Gene No.	cDNA Clone ID	ATCC Deposit NO:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
10	HJABC58	203957 4/26/99	pBluescript SK-	20	1796	1	1796	193	193	70	1	26	27	58
11	HJABR75	203957 4/26/99	pBluescript SK-	21	1328	1	1328	324	324	71	1	18	19	37
12	HJABS31	203957 4/26/99	pBluescript SK-	22	1232	1	1191	252	252	72	1	18	19	36
13	HJABT12	203957 4/26/99	pBluescript SK-	23	557	1	557	30	30	73	1	16	17	37
14	HJACE25	203957 4/26/99	pBluescript SK-	24	1320	1	1320	322	322	74	1			26
15	HJACK21	203957 4/26/99	pBluescript SK-	25	1271	1	1271	139	139	75	1	21	22	35
16	HJBCO21	203957 4/26/99	pBluescript SK-	26	587	1	553	289	289	76	1			11
17	HJBCQ40	203957 4/26/99	pBluescript SK-	27	1069	1	1069	161	161	77	1	20	21	50
18	HJBCU75	203957 4/26/99	pBluescript SK-	28	1009	1	1009	61	61	78	1			5
19	HJMAF30	203957 4/26/99	pCMVSPORT 3.0	29	603	1	603	193	193	79	1	24	25	34

Gene No.	cDNA Clone ID	ATCC Deposit NO:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
20	HJMAM72	203957 4/26/99	pCMVSPORT 3.0	30	403	1	403	300	300	80	1	17	18	25
21	HJMBK59	203957 4/26/99	pCMVSPORT 3.0	31	658	1	658	42	42	81	1	24	25	70
22	HJMBP01	203957 4/26/99	pCMVSPORT 3.0	32	633	1	633	58	58	82	1	42	43	45
23	HJMBQ17	203957 4/26/99	pCMVSPORT 3.0	33	275	1	275	145	145	83	1	15	16	29
24	HJMBW62	203957 4/26/99	pCMVSPORT 3.0	34	1439	1	1439	105	105	84	1	18	19	58
25	HJMBX54	203957 4/26/99	pCMVSPORT 3.0	35	1020	1	1020	81	81	85	1	17	18	33
26	HJPAF69	203957 4/26/99	Uni-ZAP XR	36	1076	1	1076	25	25	86	1	16	17	33
27	HJPAQ19	203957 4/26/99	Uni-ZAP XR	37	1109	1	1109	66	66	87	1	50	51	290
28	HJPBI77	203957 4/26/99	Uni-ZAP XR	38	808	1	538	68	68	88	1			25
29	HJPBN96	203957 4/26/99	Uni-ZAP XR	39	1036	1	1036	70	70	89	1	28	29	73

Gene No.	cDNA Clone ID	ATCC Deposit NO:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
30	HJPBK28	203957 4/26/99	Uni-ZAP XR	40	989	1	989		256	90	1	21	22	43
31	HJPDJ08	203957 4/26/99	Uni-ZAP XR	41	1044	1	1044	134	134	91	1	19	20	33
32	HJPCQ19	203957 4/26/99	Uni-ZAP XR	42	902	1	902	188	188	92	1			27
33	HKABN63	203957 4/26/99	pCMVSPORT 2.0	43	905	1	905	269	269	93	1	22	23	144
34	HKACP50	203957 4/26/99	pCMVSPORT 2.0	44	1987	466	1941	530	530	94	1			15
35	HKACX90	203957 4/26/99	pCMVSPORT 2.0	45	906	1	906		146	95	1			24
36	HKADP79	203957 4/26/99	pCMVSPORT 2.0	46	1442	78	1442	462	462	96	1	19	20	36
37	HKADT55	203957 4/26/99	pCMVSPORT 2.0	47	1228	1	1228	62	62	97	1	20	21	25
38	HKA EK58	203957 4/26/99	pCMVSPORT 2.0	48	2241	1	2241	320	320	98	1	22	23	29
39	HKA EK72	203957 4/26/99	pCMVSPORT 2.0	49	1577	1	1577	288	288	99	1	19	20	105

Gene No.	cDNA Clone ID	ATCC Deposit NO:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
40	HKAFF50	203957 4/26/99	pCMVSPORT 2.0	50	1801	1	1801	343	343	100	1	19	20	50
41	HKAJA95	203957 4/26/99	pCMVSPORT 2.0	51	1273	29	1273	73	73	101	1			11
42	HKAKU90	203957 4/26/99	pCMVSPORT 2.0	52	1468	1	1468	557	557	102	1	16	17	30
43	HKCSZ54	203957 4/26/99	pBluescript	53	1176	1	1176	33	33	103	1	26	27	38
44	HKFAA15	203957 4/26/99	ZAP Express	54	1779	1	1779	114	114	104	1	15	16	19
45	HKFBB08	203957 4/26/99	ZAP Express	55	1473	1	1473	142	142	105	1	29	30	30
46	HISBB66	203957 4/26/99	pSportl	56	2732	1309	2732	1536	1536	106	1	17	18	25
47	HJBDM36	203957 4/26/99	pBluescript SK-	57	2777	1716	2760	1954	1954	107	1	18	19	40
48	HJMAA03	203957 4/26/99	pCMVSPORT 3.0	58	665	1	665		527	108	1			9
49	HJMBB20	203957 4/26/99	pCMVSPORT 3.0	59	3021	1305	3021	1376	1376	109	1	25	26	36

Gene No.	cDNA Clone ID	ATCC Deposit NO.Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
50	HKADN26	203957 4/26/99	pCMVSPORT 2.0	60	558	206	558	335	335	110	1			14



Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA  
5 clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits  
10 contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq."  
15 and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is  
20 identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal  
25 peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

30 SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be

any of the polypeptide sequences disclosed in the sequence listing) are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID  
5 NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted  
10 proteins encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino  
15 acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide  
20 sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily  
25 be determined by sequencing the deposited clone in accordance with known methods. The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and  
30 determining its sequence.

The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed  
5 sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or  
10 species homologs of genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or a deposited clone, using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or  
15 the desired homologue.

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides  
20 are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification ,  
25 such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially  
30 purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40

(1988). Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the secreted protein.

The present invention provides a polynucleotide comprising, or alternatively  
5 consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or a cDNA contained in ATCC deposit Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide encoded by the cDNA contained in ATCC deposit Z. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide  
10 sequence of SEQ ID NO:Y and/or a polypeptide sequence encoded by the cDNA contained in ATCC deposit Z are also encompassed by the invention.

#### Signal Sequences

The present invention also encompasses mature forms of the polypeptide  
15 having the polypeptide sequence of SEQ ID NO:Y and/or the polypeptide sequence encoded by the cDNA in a deposited clone. Polynucleotides encoding the mature forms (such as, for example, the polynucleotide sequence in SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone) are also encompassed by the invention. According to the signal hypothesis, proteins secreted  
20 by mammalian cells have a signal or secretory leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated. Most mammalian cells and even insect cells cleave secreted proteins with the same specificity. However, in some cases, cleavage of a secreted protein is not entirely uniform, which results in two or more  
25 mature species of the protein. Further, it has long been known that cleavage specificity of a secreted protein is ultimately determined by the primary structure of the complete protein, that is, it is inherent in the amino acid sequence of the polypeptide.

Methods for predicting whether a protein has a signal sequence, as well as the  
30 cleavage point for that sequence, are available. For instance, the method of McGeoch, Virus Res. 3:271-286 (1985), uses the information from a short N-terminal

charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, *Nucleic Acids Res.* 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, *supra*.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., *Protein Engineering* 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. Nonetheless, the present invention provides the mature protein produced by expression of the polynucleotide sequence of SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited

clone, in a mammalian cell (e.g., COS cells, as described below). These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

5 **Polynucleotide and Polypeptide Variants**

The present invention is directed to variants of the polynucleotide sequence disclosed in SEQ ID NO:X, the complementary strand thereto, and/or the cDNA sequence contained in a deposited clone.

10 The present invention also encompasses variants of the polypeptide sequence disclosed in SEQ ID NO:Y and/or encoded by a deposited clone.

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

15 The present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for example, the nucleotide coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence contained in a deposited cDNA clone or the  
20 complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding the polypeptide encoded by the cDNA contained in a deposited clone, and/or polynucleotide fragments of any of these nucleic acid molecules (e.g., those fragments described herein).

Polynucleotides which hybridize to these nucleic acid molecules under stringent  
25 hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

The present invention is also directed to polypeptides which comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, for example, the polypeptide sequence  
30 shown in SEQ ID NO:Y, the polypeptide sequence encoded by the cDNA contained

in a deposited clone, and/or polypeptide fragments of any of these polypeptides (e.g., those fragments described herein).

By a nucleic acid having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention, it is intended  
5 that the nucleotide sequence of the nucleic acid is identical to the reference sequence except that the nucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a nucleic acid having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the  
10 reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragment specified as described herein.

15 As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a  
20 subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent  
25 identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

30 If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the

results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence



except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, an amino acid sequences shown in Table 1 (SEQ ID NO:Y) or to the amino acid sequence encoded by cDNA contained in a deposited clone can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are

not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred.

Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., *J. Biol. Chem.* 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., *J. Biotechnology* 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (*J. Biol. Chem* 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500

nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as to have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used.

(Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as, for example, an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which

comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and  
5 still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a peptide or polypeptide to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3,  
10 2 or 1 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

#### 15 **Polynucleotide and Polypeptide Fragments**

The present invention is also directed to polynucleotide fragments of the polynucleotides of the invention.

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence which: is a portion of that contained in  
20 a deposited clone, or encoding the polypeptide encoded by the cDNA in a deposited clone; is a portion of that shown in SEQ ID NO:X or the complementary strand thereto, or is a portion of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:Y. The nucleotide fragments of the invention are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt,  
25 and even more preferably, at least about 40 nt, at least about 50 nt, at least about 75 nt, or at least about 150 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in a deposited clone or the nucleotide sequence shown in SEQ ID NO:X. In this context "about" includes the particularly recited value, a value larger  
30 or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. These nucleotide fragments have uses that include, but are not limited to, as

diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of,  
5 a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850,  
10 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X, or the complementary strand thereto, or the cDNA contained in a deposited clone. In this context "about" includes the particularly recited ranges, and ranges larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More  
15 preferably, these polynucleotides can be used as probes or primers as discussed herein. Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

In the present invention, a "polypeptide fragment" refers to an amino acid  
20 sequence which is a portion of that contained in SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone. Protein (polypeptide) fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments  
25 comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges or values, and ranges or values larger or  
30 smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotides encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotides encoding these domains are also contemplated.

Other preferred polypeptide fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity. Polynucleotides encoding these polypeptide fragments are also encompassed by the invention.

Preferably, the polynucleotide fragments of the invention encode a polypeptide which demonstrates a functional activity. By a polypeptide demonstrating a "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) polypeptide of invention protein. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a



polypeptide of the invention for binding) to an antibody to the polypeptide of the invention], immunogenicity (ability to generate antibody which binds to a polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide of the invention.

5           The functional activity of polypeptides of the invention, and fragments, variants derivatives, and analogs thereof, can be assayed by various methods.

For example, in one embodiment where one is assaying for the ability to bind or compete with full-length polypeptide of the invention for binding to an antibody of the polypeptide of the invention, various immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

In another embodiment, where a ligand for a polypeptide of the invention identified, or the ability of a polypeptide fragment, variant or derivative of the invention to multimerize is being evaluated, binding can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel chromatography, protein affinity chromatography, and affinity blotting. See generally, Phizicky, E., et al., 1995, Microbiol. Rev. 59:94-123. In another embodiment, physiological correlates of binding of a polypeptide of the invention to its substrates (signal transduction) can be assayed.

In addition, assays described herein (see Examples) and otherwise known in the art may routinely be applied to measure the ability of polypeptides of the invention and fragments, variants derivatives and analogs thereof to elicit related biological activity related to that of the polypeptide of the invention (either in vitro or in vivo). Other methods will be known to the skilled artisan and are within the scope of the invention.

### Epitopes and Antibodies

The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide having an amino acid sequence of SEQ ID NO:Y, or an epitope of the polypeptide sequence encoded by a polynucleotide sequence contained in ATCC deposit No. Z or encoded by a polynucleotide that hybridizes to the complement of the sequence of SEQ ID NO:X or contained in ATCC deposit No. Z under stringent hybridization conditions or lower stringency hybridization conditions as defined supra. The present invention further encompasses polynucleotide sequences encoding an epitope of a polypeptide sequence of the invention (such as, for example, the sequence disclosed in SEQ ID NO:X), polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize to the complementary strand under stringent hybridization conditions or lower stringency hybridization conditions defined supra.

The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide encoding this polypeptide. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies described infra. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998- 4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as

determined by any method well known in the art, for example, by the immunoassays described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross-reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

5           Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985), further described in U.S. Patent No. 4,631,211).

          In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10,  
10   at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes  
15   include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in  
20   immunoassays. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe et al., Science 219:660-666 (1983)).

          Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow et al., Proc. Natl. Acad. Sci. USA 82:910-  
25   914; and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985)). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immunogenic epitopes may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to  
30   an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a

carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

Epitope-bearing polypeptides of the present invention may be used to induce  
5 antibodies according to methods well known in the art including, but not limited to, in vivo immunization, in vitro immunization, and phage display methods. See, e.g., Sutcliffe et al., supra; Wilson et al., supra, and Bittle et al., J. Gen. Virol., 66:2347-2354 (1985). If in vivo immunization is used, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide  
10 to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a carrier using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with  
15 either free or carrier- coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 µg of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which  
20 can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

25 As one of skill in the art will appreciate, and as discussed above, the polypeptides of the present invention comprising an immunogenic or antigenic epitope can be fused to other polypeptide sequences. For example, the polypeptides of the present invention may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination  
30 thereof and portions thereof) resulting in chimeric polypeptides. Such fusion proteins may facilitate purification and may increase half-life in vivo. This has been shown

for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., *Nature*, 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO 96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion disulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., *J. Biochem.*, 270:3958-3964 (1995). Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991, *Proc. Natl. Acad. Sci. USA* 88:8972- 897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni<sup>2+</sup>-nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers.

Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to modulate the activities of polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., *Curr. Opinion Biotechnol.* 8:724-33 (1997); Harayama, *Trends Biotechnol.* 16(2):76-82 (1998); Hansson, et al., *J. Mol. Biol.* 287:265-76 (1999); and Lorenzo and Blasco, *Biotechniques* 24(2):308- 13

(1998) (each of these patents and publications are hereby incorporated by reference in its entirety). In one embodiment, alteration of polynucleotides corresponding to SEQ ID NO:X and the polypeptides encoded by these polynucleotides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA  
5 segments by homologous or site-specific recombination to generate variation in the polynucleotide sequence. In another embodiment, polynucleotides of the invention, or the encoded polypeptides, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections,  
10 parts, domains, fragments, etc., of a polynucleotide encoding a polypeptide of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

#### Antibodies

15 Further polypeptides of the invention relate to antibodies and T-cell antigen receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of SEQ ID NO:Y, and/or an epitope, of the present invention (as determined by immunoassays well known in the art for assaying specific antibody-antigen binding). Antibodies of the invention include, but are not limited to,  
20 polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules  
25 and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule.  
30 Most preferably the antibodies are human antigen-binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab')<sub>2</sub>, Fd,

single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, ship rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described infra and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati et al.

The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol. 147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, by size in contiguous amino acid residues, or listed in the Tables and Figures. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be excluded. Therefore, the present invention includes antibodies that specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

Antibodies of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a polypeptide of the present invention are included. Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity to a polypeptide of the invention. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, or  $10^{-15}$  M.

The invention also provides antibodies that competitively inhibit binding of an antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described herein. In preferred embodiments, the antibody competitively inhibits binding to the



epitope by at least 95%, at least 90%, at least 85 %, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

Antibodies of the present invention may act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes  
5 antibodies which disrupt the receptor/ligand interactions with the polypeptides of the invention either partially or fully. Preferably, antibodies of the present invention bind an antigenic epitope disclosed herein, or a portion thereof. The invention features both receptor-specific antibodies and ligand-specific antibodies. The invention also features receptor-specific antibodies which do not prevent ligand  
10 binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described  
15 supra). In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.

The invention also features receptor-specific antibodies which both prevent  
20 ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the receptor, as well as antibodies which bind the ligand, thereby preventing receptor activation, but  
25 do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which activate the receptor. These antibodies may act as receptor agonists, i.e., potentiate or activate either all or a subset of the biological activities of the ligand-mediated receptor activation, for example, by inducing dimerization of the receptor. The antibodies may be specified as agonists, antagonists or inverse agonists  
30 for biological activities comprising the specific biological activities of the peptides of the invention disclosed herein. The above antibody agonists can be made using

methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Patent No. 5,811,097; Deng et al., *Blood* 92(6):1981-1988 (1998); Chen et al., *Cancer Res.* 58(16):3668-3678 (1998); Harrop et al., *J. Immunol.* 161(4):1786-1794 (1998); Zhu et al., *Cancer Res.* 58(15):3209-3214 (1998); Yoon et al., *J. Immunol.* 160(7):3170-3179 (1998); Prat et al., *J. Cell. Sci.* 111(Pt2):237-247 (1998); Pitard et al., *J. Immunol. Methods* 205(2):177-190 (1997); Liautard et al., *Cytokine* 9(4):233-241 (1997); Carlson et al., *J. Biol. Chem.* 272(17):11295-11301 (1997); Taryman et al., *Neuron* 14(4):755-762 (1995); Muller et al., *Structure* 6(9):1153-1167 (1998); Bartunek et al., *Cytokine* 8(1):14-20 (1996) (which are all incorporated by reference herein in their entireties).

Antibodies of the present invention may be used, for example, but not limited to, to purify, detect, and target the polypeptides of the present invention, including both in vitro and in vivo diagnostic and therapeutic methods. For example, the antibodies have use in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See, e.g., Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988) (incorporated by reference herein in its entirety).

As discussed in more detail below, the antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438; WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387.

The antibodies of the invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation,

phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, 5 metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of-interest can be produced by various procedures well known in the art. For example, a polypeptide of 10 the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum 15 hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

Monoclonal antibodies can be prepared using a wide variety of techniques 20 known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and* 25 *T-Cell Hybridomas* 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it 30 is produced.

Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art and are discussed in detail in the Examples (e.g., Example 16). In a non-limiting example, mice can be immunized with a polypeptide of the invention or a cell expressing such peptide. Once an  
5 immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC. Hybridomas are selected and cloned by limited dilution. The hybridoma clones are then assayed by  
10 methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.

Accordingly, the present invention provides methods of generating monoclonal antibodies as well as antibodies produced by the method comprising  
15 culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from a mouse immunized with an antigen of the invention with myeloma cells and then screening the hybridomas resulting from the fusion for hybridoma clones that secrete an antibody able to bind a polypeptide of the invention.

20 Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')<sub>2</sub> fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments). F(ab')<sub>2</sub> fragments contain the variable region, the light chain constant region and the  
25 CH1 domain of the heavy chain.

For example, the antibodies of the present invention can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such  
30 phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an

antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or

5 disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., J. Immunol. Methods 182:41-50 (1995); Ames et al., J. Immunol. Methods 184:177-186 (1995); Kettleborough et al., Eur. J. Immunol. 24:952-958 (1994); Persic

10 et al., Gene 187 9-18 (1997); Burton et al., Advances in Immunology 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225;

15 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and

20 expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')<sub>2</sub> fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., BioTechniques 12(6):864-869 (1992); and Sawai et al., AJRI 34:26-

25 34 (1995); and Better et al., Science 240:1041-1043 (1988) (said references incorporated by reference in their entireties).

Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston et al., Methods in Enzymology 203:46-88 (1991); Shu et al., PNAS 90:7995-7999

30 (1993); and Skerra et al., Science 240:1038-1040 (1988). For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable

to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Methods for producing  
5 chimeric antibodies are known in the art. See e.g., Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Gillies et al., (1989) J. Immunol. Methods 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen  
10 having one or more complementarity determining regions (CDRs) from the non-human species and a framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well  
15 known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entireties.) Antibodies can be  
20 humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994)),  
25 and chain shuffling (U.S. Patent No. 5,565,332).

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos.  
30 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO

98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.

Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can  
5 express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the human variable region, constant region, and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes.  
10 The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce  
15 chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human  
20 immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, Int. Rev. Immunol. 13:65-93 (1995). For a  
25 detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are  
30 incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to

provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a  
5 selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., Bio/technology 12:899-903 (1988)).

Further, antibodies to the polypeptides of the invention can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" polypeptides of the invention using  
10 techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, FASEB J. 7(5):437-444; (1989) and Nissinoff, J. Immunol. 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide multimerization and/or binding of a polypeptide of the invention to a ligand can be used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or  
15 binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand. For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligands/receptors, and thereby block its biological activity.

20

#### Polynucleotides Encoding Antibodies

The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody of the invention and fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or lower  
25 stringency hybridization conditions, e.g., as defined supra, to polynucleotides that encode an antibody, preferably, that specifically binds to a polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO:Y.

The polynucleotides may be obtained, and the nucleotide sequence of the  
30 polynucleotides determined, by any method known in the art. For example, if the nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody



may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., *BioTechniques* 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then  
5 amplification of the ligated oligonucleotides by PCR.

Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized  
10 or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe  
15 specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

Once the nucleotide sequence and corresponding amino acid sequence of the  
20 antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor,  
25 NY and Ausubel et al., eds., 1998, *Current Protocols in Molecular Biology*, John Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

In a specific embodiment, the amino acid sequence of the heavy and/or light  
30 chain variable domains may be inspected to identify the sequences of the complementarity determining regions (CDRs) by methods that are well known in the

art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA techniques, one or more of the CDRs may be inserted within framework regions, e.g., into human framework regions to humanize a non-  
5 human antibody, as described supra. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., *J. Mol. Biol.* 278: 457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds a  
10 polypeptide of the invention. Preferably, as discussed supra, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to  
15 generate antibody molecules lacking one or more intrachain disulfide bonds. Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., *Proc. Natl. Acad. Sci.* 81:851-855 (1984); Neuberger et al., *Nature* 20 312:604-608 (1984); Takeda et al., *Nature* 314:452-454 (1985)) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described supra, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived  
25 from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, *Science* 242:423-42 (1988); Huston et al., *Proc. Natl. Acad. Sci. USA* 85:5879-5883 (1988); and Ward et al., *Nature* 30 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region

via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in *E. coli* may also be used (Skerra et al., Science 242:1038- 1041 (1988)).

## 5 Methods of Producing Antibodies

The antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

Recombinant expression of an antibody of the invention, or fragment,  
10 derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the invention or a single chain antibody of the invention), requires construction of an expression vector containing a polynucleotide that encodes the antibody. Once a polynucleotide encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof (preferably containing the heavy or light chain variable  
15 domain), of the invention has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be  
20 used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention, or a heavy or  
25 light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy or  
30 light chain.

The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody of the invention. Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain thereof, or a single chain antibody of the invention, operably linked to a heterologous promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.

A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule of the invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as *Escherichia coli*, and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene

promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., Gene 45:101 (1986); Cockett et al., Bio/Technology 8:2 (1990)).

In bacterial systems, a number of expression vectors may be advantageously  
5 selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody molecule, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the E. coli expression  
10 vector pUR278 (Ruther et al., EMBO J. 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, Nucleic Acids Res. 13:3101-3109 (1985); Van Heeke & Schuster, J. Biol. Chem. 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign  
15 polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the  
20 GST moiety.

In an insect system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in  
*Spodoptera frugiperda* cells. The antibody coding sequence may be cloned  
individually into non-essential regions (for example the polyhedrin gene) of the virus  
25 and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation  
30 control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo

recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al., Methods in Enzymol. 153:51-544 (1987)).

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERY, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell line such as, for example, CRL7030 and Hs578Bst.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences,

transcription terminators, polyadenylation sites, etc.), and a selectable marker.

Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media.

The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.

- 10 A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817 (1980)) genes can be employed in tk-, hgp<sup>r</sup>t- or ap<sup>r</sup>t- cells, respectively.
- 15 Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA 77:357 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA 78:1527 (1981)); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-
- 20 418 Clinical Pharmacy 12:488-505; Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, 1993, TIB TECH 11(5):155-215; and hyg<sup>r</sup>, which confers resistance to hygromycin (Santerre et al., Gene 30:147 (1984)). Methods commonly known in
- 25 the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), Current Protocols in
- 30 Human Genetics, John Wiley & Sons, NY (1994); Colberre-Garapin et al., J. Mol. Biol. 150:1 (1981), which are incorporated by reference herein in their entireties.

The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector  
5 system expressing antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse et al., Mol. Cell. Biol. 3:257 (1983)).

The host cell may be co-transfected with two expression vectors of the  
10 invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations,  
15 the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, Nature 322:52 (1986); Kohler, Proc. Natl. Acad. Sci. USA 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

Once an antibody molecule of the invention has been produced by an animal,  
20 chemically synthesized, or recombinantly expressed, it may be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the  
25 purification of proteins. In addition, the antibodies of the present invention or fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations)  
30 to a polypeptide (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion



proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention. For example, antibodies may be used to target the polypeptides of the present invention to particular cell types, either in vitro or in vivo, by fusing or conjugating the polypeptides of the present invention to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g., Harbor et al., supra, and PCT publication WO 93/21232; EP 439,095; Naramura et al., Immunol. Lett. 39:91-99 (1994); U.S. Patent 5,474,981; Gillies et al., PNAS 89:1428-1432 (1992); Fell et al., J. Immunol. 146:2446-2452(1991), which are incorporated by reference in their entirety.

The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the constant region, hinge region, CH1 domain, CH2 domain, and CH3 domain or any combination of whole domains or portions thereof. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See, e.g., U.S. Patent Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88:10535-10539 (1991); Zheng et al., J. Immunol. 154:5590-5600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337-11341(1992) (said references incorporated by reference in their entirety).

As discussed, supra, the polypeptides corresponding to a polypeptide, polypeptide fragment, or a variant of SEQ ID NO:Y may be fused or conjugated to the above antibody portions to increase the in vivo half life of the polypeptides or for use in immunoassays using methods known in the art. Further, the polypeptides

5 corresponding to SEQ ID NO:Y may be fused or conjugated to the above antibody portions to facilitate purification. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP 394,827; Traunecker et al., Nature 331:84-86 (1988). The

10 polypeptides of the present invention fused or conjugated to an antibody having disulfide- linked dimeric structures (due to the IgG) may also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995)). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and

15 thus can result in, for example, improved pharmacokinetic properties. (EP A 232,262). Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have

20 been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, Bennett et al., J. Molecular Recognition 8:52-58 (1995); Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).

Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred

25 embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags

30 useful for purification include, but are not limited to, the "HA" tag, which

corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., Cell 37:767 (1984)) and the "flag" tag.

- The present invention further encompasses antibodies or fragments thereof conjugated to a diagnostic or therapeutic agent. The antibodies can be used
- 5 diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent
- 10 materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody (or fragment thereof) or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Patent No.
- 15 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone,
- 20 fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{111}\text{In}$  or  $^{99}\text{Tc}$ .
- 25 Further, an antibody or fragment thereof may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytocidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example,  $^{213}\text{Bi}$ . A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin,
- 30 etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-

dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor,  $\alpha$ -interferon,  $\beta$ -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF- $\alpha$ , TNF- $\beta$ , AIM I (See, International Publication No. WO 97/33899), AIM II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi *et al.*, *Int. Immunol.*, 6:1567-1574 (1994)), VEGI (See, International Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g., Arnon *et al.*, "Monoclonal Antibodies For Immunotargeting Of

- Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in *Monoclonal Antibodies For Cancer Detection And Therapy*, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", *Immunol. Rev.* 62:119-58 (1982).

Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is incorporated herein by reference in its entirety.

- 15        An antibody, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can be used as a therapeutic.

#### Immunophenotyping

- 20        The antibodies of the invention may be utilized for immunophenotyping of cell lines and biological samples. The translation product of the gene of the present invention may be useful as a cell specific marker, or more specifically as a cellular marker that is differentially expressed at various stages of differentiation and/or maturation of particular cell types. Monoclonal antibodies directed against a specific epitope, or combination of epitopes, will allow for the screening of cellular populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and include magnetic separation using antibody-coated magnetic beads, "panning" with antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Patent 5,985,660; and Morrison *et al.*, *Cell*, 96:737-49 (1999)).

These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

#### Assays For Antibody Binding

The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% Trasylol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C, adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 4° C, washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the

binding of the antibody to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding immunoprecipitation protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.

- 5 Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking  
10 the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or  
15 alkaline phosphatase) or radioactive molecule (e.g.,  $^{32}\text{P}$  or  $^{125}\text{I}$ ) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York  
20 at 10.8.1.

- ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline  
25 phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be  
30 coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the

coated well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc.,  
5 New York at 11.2.1.

The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g., <sup>3</sup>H or <sup>125</sup>I) with the antibody of interest in the  
10 presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of  
15 interest conjugated to a labeled compound (e.g., <sup>3</sup>H or <sup>125</sup>I) in the presence of increasing amounts of an unlabeled second antibody.

#### Therapeutic Uses

The present invention is further directed to antibody-based therapies which  
20 involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the  
25 invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any one or more of the diseases, disorders, or conditions described herein. The treatment  
30 and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not



limited to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may  
5 be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the  
10 antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which  
15 serve to increase the number or activity of effector cells which interact with the antibodies.

The antibodies of the invention may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of  
20 products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment, human antibodies, fragments derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or  
25 neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides of the invention,  
30 including fragments thereof. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$

M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, and  $10^{-15}$  M.

5           Gene Therapy

In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives thereof, are administered to treat, inhibit or prevent a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy  
10 performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

15 For general reviews of the methods of gene therapy, see Goldspiel et al., Clinical Pharmacy 12:488-505 (1993); Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, TIBTECH 11(5):155-215 (1993). Methods commonly known in the art  
20 of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); and Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990).

In a preferred aspect, the compound comprises nucleic acid sequences  
25 encoding an antibody, said nucleic acid sequences being part of expression vectors that express the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acid sequences have promoters operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue- specific. In another particular embodiment,  
30 nucleic acid molecules are used in which the antibody coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a

desired site in the genome, thus providing for intrachromosomal expression of the antibody encoding nucleic acids (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989). In specific embodiments, the expressed antibody molecule is a single chain antibody;

- 5 alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments thereof, of the antibody.

Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid- carrying vectors, or indirect, in which case, cells are first transformed with the nucleic acids in vitro, then  
10 transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

In a specific embodiment, the nucleic acid sequences are directly administered in vivo, where it is expressed to produce the encoded product. This can be accomplished by any of numerous methods known in the art, e.g., by constructing  
15 them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting  
20 agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, nucleic  
25 acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO  
30 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination

(Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989)).

In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can be used (see Miller et al., Meth. Enzymol. 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al., Biotherapy 6:291-302 (1994), which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., J. Clin. Invest. 93:644-651 (1994); Kiem et al., Blood 83:1467-1473 (1994); Salmons and Gunzberg, Human Gene Therapy 4:129-141 (1993); and Grossman and Wilson, Curr. Opin. in Genetics and Devel. 3:110-114 (1993).

Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, Current Opinion in Genetics and Development 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., Human Gene Therapy 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., Science 252:431-434 (1991); Rosenfeld et al., Cell 68:143-155 (1992); Mastrangeli et al., J. Clin. Invest. 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., Gene Therapy 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., Proc. Soc. Exp. Biol. Med. 204:289-300 (1993); U.S. Patent No. 5,436,146).

Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

10 In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, Meth. Enzymol. 217:599-618 (1993); Cohen et al., Meth. Enzymol. 217:618-644 (1993); Cline, Pharmac. Ther. 29:69-92m (1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.

Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes;

blood cells such as Tlymphocytes, Blymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

5           In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

          In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then  
10       administered in vivo for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and  
15       Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

          In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription. Demonstration of Therapeutic or  
20       Prophylactic Activity

          The compounds or pharmaceutical compositions of the invention are preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays to demonstrate the therapeutic or prophylactic utility of a compound or pharmaceutical composition  
25       include, the effect of a compound on a cell line or a patient tissue sample. The effect of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, in vitro assays which can be used to determine whether administration of a  
30       specific compound is indicated, include in vitro cell culture assays in which a patient

tissue sample is grown in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

#### Therapeutic/Prophylactic Administration and Composition

5           The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of a compound or pharmaceutical composition of the invention, preferably an antibody of the invention. In a preferred aspect, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is  
10           preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

            Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from  
15           among those described herein below.

            Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)),  
20           construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g.,  
25           oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be  
30           facilitated by an intraventricular catheter, for example, attached to a reservoir, such

as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compounds or compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*)

In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., *Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J. Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in *Medical Applications of Controlled Release*, *supra*, vol. 2, pp. 115-138 (1984)).



Other controlled release systems are discussed in the review by Langer (Science 249:1527-1533 (1990)).

In a specific embodiment where the compound of the invention is a nucleic acid encoding a protein, the nucleic acid can be administered in vivo to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox-like peptide which is known to enter the nucleus (see e.g., Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a compound, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion,

tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium  
5 saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation  
10 should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the  
15 composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the  
20 composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The compounds of the invention can be formulated as neutral or salt forms.  
25 Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

30 The amount of the compound of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant

expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.

For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. Diagnosis and Imaging

Labeled antibodies, and derivatives and analogs thereof, which specifically bind to a polypeptide of interest can be used for diagnostic purposes to detect, diagnose, or monitor diseases, disorders, and/or conditions associated with the aberrant expression and/or activity of a polypeptide of the invention. The invention provides for the detection of aberrant expression of a polypeptide of interest, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest

and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of aberrant expression.

The invention provides a diagnostic assay for diagnosing a disorder,  
5 comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a particular disorder. With  
10 respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier  
15 thereby preventing the development or further progression of the cancer.

Antibodies of the invention can be used to assay protein levels in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting  
20 protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99}\text{Tc}$ ); luminescent labels, such as luminol; and  
25 fluorescent labels, such as fluorescein and rhodamine, and biotin.

One aspect of the invention is the detection and diagnosis of a disease or disorder associated with aberrant expression of a polypeptide of interest in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or  
30 intraperitoneally) to a subject an effective amount of a labeled molecule which specifically binds to the polypeptide of interest; b) waiting for a time interval

following the administering for permitting the labeled molecule to preferentially concentrate at sites in the subject where the polypeptide is expressed (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that  
5 detection of labeled molecule above the background level indicates that the subject has a particular disease or disorder associated with aberrant expression of the polypeptide of interest. Background level can be determined by various methods including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

10 It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of <sup>99m</sup>Tc. The labeled antibody or antibody fragment will then preferentially  
15 accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).

20 Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5  
25 to 20 days or 5 to 10 days.

In an embodiment, monitoring of the disease or disorder is carried out by repeating the method for diagnosing the disease or disease, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

30 Presence of the labeled molecule can be detected in the patient using methods known in the art for in vivo scanning. These methods depend upon the type of label

used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patient using positron emission-tomography. In yet another embodiment, the molecule is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MRI). Kits

The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified antibody, in one or more containers. In a specific embodiment, the kits of the present invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope which is specifically immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a

kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine which can be detected by flow cytometry). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized polypeptide antigen. The polypeptide antigen of the kit may also be attached to a solid support.

In a more specific embodiment the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the polypeptide antigen can be detected by binding of the said reporter-labeled antibody.

In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The diagnostic kit includes a substantially isolated antibody specifically immunoreactive with polypeptide or polynucleotide antigens, and means for detecting the binding of the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate (Sigma, St. Louis, MO).

The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip

sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group.

- 5 Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface-bound recombinant antigens, and a reporter-labeled anti-human antibody for detecting  
10 surface-bound anti-antigen antibody.

### **Fusion Proteins**

Any polypeptide of the present invention can be used to generate fusion  
15 proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present  
20 invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

25 Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the  
30 polypeptide to facilitate purification. Such regions may be removed prior to final



preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgA, IgE, IgG, IgM) or portions thereof (CH1, CH2, CH3, and any combination thereof, including both entire domains and portions thereof), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., *Nature* 331:84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., *J. Biochem.* 15 270:3958-3964 (1995).)

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, 20 D. Bennett et al., *J. Molecular Recognition* 8:52-58 (1995); K. Johanson et al., *J. Biol. Chem.* 270:9459-9471 (1995).) 25

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, 30

Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope  
5 derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

#### 10 **Vectors, Host Cells, and Protein Production**

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In  
15 the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the  
20 vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to  
25 name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or  
30 UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells (e.g., *Saccharomyces cerevisiae* or *Pichia pastoris* (ATCC Accession No. 201178)); insect cells such as *Drosophila* S2 and *Spodoptera Sf9* cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Preferred expression vectors for use in yeast systems include, but are not limited to pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalph, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, pPIC9K, and PAO815 (all available from Invitrogen, Carlsbad, CA). Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., *Basic Methods In Molecular Biology* (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography,

phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

5 Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant,  
10 insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine  
15 encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

20 In one embodiment, the yeast *Pichia pastoris* is used to express the polypeptide of the present invention in a eukaryotic system. *Pichia pastoris* is a methylotrophic yeast which can metabolize methanol as its sole carbon source. A main step in the methanol metabolization pathway is the oxidation of methanol to formaldehyde using O<sub>2</sub>. This reaction is catalyzed by the enzyme alcohol oxidase. In  
25 order to metabolize methanol as its sole carbon source, *Pichia pastoris* must generate high levels of alcohol oxidase due, in part, to the relatively low affinity of alcohol oxidase for O<sub>2</sub>. Consequently, in a growth medium depending on methanol as a main carbon source, the promoter region of one of the two alcohol oxidase genes (*AOX1*) is highly active. In the presence of methanol, alcohol oxidase produced from the *AOX1*  
30 gene comprises up to approximately 30% of the total soluble protein in *Pichia*

*pastoris*. See, Ellis, S.B., *et al.*, *Mol. Cell. Biol.* 5:1111-21 (1985); Koutz, P.J., *et al.*, *Yeast* 5:167-77 (1989); Tschopp, J.F., *et al.*, *Nucl. Acids Res.* 15:3859-76 (1987).

Thus, a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, under the transcriptional regulation of all or part of the *AOX1* regulatory sequence is expressed at exceptionally high levels in *Pichia* yeast grown in the presence of methanol.

In one example, the plasmid vector pPIC9K is used to express DNA encoding a polypeptide of the invention, as set forth herein, in a *Pichea* yeast system essentially as described in "*Pichia* Protocols: Methods in Molecular Biology," D.R. Higgins and J. Cregg, eds. The Humana Press, Totowa, NJ, 1998. This expression vector allows expression and secretion of a protein of the invention by virtue of the strong *AOX1* promoter linked to the *Pichia pastoris* alkaline phosphatase (PHO) secretory signal peptide (i.e., leader) located upstream of a multiple cloning site.

Many other yeast vectors could be used in place of pPIC9K, such as, pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalpha, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, and PAO815, as one skilled in the art would readily appreciate, as long as the proposed expression construct provides appropriately located signals for transcription, translation, secretion (if desired), and the like, including an in-frame AUG as required.

In another embodiment, high-level expression of a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, may be achieved by cloning the heterologous polynucleotide of the invention into an expression vector such as, for example, pGAPZ or pGAPZalpha, and growing the yeast culture in the absence of methanol.

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with the polynucleotides of the invention, and

which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination, resulting in the formation of a new transcription unit

5 (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; U.S. Patent No. 5,733,761, issued March 31, 1998; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA* 86:8932-8935 (1989); and Zijlstra et al., *Nature* 342:435-438 (1989), the disclosures of each of

10 which are incorporated by reference in their entireties).

In addition, polypeptides of the invention can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, *Proteins: Structures and Molecular Principles*, W.H. Freeman & Co., N.Y., and Hunkapiller et al., *Nature*, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a

15 polypeptide sequence of the invention can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid,  $\alpha$ -amino isobutyric acid, 4-

20 aminobutyric acid, Abu, 2-amino butyric acid,  $\gamma$ -Abu,  $\epsilon$ -Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine,  $\beta$ -alanine, fluoro-amino acids, designer amino acids such as  $\beta$ -methyl amino acids, Ca-methyl amino

25 acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

The invention encompasses polypeptides which are differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage,

30 linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not

limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease,  $\text{NaBH}_4$ ; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

Additional post-translational modifications encompassed by the invention include, for example, e.g., N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of procaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

Also provided by the invention are chemically modified derivatives of the polypeptides of the invention which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent NO: 4,179,337). The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).

The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic

domains of the protein. There are a number of attachment methods available to those skilled in the art, e.g., EP 0 401 384, herein incorporated by reference (coupling PEG to G-CSF), see also Malik et al., Exp. Hematol. 20:1028-1035 (1992) (reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

The polypeptides of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to monomers and multimers of the polypeptides of the invention, their



preparation, and compositions (preferably, *Therapeutics*) containing them. In specific embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

5           Multimers encompassed by the invention may be homomers or heteromers. As used herein, the term homomer, refers to a multimer containing only polypeptides corresponding to the amino acid sequence of SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone (including fragments, variants, splice variants, and fusion proteins, corresponding to these polypeptides as described herein). These  
10   homomers may contain polypeptides having identical or different amino acid sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another specific embodiment, a homomer of the invention is a multimer containing polypeptides having different amino acid sequences. In specific embodiments, the  
15   multimer of the invention is a homodimer (*e.g.*, containing polypeptides having identical or different amino acid sequences) or a homotrimer (*e.g.*, containing polypeptides having identical and/or different amino acid sequences). In additional embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

20           As used herein, the term heteromer refers to a multimer containing one or more heterologous polypeptides (*i.e.*, polypeptides of different proteins) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional  
25   embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

          Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked, by for example, liposome formation. Thus, in one embodiment, multimers of the invention, such as, for example, homodimers or homotrimers, are formed when polypeptides of the  
30   invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed

when polypeptides of the invention contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the invention are formed by covalent associations with and/or between the polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence (e.g., that recited in the sequence listing, or contained in the polypeptide encoded by a deposited clone). In one instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the heterologous polypeptide sequence in a fusion protein of the invention.

In one example, covalent associations are between the heterologous sequence contained in a fusion protein of the invention (see, e.g., US Patent Number 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in an Fc fusion protein of the invention (as described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another protein that is capable of forming covalently associated multimers, such as for example, osteoprotegerin (see, e.g., International Publication NO: WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627 (hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional recombinant DNA technology.

Another method for preparing multimer polypeptides of the invention involves use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine

zippers were originally identified in several DNA-binding proteins (Landschulz et al., Science 240:1759, (1988)), and have since been found in a variety of different proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains  
5 suitable for producing soluble multimeric proteins of the invention are those described in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture  
10 supernatant using techniques known in the art.

Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (FEBS Letters 344:191,  
15 (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by reference. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention.

In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention  
20 containing Flag® polypeptide sequence. In a further embodiment, associations proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-Flag® antibody.

The multimers of the invention may be generated using chemical techniques  
25 known in the art. For example, polypeptides desired to be contained in the multimers of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, multimers of the invention may be generated using techniques known in  
30 the art to form one or more inter-molecule cross-links between the cysteine residues located within the sequence of the polypeptides desired to be contained in the

multimer (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Further, polypeptides of the invention may be routinely modified by the addition of cysteine or biotin to the C terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers  
5 containing one or more of these modified polypeptides (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the multimer of the invention (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its  
10 entirety).

Alternatively, multimers of the invention may be generated using genetic engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., US Patent  
15 Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic polynucleotide encoding the translated product of the polypeptide in the reverse  
20 orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In another embodiment, recombinant techniques described herein or otherwise known in the art are applied to generate recombinant polypeptides of the invention which contain a transmembrane domain (or hydrophobic or signal  
25 peptide) and which can be incorporated by membrane reconstitution techniques into liposomes (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

#### **Uses of the Polynucleotides**

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

The polynucleotides of the present invention are useful for chromosome  
5 identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers  
10 (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an  
15 amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping  
20 strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread.  
25 This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to  
30 mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides

correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

Once a polynucleotide has been mapped to a precise chromosomal location,  
5 the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and  
10 one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined. First, visible structural alterations in the chromosomes, such as deletions or  
15 translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish  
20 the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression,  
25 chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

Thus, the invention also provides a diagnostic method useful during diagnosis of a disorder, involving measuring the expression level of polynucleotides of the present invention in cells or body fluid from an individual and comparing the  
30 measured gene expression level with a standard level of polynucleotide expression

level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a disorder.

In still another embodiment, the invention includes a kit for analyzing samples for the presence of proliferative and/or cancerous polynucleotides derived from a test  
5 subject. In a general embodiment, the kit includes at least one polynucleotide probe containing a nucleotide sequence that will specifically hybridize with a polynucleotide of the present invention and a suitable container. In a specific embodiment, the kit includes two polynucleotide probes defining an internal region of the polynucleotide of the present invention, where each probe has one strand  
10 containing a 31' mer-end internal to the region. In a further embodiment, the probes may be useful as primers for polymerase chain reaction amplification.

Where a diagnosis of a disorder, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed polynucleotide of the present  
15 invention expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

By "measuring the expression level of polynucleotide of the present invention" is intended qualitatively or quantitatively measuring or estimating the level of the polypeptide of the present invention or the level of the mRNA encoding the  
20 polypeptide in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the polypeptide level or mRNA level in a second biological sample). Preferably, the polypeptide level or mRNA level in the first biological sample is measured or estimated and compared to a standard polypeptide level or mRNA level, the standard  
25 being taken from a second biological sample obtained from an individual not having the disorder or being determined by averaging levels from a population of individuals not having a disorder. As will be appreciated in the art, once a standard polypeptide level or mRNA level is known, it can be used repeatedly as a standard for comparison.

30 By "biological sample" is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains the

polypeptide of the present invention or mRNA. As indicated, biological samples include body fluids (such as semen, lymph, sera, plasma, urine, synovial fluid and spinal fluid) which contain the polypeptide of the present invention, and other tissue sources found to express the polypeptide of the present invention. Methods for  
5 obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

The method(s) provided above may preferably be applied in a diagnostic method and/or kits in which polynucleotides and/or polypeptides are attached to a  
10 solid support. In one exemplary method, the support may be a "gene chip" or a "biological chip" as described in US Patents 5,837,832, 5,874,219, and 5,856,174. Further, such a gene chip with polynucleotides of the present invention attached may be used to identify polymorphisms between the polynucleotide sequences, with polynucleotides isolated from a test subject. The knowledge of such polymorphisms  
15 (i.e. their location, as well as, their existence) would be beneficial in identifying disease loci for many disorders, including cancerous diseases and conditions. Such a method is described in US Patents 5,858,659 and 5,856,104. The US Patents referenced supra are hereby incorporated by reference in their entirety herein.

The present invention encompasses polynucleotides of the present invention  
20 that are chemically synthesized, or reproduced as peptide nucleic acids (PNA), or according to other methods known in the art. The use of PNAs would serve as the preferred form if the polynucleotides are incorporated onto a solid support, or gene chip. For the purposes of the present invention, a peptide nucleic acid (PNA) is a polyamide type of DNA analog and the monomeric units for adenine, guanine,  
25 thymine and cytosine are available commercially (Perceptive Biosystems). Certain components of DNA, such as phosphorus, phosphorus oxides, or deoxyribose derivatives, are not present in PNAs. As disclosed by P. E. Nielsen, M. Egholm, R. H. Berg and O. Buchardt, Science 254, 1497 (1991); and M. Egholm, O. Buchardt, L. Christensen, C. Behrens, S. M. Freier, D. A. Driver, R. H. Berg, S. K. Kim, B.  
30 Norden, and P. E. Nielsen, Nature 365, 666 (1993), PNAs bind specifically and tightly to complementary DNA strands and are not degraded by nucleases. In fact,



PNA binds more strongly to DNA than DNA itself does. This is probably because there is no electrostatic repulsion between the two strands, and also the polyamide backbone is more flexible. Because of this, PNA/DNA duplexes bind under a wider range of stringency conditions than DNA/DNA duplexes, making it easier to perform  
5 multiplex hybridization. Smaller probes can be used than with DNA due to the strong binding. In addition, it is more likely that single base mismatches can be determined with PNA/DNA hybridization because a single mismatch in a PNA/DNA 15-mer lowers the melting point ( $T_{sub.m}$ ) by 8°-20° C, vs. 4°-16° C for the DNA/DNA 15-mer duplex. Also, the absence of charge groups in PNA means that hybridization can  
10 be done at low ionic strengths and reduce possible interference by salt during the analysis.

The present invention is useful for detecting cancer in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias which include, but are not limited to: acute myelogenous leukemias including acute  
15 monocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute erythroleukemia, acute megakaryocytic leukemia, and acute undifferentiated leukemia, etc.; and chronic myelogenous leukemias including chronic myelomonocytic leukemia, chronic granulocytic leukemia, etc. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs,  
20 horses, rabbits and humans. Particularly preferred are humans.

Pathological cell proliferative diseases, disorders, and/or conditions are often associated with inappropriate activation of proto-oncogenes. (Germann, E. P. et al., "The Etiology of Acute Leukemia: Molecular Genetics and Viral Oncology," in Neoplastic Diseases of the Blood, Vol 1., Wiernik, P. H. et al. eds., 161-182 (1985)).  
25 Neoplasias are now believed to result from the qualitative alteration of a normal cellular gene product, or from the quantitative modification of gene expression by insertion into the chromosome of a viral sequence, by chromosomal translocation of a gene to a more actively transcribed region, or by some other mechanism. (Germann et al., supra) It is likely that mutated or altered expression of specific genes is  
30 involved in the pathogenesis of some leukemias, among other tissues and cell types. (Germann et al., supra) Indeed, the human counterparts of the oncogenes involved in

some animal neoplasias have been amplified or translocated in some cases of human leukemia and carcinoma. (Germann et al., supra)

For example, c-myc expression is highly amplified in the non-lymphocytic leukemia cell line HL-60. When HL-60 cells are chemically induced to stop proliferation, the  
5 level of c-myc is found to be downregulated. (International Publication Number WO 91/15580) However, it has been shown that exposure of HL-60 cells to a DNA construct that is complementary to the 5' end of c-myc or c-myb blocks translation of the corresponding mRNAs which downregulates expression of the c-myc or c-myb proteins and causes arrest of cell proliferation and differentiation of the treated cells.  
10 (International Publication Number WO 91/15580; Wickstrom et al., Proc. Natl. Acad. Sci. 85:1028 (1988); Anfossi et al., Proc. Natl. Acad. Sci. 86:3379 (1989)). However, the skilled artisan would appreciate the present invention's usefulness would not be limited to treatment of proliferative diseases, disorders, and/or conditions of hematopoietic cells and tissues, in light of the numerous cells and cell types of  
15 varying origins which are known to exhibit proliferative phenotypes.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Antisense techniques are discussed, for example, in Okano, J. Neurochem. 56: 560 (1991); "Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca  
20 Raton, FL (1988). Triple helix formation is discussed in, for instance Lee et al., Nucleic Acids Research 6: 3073 (1979); Cooney et al., Science 241: 456 (1988); and Dervan et al., Science 251: 1360 (1991). Both methods rely on binding of the polynucleotide to a complementary DNA or RNA. For these techniques, preferred polynucleotides are usually oligonucleotides 20 to 40 bases in length and  
25 complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991) ) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix  
30 formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into

polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat or prevent disease.

Polynucleotides of the present invention are also useful in gene therapy. One  
5 goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

10 The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for  
15 identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative  
20 to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once a unique ID database is established for an  
25 individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen,  
30 synovial fluid, amniotic fluid, breast milk, lymph, pulmonary sputum or surfactant, urine, fecal matter, etc., can be amplified using PCR. In one prior art

technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an  
5 identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with  
10 tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

15 In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA  
20 antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

#### **Uses of the Polypeptides**

Each of the polypeptides identified herein can be used in numerous ways. The  
25 following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell . Biol. 105:3087-  
30 3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay

(ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99\text{m}}\text{Tc}$ ), and fluorescent labels, such as fluorescein and rhodamine, and  
5 biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which  
10 emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with  
15 an appropriate detectable imaging moiety, such as a radioisotope (for example,  $^{131}\text{I}$ ,  $^{112}\text{In}$ ,  $^{99\text{m}}\text{Tc}$ ), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety  
20 needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of  $^{99\text{m}}\text{Tc}$ . The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds.,  
25 Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells  
30 or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed

polypeptide gene expression level compared to the standard expression level is indicative of a disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for  
5 detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Moreover, polypeptides of the present invention can be used to treat, prevent,  
10 and/or diagnose disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B, SOD, catalase, DNA repair proteins), to inhibit the activity of a polypeptide (e.g., an oncogene or tumor  
15 supressor), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth inhibition, enhancement of the immune response to proliferative cells or tissues).

20 Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat, prevent, and/or diagnose disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane  
25 (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from  
30 a recombinant cell, as a way of assessing transformation of the host cell. Moreover,

the polypeptides of the present invention can be used to test the following biological activities.

### **Gene Therapy Methods**

5           Another aspect of the present invention is to gene therapy methods for treating or preventing disorders, diseases and conditions. The gene therapy methods relate to the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into an animal to achieve expression of a polypeptide of the present invention. This method requires a polynucleotide which codes for a polypeptide of the invention that  
10   operatively linked to a promoter and any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques are known in the art, see, for example, WO90/11092, which is herein incorporated by reference.

          Thus, for example, cells from a patient may be engineered with a  
15   polynucleotide (DNA or RNA) comprising a promoter operably linked to a polynucleotide of the invention *ex vivo*, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, see Belldgrun et al., J. Natl. Cancer Inst., 85:207-216 (1993); Ferrantini et al., Cancer Research, 53:107-1112 (1993); Ferrantini et al., J.  
20   Immunology 153: 4604-4615 (1994); Kaido, T., et al., Int. J. Cancer 60: 221-229 (1995); Ogura et al., Cancer Research 50: 5102-5106 (1990); Santodonato, et al., Human Gene Therapy 7:1-10 (1996); Santodonato, et al., Gene Therapy 4:1246-1255 (1997); and Zhang, et al., Cancer Gene Therapy 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells which are engineered are  
25   arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

          As discussed in more detail below, the polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver,  
30   and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

In one embodiment, the polynucleotide of the invention is delivered as a naked polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences that are free from any delivery vehicle that acts to assist, promote or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the invention can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such methods are described, for example, in U.S. Patent Nos. 5,593,972, 5,589,466, and 5,580,859, which are herein incorporated by reference.

The polynucleotide vector constructs of the invention used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; pSVK3, pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

Any strong promoter known to those skilled in the art can be used for driving the expression of polynucleotide sequence of the invention. Suitable promoters include adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoAI promoter; human globin promoters; viral thymidine kinase promoters, such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-actin promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotides of the invention.

Unlike other gene therapy techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.



The polynucleotide construct of the invention can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular, fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the nakednucleic acid sequence injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, and so-called "gene guns". These delivery methods are known in the art.

5       The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

10       In certain embodiments, the polynucleotide constructs of the invention are complexed in a liposome preparation. Liposomal preparations for use in the instant invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA ,  
15   84:7413-7416 (1987), which is herein incorporated by reference); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA , 86:6077-6081 (1989), which is herein incorporated by reference); and purified transcription factors (Debs et al., J. Biol. Chem., 265:10189-10192 (1990), which is herein incorporated by reference), in functional form.

20       Cationic liposomes are readily available. For example, N[1-2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner et al., Proc. Natl Acad. Sci. USA , 84:7413-7416 (1987), which is herein incorporated by reference). Other commercially  
25   available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication NO: WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of  
30   DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes is explained in the literature, see, e.g., Felgner et al., Proc.

Natl. Acad. Sci. USA, 84:7413-7417, which is herein incorporated by reference.

Similar methods can be used to prepare liposomes from other cationic lipid materials.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl, choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

For example, commercially dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine (DOPE) can be used in various combinations to make conventional liposomes, with or without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas into a sonication vial. The sample is placed under a vacuum pump overnight and is hydrated the following day with deionized water. The sample is then sonicated for 2 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an inverted cup (bath type) probe at the maximum setting while the bath is circulated at 15EC. Alternatively, negatively charged vesicles can be prepared without sonication to produce multilamellar vesicles or by extrusion through nucleopore membranes to produce unilamellar vesicles of discrete size. Other methods are known and available to those of skill in the art.

The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred. The various liposome-nucleic acid complexes are prepared using methods well known in the art. See, e.g., Straubinger et al., *Methods of Immunology*, 101:512-527 (1983), which is herein incorporated by reference. For example, MLVs containing nucleic acid can be prepared by depositing a thin film of phospholipid on the walls of a glass tube and subsequently hydrating with a solution of the material to be encapsulated. SUVs are prepared by extended sonication of MLVs to produce a homogeneous

population of unilamellar liposomes. The material to be entrapped is added to a suspension of preformed MLVs and then sonicated. When using liposomes containing cationic lipids, the dried lipid film is resuspended in an appropriate solution such as sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and then the preformed liposomes are mixed directly with the DNA. The liposome and DNA form a very stable complex due to binding of the positively charged liposomes to the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are prepared by a number of methods, well known in the art. Commonly used methods include  $\text{Ca}^{2+}$ -EDTA chelation (Papahadjopoulos et al., Biochim. Biophys. Acta, 394:483 (1975); Wilson et al., Cell, 17:77 (1979)); ether injection (Deamer et al., Biochim. Biophys. Acta, 443:629 (1976); Ostro et al., Biochem. Biophys. Res. Commun., 76:836 (1977); Fraley et al., Proc. Natl. Acad. Sci. USA, 76:3348 (1979)); detergent dialysis (Enoch et al., Proc. Natl. Acad. Sci. USA, 76:145 (1979)); and reverse-phase evaporation (REV) (Fraley et al., J. Biol. Chem., 255:10431 (1980); Szoka et al., Proc. Natl. Acad. Sci. USA, 75:145 (1978); Schaefer-Ridder et al., Science, 215:166 (1982)), which are herein incorporated by reference.

Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ratio will be from about 5:1 to about 1:5. More preferably, the ratio will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

U.S. Patent NO: 5,676,954 (which is herein incorporated by reference) reports on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide methods for delivering DNA-cationic lipid complexes to mammals.

In certain embodiments, cells are engineered, *ex vivo* or *in vivo*, using a retroviral particle containing RNA which comprises a sequence encoding polypeptides of the invention. Retroviruses from which the retroviral plasmid vectors

may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

5           The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, Human Gene Therapy , 1:5-14 (1990), which is incorporated herein by  
10 reference in its entirety. The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and  $\text{CaPO}_4$  precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

15           The producer cell line generates infectious retroviral vector particles which include polynucleotide encoding polypeptides of the invention. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express polypeptides of the invention.

          In certain other embodiments, cells are engineered, *ex vivo* or *in vivo*, with  
20 polynucleotides of the invention contained in an adenovirus vector. Adenovirus can be manipulated such that it encodes and expresses polypeptides of the invention, and at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA into the host cell chromosome, thereby alleviating concerns about insertional  
25 mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for many years with an excellent safety profile (Schwartz et al., Am. Rev. Respir. Dis., 109:233-238 (1974)). Finally, adenovirus mediated gene transfer has been demonstrated in a number of instances including transfer of alpha-1-antitrypsin and CFTR to the lungs of cotton rats (Rosenfeld et al., Science , 252:431-434 (1991);  
30 Rosenfeld et al., Cell, 68:143-155 (1992)). Furthermore, extensive studies to attempt

to establish adenovirus as a causative agent in human cancer were uniformly negative (Green et al. Proc. Natl. Acad. Sci. USA , 76:6606 (1979)).

Suitable adenoviral vectors useful in the present invention are described, for example, in Kozarsky and Wilson, Curr. Opin. Genet. Devel., 3:499-503 (1993);  
5 Rosenfeld et al., Cell , 68:143-155 (1992); Engelhardt et al., Human Genet. Ther., 4:759-769 (1993); Yang et al., Nature Genet., 7:362-369 (1994); Wilson et al., Nature , 365:691-692 (1993); and U.S. Patent NO: 5,652,224, which are herein incorporated by reference. For example, the adenovirus vector Ad2 is useful and can be grown in human 293 cells. These cells contain the E1 region of adenovirus and  
10 constitutively express Ela and Elb, which complement the defective adenoviruses by providing the products of the genes deleted from the vector. In addition to Ad2, other varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

Preferably, the adenoviruses used in the present invention are replication  
15 deficient. Replication deficient adenoviruses require the aid of a helper virus and/or packaging cell line to form infectious particles. The resulting virus is capable of infecting cells and can express a polynucleotide of interest which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses may be deleted in one or more of all or a portion of the following genes: Ela, Elb,  
20 E3, E4, E2a, or L1 through L5.

In certain other embodiments, the cells are engineered, *ex vivo* or *in vivo*, using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, Curr. Topics in Microbiol. Immunol., 158:97 (1992)). It is also one of the few viruses that  
25 may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678, 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

30 For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell

integration. The polynucleotide construct containing polynucleotides of the invention is inserted into the AAV vector using standard cloning methods, such as those found in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus, using any standard technique, including lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct of the invention. These viral particles are then used to transduce eukaryotic cells, either *ex vivo* or *in vivo*. The transduced cells will contain the polynucleotide construct integrated into its genome, and will express the desired gene product.

Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g. encoding the polypeptide sequence of interest) via homologous recombination (see, e.g., U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA, 86:8932-8935 (1989); and Zijlstra et al., Nature, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting sequence will be sufficiently near the 5' end of the desired endogenous polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5'

and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter. The amplified promoter and targeting sequences are digested  
5 and ligated together.

The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can  
10 be delivered by any method, included direct needle injection, intravenous injection, topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such  
15 that an endogenous sequence is placed under the control of the promoter. The promoter then drives the expression of the endogenous sequence.

The polynucleotides encoding polypeptides of the present invention may be administered along with other polynucleotides encoding other angiogenic proteins. Angiogenic proteins include, but are not limited to, acidic and basic fibroblast growth  
20 factors, VEGF-1, VEGF-2 (VEGF-C), VEGF-3 (VEGF-B), epidermal growth factor alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin like growth factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

25 Preferably, the polynucleotide encoding a polypeptide of the invention contains a secretory signal sequence that facilitates secretion of the protein. Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence may be homologous or heterologous to the polynucleotide of interest and may be  
30 homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.



Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct needle injection, systemic injection, catheter infusion, biolistic injectors, particle  
5 accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid (tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated  
10 plasmid into the portal vein has resulted in gene expression of the foreign gene in the rat livers. (Kaneda et al., Science, 243:375 (1989)).

A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is administered by direct injection into or locally within the area of arteries.  
15 Administration of a composition locally within the area of arteries refers to injecting the composition centimeters and preferably, millimeters within arteries.

Another method of local administration is to contact a polynucleotide construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the  
20 surface of tissue inside the wound or the construct can be injected into areas of tissue inside the wound.

Therapeutic compositions useful in systemic administration, include recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic  
25 administration comprise liposomes comprising ligands for targeting the vehicle to a particular site.

Preferred methods of systemic administration, include intravenous injection, aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed  
30 using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad. Sci. USA, 189:11277-11281 (1992), which is incorporated herein by reference). Oral

delivery can be performed by complexing a polynucleotide construct of the present invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a  
5 polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise  
10 condition requiring treatment and its severity, and the route of administration. The frequency of treatments depends upon a number of factors, such as the amount of polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian. Therapeutic compositions of  
15 the present invention can be administered to any animal, preferably to mammals and birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly

#### **Biological Activities**

20 The polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists could  
25 be used to treat the associated disease.

#### **Immune Activity**

The polynucleotides or polypeptides, or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders,  
30 and/or conditions of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop

through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune diseases, disorders, and/or conditions may be genetic, somatic, such as cancer or some autoimmune diseases, disorders, and/or conditions, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of hematopoietic cells. A polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein diseases, disorders, and/or conditions (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, DiGeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, a polynucleotides or polypeptides, or agonists or antagonists of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to treat or prevent blood coagulation diseases, disorders, and/or conditions (e.g., afibrinogenemia, factor deficiencies), blood platelet diseases, disorders, and/or conditions (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the

present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment or prevention of heart attacks (infarction), strokes, or scarring.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be useful in treating, preventing, and/or diagnosing autoimmune diseases, disorders, and/or conditions. Many autoimmune diseases, disorders, and/or conditions result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polynucleotides or polypeptides, or agonists or antagonists of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune diseases, disorders, and/or conditions.

Examples of autoimmune diseases, disorders, and/or conditions that can be treated, prevented, and/or diagnosed or detected by the present invention include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated, prevented, and/or diagnosed by polynucleotides or polypeptides, or agonists or antagonists of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to treat, prevent, and/or diagnose organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction

of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polynucleotides or polypeptides, or agonists or antagonists of the present invention that inhibits an  
5 immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide or agonists  
10 or antagonist may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat, prevent, and/or diagnose inflammatory conditions, both chronic and acute conditions, including chronic prostatitis, granulomatous prostatitis and malacoplakia, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory  
15 response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

## 20 **Hyperproliferative Disorders**

A polynucleotides or polypeptides, or agonists or antagonists of the invention can be used to treat, prevent, and/or diagnose hyperproliferative diseases, disorders, including neoplasms. A polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation of the disorder through direct or  
25 indirect interactions. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating,  
30 differentiating, or mobilizing T-cells, hyperproliferative diseases, disorders, and/or conditions can be treated, prevented, and/or diagnosed. This immune response may

be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating, preventing, and/or diagnosing hyperproliferative diseases, disorders, and/or conditions, such as a chemotherapeutic agent.

5           Examples of hyperproliferative diseases, disorders, and/or conditions that can be treated, prevented, and/or diagnosed by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to neoplasms located in the: colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles,  
10    ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

          Similarly, other hyperproliferative diseases, disorders, and/or conditions can also be treated, prevented, and/or diagnosed by a polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative  
15    diseases, disorders, and/or conditions include, but are not limited to: hypergammaglobulinemia, lymphoproliferative diseases, disorders, and/or conditions, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other  
          hyperproliferative disease, besides neoplasia, located in an organ system listed above.

20           One preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or protein fusions or fragments thereof.

          Thus, the present invention provides a method for treating or preventing cell proliferative diseases, disorders, and/or conditions by inserting into an abnormally  
25    proliferating cell a polynucleotide of the present invention, wherein said polynucleotide represses said expression.

          Another embodiment of the present invention provides a method of treating or preventing cell-proliferative diseases, disorders, and/or conditions in individuals comprising administration of one or more active gene copies of the present invention  
30    to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA construct comprising a

recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA construct encoding the polynucleotides of the present invention is inserted into cells to be treated utilizing a retrovirus, or more preferably an adenoviral vector (See G J. Nabel, et. al., PNAS 1999 96: 324-326, which is hereby incorporated by reference). In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention inserted into proliferating cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e. magnetic, specific small molecule, chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the beneficial therapeutic affect of the present invention may be expressly modulated (i.e. to increase, decrease, or inhibit expression of the present invention) based upon said external stimulus.

Polynucleotides of the present invention may be useful in repressing expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes " is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the normal function of the protein.

For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any other method described throughout the specification. The polynucleotide of the present invention may be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature 320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA

delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference. In order to specifically deliver or transfect cells which are abnormally proliferating and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as  
5 described in the art and elsewhere herein) delivery system known to those of skill in the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes needed for its life cycle. Utilizing such a retroviral delivery system for polynucleotides of the present invention will target said gene and constructs to  
10 abnormally proliferating cells and will spare the non-dividing normal cells.

The polynucleotides of the present invention may be delivered directly to cell proliferative disorder/disease sites in internal organs, body cavities and the like by use of imaging devices used to guide an injecting needle directly to the disease site. The polynucleotides of the present invention may also be administered to disease sites at  
15 the time of surgical intervention.

By "cell proliferative disease" is meant any human or animal disease or disorder, affecting any one or any combination of organs, cavities, or body parts, which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

20 Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of the treated cells. Moreover, it is possible to administer more than one of the polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as  
25 decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of the present invention on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

30 The present invention is further directed to antibody-based therapies which involve administering of anti-polypeptides and anti-polynucleotide antibodies to a



mammalian, preferably human, patient for treating, preventing, and/or diagnosing one or more of the described diseases, disorders, and/or conditions. Methods for producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may  
5 be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the  
10 antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

15 In particular, the antibodies, fragments and derivatives of the present invention are useful for treating, preventing, and/or diagnosing a subject having or developing cell proliferative and/or differentiation diseases, disorders, and/or conditions as described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.

20 The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors, for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or  
25 neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of diseases, disorders, and/or conditions related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or  
30 polypeptides, including fragments thereof. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-6}M$ ,  $10^{-6}M$ ,  $5 \times 10^{-7}M$ ,  $10^{-7}M$ ,  $5 \times 10^{-8}M$ ,  $10^{-8}M$ ,  $5 \times 10^{-9}M$ ,  $10^{-9}M$ ,  $5 \times 10^{-10}M$ ,  $10^{-10}M$ ,  $5 \times 10^{-11}M$ ,  $10^{-11}M$ ,  $5 \times 10^{-12}M$ ,  $10^{-12}M$ ,  $5 \times 10^{-13}M$ ,  $10^{-13}M$ ,  $5 \times 10^{-14}M$ ,  $10^{-14}M$ ,  $5 \times 10^{-15}M$ ,  $10^{-15}M$ ,  $5 \times 10^{-16}M$ ,  $10^{-16}M$ ,  $5 \times 10^{-17}M$ ,  $10^{-17}M$ ,  $5 \times 10^{-18}M$ ,  $10^{-18}M$ ,  $5 \times 10^{-19}M$ ,  $10^{-19}M$ ,  $5 \times 10^{-20}M$ ,  $10^{-20}M$ ,  $5 \times 10^{-21}M$ ,  $10^{-21}M$ ,  $5 \times 10^{-22}M$ ,  $10^{-22}M$ ,  $5 \times 10^{-23}M$ ,  $10^{-23}M$ ,  $5 \times 10^{-24}M$ ,  $10^{-24}M$ ,  $5 \times 10^{-25}M$ ,  $10^{-25}M$ ,  $5 \times 10^{-26}M$ ,  $10^{-26}M$ ,  $5 \times 10^{-27}M$ ,  $10^{-27}M$ ,  $5 \times 10^{-28}M$ ,  $10^{-28}M$ ,  $5 \times 10^{-29}M$ ,  $10^{-29}M$ ,  $5 \times 10^{-30}M$ ,  $10^{-30}M$ .

$8M$ ,  $10^{-8}M$ ,  $5 \times 10^{-9}M$ ,  $10^{-9}M$ ,  $5 \times 10^{-10}M$ ,  $10^{-10}M$ ,  $5 \times 10^{-11}M$ ,  $10^{-11}M$ ,  $5 \times 10^{-12}M$ ,  $10^{-12}M$ ,  $5 \times 10^{-13}M$ ,  $10^{-13}M$ ,  $5 \times 10^{-14}M$ ,  $10^{-14}M$ ,  $5 \times 10^{-15}M$ , and  $10^{-15}M$ .

Moreover, polypeptides of the present invention are useful in inhibiting the angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in combination with other polypeptides directly or indirectly, as described elsewhere herein. In a most preferred embodiment, said anti-angiogenesis effect may be achieved indirectly, for example, through the inhibition of hematopoietic, tumor-specific cells, such as tumor-associated macrophages (See Joseph IB, et al. J Natl Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference).

Antibodies directed to polypeptides or polynucleotides of the present invention may also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al., Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by reference)).

Polypeptides, including protein fusions, of the present invention, or fragments thereof may be useful in inhibiting proliferative cells or tissues through the induction of apoptosis. Said polypeptides may act either directly, or indirectly to induce apoptosis of proliferative cells and tissues, for example in the activation of a death-domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1), TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et.al., Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference).

Moreover, in another preferred embodiment of the present invention, said polypeptides may induce apoptosis through other mechanisms, such as in the activation of other proteins which will activate apoptosis, or through stimulating the expression of said proteins, either alone or in combination with small molecule drugs or adjuvants, such as apoptonin, galectins, thioredoxins, antiinflammatory proteins (See for example, Mutat Res 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33 (1998), Chem Biol Interact. Apr 24;111-112:23-34 (1998), J Mol Med.76(6):402-12 (1998), Int J Tissue React;20(1):3-15 (1998), which are all hereby incorporated by reference).

Polypeptides, including protein fusions to, or fragments thereof, of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues.

Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewhere herein, or indirectly, such as

- 5 activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby incorporated by reference). Such therapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

- In another embodiment, the invention provides a method of delivering  
10 compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or polypeptide antibodies associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. Polypeptides or polypeptide antibodies of the invention may be associated with with heterologous polypeptides,  
15 heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions.

- Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present  
20 invention 'vaccinated' the immune response to respond to proliferative antigens and immunogens, or indirectly, such as in activating the expression of proteins known to enhance the immune response (e.g. chemokines), to said antigens and immunogens.

#### **Cardiovascular Disorders**

- 25 Polynucleotides or polypeptides, or agonists or antagonists of the invention may be used to treat, prevent, and/or diagnose cardiovascular diseases, disorders, and/or conditions, including peripheral artery disease, such as limb ischemia.

- Cardiovascular diseases, disorders, and/or conditions include cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral  
30 arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome. Congenital heart defects include aortic coarctation, cor

triatratrium, coronary vessel anomalies, crisscross heart, dextrocardia, patent ductus arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, trilog of Fallot, ventricular heart septal defects.

Cardiovascular diseases, disorders, and/or conditions also include heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

Arrhythmias include sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

Heart valve disease include aortic valve insufficiency, aortic valve stenosis, hear murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve

insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.

Myocardial diseases include alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, 5 pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial reperfusion injury, and myocarditis.

Myocardial ischemias include coronary disease, such as angina pectoris, coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary 10 vasospasm, myocardial infarction and myocardial stunning.

Cardiovascular diseases also include vascular diseases such as aneurysms, angiodyplasia, angiomatosis, bacillary angiomatosis, Hippel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive 15 diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular diseases, disorders, and/or conditions, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, 20 Scimitar syndrome, superior vena cava syndrome, telangiectasia, atacia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.

Aneurysms include dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary 25 aneurysms, heart aneurysms, and iliac aneurysms.

Arterial occlusive diseases include arteriosclerosis, intermittent claudication, carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

30 Cerebrovascular diseases, disorders, and/or conditions include carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral

arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural hematoma, subarachnoid hemorrhage, cerebral infarction, cerebral ischemia  
5 (including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

Embolisms include air embolisms, amniotic fluid embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and thromboembolisms. Thrombosis include coronary thrombosis, hepatic vein  
10 thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

Ischemia includes cerebral ischemia, ischemic colitis, compartment syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes aortitis, arteritis, Behcet's  
15 Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node syndrome, thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's granulomatosis.

Polynucleotides or polypeptides, or agonists or antagonists of the invention, are especially effective for the treatment of critical limb ischemia and coronary  
20 disease.

Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials,  
25 osmotic pumps, oral or suppositorial solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides of the invention may be administered as part of a *Therapeutic*, described in more detail below. Methods of delivering polynucleotides of the invention are described in more detail herein.

30

### **Anti-Angiogenesis Activity**

The naturally occurring balance between endogenous stimulators and inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad *et al.*, *Cell* 56:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound healing, organ regeneration, embryonic development, and female reproductive processes, angiogenesis is stringently regulated and spatially and temporally delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes pathologic and sustains progression of many neoplastic and non-neoplastic diseases.

5 A number of serious diseases are dominated by abnormal neovascularization including solid tumor growth and metastases, arthritis, some types of eye diseases, disorders, and/or conditions, and psoriasis. See, e.g., reviews by Moses *et al.*, *Biotech.* 9:630-634 (1991); Folkman *et al.*, *N. Engl. J. Med.*, 333:1757-1763 (1995); Auerbach *et al.*, *J. Microvasc. Res.* 29:401-411 (1985); Folkman, *Advances in*

15 *Cancer Research*, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-203 (1985); Patz, *Am. J. Ophthalmol.* 94:715-743 (1982); and Folkman *et al.*, *Science* 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have accumulated which suggest that the growth of solid tumors is dependent on

20 angiogenesis. Folkman and Klagsbrun, *Science* 235:442-447 (1987).

The present invention provides for treatment of diseases, disorders, and/or conditions associated with neovascularization by administration of the polynucleotides and/or polypeptides of the invention, as well as agonists or antagonists of the present invention. Malignant and metastatic conditions which can

25 be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers described herein and otherwise known in the art (for a review of such disorders, see Fishman *et al.*, *Medicine*, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the present invention provides a method of treating, preventing, and/or diagnosing an

30 angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide,

polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety of additional methods in order to therapeutically treat or prevent a cancer or tumor. Cancers which may be treated, prevented, and/or diagnosed with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors, including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non-small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat or prevent cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma.

Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists may be delivered directly into the tumor, or near the tumor site, via injection or a catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

Polynucleotides, polypeptides, antagonists and/or agonists may be useful in treating, preventing, and/or diagnosing other diseases, disorders, and/or conditions, besides cancers, which involve angiogenesis. These diseases, disorders, and/or conditions include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial



angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis.

- 5           For example, within one aspect of the present invention methods are provided for treating, preventing, and/or diagnosing hypertrophic scars and keloids, comprising the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

          Within one embodiment of the present invention polynucleotides,  
10   polypeptides, antagonists and/or agonists are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress (approximately 14 days  
15   after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating, preventing, and/or diagnosing neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration.

- 20           Moreover, Ocular diseases, disorders, and/or conditions associated with neovascularization which can be treated, prevented, and/or diagnosed with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity  
25   macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthalmol.* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthalmol.* 22:291-312 (1978).

- Thus, within one aspect of the present invention methods are provided for  
30   treating or preventing neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step

of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of diseases, disorders, and/or conditions can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause), toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in eyedrop form. The solution or suspension may be prepared in its pure form and administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent complications.

Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing

front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult in order to prophylactically prevent corneal neovascularization.

- 5 In this situation the material could be injected in the perilimbic cornea interspersed between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-3 times per year. A steroid could also be added to the injection solution to reduce
- 10 inflammation resulting from the injection itself.

- Within another aspect of the present invention, methods are provided for treating or preventing neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is
- 15 inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat or prevent early forms of neovascular glaucoma. Within other embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the compound is continuously released into the
- 20 aqueous humor. Within another aspect of the present invention, methods are provided for treating or preventing proliferative diabetic retinopathy, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

- 25 Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photocoagulation.

- 30 Within another aspect of the present invention, methods are provided for treating or preventing retrolental fibroplasia, comprising the step of administering to a

front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult in order to prophylactically prevent corneal neovascularization.

- 5 In this situation the material could be injected in the perilimbic cornea interspersed between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-3 times per year. A steroid could also be added to the injection solution to reduce
- 10 inflammation resulting from the injection itself.

- Within another aspect of the present invention, methods are provided for treating or preventing neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is
- 15 inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat or prevent early forms of neovascular glaucoma. Within other embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the compound is continuously released into the
- 20 aqueous humor. Within another aspect of the present invention, methods are provided for treating or preventing proliferative diabetic retinopathy, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

- 25 Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photocoagulation.

- 30 Within another aspect of the present invention, methods are provided for treating or preventing retrolental fibroplasia, comprising the step of administering to a

patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreal injection and/or via intraocular implants.

5           Additionally, diseases, disorders, and/or conditions which can be treated, prevented, and/or diagnosed with the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome,  
10       pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

          Moreover, diseases, disorders, and/or conditions and/or states, which can be treated, prevented, and/or diagnosed with the the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, solid tumors, blood born tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for  
15       example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and uveitis, delayed wound healing, endometriosis, vasculogenesis, granulations,  
20       hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophilic joints, angiofibroma fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth  
25       control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (*Rochelle minalia quintosa*), ulcers (*Helicobacter pylori*), Bartonellosis and bacillary angiomatosis.

          In one aspect of the birth control method, an amount of the compound  
30       sufficient to block embryo implantation is administered before or after intercourse and fertilization have occurred, thus providing an effective method of birth control,

possibly a "morning after" method. Polynucleotides, polypeptides, agonists and/or agonists may also be used in controlling menstruation or administered as either a peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

- 5 Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch granulomas.

- Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present invention a compositions (in the form of, for example, a spray or film) may be utilized to coat or spray an area prior to removal of a tumor, in order to isolate normal surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti- angiogenic compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the invention a surgical mesh laden with an anti-angiogenic composition may be utilized during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.
- 10  
15  
20

- Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or agonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly
- 25  
30

preferred embodiments of the invention, the anti-angiogenic compounds are applied after hepatic resections for malignancy, and after neurosurgical operations.

Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or agonists may be administered to the resection margin of a wide  
5 variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

The polynucleotides, polypeptides, agonists and/or agonists of the present  
10 invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d  
15 group" transition metals.

Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

Representative examples of vanadium complexes include oxo vanadium  
20 complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate  
25 including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten  
30 oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl

complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, 5 molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4; 10 protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan Complex (SP- PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L- 15 3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradasulfate; Eponemycin; Camptothecin; Fumagillin 20 (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrone (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312- 25 316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxyaminolmidazole; and metalloproteinase inhibitors such as BB94.

#### Diseases at the Cellular Level

Diseases associated with increased cell survival or the inhibition of apoptosis 30 that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides and/or antagonists or agonists of the invention, include cancers (such as



follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention are used to inhibit growth, progression, and/or metastasis of cancers, in particular those listed above.

Additional diseases or conditions associated with increased cell survival that could be treated, prevented or diagnosed by the polynucleotides or polypeptides, or agonists or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary

carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, 5 craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, include AIDS; neurodegenerative diseases, disorders, 10 and/or conditions (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and 15 immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic 20 shock, cachexia and anorexia.

#### **Wound Healing and Epithelial Cell Proliferation**

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing the polynucleotides or polypeptides, and/or agonists 25 or antagonists of the invention, for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds.

Polynucleotides or polypeptides, as well as agonists or antagonists of the invention, may be clinically useful in stimulating wound healing including surgical wounds, 30 excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal

ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and  
5 antimetabolites. Polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote dermal reestablishment subsequent to dermal loss

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to increase the adherence of skin grafts to a wound bed and  
10 to stimulate re-epithelialization from the wound bed. The following are a non-exhaustive list of grafts that polynucleotides or polypeptides, agonists or antagonists of the invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepidermic grafts, avacular grafts, Blair-Brown grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft,  
15 epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-Thiersch graft, omentopial graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, can be used to promote skin strength and to improve the  
20 appearance of aged skin.

It is believed that the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine, and large intestine. The polynucleotides or polypeptides, and/or agonists or  
25 antagonists of the invention, could promote proliferation of epithelial cells such as sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may promote proliferation of endothelial cells,  
30 keratinocytes, and basal keratinocytes.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may have a  
5 cytoprotective effect on the small intestine mucosa. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

The polynucleotides or polypeptides, and/or agonists or antagonists of the  
10 invention, could further be used in full regeneration of skin in full and partial thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the  
15 underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could also be used to treat gastric and duodenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly.  
20 Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large intestine, respectively. Thus, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel  
25 disease. Treatment with the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, is expected to have a significant effect on the production of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention,  
30 could be used to treat diseases associate with the under expression of the polynucleotides of the invention.

Moreover, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to prevent and heal damage to the lungs due to various pathological states. A growth factor such as the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and bronchiolar epithelium to prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of aveoli, and inhalation injuries, i.e., resulting from smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated, prevented, and/or diagnosed using the polynucleotides or polypeptides, and/or agonists or antagonists of the invention. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary displasia, in premature infants.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could stimulate the proliferation and differentiation of hepatocytes and, thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetraholoride and other hepatotoxins known in the art).

In addition, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to maintain the islet function so as to alleviate, delay or prevent permanent manifestation of the disease. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

**Neurological Diseases**

Nervous system diseases, disorders, and/or conditions, which can be treated, prevented, and/or diagnosed with the compositions of the invention (e.g., polypeptides, polynucleotides, and/or agonists or antagonists), include, but are not

5 limited to, nervous system injuries, and diseases, disorders, and/or conditions which result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated, prevented, and/or diagnosed in a patient (including human and non-human mammalian patients) according to the invention, include but are not limited to, the following lesions of

10 either the central (including spinal cord, brain) or peripheral nervous systems: (1) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (2) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the

15 nervous system, or compression injuries; (3) malignant lesions, in which a portion of the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue; (4) infectious lesions, in which a portion of the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated

20 with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, syphilis; (5) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6)

25 lesions associated with nutritional diseases, disorders, and/or conditions, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar

30 degeneration; (7) neurological lesions associated with systemic diseases including, but not limited to, diabetes (diabetic neuropathy, Bell's palsy), systemic lupus

erythematosus, carcinoma, or sarcoidosis; (8) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (9) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including, but not limited to, multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

In a preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of cerebral hypoxia. According to this embodiment, the compositions of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral hypoxia. In one aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral ischemia. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral infarction. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose or prevent neural cell injury associated with a stroke. In a further aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with a heart attack.

The compositions of the invention which are useful for treating or preventing a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of limitation, compositions of the invention which elicit any of the following effects may be useful according to the invention: (1) increased survival time of neurons in culture; (2) increased sprouting of neurons in culture or *in vivo*; (3) increased production of a neuron-associated molecule in culture or *in vivo*, e.g., choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or (4) decreased symptoms of neuron dysfunction *in vivo*. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may

10 routinely be measured using a method set forth herein or otherwise known in the art, such as, for example, the method set forth in Arakawa et al. (J. Neurosci. 10:3507-3515 (1990)); increased sprouting of neurons may be detected by methods known in the art, such as, for example, the methods set forth in Pestronk et al. (Exp. 5 Neurol. 70:65-82 (1980)) or Brown et al. (Ann. Rev. Neurosci. 4:17-42 (1981)); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., using techniques known in the art and depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor 10 neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability.

In specific embodiments, motor neuron diseases, disorders, and/or conditions that may be treated, prevented, and/or diagnosed according to the invention include, but are not limited to, diseases, disorders, and/or conditions such as infarction, 15 infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as diseases, disorders, and/or conditions that selectively affect neurons such as amyotrophic lateral sclerosis, and including, but not limited to, progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile 20 and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motorsensory Neuropathy (Charcot-Marie-Tooth Disease).

### **Infectious Disease**

25 A polypeptide or polynucleotide and/or agonist or antagonist of the present invention can be used to treat, prevent, and/or diagnose infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated, prevented, and/or diagnosed. The immune response may be increased by either enhancing an 30 existing immune response, or by initiating a new immune response. Alternatively, polypeptide or polynucleotide and/or agonist or antagonist of the present invention



may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention. Examples of viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papilloma virus, Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat patients nonresponsive to one or more other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or

agonists or antagonists of the invention are used to treat, prevent, and/or diagnose AIDS.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, include, but not limited to, the following Gram-Negative and Gram-positive bacteria and bacterial families and fungi: Actinomycetales (e.g., *Corynebacterium*, *Mycobacterium*, *Nocardia*), *Cryptococcus neoformans*, Aspergillosis, Bacillaceae (e.g., *Anthrax*, *Clostridium*), Bacteroidaceae, Blastomycosis, *Bordetella*, *Borrelia* (e.g., *Borrelia burgdorferi*), Brucellosis, Candidiasis, *Campylobacter*, *Coccidioidomycosis*, *Cryptococcosis*, *Dermatocycoses*, *E. coli* (e.g., Enterotoxigenic *E. coli* and Enterohemorrhagic *E. coli*), Enterobacteriaceae (*Klebsiella*, *Salmonella* (e.g., *Salmonella typhi*, and *Salmonella paratyphi*), *Serratia*, *Yersinia*), *Erysipelothrix*, *Helicobacter*, Legionellosis, Leptospirosis, *Listeria*, *Mycoplasmatales*, *Mycobacterium leprae*, *Vibrio cholerae*, Neisseriaceae (e.g., *Acinetobacter*, *Gonorrhea*, *Menigococcal*), *Meisseria meningitidis*, Pasteurellacea Infections (e.g., *Actinobacillus*, *Heamophilus* (e.g., *Heamophilus influenza type B*), *Pasteurella*), *Pseudomonas*, Rickettsiaceae, Chlamydiaceae, Syphilis, *Shigella* spp., *Staphylococcal*, *Meningiococcal*, *Pneumococcal* and *Streptococcal* (e.g., *Streptococcus pneumoniae* and Group B *Streptococcus*). These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, *Gonorrhea*, meningitis (e.g., meningitis types A and B), Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used

to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, agonists or antagonists of the invention are used to treat, prevent, and/or diagnose: tetanus, Diphtheria, botulism, and/or meningitis type B.

- 5           Moreover, parasitic agents causing disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis,
- 10   Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g., Plasmodium virax, Plasmodium falciparum, Plasmodium malariae and Plasmodium ovale). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS
- 15   related), malaria, pregnancy complications, and toxoplasmosis. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose malaria.
- 20           Preferably, treatment or prevention using a polypeptide or polynucleotide and/or agonist or antagonist of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the
- 25   polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

### **Regeneration**

- 30           A polynucleotide or polypeptide and/or agonist or antagonist of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues

could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

5           Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

10           Moreover, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide and/or agonist or antagonist of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases  
15           that could be treated, prevented, and/or diagnosed include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

            Similarly, nerve and brain tissue could also be regenerated by using a  
20           polynucleotide or polypeptide and/or agonist or antagonist of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated, prevented, and/or diagnosed using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic diseases, disorders, and/or conditions (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and  
25           stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated, prevented, and/or diagnosed using the  
30           polynucleotide or polypeptide and/or agonist or antagonist of the present invention.

**Chemotaxis**

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat, prevent, and/or diagnose inflammation, infection, hyperproliferative diseases, disorders, and/or conditions, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat, prevent, and/or diagnose wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat, prevent, and/or diagnose wounds.

It is also contemplated that a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may inhibit chemotactic activity. These molecules could also be used to treat, prevent, and/or diagnose diseases, disorders, and/or conditions. Thus, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention could be used as an inhibitor of chemotaxis.

**Binding Activity**

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural  
5 receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell  
10 membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

15 The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations,  
20 polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

25 Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

Additionally, the receptor to which a polypeptide of the invention binds can be  
30 identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., Current Protocols in Immun., 1(2),

Chapter 5, (1991)). For example, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the polypeptides, for example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided  
5 into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labelled. The polypeptides can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.

10 Following fixation and incubation, the slides are subjected to auto-radiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

As an alternative approach for receptor identification, the labeled polypeptides  
15 can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein microsequencing. The amino acid sequence obtained from microsequencing would  
20 be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be employed to modulate the activities of polypeptides of the invention thereby  
25 effectively generating agonists and antagonists of polypeptides of the invention. See generally, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, S. Trends Biotechnol. 16(2):76-82 (1998); Hansson, L. O., et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. Biotechniques  
30 24(2):308-13 (1998) (each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and corresponding

polypeptides of the invention may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired polynucleotide sequence of the invention molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides and corresponding polypeptides of the invention may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptides of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments, the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).

Other preferred fragments are biologically active fragments of the polypeptides of the invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, a the polypeptide of the present invention, the compound to be screened and 3[H] thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the compound to determine if the compound stimulates proliferation by determining the



uptake of 3[H] thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of 3[H] thymidine. Both agonist and antagonist compounds may be identified by this procedure.

5 In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured. Alternatively, the response of a known second messenger system following  
10 interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase, ion channels or phosphoinositide hydrolysis.

15 All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat, prevent, and/or diagnose disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptides  
20 of the invention from suitably manipulated cells or tissues. Therefore, the invention includes a method of identifying compounds which bind to the polypeptides of the invention comprising the steps of: (a) incubating a candidate binding compound with the polypeptide; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps  
25 of: (a) incubating a candidate compound with the polypeptide, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

Also, one could identify molecules bind a polypeptide of the invention experimentally by using the beta-pleated sheet regions contained in the polypeptide  
30 sequence of the protein. Accordingly, specific embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively

consist of, the amino acid sequence of each beta pleated sheet regions in a disclosed polypeptide sequence. Additional embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of, any combination or all of contained in the polypeptide sequences of the invention.

5 Additional preferred embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, the amino acid sequence of each of the beta pleated sheet regions in one of the polypeptide sequences of the invention. Additional embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, any combination or all of the beta pleated sheet regions in one

10 of the polypeptide sequences of the invention.

#### **Targeted Delivery**

In another embodiment, the invention provides a method of delivering compositions to targeted cells expressing a receptor for a polypeptide of the invention,

15 or cells expressing a cell bound form of a polypeptide of the invention.

As discussed herein, polypeptides or antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one embodiment, the invention provides a method for the specific delivery of

20 compositions of the invention to cells by administering polypeptides of the invention (including antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double

25 stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in

30 association with toxins or cytotoxic prodrugs.

By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

### **Drug Screening**

Further contemplated is the use of the polypeptides of the present invention, or the polynucleotides encoding these polypeptides, to screen for molecules which modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the present invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed

cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present invention.

Thus, the present invention provides methods of screening for drugs or any  
5 other agents which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the present invention or a fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or a fragment thereof, by methods well known  
10 in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation, free agent is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present  
15 invention, and is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and  
20 washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays  
25 in which neutralizing antibodies capable of binding polypeptides of the present invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

30

#### **Antisense And Ribozyme (Antagonists)**

In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to nucleotide sequences contained a deposited clone. In one embodiment, antisense sequence is generated internally by the  
5 organism, in another embodiment, the antisense sequence is separately administered (see, for example, O'Connor, *Neurochem.*, 56:560 (1991). *Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression*, CRC Press, Boca Raton, FL (1988). Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for  
10 example, in Okano, *Neurochem.*, 56:560 (1991); *Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression*, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee et al., *Nucleic Acids Research*, 6:3073 (1979); Cooney et al., *Science*, 241:456 (1988); and Dervan et al., *Science*, 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary  
15 DNA or RNA.

For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These experiments were performed in vitro by incubating cells with the oligoribonucleotide.  
20 A similar procedure for in vivo use is described in WO 91/15580. Briefly, a pair of oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoRI site on the 5' end and a HindIII site on the 3' end. Next, the pair of oligonucleotides is heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS  
25 HCl pH 7.5, 10mM MgCl<sub>2</sub>, 10mM dithiothreitol (DTT) and 0.2 mM ATP) and then ligated to the EcoRI/Hind III site of the retroviral vector PMV7 (WO 91/15580).

For example, the 5' coding portion of a polynucleotide that encodes the mature polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide  
30 is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense

RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into receptor polypeptide.

In one embodiment, the antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or  
5 a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid of the invention. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard  
10 in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding a polypeptide of the invention, or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early  
15 promoter region (Bernoist and Chambon, *Nature*, 29:304-310 (1981), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., *Cell*, 22:787-797 (1980), the herpes thymidine promoter (Wagner et al., *Proc. Natl. Acad. Sci. U.S.A.*, 78:1441-1445 (1981), the regulatory sequences of the metallothionein gene (Brinster et al., *Nature*, 296:39-42 (1982)), etc.

20 The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of interest. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA,  
25 forming a stable duplex; in the case of double stranded antisense nucleic acids of the invention, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a RNA sequence of the  
30 invention it may contain and still form a stable duplex (or triplex as the case may be).

One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

Oligonucleotides that are complementary to the 5' end of the message, *e.g.*, the 5' untranslated sequence up to and including the AUG initiation codon, should  
5 work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., *Nature*, 372:333-335 (1994). Thus, oligonucleotides complementary to either the 5' - or 3' - non- translated, non-coding regions of a polynucleotide sequence of the invention  
10 could be used in an antisense approach to inhibit translation of endogenous mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the  
15 5' -, 3' - or coding region of mRNA, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

The polynucleotides of the invention can be DNA or RNA or chimeric  
20 mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell  
25 membrane (see, *e.g.*, Letsinger et al., *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556 (1989); Lemaitre et al., *Proc. Natl. Acad. Sci.*, 84:648-652 (1987); PCT Publication NO: WO88/09810, published December 15, 1988) or the blood-brain barrier (see, *e.g.*, PCT Publication NO: WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, *e.g.*, Krol et al., *BioTechniques*, 6:958-976 (1988))  
30 or intercalating agents. (See, *e.g.*, Zon, *Pharm. Res.*, 5:539-549 (1988)). To this end, the oligonucleotide may be conjugated to another molecule, *e.g.*, a peptide,

hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

- The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil,
- 5 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine,
- 10 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil,
- 15 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

- The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose,
- 20 2-fluoroarabinose, xylulose, and hexose.

- In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl
- 25 phosphotriester, and a formacetal or analog thereof.

- In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., Nucl. Acids Res., 15:6625-6641 (1987)).
- 30 The oligonucleotide is a 2-O-methylribonucleotide (Inoue et al., Nucl. Acids Res.,



15:6131-6148 (1987)), or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 215:327-330 (1987)).

Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are  
5 commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (Nucl. Acids Res., 16:3209 (1988)), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., Proc. Natl. Acad. Sci. U.S.A., 85:7448-7451 (1988)), etc.

10 While antisense nucleotides complementary to the coding region sequence of the invention could be used, those complementary to the transcribed untranslated region are most preferred.

Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published  
15 October 4, 1990; Sarver et al, Science, 247:1222-1225 (1990). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs corresponding to the polynucleotides of the invention, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The  
20 sole requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, Nature, 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within each nucleotide sequence disclosed in the sequence listing. Preferably,  
25 the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA corresponding to the polynucleotides of the invention; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

As in the antisense approach, the ribozymes of the invention can be composed  
30 of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express the polynucleotides of the invention in vivo.

DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous messages and inhibit translation. Since ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular cataract surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirable in cases such as restenosis after balloon angioplasty.

The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

The antagonist/agonist may also be employed to treat, prevent, and/or diagnose the diseases described herein.

Thus, the invention provides a method of treating or preventing diseases, disorders, and/or conditions, including but not limited to the diseases, disorders, and/or conditions listed throughout this application, associated with overexpression of a polynucleotide of the present invention by administering to a patient (a) an antisense molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention.

### Other Activities

The polypeptide of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as thrombosis, arteriosclerosis, and other cardiovascular conditions. These polypeptide may also be employed to stimulate angiogenesis and limb regeneration, as discussed above.

The polypeptide may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells of different origins, such as fibroblast cells and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

The polypeptide of the present invention may also be employed stimulate neuronal growth and to treat, prevent, and/or diagnose neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's disease, Parkinson's disease, and AIDS-related complex. The polypeptide of the invention may have the ability to stimulate chondrocyte growth, therefore, they may be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

The polypeptide of the present invention may be also be employed to prevent skin aging due to sunburn by stimulating keratinocyte growth.

The polypeptide of the invention may also be employed for preventing hair loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, the polypeptides of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone marrow cells when used in combination with other cytokines.

The polypeptide of the invention may also be employed to maintain organs before transplantation or for supporting cell culture of primary tissues.

The polypeptide of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

5 The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, polypeptides or polynucleotides and/or agonist or antagonists of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing,  
10 utilization, and storage of energy.

Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, cardiac rhythms, depression (including depressive diseases, disorders, and/or conditions), tendency for violence, tolerance for pain, reproductive  
15 capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins,  
20 minerals, cofactors or other nutritional components.

### **Other Preferred Embodiments**

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95%  
25 identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of

the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization

conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1,  
5 which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous  
10 nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the  
15 complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule  
20 comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete  
25 nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X  
30 wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained

in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at  
5 least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said  
10 step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue  
15 or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by  
20 a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a  
25 nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted  
30 protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any,

comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA  
5 Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least  
10 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said  
15 panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA  
20 clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

25 Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.



Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid  
5 sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

10 Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

15 Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

20 Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

25 Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

30 Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein

encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a  
5 polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained  
10 in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group  
15 consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least  
20 one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence  
25 selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in  
30 Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA

clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of

SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein  
5 encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering  
10 to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel,  
15 horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit, goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

20 In specific embodiments of the invention, for each "Contig ID" listed in the fourth column of Table 2, preferably excluded are one or more polynucleotides comprising, or alternatively consisting of, a nucleotide sequence referenced in the fifth column of Table 2 and described by the general formula of a-b, whereas a and b are uniquely determined for the corresponding SEQ ID NO:X referred to in column 3  
25 of Table 2. Further specific embodiments are directed to polynucleotide sequences excluding one, two, three, four, or more of the specific polynucleotide sequences referred to in the fifth column of Table 2. In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a representative example. All references available through these accessions are hereby  
30 incorporated by reference in their entirety.

TABLE 2

Gene No.	cDNA Clone ID	NT SEQ ID NO: X	Contig ID	Public Accession Numbers
2	HJBCG74	12	839361	T88941, R46383, R46383, H00518, H82353, N22598, W56133, AA161161, AA161160, AA878054, AA928692, AA666012, AI022947, Z40249
5	HISAT78	15	840961	T48825, T48824, T48853, T48854, R21760, R21811, R67243, R67244, R67415, R68199, R68200, H01405, H01406, H28185, H30793, H44227, H44573, R99740, R99919, H60135, H60136, H63359, H66807, H66806, H79129, H79220, H84207, H84522, N34810, N59422, N77099, N99153, W21263, W24160, W46496, W46495, W67370, W67630, W72915, W74250, W76141, W79801, W85839, W85923, W86289, W86333, W89016, W89015, AA025253, AA024547, AA031471, AA031613, AA032244, AA033672, AA047695, AA047745, AA127715, AA127723, AA127778, AA127770, AA127819, AA127867, AA143344, AA143345, AA459714, AA461298, AA464508, AA285177, AA284030, AA284435, AA635592, AA570389, AA730201, AA745767, AA833781, AA887471, AA972658, AA989093, N55953, AA089911, AA411477, AA476754, AA476752, AA628408, AA405021, AA405137, AA703322, AA723187, AA733122, AA775796, AA776727, AA824233, AA846347, AA885202, AA909393, AA917093, AA919032, AA927223, AA947473, AI004051, AI025618, AI061202, AI073812, AI082240, AI091872, DI1834, AA694066, AA699813
9	HISCO45	19	771682	T90955, T85839, R13033, R18802, R43912, R43912, H45369, H46123, H85312, H87331, H87864, AA057597, AA181567, AA182462
12	HJABS31	22	825607	H30439, N28734, AA259109
14	HJACE25	24	835517	H81916, N30086
28	HJPBI77	38	602875	T52159
34	HKACP50	44	828243	R34911, R35618, R49303, R49303, R56040, R56153, H06234, W19914, N91260, AA256879, AA255473, AA613433, AA995671
36	HKADP79	46	754688	N22751, N29184, W04619, W31518, W45542, W45579, AA026810, AA026871
41	HKAJA95	51	834557	T47820, T77712, T77889, R80862, R80863, H70647, H91024, W38742, AA224518, AA224554, AA553758, AA582557, AA582960, AA579630, AA769229, AA808467, AA824622, Z78395, AA091136
46	HISBB66	56	839808	R09785, R09814, R12376, R12404, R74208, H61519, H73452, H89688, H98854, N23576,

				W69976, W69975, W93715, W93564, AA286904, AA286950, AA721417, AA765306, AA789077, AA805090, AA910630, AI031706, AA496532, AA703197, AA884616, AI027011, AI089207
47	HJBDM36	57	773168	T96715, R16552, R16610, R20170, R44957, R44957, R60746, R76979, H18232, H18270, H20958, H21439, H23795, H23796, H40091, H40165, H45825, H45874, R84477, R85009, R85872, R87997, R88048, H84416, H85833, W19332, W25544, W91913, W94987, W92543, W95632, W95631, AA011657, AA011672, AA026068, AA026067, AA037831, AA037832, AA045591, AA045592, AA074343, AA074581, AA084871, AA085018, AA126602, AA136025, AA167689, AA193182, AA193183, AA233051, AA243680, AA424171, AA424213
49	HJMBB20	59	824264	T93306, T93982, R70875, R70874, R73649, R73730, N26796, N39485, AA004609, AA042801, AA134550, AA134551, AA182001, AA188081, AA210803, AA223397, AA223681, AA243523
50	HKADN26	60	802131	R09706, R71934, N25086, AA252759

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

5

### Examples

#### Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector.

10 Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being  
15 isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited</u>
	<u>Plasmid</u>	
	Lambda Zap	pBluescript (pBS)
20	Uni-Zap XR	pBluescript (pBS)
	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSPORT 2.0	pCMVSPORT 2.0
25	pCMVSPORT 3.0	pCMVSPORT 3.0
	pCR <sup>®</sup> 2.1	pCR <sup>®</sup> 2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res.  
30 16:7583-7600 (1988); Altting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Altting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are



commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the f1 origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the f1 ori generates sense strand DNA and in the other, antisense.

Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR<sup>®</sup>2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample

may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly  
5 isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with  $^{32}\text{P}$ - $\gamma$ -ATP using T4 polynucleotide  
10 kinase and purified according to routine methods. (E.g., Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above.  
15 The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to  
20 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase  
25 chain reaction is carried out under routine conditions, for instance, in 25 ul of reaction mixture with 0.5 ug of the above cDNA template. A convenient reaction mixture is 1.5-5 mM  $\text{MgCl}_2$ , 0.01% (w/v) gelatin, 20 uM each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94 degree C for 1 min; annealing at 55 degree C for 1 min; elongation  
30 at 72 degree C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and

the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

**Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide**

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

5

**Example 3: Tissue Distribution of Polypeptide**

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P<sup>32</sup> using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled

15 probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70 degree C overnight, and the films developed according to standard procedures.

20

**Example 4: Chromosomal Mapping of the Polynucleotides**

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95 degree C; 1 minute, 56 degree C; 1 minute, 70 degree C. This cycle is repeated 32 times followed by one 5 minute cycle at 70 degree C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose

25

30

gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

**Example 5: Bacterial Expression of a Polypeptide**

5           A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product  
10   into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp<sup>r</sup>), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning  
15   sites.

          The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which  
20   expresses the lacI repressor and also confers kanamycin resistance (Kan<sup>r</sup>). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

          Clones containing the desired constructs are grown overnight (O/N) in liquid  
25   culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.<sup>600</sup>) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to  
30   increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4 degree C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded  
5 onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH  
10 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl.  
15 Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250  
20 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4 degree C or frozen at -80 degree C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements  
25 operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains:  
1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (lacIq). The  
30 origin of replication (oriC) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR  
5 primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

10

**Example 6: Purification of a Polypeptide from an Inclusion Body**

The following alternative method can be used to purify a polypeptide expressed in *E coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10 degree C.

15 Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10 degree C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution  
20 containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by  
25 centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4 degree  
30 C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4 degree C  
5 without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 um membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive  
10 Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4  
15 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using  
20 a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant  $A_{280}$  monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the  
25 above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 ug of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.



**Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System**

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector  
5 contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak  
10 *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such  
15 as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

20 Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP)  
25 to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a  
30 commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment

then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine  
5 procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("Geneclean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation  
10 mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five ug of a plasmid containing the polynucleotide is co-transfected with 1.0  
15 ug of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One ug of BaculoGold™ virus DNA and 5 ug of the plasmid are mixed in a sterile well of a microtiter plate containing 50 ul of serum-free Grace's medium (Life Technologies  
20 Inc., Gaithersburg, MD). Afterwards, 10 ul Lipofectin plus 90 ul Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27 degrees C. The transfection solution is then removed  
25 from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27 degrees C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of  
30 gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell

culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 ul of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4 degree C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 uCi of  $^{35}\text{S}$ -methionine and 5 uCi  $^{35}\text{S}$ -cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

#### **Example 8: Expression of a Polypeptide in Mammalian Cells**

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV, HIV and the early

promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden),  
5 pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human HeLa, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QCI-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

10 Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the  
15 encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker  
20 is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the  
25 production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the  
30 CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the

cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate  
5 restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide.  
10 Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1%  
15 agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid  
20 pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five µg of the expression plasmid pC6 a pC4 is cotransfected with 0.5 µg of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an  
25 enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in  
30 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest

concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1  $\mu$ M, 2  $\mu$ M, 5  $\mu$ M, 10 mM, 20 mM).

The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200  $\mu$ M. Expression of the desired gene product is analyzed,  
5 for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

#### **Example 9: Protein Fusions**

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For  
10 example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization  
15 signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by  
20 modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate  
25 cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated  
30 by the PCR protocol described in Example 1, is ligated into this BamHI site. Note

that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

```
GGGATCCGGAGCCCAAATCTTCTGACAAACTCACACATGCCCACCGTGC
10 CCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAAAA
CCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGT
GGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG
ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA
CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACT
15 GGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCA
ACCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC
CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAG
GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGT
GGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCT
20 CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTG
GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCA
TGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGG
GTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)
```

**Example 10: Production of an Antibody from a Polypeptide**

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing a polypeptide of the present invention is administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of the secreted protein is prepared and purified to render it

substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., *Nature* 256:495 (1975); Köhler et al., *Eur. J. Immunol.* 6:511 (1976); Köhler et al., *Eur. J. Immunol.* 6:292 (1976); Hammerling et al., in: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56 degrees C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 ug/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (*Gastroenterology* 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-



specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

It will be appreciated that Fab and F(ab')<sub>2</sub> and other fragments of the antibodies of the present invention may be used according to the methods disclosed  
5 herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

10 For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al.,  
15 BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

20 **Example 11: Production Of Secreted Protein For High-Throughput Screening Assays**

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in Examples 13-20.

25 First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel).  
30 Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered

Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at  $2 \times 10^5$  cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine  
5 (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an  
10 expression vector containing a polynucleotide insert, produced by the methods described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem  
15 I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates  
20 of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degrees C for 6 hours.

25 While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of  $\text{CaCl}_2$  (anhyd); 0.00130 mg/L  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ ; 0.050 mg/L of  $\text{Fe}(\text{NO}_3)_3 \cdot 9\text{H}_2\text{O}$ ; 0.417 mg/L of  $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ ; 311.80 mg/L of Kcl; 28.64 mg/L of  $\text{MgCl}_2$ ; 48.84 mg/L of  $\text{MgSO}_4$ ; 6995.50 mg/L of NaCl; 2400.0 mg/L of  $\text{NaHCO}_3$ ; 62.50 mg/L of  $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ ; 71.02 mg/L of  
30  $\text{Na}_2\text{HPO}_4$ ; .4320 mg/L of  $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ ; .002 mg/L of Arachidonic Acid ; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic

Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of  
 Oleic Acid; 0.010 mg/L of Palmitric Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of  
 Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-  
 Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml  
 5 of L-Asparagine-H<sub>2</sub>O; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-  
 2HCL-H<sub>2</sub>O; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0  
 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-  
 H<sub>2</sub>O; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-  
 Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0  
 10 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22  
 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2H<sub>2</sub>O; 99.65 mg/ml of L-  
 Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of  
 Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of  
 Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319  
 15 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and  
 0.680 mg/L of Vitamin B<sub>12</sub>; 25 mM of HEPES Buffer; 2.39 mg/L of Na  
 Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL;  
 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of  
 Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin  
 20 complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed  
 with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal)  
 with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L  
 DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for  
 endotoxin assay in 15ml polystyrene conical.

25 The transfection reaction is terminated, preferably by tag-teaming, at the end  
 of the incubation period. Person A aspirates off the transfection media, while person  
 B adds 1.5ml appropriate media to each well. Incubate at 37 degrees C for 45 or 72  
 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

30 On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml  
 deep well plate and the remaining supernatant into a 2ml deep well. The supernatants  
 from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

#### **Example 12: Construction of GAS Reporter Construct**

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b)

Class 2 includes IFN- $\alpha$ , IFN- $\gamma$ , and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn  
5 activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines  
10 are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

	<u>Ligand</u>	<u>tyk2</u>	<u>JAKs</u> <u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>	<u>STATS</u>	<u>GAS(elements) or ISRE</u>
	<u>IFN family</u>						
5	IFN- $\alpha$ /B	+	+	-	-	1,2,3	ISRE
	IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
	Il-10	+	?	?	-	1,3	
	<u>gp130 family</u>						
10	IL-6 (Pleiotrophic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
	Il-11(Pleiotrophic)	?	+	?	?	1,3	
	OnM(Pleiotrophic)	?	+	+	?	1,3	
	LIF(Pleiotrophic)	?	+	+	?	1,3	
	CNTF(Pleiotrophic)	-/+	+	+	?	1,3	
15	G-CSF(Pleiotrophic)	?	+	?	?	1,3	
	IL-12(Pleiotrophic)	+	-	+	+	1,3	
	<u>g-C family</u>						
20	IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
	IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
	IL-7 (lymphocytes)	-	+	-	+	5	GAS
	IL-9 (lymphocytes)	-	+	-	+	5	GAS
	IL-13 (lymphocyte)	-	+	?	?	6	GAS
25	IL-15	?	+	?	+	5	GAS
	<u>gp140 family</u>						
	IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
	IL-5 (myeloid)	-	-	+	-	5	GAS
30	GM-CSF (myeloid)	-	-	+	-	5	GAS
	<u>Growth hormone family</u>						
	GH	?	-	+	-	5	
	PRL	?	+/-	+	-	1,3,5	
35	EPO	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
	<u>Receptor Tyrosine Kinases</u>						
	EGF	?	+	+	-	1,3	GAS (IRF1)
	PDGF	?	+	+	-	1,3	
40	CSF-1	?	+	+	-	1,3	GAS (not IRF1)

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5':GCGCCTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCC  
GAAATGATTTCCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5':CTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCGAAA  
TGATTTCCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCG  
CCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCGCCCATTCT  
CCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCC  
TCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCT  
AGGCTTTTGCAAAAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol

acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and  
5 XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-  
10 SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding  
15 as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described  
20 in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

25

**Example 13: High-Throughput Screening Assay for T-cell Activity.**

The following protocol is used to assess T-cell activity by identifying factors, and determining whether supernate containing a polypeptide of the invention proliferates and/or differentiates T-cells. T-cell activity is assessed using the  
30 GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway.



The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate  
5 stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing  
10 concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in  
15 RPMI + 10% serum with 1% Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells ( $10^7$  per transfection), and resuspend in OPTI-MEM to a final  
20 concentration of  $10^7$  cells/ml. Then add 1ml of  $1 \times 10^7$  cells in OPTI-MEM to T25 flask and incubate at 37 degrees C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with  
25 supernatants containing polypeptides of the invention and/or induced polypeptides of the invention as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being  
30 screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100,000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred  
5 directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed  
10 in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophane covers) and stored at -20 degrees C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4 degrees C and serve  
15 as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

The above protocol may be used in the generation of both transient, as well as,  
20 stable transfected cells, which would be apparent to those of skill in the art.

#### **Example 14: High-Throughput Screening Assay Identifying Myeloid Activity**

The following protocol is used to assess myeloid activity by determining whether polypeptides of the invention proliferates and/or differentiates myeloid cells.  
25 Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct  
30 produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest  $2 \times 10^7$  U937 cells and

wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing  
5 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM Na<sub>2</sub>HPO<sub>4</sub>·7H<sub>2</sub>O, 1 mM MgCl<sub>2</sub>, and 675 uM CaCl<sub>2</sub>. Incubate at 37 degrees C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degrees C for 36 hr.

10 The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

These cells are tested by harvesting  $1 \times 10^8$  cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described  
15 growth medium, with a final density of  $5 \times 10^5$  cells/ml. Plate 200 ul cells per well in the 96-well plate (or  $1 \times 10^5$  cells/well).

Add 50 ul of the supernatant prepared by the protocol described in Example 11. Incubate at 37 degrees C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold  
20 induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

#### **Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.**

When cells undergo differentiation and proliferation, a group of genes are  
25 activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12  
30 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl

phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

5           The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)

10           5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

          Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1  
15           promoter.

          To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

20           PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and  
25           resuspended with pipetting up and down for more than 15 times.

          Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418  
30           for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

5        The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as  $5 \times 10^5$  cells/ml.

      Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to  
10     $1 \times 10^5$  cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

15

**Example 16: High-Throughput Screening Assay for T-cell Activity**

      NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin,  
20    and by expression of certain viral gene products. As a transcription factor, NF-KB regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

      In non-stimulated conditions, NF- KB is retained in the cytoplasm with I-KB  
25    (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded, causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class I MHC.

      Due to its central role and ability to respond to a range of stimuli, reporter  
30    constructs utilizing the NF-KB promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF-KB would be useful in

treating diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid arthritis.

To construct a vector containing the NF-KB promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGGACTTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC  
10 TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)  
Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

20 5' : CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCCATCTGCCATCTCAATTA  
GTCAGCAACCATAGTCCCGCCCTAACTCCGCCCATCCCGCCCTAACTCCGCCCAGTTCGCCCCATTC  
TCCGCCCCATGGCTGACTAATTTTTTTATTTATGCAGAGGCCGAGGCCCTCGGCCTCTGAGCTATT  
CCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTT:3' (SEQ ID  
NO:10)

25

Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

30 In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP cassette is removed from the above NF-KB/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly,

the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with Sall and NotI.

- Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

#### **Example 17: Assay for SEAP Activity**

- As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

- Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 ul of 2.5x dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C for 30 min. Separate the Optiplates to avoid uneven heating.

- Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

- Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

#### **Reaction Buffer Formulation:**

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75

14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

---

**Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability**

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.



The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog  
5 no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO<sub>2</sub> incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.  
10 A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37 degrees C in a CO<sub>2</sub> incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are  
15 re-suspended to  $2.5 \times 10^6$  cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37 degrees C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to  $1 \times 10^6$  cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is  
20 then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

25 To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular  
30 Ca<sup>++</sup> concentration.

**Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity**

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar

Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyn Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

5           To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyn plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM  
10   HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na<sub>3</sub>VO<sub>4</sub>, 2 mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub> and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4 degrees C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane  
15   bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4 degrees C at 16,000 x g.

20           Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

          Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a  
25   biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

          The tyrosine kinase reaction is set up by adding the following components in  
30   order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg<sub>2</sub><sup>+</sup> (5mM ATP/50mM MgCl<sub>2</sub>), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride,

pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl<sub>2</sub>, 5 mM MnCl<sub>2</sub>, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30 degrees C for 2 min. Initiate the reaction by adding 10ul of the control enzyme or the filtered supernatant.

- 5           The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37 degrees C for 20 min. This allows the streptavidin coated 96 well plate to associate with the  
10   biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37 degrees C for one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and  
15   incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

20   **Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity**

As a potential alternative and/or complement to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be  
25   used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by  
30   substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against  
5 Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4 degrees C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and  
10 cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As  
15 a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive  
20 incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

**Example 21: Method of Determining Alterations in a Gene Corresponding to a**  
25 **Polynucleotide**

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest  
30 in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95 degrees C for

30 seconds; 60-120 seconds at 52-58 degrees C; and 60-120 seconds at 70 degrees C, using buffer solutions described in Sidransky et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton et al., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

**Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample**

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide  
5 is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with  
10 specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample  
15 containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature.  
20 The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard  
25 curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

**Example 23: Formulation**

The invention also provides methods of treatment and/or prevention diseases, disorders, and/or conditions (such as, for example, any one or more of the diseases or disorders disclosed herein) by administration to a subject of an effective amount of a  
5 Therapeutic. By therapeutic is meant a polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with a pharmaceutically acceptable carrier type (e.g., a sterile carrier).

The Therapeutic will be formulated and dosed in a fashion consistent with  
10 good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the Therapeutic alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of the  
15 Therapeutic administered parenterally per dose will be in the range of about 1 ug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for  
20 the hormone. If given continuously, the Therapeutic is typically administered at a dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears  
25 to vary depending on the desired effect.

Therapeutics can be are administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray.  
"Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid  
30 filler, diluent, encapsulating material or formulation auxiliary of any. The term "parenteral" as used herein refers to modes of administration which include



intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics include suitable polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules), suitable hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., *Biopolymers* 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (Langer et al., *J. Biomed. Mater. Res.* 15:167-277 (1981), and Langer, *Chem. Tech.* 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., *Id.*) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988).

Sustained-release Therapeutics also include liposomally entrapped Therapeutics of the invention (*see generally*, Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317 -327 and 353-365 (1989)). Liposomes containing the Therapeutic are prepared by methods known per se: DE 3,218,121; Epstein et al., *Proc. Natl. Acad. Sci. (USA)* 82:3688-3692 (1985); Hwang et al., *Proc. Natl. Acad. Sci.(USA)* 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos.

4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal Therapeutic.

5           In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (*see* Langer, *supra*; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)).

Other controlled release systems are discussed in the review by Langer  
10 (*Science* 249:1527-1533 (1990)).

For parenteral administration, in one embodiment, the Therapeutic is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and  
15 concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to the Therapeutic.

Generally, the formulations are prepared by contacting the Therapeutic uniformly and intimately with liquid carriers or finely divided solid carriers or both.  
20 Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

25           The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten  
30 residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as

polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic  
5 surfactants such as polysorbates, poloxamers, or PEG.

The Therapeutic is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

10 Any pharmaceutical used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutics generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

15 Therapeutics ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by  
20 reconstituting the lyophilized Therapeutic using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the Therapeutics of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or  
25 biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the Therapeutics may be employed in conjunction with other therapeutic compounds.

The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the  
30 Therapeutics of the invention include, but are not limited to, alum, alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG,

and MPL. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to,

5 Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, haemophilus influenzae B,

10 whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic

15 mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

The Therapeutics of the invention may be administered alone or in

20 combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not limited to, other members of the TNF family, chemotherapeutic agents, antibiotics, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, cytokines and/or growth factors. Combinations may be administered either

25 concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination"

30 further includes the separate administration of one of the compounds or agents given first, followed by the second.

In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), TR6 (International Publication No. WO 98/30694), OPG, and neutrokine-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-IBB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7 (International Publication No. WO 98/41629), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms CD154, CD70, and CD153.

In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors. Nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™ (zidovudine/lamivudine). Non-nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, VIRAMUNE™ (nevirapine), RESCRIPTOR™ (delavirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, CRIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and

VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

- 5 In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™, 10 RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™, FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™, KETOCONAZOLE™, ACYCLOVIR™, FAMCICLOVIR™, PYRIMETHAMINE™, LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™ 15 (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In another specific embodiment, Therapeutics of the invention are used in any 20 combination with ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic *Mycobacterium avium* complex infection. In another specific embodiment, Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or 25 prevent an opportunistic *Mycobacterium tuberculosis* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with 30 FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ to

prophylactically treat or prevent an opportunistic fungal infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent an opportunistic *Toxoplasma gondii* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial infection.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered with the Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the Therapeutics of the invention include, but are not limited to, amoxicillin, beta-lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, ciprofloxacin, erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamthoxazole, and vancomycin.

Conventional nonspecific immunosuppressive agents, that may be administered in combination with the Therapeutics of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other immunosuppressive agents that act by suppressing the function of responding T cells.

In specific embodiments, Therapeutics of the invention are administered in combination with immunosuppressants. Immunosuppressants preparations that may be administered with the Therapeutics of the invention include, but are not limited to, ORTHOCLONE™ (OKT3), SANDIMMUNE™/NEORAL™/SANGDYA™

(cyclosporin), PROGRAF™ (tacrolimus), CELLCEPT™ (mycophenolate), Azathioprine, glucocorticosteroids, and RAPAMUNE™ (sirolimus). In a specific embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

5           In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the Therapeutics of the invention include, but not limited to, GAMMAR™, IVEEGAM™, SANDOGLOBULIN™, GAMMAGARD S/D™, and GAMIMUNE™.

10          In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant).

            In an additional embodiment, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-  
15          inflammatory agents that may be administered with the Therapeutics of the invention include, but are not limited to, glucocorticoids and the nonsteroidal anti-inflammatories, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-  
20          acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

            In another embodiment, compositions of the invention are administered in  
25          combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to, antibiotic derivatives (e.g., doxorubicin, bleomycin, daunorubicin, and dactinomycin); antiestrogens (e.g., tamoxifen); antimetabolites (e.g., fluorouracil, 5-FU, methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin,  
30          mercaptopurine, and 6-thioguanine); cytotoxic agents (e.g., carmustine, BCNU, lomustine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine,



hydroxyurea, procarbazine, mitomycin, busulfan, cis-platin, and vincristine sulfate); hormones (e.g., medroxyprogesterone, estramustine phosphate sodium, ethinyl estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol diphosphate, chlorotrianisene, and testolactone); nitrogen mustard derivatives (e.g.,  
5 mephallen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepa); steroids and combinations (e.g., bethamethasone sodium phosphate); and others (e.g., dicarbazine, asparaginase, mitotane, vincristine sulfate, vinblastine sulfate, and etoposide).

In a specific embodiment, Therapeutics of the invention are administered in  
10 combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or any combination of the components of CHOP. In another embodiment, Therapeutics of the invention are administered in combination with Rituximab. In a further embodiment, Therapeutics of the invention are administered with Rituxmab and CHOP, or Rituxmab and any combination of the components of  
15 CHOP.

In an additional embodiment, the Therapeutics of the invention are administered in combination with cytokines. Cytokines that may be administered with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-  
20 alpha. In another embodiment, Therapeutics of the invention may be administered with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

In an additional embodiment, the Therapeutics of the invention are  
25 administered in combination with angiogenic proteins. Angiogenic proteins that may be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as  
30 disclosed in European Patent Number EP-282317; Placental Growth Factor (PlGF), as disclosed in International Publication Number WO 92/06194; Placental Growth

Factor-2 (PIGF-2), as disclosed in Hauser et al., Growth Factors, 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth  
5 Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth  
10 Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent Number DE19639601. The above mentioned references are incorporated herein by reference herein.

In an additional embodiment, the Therapeutics of the invention are  
15 administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention include, but are not limited to, LEUKINE™ (SARGRAMOSTIM™) and NEUPOGEN™ (FILGRASTIM™).

In an additional embodiment, the Therapeutics of the invention are  
20 administered in combination with Fibroblast Growth Factors. Fibroblast Growth Factors that may be administered with the Therapeutics of the invention include, but are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

In additional embodiments, the Therapeutics of the invention are administered in  
25 combination with other therapeutic or prophylactic regimens, such as, for example, radiation therapy.

#### **Example 24: Method of Treating Decreased Levels of the Polypeptide**

The present invention relates to a method for treating an individual in need of  
30 an increased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically

effective amount of an agonist of the invention (including polypeptides of the invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a Therapeutic comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

**Example 25: Method of Treating Increased Levels of the Polypeptide**

The present invention also relates to a method of treating an individual in need of a decreased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and antibodies of the invention).

In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer. For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

**Example 26: Method of Treatment Using Gene Therapy-Ex Vivo**

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a

subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24  
5 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C for approximately one week.

At this time, fresh media is added and subsequently changed every several  
10 days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is  
15 fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an EcoRI site  
20 and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto  
25 agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the  
30 gene is then added to the media and the packaging cells transduced with the vector.

The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media,  
5 containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no  
10 selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or  
15 after having been grown to confluence on cytodex 3 microcarrier beads.

**Example 27: Gene Therapy Using Endogenous Genes Corresponding To Polynucleotides of the Invention**

Another method of gene therapy according to the present invention involves  
20 operably associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA*, 86:8932-8935  
25 (1989); and Zijlstra et al., *Nature*, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made which contain a promoter and targeting sequences, which are homologous to the 5' non-coding sequence of endogenous  
30 polynucleotide sequence, flanking the promoter. The targeting sequence will be sufficiently near the 5' end of the polynucleotide sequence so the promoter will be

operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter.

The amplified promoter and the amplified targeting sequences are digested with the appropriate restriction enzymes and subsequently treated with calf intestinal phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an agarose gel then purified by phenol extraction and ethanol precipitation.

In this Example, the polynucleotide constructs are administered as naked polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, precipitating agents, etc. Such methods of delivery are known in the art.

Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous polynucleotide sequence. This results in the expression of polynucleotide corresponding to the polynucleotide in the cell. Expression may be detected by immunological staining, or any other method known in the art.

Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na<sub>2</sub> HPO<sub>4</sub>, 6 mM dextrose). The cells are recentrifuged, the

supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains approximately  $3 \times 10^6$  cells/ml. Electroporation should be performed immediately following resuspension.

- 5           Plasmid DNA is prepared according to standard techniques. For example, to construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, NY) is digested with HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3' end. Two non-coding sequences are amplified via PCR: one  
10 non-coding sequence (fragment 1) is amplified with a HindIII site at the 5' end and an Xba site at the 3' end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5' end and a HindIII site at the 3' end. The CMV promoter and the fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; fragment 1 - XbaI; fragment 2 - BamHI) and ligated together. The  
15 resulting ligation product is digested with HindIII, and ligated with the HindIII-digested pUC18 plasmid.

- Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap (Bio-Rad). The final DNA concentration is generally at least 120  $\mu\text{g/ml}$ . 0.5 ml of the cell suspension (containing approximately  $1.5 \times 10^6$  cells) is then added to the cuvette,  
20 and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960  $\mu\text{F}$  and 250-300 V, respectively. As voltage increases, cell survival decreases, but the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of  
25 approximately 14-20 mSec should be observed.

- Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following  
30 day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a patient as described above.

5

**Example 28: Method of Treatment Using Gene Therapy - In Vivo**

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 10 5705151, 5580859; Tabata et al., Cardiovasc. Res. 35(3):470-479 (1997); Chao et al., Pharmacol. Res. 35(6):517-522 (1997); Wolff, Neuromuscul. Disord. 7(5):314-318 (1997); Schwartz et al., Gene Ther. 3(5):405-411 (1996); Tsurumi et al., Circulation 15 94(12):3281-3290 (1996) (incorporated herein by reference).

The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial 20 space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the 25 cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al. 30 (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.



The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies  
5 techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of  
10 tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers  
15 in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection  
20 into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express  
25 polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as  
30 the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence

can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or  
5 mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard  
10 recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by  
15 intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future  
20 localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that  
25 quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked  
30 DNA.

**Example 29: Transgenic Animals.**

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, *e.g.*, baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (i.e., polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, *e.g.*, Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their

cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more

than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given  
5 integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

10 Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

15

**Example 30: Knock-Out Animals.**

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (*E.g.*, see Smithies et al., Nature 317:230-234 (1985); Thomas & Capecchi, Cell 51:503-  
20 512 (1987); Thompson et al., Cell 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable  
25 marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in  
30 research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (*e.g.*, see Thomas &

Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

5           In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e.g., knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not  
10   limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention,  
15   e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve  
20   expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

          Alternatively, the cells can be incorporated into a matrix and implanted in the  
25   body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

30           When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which

prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

5 Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

10

**Example 31: Production of an Antibody**

a) Hybridoma Technology

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells  
15 expressing polypeptide(s) of the invention are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of polypeptide(s) of the invention is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

20 Monoclonal antibodies specific for polypeptide(s) of the invention are prepared using hybridoma technology. (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized  
25 with polypeptide(s) of the invention or, more preferably, with a secreted polypeptide-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml  
30 of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are  
5 selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide(s) of the invention.

Alternatively, additional antibodies capable of binding to polypeptide(s) of the  
10 invention can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to  
15 produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by polypeptide(s) of the invention. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and are used to immunize an animal to induce formation of further protein-specific antibodies.

20 For in vivo use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric and humanized antibodies are known in the art and are discussed herein. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214  
25 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

30           b) Isolation Of Antibody Fragments Directed Against  
            Polypeptide(s) From A Library Of scFvs



Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against polypeptide(s) of the invention to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

5           Rescue of the Library.

A library of scFvs is constructed from the RNA of human PBLs as described in PCT publication WO 92/01047. To rescue phage displaying antibody fragments, approximately 10<sup>9</sup> E. coli harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and  
10 grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2xTY-AMP-GLU, 2 x 10<sup>8</sup> TU of delta gene 3 helper (M13 delta gene III, see PCT publication WO 92/01047) are added and the culture incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY  
15 containing 100 µg/ml ampicillin and 50 µg/ml kanamycin and grown overnight. Phage are prepared as described in PCT publication WO 92/01047.

M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III  
20 particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37° C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-  
25 AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations (Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 µm filter (Minisart NML; Sartorius) to give a final concentration of approximately 10<sup>13</sup> transducing units/ml (ampicillin-resistant clones).

30           Panning of the Library.

Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either 100 µg/ml or 10 µg/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 10<sup>13</sup> TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100 µg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

#### Characterization of Binders.

Eluted phage from the 3rd and 4th rounds of selection are used to infect E. coli HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with either 10 µg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., PCT publication WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

**Example 32: Assays Detecting Stimulation or Inhibition of B cell Proliferation and Differentiation**

Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may impart a positive stimulus that allows a B-lineage cell to continue its programmed development, or a negative stimulus that instructs the cell to arrest its current developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak effectors but can, in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

One of the best studied classes of B-cell co-stimulatory proteins is the TNF-superfamily. Within this family CD40, CD27, and CD30 along with their respective ligands CD154, CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays designed to allow for the detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

In Vitro Assay- Purified polypeptides of the invention, or truncated forms thereof, is assessed for its ability to induce activation, proliferation, differentiation or inhibition and/or death in B-cell populations and their precursors. The activity of the polypeptides of the invention on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed *Staphylococcus aureus* Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive

cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added  $10^5$  B-cells suspended in culture medium (RPMI 1640 containing 10% FBS,  $5 \times 10^{-5}$  M 2ME, 100U/ml penicillin, 10ug/ml streptomycin, and  $10^{-5}$  dilution of SAC) in a total volume of 150ul. Proliferation or inhibition is quantitated by a 20h pulse (1uCi/well) with 3H-thymidine (6.7 Ci/mM) beginning 72h post factor addition. The positive and negative controls are IL2 and medium respectively.

In Vivo Assay- BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of a polypeptide of the invention, or truncated forms thereof. Mice receive this treatment for 4 consecutive days, at which time they are sacrificed and various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with polypeptides of the invention identify the results of the activity of the polypeptides on spleen cells, such as the diffusion of peri-arterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes to splenic cells, such as splenic disorganization, are due to increased B-cell representation within loosely defined B-cell zones that infiltrate established T-cell regions.

Flow cytometric analyses of the spleens from mice treated with polypeptide is used to indicate whether the polypeptide specifically increases the proportion of ThB+, CD45R(B220)dull B cells over that which is observed in control mice.

Likewise, a predicted consequence of increased mature B-cell representation in vivo is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are compared between buffer and polypeptide-treated mice.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

**Example 33: T Cell Proliferation Assay**

A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of  $^3\text{H}$ -thymidine. The assay is performed as follows. Ninety-six well plates are coated with 100  $\mu\text{l}$ /well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control mAb (B33.1) overnight at 4 degrees C (1  $\mu\text{g}/\text{ml}$  in .05M bicarbonate buffer, pH 9.5), then washed three times with PBS. PBMC are isolated by F/H gradient centrifugation from human peripheral blood and added to quadruplicate wells (5 x 10<sup>4</sup>/well) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying concentrations of polypeptides of the invention (total volume 200  $\mu\text{l}$ ). Relevant protein buffer and medium alone are controls. After 48 hr. culture at 37 degrees C, plates are spun for 2 min. at 1000 rpm and 100  $\mu\text{l}$  of supernatant is removed and stored -20 degrees C for measurement of IL-2 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100  $\mu\text{l}$  of medium containing 0.5 uCi of  $^3\text{H}$ -thymidine and cultured at 37 degrees C for 18-24 hr. Wells are harvested and incorporation of  $^3\text{H}$ -thymidine used as a measure of proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which does not induce proliferation of T cells is used as the negative controls for the effects of polypeptides of the invention.

The studies described in this example tested activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

**Example 34: Effect of Polypeptides of the Invention on the Expression of MHC Class II, Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells**

Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and

MHC class II antigens). Treatment with activating factors, such as TNF- $\alpha$ , causes a rapid change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FC $\gamma$ RII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional  
5 maturation of the dendritic cells.

FACS analysis of surface antigens is performed as follows. Cells are treated 1-3 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies  
10 for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

Effect on the production of cytokines. Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-  
15 12 strongly influences the development of Th1 helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to measure the IL-12 release as follows. Dendritic cells ( $10^6$ /ml) are treated with increasing concentrations of polypeptides of the invention for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell cultures are then collected and analyzed for  
20 IL-12 content using commercial ELISA kit (e.g., R & D Systems (Minneapolis, MN)). The standard protocols provided with the kits are used.

Effect on the expression of MHC Class II, costimulatory and adhesion molecules. Three major families of cell surface antigens can be identified on monocytes: adhesion  
25 molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the antigen presenting capacity of monocytes and ability to induce T cell activation. Increase expression of Fc receptors may correlate with improved monocyte cytotoxic activity, cytokine release and phagocytosis.

30 FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of polypeptides of the invention or LPS

(positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degreesC. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

5

Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or alternatively, decrease monocyte survival) are known in the art and may routinely be applied to determine whether a molecule of the invention functions as an inhibitor or

10 activator of monocytes. Polypeptides, agonists, or antagonists of the invention can be screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks (American Red Cross, Baltimore, MD) by centrifugation through a Histopaque gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal elutriation.

15

Monocyte Survival Assay. Human peripheral blood monocytes progressively lose viability when cultured in absence of serum or other stimuli. Their death results from internally regulated process (apoptosis). Addition to the culture of activating factors, such as TNF-alpha dramatically improves cell survival and prevents DNA fragmentation.

20 Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in polypropylene tubes in serum-free medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of  $2 \times 10^6$ /ml in PBS containing PI at a final concentration of 5  $\mu$ g/ml, and then incubated at room

25 temperature for 5 minutes before FACScan analysis. PI uptake has been demonstrated to correlate with DNA fragmentation in this experimental paradigm.

Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the

30 release of cytokines after stimulation. An ELISA to measure cytokine release is performed as follows. Human monocytes are incubated at a density of  $5 \times 10^5$  cells/ml with

- increasing concentrations of the a polypeptide of the invention and under the same conditions, but in the absence of the polypeptide. For IL-12 production, the cells are primed overnight with IFN (100 U/ml) in presence of a polypeptide of the invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h and kept frozen until
- 5 use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e.g, R & D Systems (Minneapolis, MN)) and applying the standard protocols provided with the kit.

- Oxidative burst. Purified monocytes are plated in 96-w plate at  $2 \times 10^5$  cell/well.
- 10 Increasing concentrations of polypeptides of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10% FCS, glutamine and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red
- 15 and 19 U/ml of HRPO) is added, together with the stimulant (200 nM PMA). The plates are incubated at 37°C for 2 hours and the reaction is stopped by adding 20  $\mu$ l 1N NaOH per well. The absorbance is read at 610 nm. To calculate the amount of  $H_2O_2$  produced by the macrophages, a standard curve of a  $H_2O_2$  solution of known molarity is performed for each experiment.
- 20 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polypeptides, polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

25 **Example 35: Biological Effects of Polypeptides of the Invention**

Astrocyte and Neuronal Assays

- Recombinant polypeptides of the invention, expressed in *Escherichia coli* and purified as described above, can be tested for activity in promoting the survival, neurite outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the
- 30 proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1



and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate a polypeptide of the invention's activity on these cells.

Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on cortical or hippocampal neurons *in vitro* have demonstrated increases in both neuron survival and neurite outgrowth (Walicke et al., "Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension." *Proc. Natl. Acad. Sci. USA* 83:3012-3016. (1986), assay herein incorporated by reference in its entirety). However, reports from experiments done on PC-12 cells suggest that these two responses are not necessarily synonymous and may depend on not only which FGF is being tested but also on which receptor(s) are expressed on the target cells. Using the primary cortical neuronal culture paradigm, the ability of a polypeptide of the invention to induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.

15

#### Fibroblast and endothelial cell assays

Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, CA). For proliferation assays, the human lung fibroblasts and dermal microvascular endothelial cells can be cultured at 5,000 cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE<sub>2</sub> assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or polypeptides of the invention with or without IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for PGE<sub>2</sub> by EIA

kit (Cayman, Ann Arbor, MI). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or with or without polypeptides of the invention IL-1 $\alpha$  for 24 hours. The supernatants are collected and  
5 assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

Human lung fibroblasts are cultured with FGF-2 or polypeptides of the invention for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with polypeptides of the invention.

10

#### Parkinson Models.

The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection neurons. An animal model for Parkinson's that has been extensively  
15 characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP<sup>+</sup>) and released. Subsequently, MPP<sup>+</sup> is actively accumulated in dopaminergic neurons by the high-affinity reuptake transporter for dopamine. MPP<sup>+</sup> is then concentrated in mitochondria by the  
20 electrochemical gradient and selectively inhibits nicotinamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and eventually generating oxygen radicals.

It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989).  
25 Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J. Neuroscience, 1990).

Based on the data with FGF-2, polypeptides of the invention can be evaluated to  
30 determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic

neuronal survival *in vitro* and it can also be tested *in vivo* for protection of dopaminergic neurons in the striatum from the damage associated with MPTP treatment. The potential effect of a polypeptide of the invention is first examined *in vitro* in a dopaminergic neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm<sup>2</sup> on polyorthinine-laminin coated glass coverslips. The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium containing hormonal supplements (N1). The cultures are fixed with paraformaldehyde after 8 days *in vitro* and are processed for tyrosine hydroxylase, a specific marker for dopaminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the factors are also added at that time.

Since the dopaminergic neurons are isolated from animals at gestation day 14, a developmental time which is past the stage when the dopaminergic precursor cells are proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving *in vitro*. Therefore, if a polypeptide of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the polypeptide may be involved in Parkinson's Disease.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 36: The Effect of Polypeptides of the Invention on the Growth of**

##### **Vascular Endothelial Cells**

On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at  $2-5 \times 10^4$  cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16 units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, Biotechnology, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8 units/ml heparin. A polypeptide having the amino acid sequence of SEQ ID NO:Y, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying

concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is determined with a Coulter Counter.

An increase in the number of HUVEC cells indicates that the polypeptide of the invention may proliferate vascular endothelial cells.

5       The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

10    **Example 37: Stimulatory Effect of Polypeptides of the Invention on the Proliferation of Vascular Endothelial Cells**

For evaluation of mitogenic activity of growth factors, the colorimetric MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium) assay with the electron coupling reagent PMS (phenazine methosulfate) was  
15 performed (CellTiter 96 AQ, Promega). Cells are seeded in a 96-well plate (5,000 cells/well) in 0.1 mL serum-supplemented medium and are allowed to attach overnight. After serum-starvation for 12 hours in 0.5% FBS, conditions (bFGF, VEGF<sub>165</sub> or a polypeptide of the invention in 0.5% FBS) with or without Heparin (8 U/ml) are added to wells for 48 hours. 20 mg of MTS/PMS mixture (1:0.05) are added per well and allowed  
20 to incubate for 1 hour at 37°C before measuring the absorbance at 490 nm in an ELISA plate reader. Background absorbance from control wells (some media, no cells) is subtracted, and seven wells are performed in parallel for each condition. See, Leak *et al. In Vitro Cell. Dev. Biol.* 30A:512-518 (1994).

25       The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 38: Inhibition of PDGF-induced Vascular Smooth Muscle Cell Proliferation Stimulatory Effect**

HAoSMC proliferation can be measured, for example, by BrdUrd incorporation.

5 Briefly, subconfluent, quiescent cells grown on the 4-chamber slides are transfected with CRP or FITC-labeled AT2-3LP. Then, the cells are pulsed with 10% calf serum and 6 mg/ml BrdUrd. After 24 h, immunocytochemistry is performed by using BrdUrd Staining Kit (Zymed Laboratories). In brief, the cells are incubated with the biotinylated mouse anti-BrdUrd antibody at 4 degrees C for 2 h after being exposed to denaturing solution and

10 then incubated with the streptavidin-peroxidase and diaminobenzidine. After counterstaining with hematoxylin, the cells are mounted for microscopic examination, and the BrdUrd-positive cells are counted. The BrdUrd index is calculated as a percent of the BrdUrd-positive cells to the total cell number. In addition, the simultaneous detection of the BrdUrd staining (nucleus) and the FITC uptake (cytoplasm) is performed for

15 individual cells by the concomitant use of bright field illumination and dark field-UV fluorescent illumination. See, Hayashida et al., J. Biol. Chem. 6:271(36):21985-21992 (1996).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to

20 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 39: Stimulation of Endothelial Migration**

This example will be used to explore the possibility that a polypeptide of the

25 invention may stimulate lymphatic endothelial cell migration.

Endothelial cell migration assays are performed using a 48 well microchemotaxis chamber (Neuroprobe Inc., Cabin John, MD; Falk, W., et al., J. Immunological Methods 1980;33:239-247). Polyvinylpyrrolidone-free polycarbonate filters with a pore size of 8 um (Nucleopore Corp. Cambridge, MA) are coated with 0.1% gelatin for at least 6 hours

30 at room temperature and dried under sterile air. Test substances are diluted to appropriate concentrations in M199 supplemented with 0.25% bovine serum albumin (BSA), and 25

ul of the final dilution is placed in the lower chamber of the modified Boyden apparatus. Subconfluent, early passage (2-6) HUVEC or BMEC cultures are washed and trypsinized for the minimum time required to achieve cell detachment. After placing the filter between lower and upper chamber,  $2.5 \times 10^5$  cells suspended in 50 ul M199 containing 1% FBS are seeded in the upper compartment. The apparatus is then incubated for 5 hours at 37°C in a humidified chamber with 5% CO<sub>2</sub> to allow cell migration. After the incubation period, the filter is removed and the upper side of the filter with the non-migrated cells is scraped with a rubber policeman. The filters are fixed with methanol and stained with a Giemsa solution (Diff-Quick, Baxter, McGraw Park, IL). Migration is quantified by counting cells of three random high-power fields (40x) in each well, and all groups are performed in quadruplicate.


The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 40: Stimulation of Nitric Oxide Production by Endothelial Cells**

Nitric oxide released by the vascular endothelium is believed to be a mediator of vascular endothelium relaxation. Thus, activity of a polypeptide of the invention can be assayed by determining nitric oxide production by endothelial cells in response to the polypeptide.

Nitric oxide is measured in 96-well plates of confluent microvascular endothelial cells after 24 hours starvation and a subsequent 4 hr exposure to various levels of a positive control (such as VEGF-1) and the polypeptide of the invention. Nitric oxide in the medium is determined by use of the Griess reagent to measure total nitrite after reduction of nitric oxide-derived nitrate by nitrate reductase. The effect of the polypeptide of the invention on nitric oxide release is examined on HUVEC.

Briefly, NO release from cultured HUVEC monolayer is measured with a NO-specific polarographic electrode connected to a NO meter (Iso-NO, World Precision Instruments Inc.) (1049). Calibration of the NO elements is performed according to the following equation:



The standard calibration curve is obtained by adding graded concentrations of  $\text{KNO}_2$  (0, 5, 10, 25, 50, 100, 250, and 500 nmol/L) into the calibration solution containing KI and  $\text{H}_2\text{SO}_4$ . The specificity of the Iso-NO electrode to NO is previously determined by measurement of NO from authentic NO gas (1050). The culture medium is removed and HUVECs are washed twice with Dulbecco's phosphate buffered saline. The cells are then bathed in 5 ml of filtered Krebs-Henseleit solution in 6-well plates, and the cell plates are kept on a slide warmer (Lab Line Instruments Inc.) To maintain the temperature at 37°C. The NO sensor probe is inserted vertically into the wells, keeping the tip of the electrode 2 mm under the surface of the solution, before addition of the different conditions.

S-nitroso acetyl penicillamin (SNAP) is used as a positive control. The amount of released NO is expressed as picomoles per  $1 \times 10^6$  endothelial cells. All values reported are means of four to six measurements in each group (number of cell culture wells). See, Leak *et al. Biochem. and Biophys. Res. Comm.* 217:96-105 (1995).

The studies described in this example tested activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 41: Effect of Polypeptides of the Invention on Cord Formation in Angiogenesis**

Another step in angiogenesis is cord formation, marked by differentiation of endothelial cells. This bioassay measures the ability of microvascular endothelial cells to form capillary-like structures (hollow structures) when cultured *in vitro*.

CADMEC (microvascular endothelial cells) are purchased from Cell Applications, Inc. as proliferating (passage 2) cells and are cultured in Cell Applications' CADMEC Growth Medium and used at passage 5. For the *in vitro* angiogenesis assay, the wells of a 48-well cell culture plate are coated with Cell Applications' Attachment Factor Medium (200 ml/well) for 30 min. at 37°C. CADMEC are seeded onto the coated wells at 7,500 cells/well and cultured overnight in Growth Medium. The Growth Medium is then replaced with 300 mg Cell Applications' Chord Formation Medium containing control

buffer or a polypeptide of the invention (0.1 to 100 ng/ml) and the cells are cultured for an additional 48 hr. The numbers and lengths of the capillary-like chords are quantitated through use of the Boeckeler VIA-170 video image analyzer. All assays are done in triplicate.

- 5           Commercial (R&D) VEGF (50 ng/ml) is used as a positive control. b-esteradiol (1 ng/ml) is used as a negative control. The appropriate buffer (without protein) is also utilized as a control.

          The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to  
10       test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 42: Angiogenic Effect on Chick Chorioallantoic Membrane**

- Chick chorioallantoic membrane (CAM) is a well-established system to examine  
15       angiogenesis. Blood vessel formation on CAM is easily visible and quantifiable. The ability of polypeptides of the invention to stimulate angiogenesis in CAM can be examined.

- Fertilized eggs of the White Leghorn chick (*Gallus gallus*) and the Japanese qual (*Coturnix coturnix*) are incubated at 37.8°C and 80% humidity. Differentiated CAM of  
20       16-day-old chick and 13-day-old qual embryos is studied with the following methods.

- On Day 4 of development, a window is made into the egg shell of chick eggs. The embryos are checked for normal development and the eggs sealed with cellotape. They are further incubated until Day 13. Thermanox coverslips (Nunc, Naperville, IL) are cut into disks of about 5 mm in diameter. Sterile and salt-free growth factors are dissolved in  
25       distilled water and about 3.3 mg/ 5 ml are pipetted on the disks. After air-drying, the inverted disks are applied on CAM. After 3 days, the specimens are fixed in 3% glutaraldehyde and 2% formaldehyde and rinsed in 0.12 M sodium cacodylate buffer. They are photographed with a stereo microscope [Wild M8] and embedded for semi- and ultrathin sectioning as described above. Controls are performed with carrier disks alone.

- 30       The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to



test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 43: Angiogenesis Assay Using a Matrigel Implant in Mouse**

5        *In vivo* angiogenesis assay of a polypeptide of the invention measures the ability of an existing capillary network to form new vessels in an implanted capsule of murine extracellular matrix material (Matrigel). The protein is mixed with the liquid Matrigel at 4 degree C and the mixture is then injected subcutaneously in mice where it solidifies. After 7 days, the solid "plug" of Matrigel is removed and examined for the presence of new  
10 blood vessels. Matrigel is purchased from Becton Dickinson Labware/Collaborative Biomedical Products.

When thawed at 4 degree C the Matrigel material is a liquid. The Matrigel is mixed with a polypeptide of the invention at 150 ng/ml at 4 degrees C and drawn into cold 3 ml syringes. Female C57Bl/6 mice approximately 8 weeks old are injected with the  
15 mixture of Matrigel and experimental protein at 2 sites at the midventral aspect of the abdomen (0.5 ml/site). After 7 days, the mice are sacrificed by cervical dislocation, the Matrigel plugs are removed and cleaned (i.e., all clinging membranes and fibrous tissue is removed). Replicate whole plugs are fixed in neutral buffered 10% formaldehyde, embedded in paraffin and used to produce sections for histological examination after  
20 staining with Masson's Trichrome. Cross sections from 3 different regions of each plug are processed. Selected sections are stained for the presence of vWF. The positive control for this assay is bovine basic FGF (150 ng/ml). Matrigel alone is used to determine basal levels of angiogenesis.

The studies described in this example tested activity of a polypeptide of the  
25 invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 44: Rescue of Ischemia in Rabbit Lower Limb Model**

To study the in vivo effects of polynucleotides and polypeptides of the invention on ischemia, a rabbit hindlimb ischemia model is created by surgical removal of one femoral arteries as described previously (Takeshita *et al.*, *Am J. Pathol* 147:1649-1660 (1995)). The excision of the femoral artery results in retrograde propagation of thrombus and occlusion of the external iliac artery. Consequently, blood flow to the ischemic limb is dependent upon collateral vessels originating from the internal iliac artery (Takeshita *et al.* *Am J. Pathol* 147:1649-1660 (1995)). An interval of 10 days is allowed for post-operative recovery of rabbits and development of endogenous collateral vessels. At 10 day post-operatively (day 0), after performing a baseline angiogram, the internal iliac artery of the ischemic limb is transfected with 500 mg naked expression plasmid containing a polynucleotide of the invention by arterial gene transfer technology using a hydrogel-coated balloon catheter as described (Riessen *et al.* *Hum Gene Ther.* 4:749-758 (1993); Leclerc *et al.* *J. Clin. Invest.* 90: 936-944 (1992)). When a polypeptide of the invention is used in the treatment, a single bolus of 500 mg polypeptide of the invention or control is delivered into the internal iliac artery of the ischemic limb over a period of 1 min. through an infusion catheter. On day 30, various parameters are measured in these rabbits: (a) BP ratio - The blood pressure ratio of systolic pressure of the ischemic limb to that of normal limb; (b) Blood Flow and Flow Reserve - Resting FL: the blood flow during undilated condition and Max FL: the blood flow during fully dilated condition (also an indirect measure of the blood vessel amount) and Flow Reserve is reflected by the ratio of max FL: resting FL; (c) Angiographic Score - This is measured by the angiogram of collateral vessels. A score is determined by the percentage of circles in an overlaying grid that with crossing opacified arteries divided by the total number in the rabbit thigh; (d) Capillary density - The number of collateral capillaries determined in light microscopic sections taken from hindlimbs.

The studies described in this example tested activity of polynucleotides and polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the agonists, and/or antagonists of the invention.

**Example 45: Effect of Polypeptides of the Invention on Vasodilation**

Since dilation of vascular endothelium is important in reducing blood pressure, the ability of polypeptides of the invention to affect the blood pressure in spontaneously hypertensive rats (SHR) is examined. Increasing doses (0, 10, 30, 100, 300, and 900 mg/kg) of the polypeptides of the invention are administered to 13-14 week old spontaneously hypertensive rats (SHR). Data are expressed as the mean  $\pm$  SEM. Statistical analysis are performed with a paired t-test and statistical significance is defined as  $p < 0.05$  vs. the response to buffer alone.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 46: Rat Ischemic Skin Flap Model**

The evaluation parameters include skin blood flow, skin temperature, and factor VIII immunohistochemistry or endothelial alkaline phosphatase reaction. Expression of polypeptides of the invention, during the skin ischemia, is studied using in situ hybridization.

The study in this model is divided into three parts as follows:

- a) Ischemic skin
- b) Ischemic skin wounds
- c) Normal wounds

The experimental protocol includes:

- a) Raising a 3x4 cm, single pedicle full-thickness random skin flap (myocutaneous flap over the lower back of the animal).
- b) An excisional wounding (4-6 mm in diameter) in the ischemic skin (skin-flap).
- c) Topical treatment with a polypeptide of the invention of the excisional wounds (day 0, 1, 2, 3, 4 post-wounding) at the following various dosage ranges: 1mg to 100 mg.
- d) Harvesting the wound tissues at day 3, 5, 7, 10, 14 and 21 post-wounding for histological, immunohistochemical, and in situ studies.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

5

**Example 47: Peripheral Arterial Disease Model**

Angiogenic therapy using a polypeptide of the invention is a novel therapeutic strategy to obtain restoration of blood flow around the ischemia in case of peripheral  
10 arterial diseases. The experimental protocol includes:

a) One side of the femoral artery is ligated to create ischemic muscle of the hindlimb, the other side of hindlimb serves as a control.

b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-3  
15 weeks.

c) The ischemic muscle tissue is collected after ligation of the femoral artery at 1, 2, and 3 weeks for the analysis of expression of a polypeptide of the invention and histology. Biopsy is also performed on the other side of normal muscle of the contralateral hindlimb.

20 The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

25 **Example 48: Ischemic Myocardial Disease Model**

A polypeptide of the invention is evaluated as a potent mitogen capable of stimulating the development of collateral vessels, and restructuring new vessels after coronary artery occlusion. Alteration of expression of the polypeptide is investigated in  
30 situ. The experimental protocol includes:

a) The heart is exposed through a left-side thoracotomy in the rat. Immediately, the left coronary artery is occluded with a thin suture (6-0) and the thorax is closed.

b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-4  
5 weeks.

c) Thirty days after the surgery, the heart is removed and cross-sectioned for morphometric and in situ analyzes.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to  
10 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 49: Rat Corneal Wound Healing Model**

15 This animal model shows the effect of a polypeptide of the invention on neovascularization. The experimental protocol includes:

- a) Making a 1-1.5 mm long incision from the center of cornea into the stromal layer.
- b) Inserting a spatula below the lip of the incision facing the outer corner of  
20 the eye.
- c) Making a pocket (its base is 1-1.5 mm from the edge of the eye).
- d) Positioning a pellet, containing 50ng- 5ug of a polypeptide of the invention, within the pocket.
- e) Treatment with a polypeptide of the invention can also be applied topically  
25 to the corneal wounds in a dosage range of 20mg - 500mg (daily treatment for five days).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the  
30 invention.

**Example 50: Diabetic Mouse and Glucocorticoid-Impaired Wound Healing Models**

**A. Diabetic db+/db+ Mouse Model.**

5 To demonstrate that a polypeptide of the invention accelerates the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound healing model in the db+/db+ mouse is a well characterized, clinically relevant and reproducible model of impaired wound healing. Healing of the diabetic wound is dependent on formation of granulation tissue and re-epithelialization rather than contraction (Gartner, M.H. *et al.*, *J. Surg. Res.* 52:389 (1992); Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)).

The diabetic animals have many of the characteristic features observed in Type II diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal heterozygous (db+/+m) littermates. Mutant diabetic (db+/db+) mice have a single  
15 autosomal recessive mutation on chromosome 4 (db+) (Coleman *et al.* *Proc. Natl. Acad. Sci. USA* 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria. Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and suppressed cell-mediated immunity (Mandel *et al.*, *J. Immunol.* 120:1375 (1978); Debray-Sachs, M. *et al.*, *Clin. Exp. Immunol.* 51(1):1-7 (1983); Leiter *et al.*, *Am.*  
20 *J. of Pathol.* 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and microvascular lesions, basement membrane thickening and glomerular filtration abnormalities have been described in these animals (Norido, F. *et al.*, *Exp. Neurol.* 83(2):221-232 (1984); Robertson *et al.*, *Diabetes* 29(1):60-67 (1980); Giacomelli *et al.*, *Lab Invest.* 40(4):460-473 (1979); Coleman, D.L., *Diabetes* 31 (Suppl):1-6 (1982)). These  
25 homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel *et al.*, *J. Immunol.* 120:1375-1377 (1978)).

The characteristics observed in these animals suggests that healing in this model may be similar to the healing observed in human diabetes (Greenhalgh, *et al.*, *Am. J. of Pathol.* 136:1235-1246 (1990)).

30 Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic (db+/+m) heterozygous littermates are used in this study (Jackson Laboratories). The

animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study. Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional  
5 Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., *J. Exp. Med.* 172:245-251 (1990)). Briefly, on the day of wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01  
10 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is then created using a Keyes tissue punch. Immediately following wounding, the surrounding skin is gently stretched to eliminate wound expansion. The  
15 wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of surgery and at two day intervals thereafter. Wound closure is determined by daily  
20 measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

A polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups  
25 received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

30 Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds are used to assess whether the healing process and the morphologic appearance of the repaired skin is altered by treatment with a polypeptide of the invention. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-epithelialization and epidermal maturity (Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

Tissue sections are also stained immunohistochemically with a polyclonal rabbit anti-human keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control. Keratinocyte growth is determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon cancer can serve as a positive tissue control and human brain tissue can be used as a negative tissue control. Each specimen includes a section with omission of the primary antibody and substitution with non-immune mouse IgG. Ranking of these sections is based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.



### ***B. Steroid Impaired Rat Model***

The inhibition of wound healing by steroids has been well documented in various *in vitro* and *in vivo* systems (Wahl, Glucocorticoids and Wound healing. In: Anti-Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahl *et al.*, *J. Immunol.* 115: 476-481 (1975); Werb *et al.*, *J. Exp. Med.* 147:1684-1694 (1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular permeability (Ebert *et al.*, *Am. Intern. Med.* 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989); Pierce *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 2229-2233 (1989)).

To demonstrate that a polypeptide of the invention can accelerate the healing process, the effects of multiple topical applications of the polypeptide on full thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and are 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water *ad libitum*. All manipulations are performed using aseptic techniques. This study is conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

The wounding protocol is followed according to section A, above. On the day of wounding, animals are anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue punch. The wounds are left open for the duration of the experiment. Applications of the testing materials are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of wounding and at the end of treatment. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

The polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

Four groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total area of the wound. Closure is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using an Olympus microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds allows assessment of whether the healing process and the morphologic appearance of the repaired skin is improved by treatment with a polypeptide of the invention. A calibrated lens micrometer is used by a blinded observer to determine the distance of the wound gap.

Experimental data are analyzed using an unpaired t test. A p value of  $< 0.05$  is considered significant.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

15

#### **Example 51: Lymphadema Animal Model**

The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of a polypeptide of the invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4 weeks.

Prior to beginning surgery, blood sample is drawn for protein concentration analysis. Male rats weighing approximately ~350g are dosed with Pentobarbital. Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing. Circumference and volumetric measurements are made prior to injecting dye into paws after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal paw). The intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's

Blue. Circumference and volumetric measurements are then made following injection of dye into paws.

Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats are used to dissect and separate the skin flaps. After locating the femoral vessels, the lymphatic vessel that runs along side and underneath the vessel(s) is located. The main lymphatic vessels in this area are then electrically coagulated suture ligated.

Using a microscope, muscles in back of the leg (near the semitendinosus and adductors) are bluntly dissected. The popliteal lymph node is then located. The 2 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are then and ligated by suturing. The popliteal lymph node, and any accompanying adipose tissue, is then removed by cutting connective tissues.

Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving a gap of ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying muscle when necessary.

To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated places on each paw before operation and daily for 7 days are measured. The effect plasma proteins on lymphedema is determined and whether protein analysis is a useful testing perimeter is also investigated. The weights of both control and edematous limbs are evaluated at 2 places. Analysis is performed in a blind manner.

Circumference Measurements: Under brief gas anesthetic to prevent limb movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people then those 2 readings are averaged. Readings are taken from both control and edematous limbs.

Volumetric Measurements: On the day of surgery, animals are anesthetized with Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under

brief halothane anesthetic (rapid immobilization and quick recovery), both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then dipped into instrument to each marked level then measured by Buxco edema software(Chen/Victor). Data is recorded by one person, while the other is dipping the  
5 limb to marked area.

Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and Ca<sup>2+</sup> comparison.

Limb Weight Comparison: After drawing blood, the animal is prepared for tissue collection. The limbs are amputated using a quillitine, then both experimental and control  
10 legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.

Histological Preparations: The transverse muscle located behind the knee (popliteal) area is dissected and arranged in a metal mold, filled with freezeGel, dipped into cold methylbutane, placed into labeled sample bags at - 80EC until sectioning. Upon  
15 sectioning, the muscle is observed under fluorescent microscopy for lymphatics..

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

20

**Example 52: Suppression of TNF alpha-induced adhesion molecule expression by a Polypeptide of the Invention**

The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules  
25 (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium  
30 determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The

local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Tumor necrosis factor alpha (TNF- $\alpha$ ), a potent proinflammatory cytokine, is a stimulator of all three CAMs on endothelial cells and may be involved in a wide variety of inflammatory responses, often resulting in a pathological outcome.

The potential of a polypeptide of the invention to mediate a suppression of TNF- $\alpha$  induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF- $\alpha$  treated ECs when co-stimulated with a member of the FGF family of proteins.

To perform the experiment, human umbilical vein endothelial cell (HUVEC) cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-2; Clonetics, San Diego, CA) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C humidified incubator containing 5% CO<sub>2</sub>. HUVECs are seeded in 96-well plates at concentrations of  $1 \times 10^4$  cells/well in EGM medium at 37 degree C for 18-24 hrs or until confluent. The monolayers are subsequently washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the cells are then evaluated for CAM expression.

Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well plate to confluence. Growth medium is removed from the cells and replaced with 90  $\mu$ l of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10  $\mu$ l volumes). Plates are incubated at 37 degree C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100  $\mu$ l of 0.1% paraformaldehyde-PBS(with Ca<sup>++</sup> and Mg<sup>++</sup>) is added to each well. Plates are held at 4°C for 30 min.

Fixative is then removed from the wells and wells are washed 1X with PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10  $\mu$ l of diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10  $\mu$ g/ml (1:10 dilution

of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

- Then add 20 µl of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution) to each well and incubated at 37°C for 30 min. Wells are washed X3 with
- 5 PBS(+Ca,Mg)+0.5% BSA. 1 tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml of glycine buffer (pH 10.4). 100 µl of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer:  $1:5,000 (10^0) > 10^{-0.5} > 10^{-1} > 10^{-1.5}$ . 5 µl of each dilution is added to triplicate wells and the resulting AP content in each well is
- 10 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 µl of pNPP reagent must then be added to each of the standard wells. The plate must be incubated at 37°C for 4h. A volume of 50 µl of 3M NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on blank wells filled with glycine buffer only. The template is set up to indicate the concentration of AP-conjugate in each standard well [
- 15 5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

- The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the
- 20 invention.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

- 5       The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both
- 10   incorporated herein by reference in their entireties.



## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>77</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT <span style="float: right;">Further deposits are identified on an additional sheet <input type="checkbox"/></span>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 26 April 1999	Accession Number 203957
C. ADDITIONAL INDICATIONS (leave blank if not applicable) <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p>For receiving Office use only</p> <p><input checked="" type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer <i>Virginia L. Lely</i></p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
--	--

**ATCC Deposit No.: 203957**

**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**ATCC Deposit No.: 203957**

#### **DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

#### **SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

#### **NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

***What Is Claimed Is:***

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group  
5 consisting of:
  - (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a  
10 polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - 15 (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X,  
20 having biological activity;
  - (f) a polynucleotide which is a variant of SEQ ID NO:X;
  - (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
  - (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
  - 25 (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.
- 5 3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.
- 10 4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.
- 15 5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide  
20 sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.
- 25 8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.
9. A recombinant host cell produced by the method of claim 8.
- 30 10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

- (a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence  
5 included in ATCC Deposit No:Z;
- (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;
- (c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
- 10 (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
- (e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
- (f) a full length protein of SEQ ID NO:Y or the encoded sequence included in  
15 ATCC Deposit No:Z;
- (g) a variant of SEQ ID NO:Y;
- (h) an allelic variant of SEQ ID NO:Y; or
- (i) a species homologue of the SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, wherein the secreted form or the  
20 full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

25

14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:

- 30 (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

5 17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

10 18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

15

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

20 (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

25 (a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

30

22. A method of identifying an activity in a biological assay, wherein the method comprises:

- (a) expressing SEQ ID NO:X in a cell;
- (b) isolating the supernatant;
- 5 (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.



<110> Komatsoulis et al.

<120> 50 Human Secreted Proteins

<130> PS521PCT

<140> Unassigned

<141> 2000-03-22

<150> 60/126,502

<151> 1999-03-26

<150> 60/172,410

<151> 1999-12-17

<160> 166

<170> PatentIn Ver. 2.0

<210> 1

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1

gggatccgga gccc aaatct tctgacaaaa ctcacacatg cccaccgtgc ccagcacctg	60
aattcgaggg tgcaccgtca gtcttctctt tcccccaaa acccaaggac accctcatga	120
tctcccggac tcctgaggtc acatgcgtgg tgggtggacgt aagccacgaa gacctgagg	180
tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg	240
aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact	300
ggctgaatgg caaggagtac aagtgaagg tctccaacaa agccctccca acccccatcg	360
agaaaacccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc	420
catcccggga tgagctgacc aagaaccagg tcagcctgac ctgcctgggc aaaggcttct	480
atccaagcga catgcgccgtg gagtgggaga gcaatgggca gccggagAAC aactacaaga	540
ccacgcctcc cgtgctggac tccgacggct ccttcttctc ctacagcaag ctcaccgtgg	600
acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat gaggctctgc	660
acaaccacta cagcagaag agcctctccc tgtctccggg taaatgagtg cgacggccgc	720
gactctagag gat	733

<210> 2

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> Site

<222> (3)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 2

Trp Ser Xaa Trp Ser

1

5

<210> 3  
<211> 86  
<212> DNA  
<213> Homo sapiens

<400> 3  
gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60  
cccgaatat ctgccatctc aattag 86

<210> 4  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 4  
gcggcaagct ttttgcaaag cctaggc 27

<210> 5  
<211> 271  
<212> DNA  
<213> Homo sapiens

<400> 5  
ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60  
aaatatctgc catctcaatt agtcagcaac catagtcccc cccctaactc cgcccatccc 120  
gcccctaact ccgcccagtt ccgcccattc tccgcccatt ggctgactaa ttttttttat 180  
ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240  
ttttggaggc ctaggctttt gcaaaaagct t 271

<210> 6  
<211> 32  
<212> DNA  
<213> Homo sapiens

<400> 6  
gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 7  
<211> 31  
<212> DNA  
<213> Homo sapiens

<400> 7  
gcgaagcttc gcgactcccc ggatccgcct c 31

<210> 8  
<211> 12  
<212> DNA  
<213> Homo sapiens

<400> 8  
 ggggactttc cc 12

<210> 9  
 <211> 73  
 <212> DNA  
 <213> Homo sapiens

<400> 9  
 gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg 60  
 ccattcctcaat tag 73

<210> 10  
 <211> 256  
 <212> DNA  
 <213> Homo sapiens

<400> 10  
 ctcgagggga ctttcccgga gactttccgg ggactttccg ggactttcca tctgccatct 60  
 caattagtcg gcaaccatag tcccgcctct aactccgccc atcccgcctc taactccgac 120  
 cagttccgac cattctccgc cccatggctg actaattttt tttatttatg cagaggccga 180  
 ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg 240  
 cttttgcaaa aagctt 256

<210> 11  
 <211> 1599  
 <212> DNA  
 <213> Homo sapiens

<400> 11  
 tcccgggtcg acccacgcgt ccggcgaggc tgggttacgt gaggaagctg ggggtttcgc 60  
 gggcagcttt agagccccag tcagggaaac cgaggccggg ctctctggct gcctcgcgag 120  
 cctcttcctg gctctcgccg ccgccttgag gtgcctagaa tgggttccgg cctccgggga 180  
 gggttccagt aaccgcagga gccaccattg atttgccgtc tgcctgggtg aaagcccagc 240  
 gcgctaacc tttactcgcg acctttcgtc tcaccttcac agcagccctg cgaggagagt 300  
 tgtggactgg ggcaaccttt gccagtgatg agaagtgatg ctctgtggcag tgcctgaatct 360  
 ctctgaatat gattcgaatt gcagccttaa atgccagctc caccattgag gatgatcatg 420  
 aaggaagctt taaaagtcac aaaaccaga caaaggaggc tcaggaagca gaggcttttg 480  
 cattgtacca caaggccctt gatctgcaga aacatgaccg gtttgaggag tctgccaaag 540  
 cctaccatga gctcttgag gcgagcctgc tgcgggaggc agtttcatcc ggtgatgaga 600  
 aagaggggtt gaaacaccct gggctgatac tgaaatattc cacttataag aacttggccc 660  
 agctggcagc ccagcgggag gatctggaga cagccatgga gttctactta gaggcagtga 720  
 tgcctgactc cacagatgac aacctctggt ataagattgg acatgtggcc ctgaggctca 780  
 tccggatccc cctggctcgc catgcttttg aggaagggtc gcggtgcaat cctgaccact 840  
 ggccctgttt ggataacctt atcactgtcc tgtacacctc cagtgtattc acaacatgac 900  
 tgtacttcat ctgcaaagct ttggagaagg attgccggta cagcaaaggc ctggtcctca 960  
 aggagaagat ttttgaggag cagccttctc tccggaagga ctctctcaga atgttctctca 1020  
 aatgtgacat gtcgattcac gatgtttcgg tgagtgcagc tgagacacag gcgattgtag 1080  
 ataggccctt ggggctgcga aaaaagaggc aagcgtctgt tgtgcgggag aaggagccgg 1140  
 acctgaaact tgtgcagccc cattccttcc tttcttcacc tgggaagtgc tcggagagag 1200  
 cttgctggcc atgtacaatc atctcaccac ctgtgagccc ccacgtccca gccttggcaa 1260

aaggattgat	ttgtcggact	accaggaccc	cagccagcct	cttgagtcct	ccatgggtgt	1320
gacgccagtt	aacgtgatcc	agccaagcac	tgtcagcacc	aacccagctg	tggtgtgcgc	1380
cgagcctgtg	gtctcctaca	cctctgtggc	tacaaccagc	ttcccactgc	acagtcctgg	1440
tctgttggag	acaggcgctc	ctgtgggtga	tatttctggg	ggagataaat	ccaagaaagg	1500
ggtaaaacgg	aagaagattt	cagaagagag	tggagaaaca	gcaaagcggc	ggtctgcccg	1560
tgtccgaaac	accaagtgca	aaaaaaaaaa	aaaagggcg			1599

&lt;210&gt; 12

&lt;211&gt; 2455

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1769)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (2433)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (2434)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 12

gggctcggcg	cactccactg	accgtcccga	cgatgctacg	cgcgcccggc	tgccctctcc	60
ggacctccgt	agcgccctgcc	gcggccctgg	ctgcggcgct	gctctcgctg	cttgccgcgt	120
gctctcttct	agagccgagg	gaccgggtgg	cctcgctcgt	cagcccctat	ttcggcacca	180
agactcgcta	cgaggatgtc	aaccccgctg	tattgtcggg	ccccgaggct	ccgtggcggg	240
accctgagct	gctggagggg	acctgcaccc	cggtgcagct	ggtcgcccct	attcgccacg	300
gcacccgcta	ccccacggtc	aaacagatcc	gcaagctgag	gcagctgcac	gggttgctgc	360
aggcccgccg	gtccagggat	ggcggggcta	gtagtaccgg	cagcccgcac	ctgggtgcag	420
cgctggccga	ctggcccttg	tggtacgcgg	actggatgga	cgggcagcta	gtagaraagg	480
gacggcagga	tatgcgacag	ctggcgctgc	gtctggcctc	gctcttcccg	gcccttttca	540
gccgtgagaa	ctacggccgc	tgcggtcat	caccagtcc	aagcaccgct	gcatggatag	600
cagcgccgcc	ttcctgcagg	ggctgtggca	gcactaccac	cctggcttgc	cgccgscgga	660
cgctgcagat	atggagtttg	gacctccaac	agttaatgat	aaactaatga	gattttttga	720
tcactgtgag	aagtttttaa	ctgaagtaga	aaaaaatgct	acagctcttt	atcacgtgga	780
agccttcaaa	actggaccag	aaatgcagaa	cattttaaaa	aaagttgcag	ctactttgca	840
agtgcagta	aatgatttaa	atgcagattt	aattcaagta	gcctttttca	cctgttcatt	900
tgacctggca	attaaagggt	ttaaatctcc	ttggtgtgat	gtttttgaca	tagatgatgc	960
aaaggattta	gaatatttaa	atgatctgaa	acaatattgg	aaaagaggat	atgggtatac	1020
tattaacagt	cgatccagct	gcacctgtgt	tcaggatata	tttcagcact	tgacaaagc	1080
agttgaacag	aaacaaagg	ctcagccaat	ttcttctcca	gtcatcctcc	agtttggtca	1140
tgacagagact	cttcttccac	tgctttctct	catgggctac	ttcaaagaca	aggaaccctt	1200
aacagcgta	aattacaaaa	aacaaatgca	tcggaagttc	cgaagtggct	tcattgtacc	1260
ttatgcctcg	aacctgatat	ttgtgcttta	ccactgtgaa	aatgctaaga	ctcctaaaga	1320
acaattccga	gtgcagatgt	tattaaatga	aaagtggtta	cctttggctt	actcacaaga	1380
aactgtttca	ttttatgaag	atctgaagaa	ccactacaag	gacatccttc	agagttgtca	1440
aaccagtga	gaatgtgaat	tagcaagggc	taacagtaca	tctgatgaac	tatgagtaac	1500
tgaagaacat	ttttaattct	ttaggaatct	gcaatgagtg	attacatgct	tgtaaatagg	1560

aggcaattcc	ttgattacag	gaagctttta	tattacttga	gtattttctgt	cttttcacag	1620
aaaaacattg	ggtttctctc	tgggtttgga	catgaaatgt	aagaaaagat	ttttcactgg	1680
agcagctctc	ttaaggagaa	acaaatctat	ttagagaaac	agctggccct	gcaaattgtt	1740
acagaaatga	aattctycct	acttatatna	gaaatctcac	actgagatag	aattgtgatt	1800
tcataataac	acttgaaaag	tgctggagta	acaaaatata	tcagttggac	catccttaac	1860
ttgattgaac	tgtctaggaa	ctttacagat	tgttctgcag	ttctctcttc	ttttcctcag	1920
gtaggacagc	tctagcattt	tcttaatcag	gaatattgtg	gtaagctggg	agtatcactc	1980
tggaagaaag	taacatctcc	agatgagaat	ttgaaacaag	aaacagagtg	ttgtaaaagg	2040
acaccttcac	tgaagcaagt	cggaaagtac	aatgaaaata	aataattttt	gtattttatt	2100
atgaaatatt	tgaacatttt	ttcaataatt	cctttttact	tctaggaagt	ctcaaaagac	2160
catcttaaat	tattatatgt	ttggacaatt	agcaacaagt	cagatagtta	gaatcgaagt	2220
ttttcaaact	cattgcttag	ctaacttttt	cattctgtca	cttggcttcg	atttttatat	2280
tttctatta	tatgaaatgt	atcttttggt	tgtttgattt	ttctttcttt	ctttgtaaat	2340
agttctgagt	tctgtcaaat	gccgtgaaag	tatttgctat	aataaagaaa	attcttgtga	2400
ctttaaaaaa	aaaaaaaaaa	aaaaaaaaaa	atnnctgcgg	tccgcaaggg	aattc	2455

&lt;210&gt; 13

&lt;211&gt; 1298

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 13

ctcttgcttg	ctgtgactgg	tggagctgcc	gcgctgtccg	cgttatctcc	tcccgggtgag	60
aacgaaccgc	agtgtccacc	ggcgaggagc	cagccctgtc	ccggtcagag	aaagacgacg	120
aggataacctg	ggagcgggcg	gcggccgggc	tgggcccgcg	cggtgcgggc	tggcgactct	180
gctcctccgc	ttgctgctgt	ctctgggaac	tgggtgccag	cgctgagggg	cttcacgagg	240
acagggaccc	ccttccccgg	ctccccgcc	cacctgtccg	gggagggcgg	aagatgccgg	300
tgaagaagaa	gagaaaatcc	cctgggggtg	cagcagcagt	agcgggaagac	ggaggcctca	360
aaaagtgtaa	aatctccagc	tattgcagat	cccaaccccc	tgctagacta	ataagtggag	420
aggaacattt	ttcaagcaag	aagtgcctgg	cttggtttta	tgaatatgca	ggtcctgatg	480
aagtgttagg	gccagaagga	atggaaaaat	tttgtgaaga	cattggtggt	ggaacctgaa	540
aatattatta	tgtagtttt	agcgtggaaa	ttggaggctg	aaacatgggg	attttttacc	600
aaggaagaat	ggttttaaagg	gaatgacttc	attacagtgt	gactgcacag	aaaagttaca	660
aaacaaattt	gactttttgc	gctcaacagt	tgaatgatat	ttcgtcattt	aagaatatct	720
acagatatgc	ctttgatatt	gcaagggata	aagatcagag	aagccttgat	attgatactg	780
ctaaatctat	gttagctctt	ctgcttgagg	ggacatggcc	actgttttca	gtattttacc	840
agtacctgga	gcaatcaaag	tatcgtgtta	tgaacaaaga	tcaatggtac	aatgtattag	900
aattcagcag	aacagtccat	gctgatctta	gtaactatga	tgaagatggt	gcttggcctg	960
ttcttcttga	tgaatttggt	gagtggcaaa	aagtccttca	gacatcatag	caagaactat	1020
gtgaagaaaa	tgcaaacctt	tcaattccca	cgtgtatata	agctaattgt	atgaggggga	1080
aaaaaatcca	acgggtgcat	tttcattcat	atgaaagact	tctcatagta	cttttttttc	1140
ctttttttta	aggaggtttt	tcttggtaca	tgtgatgggc	attgagccac	acctcttctt	1200
agactgaata	ttgaagtttt	tgttttgagt	tatgtttata	acattttatt	cagaacaata	1260
aagattcaga	tttgtgacaa	aaaaaaaaaa	aaaaaaaaaa			1298

&lt;210&gt; 14

&lt;211&gt; 2124

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (8)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (76)

<223> n equals a,t,g, or c

<400> 14

ggcgggttnaa	agggcaatca	gctgttgccc	gtctcactgg	traaaagaaa	aaccaccctg	60
gcgccaata	cgcaanccgc	ctctcgccgc	gcgttgccga	ttcattaatg	cagctggcac	120
gacaggtttc	ccgactggaa	agcgggcagt	gagcgcaacg	caattaatgt	gagttagctc	180
actcattagg	caccccaggc	tttaccttt	atgcttccgg	ctcgatgtt	gtgtggaatt	240
gtgagcggat	aacaatttca	cacaggaaac	agctatgacc	atgattacgc	caagctctaa	300
tacgactcac	tatagggaaa	gctggtacgc	ctgcaggtag	cggtcgggaa	ttcccgggtc	360
gacccacgcg	tccgagttaa	tagacacttg	aattgttttc	ggtttttggc	aattaggaat	420
aaagccactg	ttaacattca	catataagtc	tttgtgtggg	tgtgtatttt	cttacttctt	480
ctgtgaatac	tcataaatgg	gactgctcag	ttatatgata	aatatatgtt	taactttgta	540
agaaactgct	gaattatttt	mcaaagtggg	tgtaccatcc	cgcatcccca	tcagcaatgt	600
ttggaaattc	cagttgctcc	acatacttgt	tatgggtcag	tctttttaat	ttcggccatt	660
ctagtgtgtg	tataatgatt	tcttgctatg	gttttaaat	tgcgttttcc	taaagactaa	720
tgatgttgag	tattttataa	tagttattgg	accaaaggga	gttcttcac	tttgtaacat	780
tgatataata	agattattta	attgctagtt	gatactcagg	ttttgtcact	tgtcccaata	840
atgtccataa	caagcttttc	cttcctctag	atmcaaaact	tgaccacaca	ttgggttttag	900
ttgtcatgtt	tctttgggtt	cttttaactc	cagttttctt	tgtctttctt	agacctcaac	960
ttaaaaaaa	ataataaaaa	agcataggcc	tattattttg	taacatgtct	gtcaatttgg	1020
gtttatctga	tatttcctta	tgataagatt	caggttggtg	tttttggcaa	gaatgttaca	1080
gaaattatct	tataaccttt	tcaagggcat	tgtatcaagg	acccccgtat	gtgactatta	1140
gtgatgactt	tgatgtgtgc	ccaagaaatt	tatgcctatt	ctaagtgtgc	taataatttt	1200
cctgttttct	tctagaattt	tcatagtttc	ggcttttaag	tttatgaact	atttagaaat	1260
attttgtgtg	tgtgatgtga	aatagggatt	gaggttcatt	catttttttt	ttcaactttt	1320
tgccttatta	gcttttccca	ttcttttgay	ttctgcttat	tattattcta	ctttctttga	1380
aatttaattt	gctcttcttt	ttctaccttt	ttaagttgaa	aacttaggtc	aatgttttat	1440
gacctttctt	ttttttaata	taagtattta	aagctatgta	tttcctgcta	agtactagta	1500
tactgcatcc	catgaatttt	gatatgtaat	ttttattatc	acttagttca	aaatatttcc	1560
taattccctt	tgtaattttt	ttgaccttg	ggttattgag	aactgtattt	aggaataactt	1620
ggggctttta	tagatatattt	actgctagtg	gttttttggt	taagtgtgtg	tctktgtgta	1680
tgtgtgtgtg	tatgtgtgta	tcagcaacta	taaagatctc	agtattttga	aatgtattga	1740
aacttatttt	atggttagtc	tattctcaca	ctgctataaa	gaactgcctg	arcgtgggta	1800
aattttacaaa	gaaaagaggt	ttaattgact	caaggkktaa	ttgactcaag	gttctgcatg	1860
gctggggagg	ccttaggaaa	cttacaatga	tggcagaagg	ggaagcaggc	atgtcttaca	1920
cagcagcagg	caagagagta	tgtgagagca	caggaaaaac	taccgtttat	aaaaccttca	1980
gatctggtga	gaattcactc	actatcacga	gaaggcttag	aagaaaaccc	cacaaaacccc	2040
attactaaac	ccacactcaa	cagaaacaaa	gcatacaaaa	aaaaaaaaaa	aaaaaaaaaa	2100
aaaaaaaaaa	aaaaaaaaaa	aaaa				2124

<210> 15

<211> 2312

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (239)

<223> n equals a,t,g, or c

&lt;400&gt; 15

ggcggactga	caggcccg	caagggtcgc	ttcctcgtcc	gcattctgtt	ccaggagagac	60
gagggcgcc	gccgaaccg	ggacttcgtg	gtaggagcgc	ttatcctcgc	ctcatcggca	120
tggacccgag	cgacatctac	gcggtcatcc	agatcccg	cagccgcgaa	ttcgacgtga	180
gcttcgctc	agcgagaagc	tggccctgtt	cctacgcgtc	tacgaggaga	agcgggasna	240
ggaggactgc	tgggagaact	ttgtggtgct	ggggcgga	agtccagctt	gaagacgctc	300
ttcatcctct	tccggaacga	gacggtggac	gtggaggaca	ttgtgacttg	gctcaagcgc	360
crctgcgacg	tgctggccgt	gccggtgaaa	gtgaccgaca	ggtttgggat	ctggaccggg	420
gagtacaaat	aaagacatca	gctgcgccag	ggggaggggc	gggtcaggca	cttgccaggg	480
gccttcttcc	tggggggccga	gaggggctac	agctggtaca	aggggcagcc	caagacatgc	540
tttaaatgtg	gttcccgga	ccacatgagc	ggcactgcac	gcaggacagg	tgcttcaggt	600
gcggggagga	ggggcacctg	agcccttact	gccggaaggg	catcgtgtgc	aacctctgtg	660
gcaagcgagg	acacgccttt	gccagtgctc	ccaaagcagt	gcacaattcc	gtggcagctc	720
agctaaccgg	cgtggccggg	cactaaacac	ccgctgcct	gccagggtga	acacacagcc	780
agcttatccc	tcttaagtgc	caaaactttt	ttttaacca	tttttatcgc	ttttgaagg	840
agattctttt	aaaacctaca	agagacatct	ctctatgcct	tcttaaaccg	agtttactcc	900
atttcagcct	gttctgaatt	ggtagctctg	tcaccaataa	cgactgcgga	gaactgtagc	960
gtgcagatgt	gttgccctc	ccttttaaaa	ttttattttc	gtttttctat	tgggtatttg	1020
ttttgtttct	tgtacttttt	ctctctctcc	ttgccccct	ccgcccctcc	ccgccccata	1080
ccttttcttc	ccctggattt	tcaccctttg	ggctgccttg	ctcatcttta	tgccccagca	1140
ctaggtacgg	ggcccaacac	gtggtaggca	ctccatcagt	gtttgttgaa	ttgaaaacat	1200
tgttgactgt	ggcttctatc	agagtgtcta	ccttttgag	ctcttccctc	ccctcattta	1260
atttgctgct	tttaactctac	gtggtctgag	aatttgtgaa	accagtgttg	ttagaagtgt	1320
atataatctg	aatcaataag	ctctgaatgg	tggccaaggg	ctctcttatg	gcacaaagat	1380
gcattggactt	catgacagct	ccttttggtg	ctcagaagcc	attttttata	gaatcatgga	1440
atctagaata	ttctgctg	aaagaacctg	agagtgtggt	tggaccaatt	ccctggtttt	1500
ccagcagatg	aaacaggccc	aaagaggtta	aatgactggg	tgaaaatcac	atagctgtct	1560
ggtgccagag	ccagcctata	gtagagtccc	ctgaccccaa	gcccgtgtgt	cattccacta	1620
cctctcacac	ttcacaca	tttctcaac	acttgagggc	ccagaaagtc	tgatctctcc	1680
agaatgata	gccagagga	atgctgagaa	atcacctgga	ggaggagca	gaaagagaag	1740
gtttttaagg	aggggcttct	gaatacttgg	gagatacgga	acggaccaag	gaccacactc	1800
cagggtgcat	tcgttgctcc	ctggggcacc	acttctggat	tacagtgtgc	caggctcttt	1860
ggaggcccta	ccccttcccc	attcattgcc	accagtgaga	aatgggggtg	cccctgtgta	1920
aagaaacctt	ccaaagggtt	acatttgcac	cttagcctca	atagctacga	accctagaga	1980
agcagctagc	tggagctcat	gtgcaactcc	tgattctcag	gagaaagatg	gattttaacc	2040
caaaatttat	agttagctgt	taactctaaa	atgtacttgg	gagataggcc	aagcgagagg	2100
tcatgggcca	actaagtgtt	atccagtaga	aaagacagta	cactgctttt	cttttagtgt	2160
ttgcttttcc	tttgctatat	gttttgcctt	ttccttgtgg	cttagaatgt	aaaattgatt	2220
gttaaaagtt	ttgttctgaa	taaatattta	tcttttgtat	tgctaaaaaa	aaaaaaaaaa	2280
aaaaaaaaaa	aaaaaaaaaa	aggggggggg	gc			2312

&lt;210&gt; 16

&lt;211&gt; 1058

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 16

gacttttttt	catctgctta	ttttcagcct	atgtgtgtct	ttataagtga	aatgtgtttc	60
ttgtagacaa	cagataattg	ggctctgttt	ttttatccat	tcagagccac	tctgtgtctt	120
ttgatttgag	agtttagtgc	gtttccattg	ttattaagaa	gtaaggatat	gttctgccat	180
tgtattgttt	gtcttttggc	gttttctctc	ctttctctcc	ctttctctcc	tccttccatt	240
cttttattga	aggtgatttt	gtcttctgtg	atgatttaat	ttcttctctt	ttatttttta	300
ggatatatgy	atatggtttt	tgatttgagg	ttatgatgag	tcttgcaaat	attatcttac	360

aacctattat	tttaagctga	taaccactta	acattgcata	ggcaaaaaca	cacagaggca	420
aaaagaaaac	caataaaagc	tctacacttt	agcctcttgc	tttttaactt	tttgttgtct	480
ctgtttatat	ctcattataa	tttctatgtc	ttgaaaagtt	gtcattatta	gttttggttg	540
gttcatcttt	tagtctttct	ccttaagatc	agagtatttt	atatacaca	tttacagtgt	600
tataatatgc	tgcatTTTTT	tgtgtactta	ctattaccag	tgagtTTTgg	accttcagtt	660
gatttcttat	tactcatcaa	cttccttttc	tttctgattg	aaaaactccc	aggctggaca	720
cgggtggccc	tgctgtaat	cccagcacty	tgggaggctg	agggtggctg	atcccttgag	780
gtcaggagtt	cgagaccatc	ctggaaaatg	tggcaaaagc	ccatctgtwc	taaaaatata	840
aaaaattagt	tgggtgttgt	ggcgagcacc	tgtaatccca	gctacctgtg	aggctgaggc	900
aggagatcgc	ttgaacccgg	gagacgaagg	ttgcagttag	ccgagatcgc	accgctgtac	960
tccagtcctg	ggtgacagag	cgagacgcca	tctcaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1020
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	gggcggcc			1058

&lt;210&gt; 17

&lt;211&gt; 372

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 17

ccacgcgtcc	ggtgaacaca	gagaaatgaa	tttattcccc	atatgggtat	gtttgcccc	60
tggcaatgca	tttccatact	ctttaacttg	gggactgaaa	tggtataaat	tgacagttct	120
actcagaaga	cctttcaagc	atcttgtgtt	tatgagaata	caggggcata	tgcggaatga	180
attcgaacac	atggatgaat	taaatttgaa	aacacacaga	ccgagaggca	gacagttcct	240
aggctgtggt	cgttgcatgg	attttacaaa	actgttaacc	tacacctttg	gctttgctgt	300
gttcattgtc	ctggggaaga	attgtgggtt	taagaattac	tctttgatta	aactacttaa	360
aaaaaaaaaa	aa					372

&lt;210&gt; 18

&lt;211&gt; 2043

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (308)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1672)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 18

gtgcatctac	agggtatgtg	tttaaatgag	gggtagttag	cccacataac	tccccaccct	60
cctgcctcat	ggttagaatg	tatgttcatt	ggggattctg	catacatttt	catcacatat	120
ctacttttct	ggcttttaag	taatatectc	tcctttgttt	ttgccaacag	tgttcatgaa	180
tagtgaatgt	aggaaagcat	tatcattgct	atgttttatt	ttcacactgt	atctcagtat	240
cagcccatat	tttcaatgta	ctaacaactg	tcactgaggc	aaaaagtttt	aattaaagctc	300
acacatgnat	tattttccag	caaacagagc	ctaattgatg	aaattgctaa	ctgtacttcc	360
agggtgcagtc	agtagccagt	agtgcatgtt	agtatgcaat	atggcatggg	ctgttacatg	420
gtgtgatact	agattatata	tttactatga	acgtatgtat	tgttctttta	tgacatctaw	480
ttgktcattc	caaaaatatt	tattgagcac	ggactctgtg	ccagttatta	gttagagtaa	540
taatagctgc	tgtggcaaat	gaatttcctc	acctaagaaa	aataaaagtt	aattatTTTT	600



tctccacata	aaggctctaga	atgttctgcc	gcattgccttc	catgtcatga	ttcagggacc	660
caggtctcctt	ccatcttgtg	gctgccccat	ccactaagtt	ctcagactct	ttcattttcca	720
actggtgggtt	gttgaaagag	aagggtgatga	agggtgtaccc	cacttacatc	ttaccacactt	780
tcacctaraa	gtggcacata	tcacttttat	tgacgtttca	ttagcaagaa	ttgtcctgca	840
acacacttgg	aggaaggcag	ctgggaaatg	ctgtccctgg	ctgtgcacag	ggacatatgt	900
attttatgta	ttttatgaga	ctctttgcag	gatagtctggc	tatctctgcc	acagctggcc	960
atgtctgcca	tggctagaca	tcatttcagg	ctctaggga	atagcagtga	agagaaacag	1020
acaaaaatat	ctgacctcat	ggagcataaa	ttcttgaatt	aaaattctta	aattcttcat	1080
gggatgagac	agacaataac	caggctaaat	cagtatgttg	caaagcagtg	agagctgcta	1140
aaactaagca	gaaaaagggg	tacaaagcat	gagagagaag	gatttgagat	gagatagtgt	1200
ggtcatagaa	armcacactt	tcwatcagca	tgagagaaaa	gctaaagcag	gaaaaggggt	1260
agaaagcatg	agagaaaggt	ttgagatgag	ttagtgtgct	catagaaagc	gtcttgaaag	1320
aatgatatt	ttaagtaaag	aatcagagag	cataaggtgt	ccaactaggt	gaatatctaa	1380
agcaaaaaca	ttccagatgg	agagaatagc	aggtaaaagg	actctgaagc	tggtgaagat	1440
aataagggtg	agaataatag	aagggtgagat	cggagaggca	atcgtcaggc	cagactgtgt	1500
cgggccattt	aggctcatagt	aaaaatctgg	gctttttttt	ttgttttttt	ttttgttttt	1560
gtaactaact	ttattgaact	atgattttca	taaaatatac	ccattcggta	ggttttaaaa	1620
atgtagactg	aagacattca	tataatcacc	actacaataa	aaatatagaa	cntttttatc	1680
atccccataa	gtatccctat	ttatagttca	tacctggccc	cagcaatcac	tgatatgcca	1740
tcacagatta	gtttgttttt	tctaggattt	catacaaatg	gaaaggaaca	gtatgtactc	1800
ttctgtgtct	gtattctgtc	actcaacata	attgctttga	gattcattca	tattgttgtc	1860
agtatcacta	ctttatttct	atttactgcc	attatatgaa	ttctattatg	tggatatacc	1920
ataattttatt	taatctttca	cctactgaga	ggcatttgag	ttgttgataa	tttggggctg	1980
ctatgaataa	atctgctatg	aacataaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaagggcg	2040
gcc						2043

&lt;210&gt; 19

&lt;211&gt; 1557

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1557)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 19

atcccatgag	cgctgcttac	tgttgaatac	caaggctctag	ggctctgctt	cctgtagaca	60
cgcacacgtt	gtctccatcc	aatggccttt	tctgaagtta	cagaaaaacac	caacatggga	120
gggagtttat	gaagcaaagg	caaaggcaac	acgtcggcta	gcttcaggrr	agcaccgtga	180
gaaatgggct	gtattgatac	tgtgaatggt	tgttttccaa	gctgttttat	acaggtttgt	240
tttttcatgg	tgtaggggtat	ttatgacaaa	gtaaatgttg	tgaagggttaa	agataaatta	300
agattatcca	ccaaatgcta	aaaatactga	tgtgtaaatc	acctttatcg	cctcacctct	360
tctacaagct	tttgtggctt	gagggccttt	gtttttggct	tttgtctgga	tgaaagtttt	420
gcccagttgt	gttttaaaaa	caattcctca	tgaacactaa	gattaattgt	gtctgtatct	480
ctggaactgg	gtgctcatgt	tggttttaat	gagcttgcaa	cccttccccg	tttgctttgt	540
ttaaggaggt	gcctctgttc	tttgtggagg	agtgaatgg	agctttaagt	gtgtgtgtgt	600
gttatgtgtg	tttgcacaca	cgcgtgtgtt	attgtagcaa	taacaaaaag	tagccatctc	660
cttgttccag	ctgaaaacct	gctgtgagag	ttttgacaga	gcactttatt	ttcgtcaagt	720
ttcaagtctg	agttcaaaac	cagccctgat	cccttatgac	caactgctac	tcgaccagtc	780
gccactcagt	ggccacctgg	tgcccgttta	gatttttgct	tgggttttac	tggccacctc	840
tatagacgag	agttgcaaag	ttgctttgag	cagagaggga	aagattaatt	tacactgctg	900
gccaccgaag	caggtgtttc	ctgggtagta	atctcacggc	tcttgatctg	gaaacttcag	960
agtacaaatt	gggtggatggt	ggaaggcagg	acacgtatct	ctgtctgacg	gaaaacagac	1020

ctcggggctg	gcgtaaacc	tgctgccagg	ccctctcccc	actgcccac	accggcctag	1080
acacgaagac	caaagcagcc	tgacagggc	aaggccccc	cggaatcctg	cagagcaaac	1140
tcaggttamc	ttgggtccat	gaccgtttgc	attcgaaaca	caatacactg	cctcgttctc	1200
tcagtttagca	gctgggcagc	agcgcacccat	tcatcattta	ggcttggtgt	ttgttgttta	1260
ctctaccaat	gttatgtyga	aactgcattg	taaaaagaga	agaaaatggc	aggtttttcca	1320
ggtccacgga	aaggtttggc	ctgacgctgg	agtgcggtga	tgaacttacg	tgacaatgat	1380
tgtattcctc	agtagcactt	taaacgccga	agacagccct	gcagcaagcc	tgcacacggg	1440
cttggttggg	ttcctttgga	gaagatgtgg	ctggaacaca	aacaatcttt	gaaagaaata	1500
aatgtgcaca	cagaacamwa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaatn	1557

&lt;210&gt; 20

&lt;211&gt; 1796

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 20

ggggacccaa	gatggactgc	ctgtattgct	tccaggataa	agtccaattt	ctagctctgg	60
tttttataac	cttgcttcag	ctcacctttt	ccgtcatcat	ccccctccatc	tcctctccca	120
cgctgggaaa	tggatggctg	cactataactg	tgtgatgtta	ttgctatggt	catgccatcc	180
cctctgcctg	gaatgccctt	ctgcatgaat	gcctgtgaaa	tgttggtgct	cctttgtatg	240
gcctggcttc	cgtggttggc	aggaatctct	tctttcgtgg	tattcctgtc	atctttgtgc	300
atcacagtca	gctttgtatt	cctagcttgt	aagctacttg	aggataaggg	catgtctgaa	360
tctattttaat	ctctttgcac	ctgtttgggc	aattgatggt	ttaaatattt	aaataactaa	420
actctctcta	cagtacatac	tcacttttga	tttatgaatt	ggcaaaattc	aacttttttc	480
cttgaatatt	cttaactga	gatgaattcc	aaaggagagt	gttctgtgtg	tggccttcac	540
tgagtggttt	tctgttacca	gaaagctctt	ggtggccttc	ctcttccctg	gtgtcaaggt	600
tgactgttat	aggaaatggg	aggggagagg	gccgtttctg	ccacgcattg	tcctagggtc	660
ttaacattat	ttaatcctta	taatgcaatg	tatcctcatt	ttacagatga	aacctgagac	720
caaagaacat	gtaacacata	aagtacattg	cagagttagg	atgtgaacct	aactctgatt	780
ctaaacctaa	tgctctcact	ctttcattca	gaggttcagt	cagttctttg	taggctgtag	840
atccagagaa	gctgccgtag	ccaacaatga	agttgttagt	ttttaaaaca	tctatgtggg	900
aagttggctc	ggcacttaaa	aatgtattgt	ttcccaggca	cggtgggttca	cacctgtaat	960
cccagcattt	tgggaggccg	aggcaggcgg	atcattaggt	caaaagattg	agaccatcct	1020
gaccaacatg	gtgaaacccc	gtctctacta	aaagtacaaa	aattagctgg	gtgtggtggc	1080
gcatgcctct	agtcccagct	acctgggagg	ctgaggcagg	agaattgctt	gaaccagga	1140
ggcagagggt	gcagtgagcc	aagatcatgc	tactgcacta	cagcctggca	acaaagcgag	1200
actctgtcta	aaatatatat	atatatatat	attgtttact	actcaccaca	gatctgcagg	1260
agttcactga	tctctaggat	ctgccttaac	tccaacttac	atgttttggg	cactattaca	1320
aactgtcatc	ccagaatgat	gctgcagagg	ctagggctag	gacacagacc	agtgtttcca	1380
tgtgggaatt	ccctcccagt	atttcttagg	aaatgtatgt	tttttgaatc	cataatccct	1440
agaaaaatca	gttgaggaaa	tgagaagtat	tgtaattatt	ctgtgaatag	taacacttac	1500
cattatggag	acatcactag	tttgaaagaa	tccaacttca	tcaaatatta	acgtaccgag	1560
ttgaaggcta	caagaactga	gacaggagca	tagcagagag	aaacgggtcac	catctcatta	1620
gccctatttt	tgggtgttgt	gatgccatta	catctgtata	tctggccata	tcagctgcta	1680
atggtgagtt	cttgcaaaca	aaatgatttg	ataaacaacc	taccatactt	tatacaaatc	1740
ttatggtggt	ccgagaaata	aactttggaa	gcaaaataaa	aaaaaaaaa	aaaaaa	1796

&lt;210&gt; 21

&lt;211&gt; 1328

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 21

gctgcaggaa	ttcggcacga	ggtgacccag	gcacatggtg	caaacctagg	acctccacct	60
cccagctctg	tagccagggg	cagctcactc	caccctgggc	cctggagtgt	gcttacaggc	120
ttccgtgttg	gggggctgcg	aggcctgggc	agcaaaccgc	cttgactgc	ctctggcctg	180
tggaatagtag	atgctcaata	aacctctcct	tcctgtcaga	aactcagtct	ccctatgtgg	240
atgacagcat	tttcctaaag	gatctaaagt	tccatccacc	ttaaactctg	cctgaaggga	300
agactatgaa	actagaaaag	aaaatggtgt	ggatttgtgt	gctactgcag	acactgctgc	360
gacatatatt	aaggagcatg	gaacggaacc	gcgtggatga	taaagtctgc	gtggtgttta	420
caaaggaata	ttcataagca	ctttctgaga	agccccgtgc	agctgctaac	agtgactgcc	480
taggggaaaa	tggacttgaa	ggagtagagg	ccaacttttc	attttatacc	tttctatact	540
ttttaggact	accacctatg	tacgtgcatt	ttatttttgt	taaatgttcg	caggggatat	600
ctggcaggac	aaggaaactgg	ctggaaaggg	gcgcgaggag	atcttctggg	tgacggagat	660
ccagggtggtg	gttactcaga	tgtattttat	ccttcaatga	gaagtttatt	tcgaaaacgt	720
cctgtgtctc	ttccaaagat	agctccagct	gggcaaagtg	gcagctctgt	gggctccaac	780
ggaagaggcc	aaaaggccca	tcctcctcct	gtcccctggg	ttcaattcac	agccctgcct	840
gtctctagct	gtgtgaccc	ggacgtgcct	ctctgcttcc	tcagctcctg	cttcaagaca	900
ggcctaacca	aattttgaga	agtcctccag	agagctcccg	accctaata	gagaagaaga	960
atgaatgttc	tgagtgggta	ccacatggca	gggtgctattc	taaatactga	acagctgtga	1020
accattttaa	tccccgtaag	aaactggtga	gcttggtttc	atttgactca	agaggcccag	1080
agacgaaagc	aactggtcca	gggtcacaca	gccagcagga	agtggtatcag	gggtggaacc	1140
tgggcagctc	ggccctgaag	cgctgcagaa	agtattatct	tgggagcaaa	taggtaatag	1200
gtggtgagag	ccacctaaaa	ataccctcc	tctctggccc	agtaaccact	tctagaaatc	1260
tgccctaaac	aagtaactca	aataaagcga	aagctgagat	aaaaaaaaa	aaaaaaaaa	1320
aactcgag						1328

&lt;210&gt; 22

&lt;211&gt; 1232

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (6)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1211)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 22

ccgggnttcc	agaattcggc	mcsagaaaca	ctacagattt	tacctagtgc	actatcaata	60
ctgttatgct	catagtgcct	ggtggaaaga	ttgtcaatct	gctcttttgt	taaaccacgt	120
attcgatcat	catcatcact	ttcatttagt	aaaaaaaaag	gagcaaggcg	aagaatgggt	180
agtgttccag	tttcaactaa	attgtttgga	tttcgcaact	gcctgccacc	cctactgtca	240
ctgtttcag	tatgaggctg	ggtggtctcg	ttttcaccat	gcatttcagt	gctgtctcct	300
tgggcctgcc	tgtcttgaga	ggaaccttcc	ctgtgctggc	tcctgttgtt	atctgtacct	360
aagttactca	gttctgagtg	catgtctggt	aaatgctggc	catttctttg	aagttctgac	420
tcagaatcgg	cctccattag	agaactcagt	tctccaaacc	cagtcatgat	ctgccttaaa	480
attgaccgaa	gagccactga	tgatggctca	acaagctcat	tctcagaaat	cctacgaaga	540
ggaactgtta	tggtactaac	ataggttcga	atactgacc	gctctaaacg	agaaatgggt	600
cggcgaaagc	ccccactatt	gctttcaata	gtgactgtat	tttctgctag	ccctactctg	660
gatcgagtcc	tatttgcaat	actatcccga	tctctatttt	ctccaggacg	gatactcttc	720
acttgaaggt	ccagtgtgat	tgttggtgat	cgctgtacag	cagttgagga	tctgctggat	780
tcttctcctt	cttctactgt	tattcttgac	acaagccttg	aattagagaa	tggggtatat	840

gcagtacctc	tgcgtttctcg	ttctctatct	tgctctaaaa	agactcgagt	tctacctctc	900
ctcctaacag	atcttctagt	ggtttgctgt	actgggtctac	tttccctttg	ggaattatga	960
taaacagtgc	cactctgtct	ctgaattggg	gaacggcttc	gactattgga	agtagatcgt	1020
aatcttattg	gctctaattc	ttggtttgta	ttcctcactg	taacattact	tctagcccca	1080
ttttccaaa	catgtgctgc	tccaaaccgt	tgccccctcc	tttgccctgag	ttcactacca	1140
cctgattggg	ttgtgtgact	actgaaatta	gtgcgtgaag	cgttagctcg	aggaatgcc	1200
gctgctcccc	naattccatt	tcttaacctt	cc			1232

&lt;210&gt; 23

&lt;211&gt; 557

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 23

gaattcggca	cgaggaggac	tggagagaca	tggcagatgc	tacctgcaca	cttttggtaa	60
tattctgtgt	gatgggatat	gaaatgggtcc	atagaaaaaa	accggaaaaa	tacgccaagg	120
ttaggttcat	tctaagagtc	taaaaatttc	aaaaaccaa	acaacattat	aaatgggtgt	180
tctcaaggac	ctttcactac	ctttttagat	tgtgcttggt	attttcaggc	aagctaaatg	240
tctgatgaag	actgctcttc	ttttgttctg	tgtctgacct	actaattcct	gcccatgctt	300
caaactcagt	tcagaaatca	ctgaagggaac	catccactgc	cggcctgcct	gcaaccacag	360
ctgacagctg	agttagttag	gttttcctgt	ccctattatt	taccagtttg	tactgaaatg	420
ctttcatggg	ctgtgcttcc	agattatgag	ttctgtggaa	tcaggaagta	tgtctctgta	480
ttcttgattt	ctttggcttt	tttgtgtagt	aaagggaactc	aagtaatgtt	aaaaaaaaa	540
aaaaaaaaa	actcgag					557

&lt;210&gt; 24

&lt;211&gt; 1320

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (3)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (52)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 24

ncnaaattaa	ccctcactaa	agggacaaca	agctggagct	ccaccgcggt	gncgtccgct	60
ctagaactag	tggtatcccc	gggctgcagg	aattcggcac	gaggcacctt	cttcaagatg	120
gagctttttg	aaggcatgcy	agagagcacc	aagatttcat	ctctgttggc	agaattggag	180
gcaattcaaa	gaaattcagc	atcccaaaag	agtgtcattg	tctctcagtg	gaccaacatg	240
ctgaaagttg	tagcattgca	cctgaagaag	catggactga	cttatgccac	catcgatggc	300
tctgtcaatc	ccaagcagag	aatggacttg	gtagaggcat	ttaaccactc	cagaggccct	360
caggtaatgc	taatctctct	cttggccgga	gtgttggtct	aaacctgact	ggaggaaatc	420

acctctttct	tttggacatg	caactggaatc	catcacttga	agatcaagct	tgtgaccgaa	480
tttaccgagt	agggcagcag	aaagatgttg	tcatacacag	rtttgtttgt	gaggggaacag	540
tagaagaaaa	gatcttacag	ctccaagaaa	aaaagraaga	tttggccaaa	caagttctat	600
cagggctctg	agaatctgtc	accaagctca	ccttggtgta	cctcagagtc	ctttttggca	660
tctaacctcc	tgtggataag	ggctcagaat	agcaccattg	ctgtgatgtt	gcacctgtaa	720
ccatcttttt	atgggtggag	cagagagtca	atccctgcag	ccaccctgca	gcgcattctt	780
gcagttctct	cagtgcaggc	agttcttcct	ctcaggctga	agatcaagga	gatgctttgt	840
acatgaacag	atgctgagta	tctgttatca	ttgtattgtt	tagtgtcagt	gtatcattta	900
gtatttgtat	cactgtacca	tttagtggtt	tatatcactc	agtcatttaa	tattggttat	960
caccatacag	tttaatat	gtatcatttg	gttcattgta	tcgtttagta	tttctattat	1020
aacatttcta	ttttagtagt	ttgtataata	tttgtgtcat	ttttaatagt	atttgtattt	1080
ttacaaat	gcagtatttg	tagcatttag	tatcattgtt	tcatttagta	tttggtacaa	1140
tctaataaat	actaatccag	tccaatacta	atccaatcca	atactaataa	tactattggg	1200
acaatccaat	actaataata	ctattggtac	aatccaatac	taataatact	aacagtagta	1260
ttgatacaat	ctaataaata	atgtgtttga	cagtgaaaaa	aaaaaaaaaa	aaaaactcga	1320

&lt;210&gt; 25

&lt;211&gt; 1271

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 25

ggcagcagat	cttgacagta	ttatctgtac	ctcctcatga	ggcagataac	ctagatccca	60
gtgacgactc	gttgggacaa	tcattttatg	attacacaga	aaagcaagca	gtgcccata	120
cgggtccccag	atacaaacat	gtggagcaga	atgggtgagaa	gtttgtggta	tataatgttt	180
acatggcagg	gaggcagctg	tgttctaagc	ggtaccggga	gtttgtctatc	ctacaccaga	240
acctgaagag	agagtttgcc	aactttacat	ttcctcgact	cccagggaag	tggccatttt	300
cattatcaga	acaacaatta	gatgcccagc	gtcggggatt	ggaagaatat	ctagaaaaag	360
tgtgttcaat	acgagtaatt	ggtgagagtg	acatcatgca	ggaattccta	tcagaatccg	420
atgagaacta	caatggtgtg	tccgacgtag	agctgagagt	agcattacca	gatggaacaa	480
cggttacagt	cagggttaaa	aagaacagta	ctacagacca	agtatatcag	tacgtaaatt	540
ggcaccta	gagtttctc	acaaaactc	cattcagaat	tatacatcag	ctgtgcccagg	600
cacctgcttg	accattcgaa	agtggctttt	tacaacagaa	gaagaaattc	tcttaaatga	660
caatgacctt	gctgttacct	actttcttca	tcaggcagtc	gatgatgtga	agaaagggtta	720
catcaaagca	gaagaaaagt	cctatcaatt	acagaagcta	tacgaacaaa	gaaaaattggt	780
catgtacctc	aacatgctaa	ggacttgtga	gggctacaat	gaaatcatct	ttccccactg	840
tgcctgtgac	tccaggagga	aggggcacgt	tatcacagcc	atcagcatca	cgcacttta	900
actgcatgcc	tgcactgaag	aaggacagct	ggagaaccag	gtaattgcat	ttgaatggga	960
tgagatgcag	cgatgggaca	cagatgaaga	agggatggcc	ttctgtttcg	aatatgcacg	1020
aggagagaag	aagccccgat	gggttaaaa	cttcacgcca	tatttcaatt	acatgcatga	1080
gtgcttcgag	aggggtgtct	gcgagctcaa	gtggagaaaa	gagaacattt	tccagatggc	1140
gaggtcacag	cagagagatg	tggccacct	gcctttcctt	atcccccttc	cttccccctca	1200
cccccatcct	cttactcctt	tcattgtccc	tttcagacag	agtaaccatt	aacaaaaaaa	1260
aaaaaaaaaa	a					1271

&lt;210&gt; 26

&lt;211&gt; 587

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 26

ggcagcagga	ggagcccatc	atggcgacgc	cccctaagcg	gcgggcgggtg	gaggccacgg	60
gggagaaagt	gctgcgctac	gagaccttca	tcagtgcagc	gctgcagcgg	gacttgcgaa	120

agggtgctgga	ccatcgagac	aagggtatatg	agcagctggc	caaatacctt	caactgagaa	180
atgtcattga	gcgactccag	gaagctaagc	actcgaggtt	atatatgcag	gtggatttgg	240
gctgtaactt	cttcgttgac	acagtgggtcc	cagatacttc	acgcatctat	gtggccctgg	300
gatatgggtt	tttcctggag	ttgacactgg	cagaagctct	caagttcatt	gatcgtaaga	360
gctctctcct	cacagagctc	agcaacagcc	tcaccaagga	ctccatgaat	atcaaagccc	420
atatccacat	gttgctagag	gggcttagag	aactacaagg	cctgcagaat	ttcccagaga	480
agcctcacca	ttgacttctt	ccccccatcc	tcagacatta	aagagcctga	atgccaaaaa	540
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaa		587

&lt;210&gt; 27

&lt;211&gt; 1069

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 27

cgcgcggtctg	ctccgctctc	cccgtctcaa	gcgccgatct	gggcacccgc	caccagcatg	60
gacgctcgcc	gcgtgccgca	gaaagatctc	agagtaaaga	agaacttaaa	gaaattcaga	120
tatgtgaagt	tgatttccat	ggaaacctcg	tcctcctctg	atgacagttg	tgacagcttt	180
gcttctgata	atthttcaaa	cacgaaacct	aaattcaggt	cagatatcag	tgaagaactg	240
gcaaatgttt	tttatgagga	ctctgataat	gaatctttct	gcggcttttc	agaaagttag	300
gtgcaagatg	tawtagacca	ttgtggattt	ttacagaaac	caaggccaga	tgctactaac	360
gaactggccg	gtatttttca	tgccgactct	gacgatgaat	cattttgcgg	tttctcagag	420
agtgagatac	aagatggaat	gaggctgcag	tcagttcggg	aaggctgtag	gacccgcagc	480
cagtgcaggc	actctggacc	tctcaggggt	gcgatgaagt	ttccagcgcg	gagtagaccg	540
ggagcaacca	acaaaaaagc	agagtcccgc	cagccctcag	agaattctgt	gactgattcc	600
aactccgatt	cagaagatga	aagtgggaat	aatttttttg	agaaaagggc	tttaaataata	660
aagcaaaaaca	aagcaatgct	tgcaaaactc	atgtctgaat	tagaaagctt	ccctgggtcg	720
ttccgtggaa	gacatccccct	cccagggtcc	gactcacaat	caaggagacc	gcgaaggcgt	780
acattcccgg	gtgttcttcc	caggagaaac	cctgaacgga	gagctcgtcc	tcttaccagg	840
tcaaggtccc	ggatcctcgg	gtcccttgat	gctctaccca	tggaggagga	ggaggaagag	900
gataagtaca	tggttggtgag	aaagaggaag	accgtggatg	gctacatgaa	tgaagatgac	960
ctgcccagaa	gccgtcgctc	cagatcatcc	gtgacccttc	cgcataataat	tcgcccagtg	1020
gaagaaatta	cagaggagga	gttgagagaac	gtctgcagca	attctcgag		1069

&lt;210&gt; 28

&lt;211&gt; 1009

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 28

ggcacgagca	aagggtgaagc	tggttttcat	ggtctcctga	gggcccctgg	cccctgggag	60
atgggtcaca	ctccctgaat	gctgtgctgt	tggtttccct	ggaggattct	tgctgcaggc	120
cagggtcccg	attctccaca	ctcaccacaa	gtggctgggt	gtgacttgac	acgggtgtgaa	180
agtgaggagg	cgcgagcact	cagtatccag	cgagcagcat	tggtgggtct	agaaaattac	240
tacaaagatt	tcaccatcta	taaccacaaac	ctcctaacag	cctccaaatt	ccgagcagcc	300
aagcatatgg	ccgggctgaa	agtctacaat	gtagatggcc	ccagtaacaa	tgccactggc	360
cagtccccgg	ccatgattgc	tgacgctgct	cggcgccagg	actcaagcca	caacgagttg	420
tattatgaag	aggccgaaca	tgaacggcga	gtaaagaagc	ggaaagcaaa	ggctgggtgt	480
tgcaaggtaa	gaggccttca	tccacattca	gcgtctccag	gctgaggagc	agcagaaagc	540
ccaggtggag	gtgatggacc	ctagggagcc	cgccaggccg	atthttccct	ccatggccag	600
ggctctccag	aagtaacctgc	gcatcacccg	cagcagaaac	taccacagca	tggagagcat	660
cctgcagcac	ctggccttct	gcatcaccaa	cgcatgacc	cccaaggcct	tcctagaacg	720
gtacctcagt	gcgggcccga	ccctgcaata	tgacaaggac	cgctgggtct	ctacacagtg	780

gaggcttgtc	agtgatgagg	ctgtgactaa	tggattacgg	gatggaattg	tgttcgtcct	840
taagtgtttg	gacttcagcc	tcgtagtcaa	tgtgaagaaa	attccattca	tcatactctc	900
tgaagagttc	atagacccca	aatctcacia	atttgcctt	cgcttacagt	ctgagacatc	960
cgttttaaag	ttctatatatt	gtggctttat	taaaaaaaaa	aaaaaaaaaa		1009

<210> 29  
 <211> 603  
 <212> DNA  
 <213> Homo sapiens

<400> 29	
cccacgcgtc	cggtcggact gttttgatct cttttaattg ttctgacaga tagttgggga 60
tgagagccga	ataagggtttg cctgaaataa ctgacactat ataatttctg ctttggcaaa 120
tactaagttc	taacttgtca ttcctggtag aacaagcttt atttttcgag cctagcaatg 180
atctagaagc	agatgttata tcagtgcctt ttgcaatttg ttgtgtgggt tttttttttt 240
ttaaagccac	acaataattt tggaaaacaa tgtatgggta gaacatgtgt ctgttaattg 300
cacacaaaaac	cacttttaata gggtagacag tttaatttga aggaataagt tcataatact 360
gaagctagaa	ccaagcagaa tctgtttttt tctgaggagt atcggttagca taaatgtgat 420
tataaacata	gtacacttga tataatggagg cagtgcacgc tattttttaca aaatttaaat 480
ctgcaaatgg	attcaacatg tttatgggtt attaaaattg tctgatttct taggttcttt 540
atagtacacg	tgttgaaaat aaatgattaa gaattgtttc aagaaaaaaaaa 600
aaa	603

<210> 30  
 <211> 403  
 <212> DNA  
 <213> Homo sapiens

<400> 30	
ccacgcgtcc	gaccaattct gatgtagatc tcacattata gcataacatt acagtagaag 60
gaatgaaaac	taagaaagta aatagtgaac atacagaact tactgcattt ccactttaaa 120
acctatttat	tttccctttt tctaatttta aacttttgtg gtcattcaga acctaattgtg 180
ccttgtgttg	acatttccat agacttcaca ctttacaaaa tttactgttt aaaaatactt 240
gtcaaatgat	ttactgaacc tttatacaaa agtacccttt ctaaattgac catttaaaaa 300
tgtatttttg	tgataccgtc attatgttct gcatttgcct cattttggca gatctacagt 360
atgccattaa	agtttagtgt tgtttttgaa aaaaaaaaaa aaa 403

<210> 31  
 <211> 658  
 <212> DNA  
 <213> Homo sapiens

<400> 31	
gcagtttata	ctttccaggt ttgcactcct ggagcaggtg aatgccttgg tgcccatgct 60
ggacagtgtc	cacatcaaag cgtttcctga gcatgctgcc cgctgcagc gcttggccca 120
gatccacatt	cagcagcagg accagtgtgt ggaaatcact gaggagtcca aggcctctct 180
ggaggaatac	aacaagacta caatgcttct ctccaagcaa ttcgtgcagt gggatgagct 240
actttgccag	ctagaggccg ccacgcaagt gaagccagca gaggagtgat agctgtctcc 300
catcccaaag	tgggcctggg cagtcaggct ccagggccct atgccaacct gcctttgtta 360
caaggcagag	gaagctttgt atttattggc ttcaaggccc acctctctgt actctgggct 420
ctaaagtggg	aggtcagggt acctgagggt tgcaatttgc aacacccacc ctcccccaa 480
tcagtgttct	tatttcagtg acaataaacc atagagatga aaaaaaaaaa aaaaaaaaaa 540

aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	600
aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaa	658

<210> 32  
 <211> 633  
 <212> DNA  
 <213> Homo sapiens

<400> 32						
cccacgcgtc	cggccacttg	gaatatatat	cgatacatta	tggtgccgag	tggtaacatg	60
ggagtgtttg	atccaacaga	aatacacaaat	cgagggcagc	tgaagtcaca	catgaaagaa	120
gccatgatca	agcttggttt	ccacttgctc	tgtctcttca	tgtatcttta	tagtggtagc	180
aactgccctt	gctaatacacc	gtaacctcgg	ctgagaaaga	agaggaagcg	aaatccaaga	240
tgcagctcag	ttcatcaaag	cctagcaggt	cccctcagct	gccttttcat	gcctgccaca	300
gactacagta	ggacaaaacc	tgacctggtc	tttgaagtta	agagctaaga	aagcttccta	360
tagtagtata	tcccatggca	cttaccacat	tctatctggg	attacaatta	tttgtatgca	420
attaatcact	cttagattgt	atgttctctg	agggcagaat	atgccattc	atatttgtat	480
cttcttctct	ctgctcttgg	cacctaacac	agtgccttgc	acacaaacaa	taaattgattg	540
ttgagtgaat	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	600
aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaa			633

<210> 33  
 <211> 275  
 <212> DNA  
 <213> Homo sapiens

<400> 33						
ccacgcgtcc	gagcttcact	ccttgctggc	cagggagtgt	gggactcaga	gggaccactt	60
ggggccagcc	agactggcct	caatggcgga	ctcagtcaca	ttgactgacg	gggaccaggg	120
cttgtgtggg	tgcagagcgc	cctcatgggt	ctgggtgctgt	tgtgtgtagg	tcccctgggg	180
acacaagcag	gcgccaatgg	tatctgggcg	gagctcacag	agttcttggg	ataaaagcaa	240
cctcagaaca	cttaaaaaa	aaaaaaaaa	aaaaa			275

<210> 34  
 <211> 1439  
 <212> DNA  
 <213> Homo sapiens

<400> 34						
ccacgcgtcc	gggtctcttc	atttccagca	gacacccttc	ctcttaccca	gtggagagga	60
ctcaggggaat	cttggcagaa	ccctgctggc	accatcagcg	gcgtatgctc	ctcctcgttt	120
ctgtcttttc	accggttctc	ttctctcggt	cttccactgt	ggagatggat	gtggaacctt	180
tttgcttagt	cctgtcttct	gcctttctct	agattacccc	accgatctcc	tgtttgtgtc	240
tcaatatgtt	cttttctctg	ctcagatctc	cccattctta	aaagaactgt	cccctctctc	300
tgcctctctt	cttcaattct	gccctctctg	tgtctgagac	cgttcacagg	aacgctctgc	360
caaggatgcc	tgactggccc	ccagcaagcc	actcctgggg	cccttggtgt	ctggctccct	420
tccagccctg	ccttctctgt	tctgtctctc	gactccgtgg	tctctcttgg	gcttcagggc	480
ctgggacctc	ctggcagcag	tgggtacccc	caccccccaa	ccccacacac	acgggaaacc	540
accctgggtg	ccagatatat	atatatatat	atatatacac	atatatatat	gcatgtgtat	600
gtattttacac	acacctggga	aatatatata	tctggtgtat	atatatttac	acacacctgg	660
gaaactgccc	tgatgaccag	agcacactgt	ctttctcttc	tgccctctga	gcacctcaag	720
ctgtgtgtcc	tggcgctctt	cttctgttct	cccctcacag	aattcacgtt	cctccacagt	780



ctcagagaac	atctttgagg	aaatggctct	cccatatggg	actctcactt	ctgtcagtc	840
tgaacatcag	tgggtgagga	cagggctggg	cttgccctc	agaagaggag	aggagcacct	900
gcctccgggg	agggtcccta	tcccaaggag	tctgtcccta	aggctgggat	ggggcttctt	960
ggtctccaca	ggttccactc	ccaccagcca	gctcttcttc	ctgactccct	gtgtctgtgc	1020
tgggcacctc	ctcctgtctg	ccaccaggct	tggagtttgg	gaatcatctc	caatactttt	1080
ctctccctgt	cctgcagcta	cctgtttgtt	tgtctttaac	gggtccccc	tccctttcct	1140
ccctacccca	gtgcccacag	agaatatcta	acagcaaac	gtacttttcc	tccactggac	1200
tccaccctgg	cttggagcag	atatggaatt	cccagttctg	cccacagcct	cctcccttag	1260
ctcccgtccc	cagctgtctc	cccccaaca	ccccactcct	cctgccacag	ttttaaaaag	1320
tgttgcttgg	attgggccat	cgcctgttta	gaaacttaaa	tgtcttttgt	ggcttctcaa	1380
ataaacattt	aggcccttag	tttggaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	1439

&lt;210&gt; 35

&lt;211&gt; 1020

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 35

gggggacacg	ggaaggccc	gtgggaatag	gcctttgagg	ggaagcacgc	tgatctcttg	60
ttctgcagcg	catgcttggg	atgggatgcg	catgccttct	ctcactaaga	ctaggactgc	120
ttacagaatg	cgaatataag	tatccttatt	tgggagaaaa	gtacattttc	aagggtggt	180
aaaatggcgt	ggaggaagg	aggatccagg	gagccttctg	aagagtattg	tcaggatgtc	240
tcttctcttt	cagccacctg	gatatgtttc	acattttgtt	tcccaaacaa	ggactagatt	300
ggatcccaga	agggaatggt	ttccttagta	tacattccga	attcctttgt	aagggaaaaa	360
tccacttcat	ctggctctaag	aatacataag	aacaaatgaa	aatgttgttg	ctggagatgt	420
tcctgagtta	atatcaggat	gtttgcctgc	tgtttctctg	tttaccaaac	aaaacatagc	480
tgccaattca	tccatctgta	aaagtgtccc	ttgtggaccc	cctcaagaga	agtactgggt	540
attttatctg	cagaaaacgt	tttatkggga	gttggtactt	tctgtgactg	aagtggggaa	600
catgagggtc	cctttaccga	gccctcatat	tccatgtgta	ctctgtattt	tattgaggct	660
gtttcccgat	cagaacacgc	tctctctttg	tttgtcattc	caaactcttc	agtgctctta	720
gggtctctgag	ggccctggag	agcctcacc	aacctctcat	ccttccatgg	ctgtccccac	780
ctctgtgcac	ttatgagtca	atgttgccgc	acttcattac	atgctgttca	tattacagca	840
ttataagatt	ttttctttta	aaagcctatc	ttcttcaatc	gggtagtaag	accattgtgg	900
gttgaggcat	gtttcatact	tcccacataa	tactccaga	cttaaaacag	aaccggaaat	960
acatgaaata	aaaaattatt	tttctgttct	caaataaaaa	aaaaaaaaa	gggcggccgc	1020

&lt;210&gt; 36

&lt;211&gt; 1076

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 36

gagacaatag	gggaagagat	ttttatgttt	tgttccactgc	tgttttcaca	gtatgttcaa	60
tggctcttgg	cacagaatag	acaatatctg	ttgactgaat	gctattggac	attatctgtt	120
tattgaatta	gtgataaata	ttttacccta	cgttgatata	aatggacata	ttctacaggt	180
aacaaccctt	tattttctaaa	gcatgatctc	aatgtattat	aaattactga	agtagattag	240
ttcttttctt	tttttttttg	agacggagtc	tcgtctgtgc	acccaggttg	gagtgcagtg	300
gcgtgatctc	gtttccactgc	aacctccgcc	tcccagggtc	aagtgattct	cccgcctcag	360
cctcccgagt	agctgggatt	acaggcatat	accacccgcc	cagcgaatgt	ttgtagagac	420
gggtctctgc	tgtgttgcca	ggctggctcat	caactctga	cctcaggtga	tccaccacc	480
tcggcctccc	aaagtgtctg	gattacaggc	gtgaaccacc	tcgcccggcc	gattagttct	540
taaagtagta	atagacatct	cccctccacc	tttggaact	gcctcctcta	gggagaagag	600
taccccgtag	gttaggaagc	caggtgatat	ggtttgaata	tttgttctct	ccaaatctca	660

cgtggcaatg	tgacctcctg	tgttgagggt	agggcctggt	gagagggtgtt	tggatcatgg	720
ggcagatgcc	tcctgaatgg	cttgggtgtca	tcctgtaaca	agtgtattct	tgccctattt	780
gttcccatga	gaacctactg	tttaaaagag	tctgggtactt	cctcttctcg	ctctctctct	840
ctctcgcttc	tgtctcacca	tgtgacatgc	tggctttcct	tcaccttctg	ccatgagtag	900
aagggtcctg	gggccctcac	cagaaaaaaa	tgtcgggtgcc	atgcttcttg	tacagcctgt	960
gggaccatga	gccaaataaa	cctcttttct	ttataaatta	ccctagcctc	aggattttct	1020
ttgtatcaac	aacaacaaca	agggcacaca	caaaaaaaaa	aaaaaaaaaa	ctcga	1076

&lt;210&gt; 37

&lt;211&gt; 1109

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 37

ggcacgagct	ggagtccgac	ctgccaaagt	ccgtgacact	tctgaaaaat	ctccaggagc	60
aagtgatggc	tgttaactgca	caagtgaaat	caactgacaca	aaaagttcaa	gctgggtgcct	120
atcctacaga	aaaggggtctc	agcttcttgg	aagtgaaga	ccagctgctg	ctcatgtacc	180
ttatggattt	gacccacctc	attctggaca	aagcctcagg	aggatctctt	cagggacatg	240
atgcagtttt	gagactggta	gagattcgaa	cggttttgga	aaagcttcgt	cccttggacc	300
aaaagctgaa	gtatcaaatt	gacaagctga	tcaagactgc	agtgcagggc	agccttagtg	360
agaatgacct	acttcgtttt	aagcctcatc	ccagcaatat	gatgagcaag	ttgagctctg	420
aggatgagga	ggaagatgaa	gcagaagatg	accagtctga	ggcttcaggg	aagaaatctg	480
tgaaggaggt	gtctaagaaa	tatgttcctc	cacgcttggg	tccagtacat	tatgatgaaa	540
cagaagctga	gcgggagaag	aagcgtctag	aacgagccaa	gagacgggca	ttgagcagct	600
ctgtcattcg	tgaacttaag	gagcagtact	cagatgctcc	agaggaaatc	cgtgatgctc	660
ggcatcccca	tgttacccgc	cagagtcagg	aggaccaaca	caggattaac	tatgaggaga	720
gcatgatggg	gcgttttgagc	gtcagtaagc	gagagaaaag	acggcgaaaa	cgagcaaattg	780
tcattgagctc	acaacttcatt	tcccttacac	actcagtga	catcagtgtc	ttgacagggg	840
gaactgttca	tcttgatgag	gatcagaatc	ctattaagaa	gcggaagaag	atacctcaga	900
aagggtcgaa	gaaaaaaggt	tttcggaggc	ggcgggtgatt	atgggtgtac	atatttgtat	960
atcttttgct	atcctgagat	acttctaatt	tcattgtata	taggtggttt	tccctggaat	1020
tcattaattg	tttgctttgg	acatgtggaa	agagccttac	taataaaatt	gattttactt	1080
atgaaaaaaa	aaaaaaaaaa	aaaaaaaaaa				1109

&lt;210&gt; 38

&lt;211&gt; 808

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (794)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 38

gaattcggca	cgagaaaaga	cctcatttat	aataagggtca	ctccaacatt	tcaccactgg	60
aagattgatg	acaagaagtt	tggctcttacg	tttcaaagtc	ctgctgatgc	tagggctttt	120
gatagaggta	tccgaagagc	tatagaggat	atttctcaag	gatgccccga	atcaaaaaat	180
gaagctgaag	gggcagatga	cttacaagca	aatgaagagg	attcttccag	ttctctagtg	240
aaggatcacc	tttttcagca	agagacagtt	gttaccagtg	agccttatag	aagctcaaat	300
ataagacctt	ctccctttga	agatctgaat	gccagaagag	tctacatgca	aagccaagcc	360
aatcagataa	catttgggtca	gccaggcttg	gacattcaga	gcagaagtat	ggaatacgtg	420
cagcggcaaa	tatccaagga	atgtggaagc	ctaaagtccc	aaaatagggt	ccctttgaaa	480

tcaatcagac	atgtcagctt	tcaagatgag	gatgagattg	tcagaataaa	ccctcgagat	540
atcttaatac	gtcgtatgc	agactacaga	catcctgaca	tgtggaaaaa	tgacttggaa	600
agagatgatg	ctgattccag	tattcagttt	tctaaaccag	acagtaaaaa	atcagactat	660
ctgtactctt	gtggggatga	gactaagtta	agttcaccca	aagactctgt	ggtatttaag	720
acgcagcctt	cctcattaaa	aattaagagt	caaaacgagg	aaaagaggat	ggtgaacgtt	780
ctcgttgctg	atanggccag	gaaagttt				808

&lt;210&gt; 39

&lt;211&gt; 1036

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 39

ggcacgaggc	ggcttctacg	ctccggcact	ctgagttcat	cagcaaacgc	cctggcgtct	60
gtcctcacca	tgcctagcct	ttgggaccgc	ttctcgtcgt	cgtccacctt	ccagctgacc	120
ctcgtgctgc	gcctggactc	acgactctgg	cccaagatcc	aggggctgtt	tagctccgcc	180
aactctccct	tcctccctgg	cttcagccag	tccttgacgc	tgagcactgg	cttccgagtc	240
atcaagaaga	agctgtacag	ctcggaacag	ctgctcattg	aggagtgttg	aacttcaacc	300
tgagggggcc	gacagtgcc	tccaagacag	agacgactga	acttttgggg	tggagactag	360
aggcaggagc	tgagggactg	attcctgtgg	ttggaaaact	gaggcagcca	cctaaggtgg	420
aggtggggga	atagtgtttc	ccaggaagct	cattgagttg	tgtgcgggtg	gctgtgcatt	480
ggggacacat	acccctcagt	actgtagcat	gaaacaaagg	cttagggggc	aacaaggctt	540
ccagctggat	gtatgtgtag	catgtacctt	attatttttg	ttactgacag	ttaacagtgg	600
tgtgacatcc	agagagcagc	tgggctgctc	ccgccccagc	ccggccccagg	gtgaagggaag	660
aggcacgtgc	tcctcagagc	agccggaggg	aggggggagg	tcggaggctcg	tggaggtggt	720
ttgtgtatca	cttgggatct	ttgacacttg	aaaaattaca	cctggcagct	gcgtttaagc	780
cttcccccat	cgtgtactgc	agagttgagc	tggcagggga	ggggctgaga	gggtgggggc	840
tggaaacctt	ccccgggagg	agtgccatct	gggtcttcca	tctagaactg	tttacatgaa	900
gataagatac	tcactgttca	tgaatacact	tgatgttcaa	gtattaagac	ctatgcaata	960
ttttttactt	ttctaataaa	catgtttgtt	aaaacaaaaa	aaaaaaaaaa	aaaaaaaaaa	1020
aaaaaaaaaa	aaaaaa					1036

&lt;210&gt; 40

&lt;211&gt; 989

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (338)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (352)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 40

ggcacgagtg	aaggaggggg	gcattaagca	ccctggggcc	ccacgatggg	cagcaagagt	60
ttgccgaggg	aggaaagccc	accggtggag	tgggcagagg	ggttggtgtg	tggacttctg	120
gagcctcagg	aggaaagggtg	cggtttcccc	tggctgcaga	cgtccctgag	gctgccctgc	180
ctcccccagg	agagaccttc	ctgccctact	acacggggcg	cgccattgat	ggcatcgtca	240
tccagaaaag	catgggatca	gttcagcacg	gctgttcgtc	atcgtgtgcc	tgctggccat	300

tggcaggtag	ctggctcaac	ccccacgccc	tgccccgnaa	accccgcact	gnaaccaggg	360
aaggaaaagg	aggggcctgt	ttcctaagga	agacaagggg	ccaggggaggc	cctggaaatg	420
cccctggtgg	gcctgtccct	cagctggtca	ccctgggaac	cggcttccac	actgtcttag	480
agcaccctag	aaccacaccc	tctggtccct	gaaaagggct	tcagtccca	gggttccctg	540
ctcaccctcc	ctggctgttt	tccaagtagg	aatctgggtcc	caaacagaac	cggctttgtc	600
tgagttgttc	tggaaggaag	agggtctggc	tggcacattt	gggtctcttg	tcccacaact	660
gtcccccttg	ccctcacctt	gagggggggt	cccactggga	atgaggggga	ccccgcaggg	720
atgccagccc	tggagtgggg	ctgcggtggg	gctcccaggc	ctgcagctgc	aggcattctg	780
agggggcaacg	tggaggaagg	gccagggatg	catgggattt	taattgtttc	atcacacctt	840
ccccgtggca	aagaaacagt	cagtcctctt	cagggtgtctt	ctggattttc	ggtgatggac	900
agagaaatct	ttttacagtt	tcaaattatg	ttcaacaaat	aaaaattgca	ttttttattt	960
tgaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa				989

&lt;210&gt; 41

&lt;211&gt; 1044

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 41

cgggattcgc	acgagagraa	agcacattgt	catctttaat	cctttccatt	tatttgccctc	60
ttgatagatg	acctttatat	ttttgctttt	tgacaatttc	tacctgaggc	atgatgtaac	120
taaaatttct	aacatgatag	tggtagtctc	ctggattaat	ttatgctcat	ggttttgctt	180
tgtttctccc	ttacaaaaat	gctcttttca	gtattacaca	agaaaaagat	catgatattgc	240
atcatgatgt	acatagcaaa	tttcatgtat	gatcgtgttt	cctgttccat	cacatttctg	300
gcattttttt	taaccactg	ggacattagg	atgtcataac	ataattggat	gtagacata	360
ggttgagaaa	tcaagggtag	tggtagatgg	aggctgacag	acaccttcca	gatccacttt	420
agaggtagctg	agtattccta	aaccagttat	gtaatttgca	tgtggtcata	tagctagtgtg	480
gtggcgaat	cagggataca	acatgtatgt	gagtatcatt	ctatcatcta	tctatctact	540
tattgacaga	taagaatata	cttgctttgt	gtaaatgatt	accctttgat	tttgtggttg	600
tcacaaacac	atgaaactat	tcatggatgg	acctacctgt	ctgatgatgg	tggtagtgtat	660
gatgatgatg	atgtttatcct	aggatataac	cactattctt	taacccttga	aactgagggtg	720
cataagggtac	aataattcgc	ccaagctcac	atagataaca	agtttgacag	gctagaaatc	780
ttactgagtt	tcatctgaaa	tgcagacttt	cagagagaga	gagagaggat	gcttagtgtg	840
ccatatctta	cgtctaacaa	tggctaata	atctttaaag	agaggactac	tccctagaca	900
tgagcgtgtt	aggactctgt	tcccatttct	acacatttat	gcttatatga	gggccattga	960
ttggccaatt	ttagcatttc	ttgtactcgt	tgggatgata	tttaaaaata	caaaaaaaaaa	1020
aaaaaaaaaa	aaaaaaaaac	tcga				1044

&lt;210&gt; 42

&lt;211&gt; 902

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 42

ggcacgagct	gacacactag	tggcctcgag	tactgatag	tgggtgcctcc	tccttacctt	60
ggcaagccct	tgtagccctc	tgagccctca	tcttgacaggc	agagccctcc	agtgtctctga	120
gaaacctgcc	ctgaactcac	cgctccctcc	gcttgggcac	tccctcctcc	ctgcgcccac	180
agcccccatg	ccaatctccg	tcagctcttt	ctgtgctgct	gtaattgttg	gtttgcctgt	240
ctccttttgg	ctgtgggcat	tgcgggggta	gggtgggtgc	ttcaccacag	ctccagaagg	300
cactggtggg	atgtggagtc	aggagcaacc	agagaccccc	caatactaga	atgggtttga	360
gcttgggggtg	gggtggatgg	ggaagactta	ctctgaatgt	tcgttcacca	tccgtgggca	420
ccaggtctgt	gccaaagcaca	gggactccag	gggcagctgc	cattcgttcc	agtgatgtat	480
ttggggcctt	ctcaggtgag	gaagccaagg	tggccaaggc	cctcggtccc	ctgccctgat	540

agggccttacc	tgtgggtggg	ggagggagac	cacacatgtc	agaggtagt	aaggccgctc	600
caaatagtga	ctggggccag	gcaggcggaa	aagagaacag	aagagaatcc	agaagtgttc	660
agacagaact	agggacaaca	gaggggcctc	catggtggca	tgggtcagca	gagcatggag	720
caggcagagg	aagcctatct	gtggggctgg	gtacatttct	ctgagactca	cggaatgtaa	780
gtgttgaggt	ttctgcaaag	agggcgcagg	cctgcagtga	cggttcagat	attgataacc	840
catccccctt	ggcaggtggg	ggcttaggca	tccatattgg	attcaaaaaa	aaaaaaaaaa	900
aa						902

&lt;210&gt; 43

&lt;211&gt; 905

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 43

ccacgcgtcc	ggggatcagc	gctaccaagg	cgcacgagtt	ctgcccccta	cgatttggttc	60
ggggacttct	cctccttccg	tgccctccta	gagccggagc	tgccggcccga	ggaccgtatc	120
cttgtgctag	gttgcgggaa	cagtgccttg	agctacgagc	tgttcctcgg	aggcttccct	180
aatgtgacca	gtgtggacta	ctcatcagtc	gtggtggctg	ccatgcaggc	tcgctatgcc	240
catgtgccgc	agctgcgctg	gggagaccat	ggatgtgcgg	aagctggact	tccccagtgc	300
ttcttttgat	gtggtgctcg	agaagggcac	gctggatgcc	ctgctggctg	gggaacgaga	360
tccctggacc	gtgtcccctg	aagggtgtcca	cactgtggac	caagtgttga	gtgaggtgag	420
ccgcgtgctt	gtccctggag	gccggtttat	ctcaatgact	tctgctgccc	cccactttcg	480
gaccagacac	tatgccaag	cctattatgg	ctggtccctg	aggcatgcta	cctatggcag	540
cggtttccac	ttccatctct	acctcatgca	caagggcggg	aagctcagtg	tggcccagct	600
ggctctgggg	gccccaatcc	tctcaccccc	cagaactccc	acctcacctt	gcttccttca	660
ggactcagat	catgaggact	tccttagtgc	cattcagctc	tgaggccaga	gcatggtcct	720
ccacccttcc	tgccattctg	ccctgggctc	ctcaggtagt	tgggaattcct	gacttaggac	780
ttggggttgg	gtccaaggtg	cttacatccc	aggggcctca	tgccctaagat	agaggttggg	840
agcgaaccca	catgaaccaa	tacagcccag	ctccaactag	aaaaaaaaaa	aaaaaaaaaa	900
aaaaa						905

&lt;210&gt; 44

&lt;211&gt; 1987

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (435)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 44

aaatatttcc	aatataattt	gaatggctaa	ttttcagttg	ctaattaatt	agcagctttg	60
taataacttg	tttgggagca	tttacttgga	aatcctaagg	actataataa	aagttttcaa	120
catattttcta	aattgtgtga	gtttccagct	gtagcttttg	tctttgtcac	attttaaaaa	180
ataataagca	agacacattg	gggacactgg	cagcagttgc	caggtttttag	ctgccaccgc	240
ttcagtatga	gatatagctg	tcccattctc	ccccattcag	ggtaggagat	atagtgacct	300
agacttcatg	caaattgaaa	aaaagtttta	actgaaatat	ttatttagat	ttcaggtgtc	360
agatggatgg	gaaagtagaa	aaacatatgc	aaatctcagt	gttctcacta	tgaccactct	420
gagcagagat	ttggnntttg	tttccttttg	taacaaagtg	aaaacaggtg	agacaatgtg	480
cccaaaaaca	aggggaagaag	agaaccttct	gtgactccta	aaatgttcca	tgctgcattt	540
ttgtttcatt	ttttattttt	ccttgctttg	tttttaaaaca	tgaatataat	gcttacttca	600
aattgttttag	taaaacaaaa	taactaaaga	aatgtgagct	tccaaggtt	tctaaactat	660

cgctgttgta	tattctatag	cgttccttat	tctttgaggg	aaactgtgct	tgctgtgac	720
cattttgtct	ctagcttcta	gttgtgattc	ttgtccataa	gcaccaaatt	tgatgcccc	780
gatttcaaaa	ggtcattctt	ttatctgaat	gaaaatgggtg	gtactaagac	tgtgaaaatt	840
atgtgaaacc	taaagtagtt	gccaaagtgg	ctcaggggtg	taaaattcat	tgacttaatt	900
attcatgtgc	cagatcaacc	cctttatttt	ctcttttagct	gtgcataatt	aaaatattgg	960
aaagtatcag	atttacagat	tttctttgac	taattttttt	cacataactt	taggattttc	1020
gaaagtgtga	accataactg	gatatcttag	ctgagcaaag	gcgggtataa	tttgtctttt	1080
taagatcact	ggaaattgat	aaaattttgt	gataattatg	attattctgt	gccatttaca	1140
gtttctaata	ctatactgta	tgaaatatgt	ataaatatat	gatgctgagt	ctgtggaatg	1200
atacttctga	aatcaaaatt	cctcataagg	catgaagttg	taaaaacttg	aatgtgtata	1260
gttagatatt	taaattggtg	cttcttcata	gaattgtctg	ctttttaaaa	ctggaagtac	1320
aggattttct	tcaggtaaaa	tctgtgtgtt	ccaattacag	ttgtagctga	aggaagtatg	1380
ctttgggtgag	tcaattagta	tgggaacttg	actaaagacc	cccagtggtg	taacgtacct	1440
ttgtacccag	acaaaacaat	tatgttacat	tcctcaaaag	ggcatgggct	ttcttctcta	1500
attcttytgt	tttattagac	ccaagacaag	ttctaaaaat	tgaatgcaat	gagagattgt	1560
ccagaaatgt	aatatatact	aaaatatacc	acttaagcat	tgattgcctt	ttcttgtttg	1620
cttcaagaat	ataaaacttg	ttacttgagc	ttggaatcat	gggcttgatt	gaattaatta	1680
ctcttgggga	aaaaagacac	cttgtggcat	taagtcttgc	tttggtaaaa	gccttatttc	1740
acataattgc	taaaaactca	tttttgttta	atatactacc	tatagttaa	ttatcggcac	1800
ttgtattttg	taacttgata	tcttacctag	gattgggaat	ttgggacatg	acacgtacta	1860
taaaagtcag	tctatgtaca	tactgcttat	tgatgtgctg	tgatatgagg	gaatctgaaa	1920
tgtttcataa	aaataaagct	taaaaattgt	cttacactgg	aaaaaaaaaa	aaaaaaaaaa	1980
aaaaaat						1987

&lt;210&gt; 45

&lt;211&gt; 906

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 45

ccacgcgtcc	gaatggaggc	gactacggct	ggtgtggggc	ggctagagga	agaggcggtt	60
cggcgaaagg	aacggctgaa	ggccctacgg	gagaaaaacc	ggcgcaagga	caagggaagat	120
ggggagccaa	agaccaagca	tctcagagaa	gaggaggaag	aaggcgagaa	gcacagggaa	180
cttaggctgc	ggaactatgt	cccggaggat	gaggacctga	agaagaggag	ggtgccccag	240
gccaaaccgg	ttgcagtgga	ggagaagggtg	aaggagcagc	tggaggccgc	caagccccag	300
cccgtcatcg	aggaggtgga	cctggccaac	ctcgctcttc	ggaagcctga	ctgggacctc	360
aagagagatg	tggccaagaa	gctggagaaa	ctaaaaaagc	ggactcagag	ggccattgcc	420
gagctgatcc	gtgaaaggct	gaaaggccag	gaagacagcc	tagcctctgc	agtggatgct	480
gccaccgaac	aaaagacctg	tgactccgac	tgaggcatgc	cctgccccac	cactcgccca	540
tcaggcctgt	cctgcagggg	atggtcttgg	gcagggatgg	gggctaggct	tgccatcacc	600
tccagtttgg	cttctgagca	gagactccct	gcccatcaag	tctgaaacct	ccatggatga	660
ggtcagctcc	ttgtctgctg	ggtggccctt	gccattctga	atggaggcag	aaccagcaac	720
aactctgggc	gtgcctgtgt	ctgcacatgt	ggatgtacat	atgtctgtat	atatgtatat	780
attttgaact	ttctaaaaaa	aaaatctgga	aatagaaaca	agtaaacccc	tgaaaaaaa	840
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	900
aaaaaa						906

&lt;210&gt; 46

&lt;211&gt; 1442

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 46

ccagagactg	cctcacaccc	ctcaaccaga	cggccatgac	tgcccttttg	tgaacacaat	60
gtgaaagaag	cctgctgtgg	tactgagcgt	csggctgtca	caaggcactg	gaagaaggga	120
gcctgctggg	ccagagtgtg	cgtgtgtatc	gggtgtgtgt	tacacttgca	tgtgtgtgtg	180
tgatccagta	ggatccctaga	gacaacctgt	catactgttt	acaaaattgt	gcagctgggt	240
tcgtgctgac	ccttaggggtg	cgtctgttgg	gttttgttgg	gctagaaaaa	tgaaaatttt	300
cagatggcgt	tttcattcct	ctgactgata	ttgagctgct	ttgggtgtaa	aggtgtaatg	360
tgtacagagt	tgtattttaac	aataataaaa	gtaacttaag	tttgctctat	cagatttttag	420
ttctgcacag	aggttaagtg	ggaaaatgca	gctgttgcaa	aatgtatata	aatagtatgt	480
tcattttttt	cagtataatta	tctgatactg	tgtagcagc	aggtctgctt	aaacctagtc	540
ttgttgttat	tgaatcattt	cctctccttt	gataactaga	actgaaagca	tttttaacat	600
tcttctcctg	gaagaaatga	attacttgaa	gcatgaaaag	cacaccaggg	tggttgttta	660
tttagcaatt	atgactgtag	atttaaaaac	aagcaaagaa	acaacacctc	agcagctgcc	720
cgtttcctta	gtctccactt	cagaggggga	tgcaagagg	tcggcccagc	tccggtgacc	780
atgaagggtg	cacaggaatt	acagtgtgaa	tggctgtgtc	agatgttttc	gtacctcaga	840
ttaaaaaat	tgctgaggtc	agacgccaca	attttcatga	ctttcttcag	aagtagcaca	900
ttttcgtgac	ttccgctgtc	ctctgaaaaa	caaagttatt	tggaacatgt	tcatgcaaaa	960
gtgattctga	ccaagtctaa	atcgagcttt	tctactgaca	tgaaactgtt	ggaaactgat	1020
ctcattttat	aagaaatgat	tttccctca	aggaggcgct	tgtaattcca	gaacagtcca	1080
gacatcagct	gtacctcatg	ctcagtagtt	tttatttgag	tttcttttgt	gagttaacta	1140
tgggagattt	aacctctttt	gccaaagagg	gaagtgtgtg	tgttttttta	atagaaaata	1200
tggaccaaaa	atttttttcc	ctgaagaatg	tattataacc	ctatttgtgt	ggttattaca	1260
tcctgtgaaa	tgtatatatg	ttaaaataat	gggggtgctg	gaagggtcatg	gcagactagc	1320
tgctggttag	tgtggagggg	aartggttta	ctttgtagag	tttacatggt	tttatgcgca	1380
cactaattgt	aataaactat	gccaaaccaa	aaaaaaaaaa	aaaaaaaaaa	aaaaggcgcg	1440
cc						1442

&lt;210&gt; 47

&lt;211&gt; 1228

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 47

cccacgcgtc	cgggaggtga	agagcatgcc	ttcctgactg	taggatcaaa	ggaagccaat	60
aatgggcctc	catttaactt	tcctggtaat	tttggtggat	caaatgcctt	tgggccacca	120
atccctcctc	caggattagg	aggcggggcc	tttggtgatg	ctaggcctgg	tatgccttca	180
gttggaacaa	gtggtttgcc	tgggtctagga	ctggatgttc	cgggttttgg	aggtggacca	240
aacaatttaa	gtgggccatc	gggatttggg	gggggccctc	agaattttgg	aaatggccct	300
ggtagcttaa	gcggtccccc	ggggtttggg	agtggccctc	ctgggtcttg	aagtggccct	360
gggcatttgg	gtgggccacc	agcttttggg	cctggccccc	gccccggccc	cggccctggc	420
ccaatccata	ttggtgggtc	ccctggcttt	gcatctagtt	ctggaaaacc	aggaccgaca	480
gtaattaaag	tgcaaaacat	gccctttact	gtgtctattg	atgagatttt	agatttcttt	540
tatggctatc	aagtaatccc	aggctcagtg	tgtttaaaat	acaatgaaaa	aggtatgccc	600
acaggtgaag	ccatgggtggc	ctttgagtct	cgggatgaag	ccacagctgc	tgtcattgac	660
ttaaatgaca	ggcctatagg	ttcaagaaaa	gtaaaacttg	tattagggtg	gccattcaca	720
tcatttttta	tagggtagat	cttcattattg	ctgtgattaa	tgcattccaga	ttgttttctt	780
agtatttcca	ggttagaacc	tgtggattgt	ttcaattgca	tatagcttgg	tttcataaac	840
atagagcatt	ggttgactgt	ttacagaaga	ctcactcacc	aggataaaca	ttgctgtatg	900
ttacagtaaa	gctatctgga	gagaacacat	aaatgatatt	ggcataccat	tagagaacc	960
atttgtaaaa	ctcaaatgac	cacataaagc	ttatcaagga	gtctagattg	gttttgtttt	1020
ataccatatg	ggatgaagaa	aatagaaatg	tcagtagaac	tcattgaggg	tgctcttgcc	1080
agctgtcgaa	aatagaagtt	ggctactctc	agaatttggg	ttaaagctgg	acagatttgc	1140
tttgttatag	ggtaaaagctt	tgtctaaagc	cctcattttc	ttttaaaatt	gaataaaatt	1200
tctgtatata	aaaaaaaaaa	aaaaaaaaaa				1228

<210> 48  
 <211> 2241  
 <212> DNA  
 <213> Homo sapiens

<400> 48  
 ccacgcgtcc gcgagcgtg gacggagctg cggcggctat gctgtggagc ggctgccggc 60  
 gtttcggggc gcgcctcggc tgcctgccc gcggtctccg ggctcctcgc cagaaccggc 120  
 caccggagct tgacctcctg catcgacct tccatgggac ttaatgaaga gcagaaagaa 180  
 tttcaaaaag tggcctttga ctttgctgcc cgagagatgg ctccaaatat ggcagagtgg 240  
 gaccagaagg agctgttccc agtggatgtg atgcggaagg cagcccagct aggcttcgga 300  
 ggggtctaca tacaaacaga tgtggcgagg tctgggctgt cacgtcttga tacctctgtc 360  
 atttttgaag ccttggctac aggtctgacc agcaccacag cctatataag catccacaac 420  
 atgtgtgcct ggatgattga tagcttcgga aatgaggaa agaggcaca attttgccca 480  
 ccgctctgta ccatggagaa gtttgcttcc tactgcctca ctgaaccagg aagtgggagt 540  
 gatgctgcct ctcttctgac ctccgctaag aaacaggagg atcattacat cctcaatggc 600  
 tccaaggcct tcacagtggt tgcgtgtgag tcagacatct atgtggtcat gtgccgaaca 660  
 ggaggaccag gccccaagg catctcatgc atagtgttg agaaggggac ccctggcctc 720  
 agctttggca agaaggagaa aaagggtggg tggaaactccc agccaacacg agctgtgatc 780  
 ttcgaagact gtgctgtccc tgtggccaac agaattggga gcgaggggca gggcttcctc 840  
 attgccgtga gaggactgaa cggaggagg atcaatattg ctctctgtc cctgggggct 900  
 gcccacgcct ctgtcatcct cacccgagac cactcaatg tccggaagca gtttgagag 960  
 cctctggcca gtaaccagta cttgcaattc aactggctg atatggcaac aaggctgggtg 1020  
 gccgcgcggc tgatggctcg caatgcagca gtggctctgc aggaggagag gaaggatgca 1080  
 gtggccttgt gctccatggc caagctctt gctacagatg aatgctttgc catctgcaac 1140  
 caggccttgc agatgcacgg gggctacggc tactgaagg attacgctgt tcagcagtac 1200  
 gtgcgggact ccagggtcca ccagattcta gaaggtagca atgaagtgat gaggatactg 1260  
 atctctagaa gcctgcttca ggagtagaac ccacacttgt tctggcctgg tgttcagtgc 1320  
 gactgcagtc agtgttgagt ggtgccatgt gggccgctct attccaaaagg aatcatggat 1380  
 tagaccaag ggctgagctc ctctagggca ggacctgcac cctgtgtgtt ggcaccagca 1440  
 tcgggtcttg gactggggca gaatccccag tggaaaccga agagctggac tgatgagaaa 1500  
 catcagaaga acacatacta ccttgttttc ctaatgccag aagggtgacc agtgaagatt 1560  
 caccgtcaaa ccatgaaagt cctttcctgg atccacttta tcttgattag tctgcatttt 1620  
 actagttcac tggatccctc ctctaggggc ctggggactt tcaactgatgc tcttcctgat 1680  
 tctagagcaa aggtgtggga aggggaaatg gaggaatgcc ctctgtctg tgtcgttctc 1740  
 tgtgccacag ctacagatgc agaaggtttc tctggatagc acacctctga atgtaaatca 1800  
 tgataaaatg gatatttga aacttactcc taagctgtga tttagggtgt atttctactt 1860  
 ctggactgcc tcaatatcaa gggctgagac ttttgaattt tgaatatctg ttgggtttca 1920  
 tgttaagaag cctgtggtct aggagtgtc ttcagtgttt cttttcctga taaacacttt 1980  
 gaatatTTTT tttgggtttt tgtttccttt tctgaagctg ttcccccttt taaatatTTT 2040  
 taatcccat gataaaatct atccttcacc ccctttgggt ctactatagt tgattttaat 2100  
 tttaaatgtt taattgtatt tgattaaaca cttaactgga ttttggaata ataaaactct 2160  
 cgtccaattt ggctttttaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2220  
 aaaaaaaaaa aaaaaaaaaa a 2241

<210> 49  
 <211> 1577  
 <212> DNA  
 <213> Homo sapiens

<400> 49  
 ccacgcgtcc gcccaaggac gacgcagcca tcgttggggc cgtgcggctc ctgtccgtgc 60  
 tgatcgccgc cctcaccatg gacctcgag gccgaagg gctgctcttc gtctcagcgg 120



ccatcatgtt	tgctgccaac	ctgactcttg	ggctgtacat	ccactttggc	cccaggcctc	180
tgagcccaaa	cagcactgcg	ggcctggaaa	gcgagtcctg	gggggacttg	gcgcagcccc	240
tggcagcacc	cgctggctac	ctcaccctgg	tgcccctgct	ggccaccatg	ctcttcatca	300
tgggctacgc	cgtgggctgg	ggtcccatca	cctggctgct	catgtctgag	gtcctgcccc	360
tgcggtgccg	tggcggtggc	tcagggctct	gcgtgctggc	cagctggctc	accgccttcg	420
tcctcaccaa	gtccttctcg	ccagtgggtga	gcaccttcgg	cctccagggt	cctttcttct	480
tcttcgcggc	catctgcttg	gtgagcctgg	tgttcacagg	ctgctgtgtg	cccagagacca	540
agggacggtc	cctggagcag	atcgagtcct	tcttccgcac	ggggagaagg	tccttcttgc	600
gctagggtcaa	ggcccccgcc	tggagggggc	caaaccacca	gtggctgggc	ctctgtgttg	660
gctacaaaac	tgccccctgg	gaccaagagg	cagcagtcac	ccctgccacc	agccagagca	720
caggaagagc	agtgtgatgg	ggcctcagca	gcgggtgccc	ctggctcggg	acaggtagca	780
ctgctgtcca	gccacagccc	cagcccaggc	agcccacagt	gctgcacgta	gccatggggc	840
gcaggagtgc	atacaaccct	gcattccagg	acacggccct	gctgggtgac	ctcaggccta	900
gtccctttcc	cttgctgtaa	ggacacgccc	cacagaaggc	tacggggagg	actgagagga	960
cagggctgga	ggcagccaa	taacgtagtc	atatcatcgc	gctctgatct	ggtggcatct	1020
ggctgtgcaa	ggaagaccgc	gctttgccct	cacaagtctt	atgggcacca	cagggaaacat	1080
cctggactta	aaaagccagg	gcaggccggg	cacagtggct	cacgcctgta	atcccagcac	1140
tttggaggcg	caaagcagg	ggattaccca	aggccaggag	ttcaagacca	gcctggccaa	1200
catggtgaaa	ccccgtctct	actaaaaaat	acaaaaaagg	tgggtgtggt	ggcacacacc	1260
cgtagttcca	gctacttggg	aggctgaggc	agcattgctt	gaaccgggga	ggtggaggct	1320
gcaatgagct	gagatcatgc	cattgcactc	cagcctgggc	aacgagagtg	aaactccgtc	1380
cccacccctc	gccaaaaaaa	aaaaaaaaaa	aagccagggc	aaaggacctg	gcgtggccac	1440
ttcctctctg	cccagcccaa	cctctgggaa	caggcagctc	ctatctgcaa	actgtgttca	1500
cccttttgta	aaaataaagg	aactggacct	gtaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1560
aaaaaaaaaa	aaaaaaa					1577

&lt;210&gt; 50

&lt;211&gt; 1801

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 50

acgcgtccgc	gccctttttt	tttttttttt	ttttttcaga	cagcatctca	ctaagccgcc	60
caggctacag	tgagtggtca	caatctcagt	tcactgcagc	ctcaacctcc	tgggcataag	120
tgatcctccc	acctcagcct	cccaagtagc	tgggattaca	ggcatgcacc	actatgttcg	180
gctactttta	aaaatttttt	tgtcgagacg	acatctcatt	atattgcccc	agctggtctc	240
aaactcctag	gctcaagcaa	tcctcccacc	taggcctcgc	aaagtactgg	aattaaggca	300
tggaccacca	tgcccagccc	cacagccaaa	cttcttgaaa	gaatgggtcta	tatttactat	360
ctttactttc	tgaccttcta	ttacctctc	aacctactcc	accagaccac	cacatatggg	420
acttcccagg	gctccagcct	gggtgccctc	ttcttttaaa	actcagtact	aatgaaaaat	480
aaattcaaca	tataggagct	gccttttctc	gactcctccc	tccttttgct	catcttcagc	540
tctctattcc	atccctctct	tcagcagaac	aagagattgt	gtttgtgtgg	tggtaggggc	600
aggagaggct	aagaacagga	ttggggggacc	aagagtatat	cagggggagat	gggccctatc	660
tatcagccca	agccctcagc	agctctttac	acagccagtt	acctgtggca	gcaagagggg	720
gaaagtcttg	agagcacaga	agagggaaga	agggggagat	gaaaggaaat	gtgctgaaag	780
agtacagctg	taagactggg	tggcaatgga	cctggcgggtg	gtactggggg	cctgagattc	840
acagggtggg	gtgtaagaat	tgggtggaggt	ggggggagtc	caggaggagg	tggctccttca	900
acaacaggag	gctgtgctgg	gaaaggcagc	ataccaggaa	gattcacatc	ttctacaact	960
actggatcac	ttccatgac	aaaaggacac	atgtctcttc	tcatacaaaa	acccttttca	1020
tcatagtctc	tacaccgttt	ctttggcatg	gggtgtctta	cgtaagagtt	atgggtccact	1080
tggcttccat	gaaattcaga	ccaactttctg	gtagtgttgt	ttccatgatg	agtaggagca	1140
attactgtaa	tagtgctgct	caaagtaggt	acagggtagt	ggccagatga	aatactaggt	1200
accgaagaga	ctggagtata	attattttct	aatggatctg	ttctatccag	gtcatattta	1260
ggttttacca	gatccctttc	cctgcttcgt	gttctgcttc	tgcttctagt	cctgcttcta	1320

tctctgtccc	tctcacgaag	cctctcttta	ctccaacttc	gacttcgact	cctgctataa	1380
ctgcgactcc	gccctcgtct	tctattgtac	cggctctctgt	atgaatctct	tccttcttta	1440
tatctttttc	ttgggtgtga	aaaaattcta	ccttcaggct	tcctgatgat	ggctgctctg	1500
gaggaggtag	gtaactcttt	gtattcacag	catcaaaaag	ttttccaca	aatatctgtg	1560
tctctttctg	aagaaataca	tccagctgat	caatacataa	tgcccttaac	tctttttcac	1620
ttttgtcttt	ctttaccaa	gccagaacat	attttgctag	ggcggatgga	tctgcatcac	1680
agatgggctc	gagagtcttg	ctgagccagg	acttgagtgc	ctcgaagttt	tcaatgatca	1740
ttttagaaac	catccacagc	ggccctaagg	cccgtcacac	tcctccgccc	gcccaggctg	1800
c						1801

&lt;210&gt; 51

&lt;211&gt; 1273

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 51

cttaatacct	tcttaaatgt	ctatatatcc	cagtgtctctg	gatcagtgtc	taaaaatcac	60
tggcaacact	gcatgaggtt	gttggttttg	ttttgtttta	tttaattagtc	ttcacagga	120
ggaataattg	ccctccttta	tatacttata	tattgataat	ccccctctccc	tccagaacac	180
aaatcagagg	gaaagggggt	gttcagctgt	actaccaa	caggaagatg	taaggtttac	240
aaattggcta	agaatcatgg	ctctgtagcc	atttcaacca	gaataatttt	attgctaata	300
tgctttgtgt	gacagcattc	caggccagcc	agatgggact	gccttgtctg	gaggctttgt	360
tcattctcgaa	ggacacacac	ttccacactg	tttgtgagcc	ctcccacctc	cacaacttca	420
gttgtaaate	aagtgtgtgg	atctcaaagg	gtgcaattta	tctttatata	ggaatacatt	480
tctagggctt	ccttcaagcc	cactctcttc	accctatttt	ttcttatctt	aaattgagag	540
aaagagaatt	aatcttatac	tttgtcaaaa	cattttctac	catatttcca	gatgacatct	600
gcgcttgaag	agtcaaagga	atctgtgtct	aatatcctgt	ttttaactgc	tgtaggggca	660
ggatggaaag	gatgatgggg	gctgccacac	cactgattgg	ccttttcttt	cacgtgattc	720
atccttcctc	attgtggcaa	ggagtttctt	tctctttttc	ttcctccttt	gggatcattg	780
tgtatgaaaa	gaaaaacttt	aaatgacaaa	cccagactcc	agggtgccttg	caaaggttga	840
aggccagcca	ggattgctgc	tgctgtgtct	actcctgcc	acacccttt	cattggcatg	900
acggaatgaa	aggatgcatg	tctccacttc	ctgacctccc	gcccacttcc	ttctccctcc	960
accaccccca	gtcgtcagct	ccttccctca	tttatttttg	ttaagtgtg	tgaattattt	1020
ttaacccatt	tatctgtttt	gtgcataggg	tttttaagaa	gaaacagcac	agtgaacga	1080
gcaaatcttt	ttgggggtgtg	tggaagcaa	gggagggagg	acatggagaa	aagtctctta	1140
aacaaatagc	aaactattga	acatgtgtaa	aatcctgtat	catttatgaa	atatgtataa	1200
aaagcaatgt	accttctgga	acaataaata	cttattcaat	ttttgaaaaa	aaaaaaaaaa	1260
aaagggcggc	cgc					1273

&lt;210&gt; 52

&lt;211&gt; 1468

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 52

aattcccggg	tcgaccacag	cgccgggga	gagataccaa	tatcatcaag	ccagaccaac	60
agaagttcct	tcgatttgct	cccacgggag	ttcgtctctg	tggaagtcca	tgaccacccc	120
ctgcaccaac	cctcagccaa	caagccgaag	ccccccacta	tgctggacat	cccctcagag	180
ccatgtagtc	tcaccatcca	tacgattcag	ttgattcagc	acaaccgacg	tcttcgcaac	240
cttattgcca	cagctcaggc	ccagaatcag	cagcagacag	aagggtgaaa	aactgaagag	300
agtgaacctc	ttccctcgtg	ccctgggtca	cctcctctcc	ctgatgacct	cctgccttta	360
gattgtaaga	atcccaatgc	accattccag	atccggcaca	gtgaccaga	gagtgaactt	420
tatcgtggga	aaggggaacc	tgtgactgaa	ctcagctggc	actcctgtcg	gcagctcctc	480

taccaggcag	tggccacaat	cctggccccc	gcgggccttg	actgtgctaa	tgagagtgtc	540
ctggagaccc	taactgatgt	ggcacatgag	tattgcctta	agtttaccac	gttgctgcgt	600
tttgctgtgg	accgggaggc	ccggctggga	cagactcctt	ttcccttgaa	tgggaaggag	660
cagggattcc	atgaagtggg	tattggcagt	gtgctctccc	tccagaagtt	ctggcagcac	720
cgcacacagg	actatcacag	ttacatgcta	cagattagta	agcaactctc	tgaagaatat	780
gaaaggattg	tcaatcctga	gaaggccaca	gaggacgcta	aacctgtgaa	gatcaaggag	840
gaacctgtga	gcgacatcac	tttctctgtc	agtgaggagc	tggaggctga	ccttgcttct	900
ggagaccagt	cactgcctat	gggagtgtct	ggggctcaga	gcgaacgctt	cccatctaac	960
ctggagggtg	aagcttcacc	acaggttcca	agtgcagagg	taaatgcttc	tcctctttgg	1020
aatctggccc	atgtgaaaat	ggagcctcaa	gaaagtgaag	aaggcaatgt	ctctgggcat	1080
ggtgtgctgg	gcagtgatgt	cttcgaggag	cctatttcag	gcatgagtga	agctgggatt	1140
cctcagagcc	ctgatgactc	agatagcagc	tatggttccc	actccactga	cagcctcatg	1200
gggtcctccc	ctgttttcaa	ccagcgctgc	aagaagagga	tgaggaaaat	ataaaaggaa	1260
aagagggaga	ttttttgtcc	agacctacta	gacccaacag	aaaagggtttt	tgtattagaa	1320
tctgtttcct	taaaaattga	tttgactcct	gttcttaaac	acaagtgggt	tttcctaatt	1380
ccagaggaac	tggacgtcac	caaacaaggt	tgcattttac	ttttgcaaaa	aaaaaaaaaa	1440
aaaaaaaaaa	aaaaaaaaaa	agggcggc				1468

&lt;210&gt; 53

&lt;211&gt; 1176

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (639)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (700)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 53

aattcggcac	gaggttttctc	tagaagtaat	ttatgtttatc	aggttatccc	ctgagttttt	60
tcttactcac	catatgtctg	gtggttctca	cagccagggg	cactgagggg	ctctgccctg	120
ggatctggag	gccagcactg	ttcacctgat	ctccaccact	gagatacctc	tggctagagc	180
cataatcagg	tggcccaaag	gactgaacaa	ggaagaatgg	gagggcactc	tagactaatt	240
aaggttgtct	tttcagtcta	aagttaacaa	tgacacacat	gaattttcat	atcagtataa	300
ttagatgcgg	gtcccatacta	attacagtgg	gtcattatgg	ctgttcgggt	agagcagctt	360
gggtgctctg	tgaccatggc	atgtgcccg	gtcaggacta	gacaaaagtc	tttgcttggg	420
gaagctctct	ccccttcagg	tgtgaggcca	ggagcacctg	gtgtgggtcc	tgtccctgag	480
gttctgtcct	acaccaccct	catgcaacac	ctactacaca	caggtgcaca	gcgactgtca	540
caggcgcttc	atgtttaagg	atgggcctcc	gtgtcataaa	cttttttaaa	gggtatatag	600
rgatagctta	tgraatccaa	atcaaaggtc	cagagtttnc	agcaaatgt	acctacctat	660
ttgccaaact	aacctcacca	tagaaagcca	aaagattcan	cctgtggcca	gtctttcaca	720
ttacagagtt	taaagtactt	tttttaaat	ycatttttat	ttttaacaaa	atatttaaca	780
aaatatagta	tatctcatgt	gccaggtact	atttghtaata	tttataaaca	ctgatttayt	840
taatcttcac	agagactcat	tttacagatt	ggaaaacaga	ggcagagaga	agttaagtaa	900
ctttaatgtc	actcagctgg	gtagtatcaa	agtcttggct	gctggctcca	gagtctagac	960
ctttaaccac	tgtgtttatgc	tttccatggg	taaagcaacc	taaaaaggcc	cctggaatca	1020
gttacatgtg	gttggagact	aactctgtca	tgtacttact	aatgcttga	tattgggcaa	1080
tttatctaac	ctctctctgc	atttagtaag	tcaatgacag	agttagtctc	caaccactgt	1140
gttatgtctt	ccatgggtaa	agcaacctaa	aaaggc			1176

<210> 54  
 <211> 1779  
 <212> DNA  
 <213> Homo sapiens

<400> 54  
 cctcagtgag atatttggtg ccatgggtgta agctgatagc acaagttctg gcgacaggta 60  
 gcacgtatct gagagacacc tgcaagcaca cactgtccca gctggtaccc ataatgctgc 120  
 tgttcctgct gctgctcctg ctttcctctc ttctcgcttt aaatgattgt tagcaagtta 180  
 gattttcctg gagcttcgga agaaatgaaa atggaaacat gatgaagata tagtcaactga 240  
 atcaatgaga aaaataatga acatatgaat accacctaata aatacactga ataaagtaca 300  
 ccatatagca ttatttttat aggaaatatt tcatgtccct taaatatctt gttagttata 360  
 gggatggaca gtttatgtta agcacttagc ttaaacaatc cgtttatatt agcactgtat 420  
 cccttggtgcc atccaacatt ttgtatgttt ttgtaaacag ttcataataca gtacatttct 480  
 gtactgcttt ctttaatgta tacatgcctt gtttaacttg gaatctatta ttattaatca 540  
 attgactatt aaatctgggt aaatagttca cctggattaa cagtattgtt ggacagtcct 600  
 aaaaatggcc agattgtgga acagctgttg aatgtaatac ttccaaaatg tacatatctt 660  
 tccccacgtc tgtttcactg gttcgttcat ttgtttgttt cttaaagtca ggtgctctgt 720  
 cagactaacc tagagagctg ttatggtaga gaaagttatc atatgtgtgt ggcatgaaat 780  
 caagaataca cctatgaagt tagtccatat actttgcaac tccttagagt acttttttcc 840  
 ttaattaaagg aagtagtcct tgcacttcta atcttacata gcatccatac ttagaatttg 900  
 gcatatcatc tgggattttg ccaatatacg tcaaagccct ttaagagtca tggtaaggag 960  
 atgggtgaag gaaaatttag caacaggtaa ttgaagtcct attggatatt tcatgtttaa 1020  
 atagatattc tatattaaac actaatttaa atgtaataaa ggccaaaggc ctctgtatga 1080  
 aattggattt aaactttctt attttaggga ataaaacatt attgatcaa cagtatctgt 1140  
 tctaacctaa aattataggt agggcaggct aagtgaacag cattgaggat tttctgaatc 1200  
 cctcatgata atttatagcc acatactgct tcctttgact tcaggaatga tcagggttca 1260  
 taatggccac tgggcctgct tagattgcag tattcattat ctgcatctaa tttggtagtt 1320  
 tccacaatcg gtaattgatg aaagaaactt cagtcccat tattacctgt gtctttgcca 1380  
 agctgcctag catcacatcag tatgtaatgt aaaagacata tgagcaagaa aaaagtgatt 1440  
 taacttacct catcaagaat gtgcccctac aggcggggcg cagtggctca cgctgtaat 1500  
 cccagcattt tgggaggccg aggcaggtgg atcacctgag gtcaggagtt tgagaccagc 1560  
 ctggccaaca tggtgaaacc cgtctctac taaaaatac aaaaattagc tgggcatggt 1620  
 ggctgtcacc tgtaatccta gctactcagg aggcgtgagg aggagaatcg cttgaacctg 1680  
 ggaggtggtg gttgcagtga gccaaagatca caccattgca ctccagcctg ggtgacagag 1740  
 tgagactctg tctcaagaag gaaaaaaaaa aaaaaaaaaa 1779

<210> 55  
 <211> 1473  
 <212> DNA  
 <213> Homo sapiens

<400> 55  
 cggggtggta ggcaaagggtg cttgggggtcc ggccaacgct tgggctgggc acagggcgga 60  
 tcagtagatt gggtcagata agacgccatt tgaccagggt caggtttttg tggatcgagg 120  
 ggtttcccat ggagtgatat aatggggggcg cctactagga agtgacagtgt tcagtggctt 180  
 tctctatctg ttcttttctt cagcgcccag tgtagcgcgt ggcgttccat ataagtgtg 240  
 gaattgaaat ggattccagg gccatgccat tccccctctc tcattctcct cgctctccac 300  
 cccccctccc ccgccaatgt cctggaagga cgccctttag tgggtgcctc ctaggagctt 360  
 ggagcagctg gcagctctct tgccgggctt gcacggcacc cgggctcagt tgtaggtggt 420  
 aagggggctg gaagactgtg tccggctcct gccttgggga ttccgaattg aatccgcgct 480  
 gagactagaa cacgccctcc caaggaggca gtcccagagt catccaccgc aggcggatta 540

atcttctctg	agtagaaatg	tgaaaagccc	acaccggcca	ggaaccctcg	cttcgattca	600
ctttattttc	cagccagcga	ttttcctttg	aacataggga	tcccatccag	gaggaggaga	660
cacagctcct	agaaacagga	tccgccgggt	cctcctcctg	cgcgggtaga	cgcagaacgt	720
tcccacagtc	tactttatgc	gagcgtggca	ccctgcttg	aggcacccca	gagcaccctc	780
gggccgctcc	ttttcacccg	aaagatagga	tcacccccca	gttaagtcgc	ttctgggttt	840
tccgaaactc	acctgacact	cccaacaccc	cgaccccgctc	ccggggctcg	ctgctgccac	900
ctactgcccc	actcgaatga	aatttcagac	gcatgatcaa	gccagttta	ataggaggga	960
aaaaaaaaaa	ccttttcttc	tccatgactg	gggctaagag	ctgttctggg	acaagcatgt	1020
atgtgtgtgt	ggtgggatgg	gatgggatgg	ggtgggagga	gggggcagca	ggggattttt	1080
ctagctggtg	ccagagcagc	caggcctctt	agagggtggg	tgagtctggc	cattgtgcaa	1140
ccccttccag	ttcctctgag	cagataatag	ctgaatccag	atggtgacag	cccgtgtgtc	1200
accgtttcca	gttgagtcta	ggatatgagt	aactggactg	aacaaaaggc	ctttaagag	1260
accagccagc	ttcctagaag	agaggagatg	ctactcattc	taggggtggg	gtcgggtgtg	1320
gggggataaa	caaacaagtg	gaaaacccat	tcgcaggatt	ccataccctt	cctgtgagaa	1380
ttgttaactca	aggctgctta	cacttgagtc	ggactgtagg	cagggtgctt	aaggctgcat	1440
tgtccagcgc	tccccaaaaa	aaaaaaaaaa	aaa			1473

&lt;210&gt; 56

&lt;211&gt; 2732

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (334)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1885)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 56

aggccaggca	gcccgtatc	cttggatggc	ctttccacgc	aatagcatca	tgcacttgaa	60
ccacacagca	aacccacact	caaatagtaa	tttcttggac	ttgaatctcc	cgccacagca	120
caacacaggt	ctgggaggga	tccctgtagc	aggatttcca	gcgtcttcag	gaaacagttt	180
agactctctt	caagatgaca	atcctccaca	ctggctaaaa	tcccttcagg	ccctcacaga	240
gatggacggc	cccagcgtg	ctccatcaca	gacccaccac	agcgccccct	tcagcrcaca	300
gatccccgtg	cacagagcca	gttggaatcc	ctancctcct	ccttcaaacc	cttcagctt	360
ccactcccc	ccccaggct	ttcaracggc	cttcagaccc	cccagcaaaa	ccccacaga	420
tttactacag	agttcaacac	tggaccgcca	ttaggcawag	aggagcaacc	attakaaaat	480
gcaggatttg	tcccactctk	ttttctccct	ctcagcccac	caccacagc	tcccttctca	540
tctcttatgt	tctgaagaat	ccagtacctg	atcaattttt	tttctcccta	acccagatg	600
caatgcgac	acagggtcat	taccatctct	ttattaattg	taaaaatttt	tggtgatcca	660
gcatttgagt	gacactgttg	aatgtttcta	aaaatgcctt	tttaaggaga	gaaaaaaaaa	720
tcaaagggca	gtctcaatac	ttagaaaatt	attgtttgtc	tgttgcgcac	aataatgaca	780
taatctgctt	agcagaaaat	gacgattaat	ctataggaaa	gctcaagtaa	atgcattatc	840
aactgcagaa	gtttgaaaac	caggttcatt	tacgtgagat	tgctaaatgc	atgggggaaa	900
gcagtggctc	tagcatccat	cttgatttca	gcttatcatt	attgcaggga	aaatgctttt	960
aattttaaatt	aatttttaatt	tcttttgcca	agttgatggc	aaggacttga	ttgtgtcatt	1020
aagcaaaaga	atgtatttga	agttgatgga	aagacaaatt	catctgtagt	agtaactggc	1080
cgatttgctaa	agagttcata	aggaggtgag	aagtaatttt	tttaaaggag	aaaaattttt	1140
tggctttaga	tttaaagtaa	attgaaatgt	tttaaagaaa	aaagtattca	cagattttaat	1200
acctattaat	aataataagag	ctgaaatgta	agtcatttct	tcagtccttc	tcctctgtcg	1260

gaatcttttt	tgttttacca	taaattcacc	tgacgagggc	actctgagat	agcactgctc	1320
tggggccatc	tgatcaccat	cgggagcaaa	tctctgacct	ccttgccctg	agcttttact	1380
taacctgtga	gtttctggac	gtttgtgcag	tattgaaaag	acaggagaaa	agaaaacaga	1440
aacctgggta	taacctgacg	ctaaaactaa	aaacaaggaa	atgtacctct	ttcttcagaa	1500
ttaaaactaa	aatctttaa	aaaacagaaa	acttgatgat	gacacttggg	ttgtccttgt	1560
ttttgttttt	ctgttttgtt	ggatgtgagt	ttgaaagggt	ttgtgacaag	tagccatcag	1620
atgtttccat	ttgattttac	atcttcaaca	gtggggaggg	aggatgggtt	agaagaagaa	1680
agtggrrggag	aaacaacccat	tttattgaca	gycaatggca	tccttgacgt	tcagcccatc	1740
ttgtcctcaa	gaatccctct	tccagtgcct	ttcagtagaa	gattccctct	tctgctattg	1800
tattatgcat	gccaagcctt	cyyaactgag	aagccytatg	ygccagtaat	ggagagggtta	1860
ttgacatggt	gagatgttgg	ttctnttttag	ggagacctgg	caggagcagc	agtcactatg	1920
tcacacaagt	gacatctctt	tgtgagtgcc	atgatgggaa	agagatcggg	aaacactgat	1980
gtagatgata	cacagacaca	tcttttatga	ctgaccattt	taggaagtac	ctgatgatgg	2040
ggcaacgata	gcaccactga	ccaaaagagg	gtagaggatg	aaagttacct	gttccccaac	2100
agagcaccag	gatctgtgtg	gtttgtatgt	cttgcccttg	gctgcattca	gaagcccaaa	2160
gctggaactg	gcataattttc	agccatgtcc	attaagggat	gtgatgtagg	atcaactaaa	2220
tagatctaga	tcgtacgttc	tgtgctttca	ggtgggtttt	tttcgtcctt	acctttatgc	2280
tgtactttta	ttgtttaaaa	tttcaacaca	atttttagaa	acttaaacat	gatattctca	2340
aataaatgtc	accagaaata	gatgggtgatc	aagtggatag	taaattgttt	tgtaaaactw	2400
acaaaatttc	cctggataag	aggagaggac	tagaaatgac	aggctctctt	tgcccttgaa	2460
cttcaactca	gtctcctgaa	ccttcacatt	gtactgcaaa	gtgatggacc	aatgcacaaa	2520
taatatccag	atggcagtga	attgtaatca	aggctttttg	cggggatgcg	gggaagtcct	2580
gakatggggc	atatcaataa	aaatgttgct	ttttttgtaa	aaggagggaa	ctcctacctt	2640
ataaggtgtg	gctgtaattg	tgtgtgtgtt	taatcagtca	tacagaagag	tttataaaaa	2700
gcatgacttt	ataaaaagta	tgaagaataa	aa			2732

&lt;210&gt; 57

&lt;211&gt; 2777

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 57

ggcacgaggt	cagcagccgg	ctgctgagag	gccggtagcg	gcggcggtcc	cgagggggcg	60
cggccgcgct	gtccctgag	aacgggtccc	gcagctgggc	aggcgggcg	cctgagggcg	120
cggaccatga	agctgtacag	cctcagcgtc	ctctacaaa	gcgaggccaa	ggtggtgctg	180
ctcaaagccg	catacagatg	gtcttccctc	agctttttcc	agagatccag	cgttcaggaa	240
ttcatgacct	tcacgagtca	actgattgtg	gagcgctcat	cgaaaggcac	tagagcttct	300
gtcaaagaac	aagactatct	gtgccacgtc	tacgtccgga	atgatagtct	tgaggtgtg	360
gtcattgctg	acaatgaata	cccatcccgg	gtggccctta	ccttgctgga	gaaggtaata	420
gatgaattct	ccaagcaagt	cgacaggata	gactggccag	taggatcccc	tgctacaatc	480
cattacccag	ccctggatgg	tcacctcagt	agataccaga	acccacgaga	agctgatccc	540
atgactaaag	tgaggccga	actagatgag	accaaataca	ttctgcacaa	caccatggag	600
tctctgttag	agcgaggtga	gaagctagat	gacttggtgt	ccaaatccga	ggtgctggga	660
acacagtcta	aagccttcta	taaaactgcc	cggaaacaaa	actcatgctg	tgccatcatg	720
tgatgcagcc	tgccagaggc	ccaatgctgg	aatggcacca	tcattcacat	cagaactgca	780
gcccctggaa	aagaagagac	agccatagac	gaggagccag	agtgggggca	gactggccat	840
ttttattttg	aagttcctgc	gagaaatgga	tgggtggaag	gtggcgaaatg	ttcaaattca	900
tatgtgtggt	agtgattctt	ggaaagaatt	tgaggtcccc	aaaggtgtat	ttttgggcaa	960
atgaaacccat	aaactccgac	tggcttctgt	agatgccaaa	gggctctttt	tcagctaacc	1020
ctgggaaggc	tctgtgggag	ggaggtcgga	gccagctggt	tctcgatctt	tggtatatct	1080
ttggatctta	ttgtacatt	aatgatatta	acactccagt	gggggggtgg	gagtccttga	1140
tgctagggct	ggggtgggtg	gagtttgaag	actcttggga	aagcctctcc	tggggccact	1200
gttgggggtg	ggagtgaacc	caccacagag	gccacaggca	ggccccact	tcaggcccaa	1260
ggcctggggc	ggggggaaca	gtcactgggt	ctcagattct	gagactgttg	tttagcttac	1320

ctttctgcta	ggattggctt	cccgcagagg	gcagggccca	tcctaagcag	cttccaagtc	1380
ccacaaaggt	ggcttgtggg	aggatttggg	aggagctgca	ttgtgggagg	ggagtgtgtg	1440
ggttgggttc	gtaccagcaa	gtagactagg	aactgagccc	aggaaagggg	gatgttttcc	1500
tgggtgtttg	atggtcagct	gggagtgtcc	atcatcaggg	gaagatcaaa	cacaggtgca	1560
ctcagctgcc	cagggcctct	gggacacttg	ccttgacttg	caacttgcct	tgaacatcac	1620
gatcaaagca	gcaggtgctg	tggctctctc	aaattgattt	ttatttgact	ctgtggctct	1680
aagactgcct	tgaaccgcct	gaggcctatg	catctgaaca	agtgggtctc	tcccttgagc	1740
accaggagtg	ggtgccagcc	ggccccgagg	attcccagca	cccacctat	ggtcttgcca	1800
gcataggctt	gctagtctct	tcttggctcag	aggtagctgc	agagggggga	ggccaagggg	1860
ttggcttaag	ctgtgccctg	ccacctggca	ggaggccca	tcactgcca	agtcattgca	1920
acaggctgga	gcagcccagg	agatgggcct	aaaatgttct	ggatcccttg	ggtccctagt	1980
ttatgttcca	gtctgcccac	ctgtgctcag	gatgcagccc	tgggatccag	cacccatgga	2040
agcttctgct	gggatgggtg	cacctatggg	ttttgaacca	gtgtggtatg	gtccttgagg	2100
gctctgctct	gagcttgcca	cactgctgag	agcaccact	gtcctgacca	gagtctcagt	2160
ggtcctgacc	cccaatgtgg	gcaggggctg	ggcaggaggg	tgggtctctg	tgtgggttca	2220
gaggactcca	cctcctggct	ggtttacctg	ctgctgcca	ttttctctgg	gtactgctgg	2280
ccagaggact	ttagcctacc	cctgaagagc	ctgtccatgt	cattttccta	ctgccataga	2340
taccctaagc	ccagggcccc	ttgaggccca	gactcagcct	gcccactggg	gccggagacg	2400
gagtgaggag	ggcctggatc	cgagggatgc	tacctctccc	tttcccactt	gaggaccctg	2460
gggagagatg	ggggcgggga	aaatggaggt	atgaatttgg	ggtaagagga	agtgagatct	2520
ccgcttgagc	gtcagcccct	gccttgaggg	gcgggctggc	ttgactcagg	ccctgtgaga	2580
tagaggccca	gcccagcccc	acccacagat	ccctgtctcc	tgtgtgttcc	tgtgtgaaat	2640
catttggcga	gactgtattt	tagtaactgc	tgccctaact	ccctgtgttc	tatttgagag	2700
gcgcctgtct	ggataaagtt	gtcttgaaat	ttaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2760
aaaacatcca	gcgtccg					2777

&lt;210&gt; 58

&lt;211&gt; 665

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 58

cccacgcgtc	cgcacaggaa	gagtggtgag	aagtggaaat	acgtatgcct	cctttcccaa	60
atgtcactgc	cttaggtatc	ttccaagagc	ttagatgaga	gcataatcatc	aggaaagttt	120
caacaatgtc	cattactccc	ccaaacctcc	tggctctcaa	ggatgaccac	attctgatac	180
agcctacttc	aagccttttg	ttttactgct	ccccagcatt	tactgtaact	ctgccatctt	240
ccctcccaca	attagagttg	tatgccagcc	cctaatatcc	accactggct	tttctctccc	300
ctggcctttg	ctgaagctct	tccctctttt	tcaaagtctt	attgatattc	tccatttttc	360
actgcccac	taaaatacta	ttaatatctt	tttcttttct	tttctttttt	ttgagacaag	420
gtctcactat	gttgcccagg	ctggctctca	actccagagc	tcaagagatc	ctcctgcctc	480
agcctcctaa	gtacctggga	ttacaggcat	gtgccaccac	acctggctta	aaatactatt	540
tcttattgag	gtttaacctc	tatttcccct	agccctgtcc	ttccactaag	cttggttagat	600
gtaataataa	agtgaataa	ttaacattaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	660
aaaaa						665

&lt;210&gt; 59

&lt;211&gt; 3021

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 59

cttgtgaatc	agccagtgtg	atggctgcga	cactggctaa	tgggtgtttc	tgcccaatta	60
ctggtgaaag	agtactgagc	cctgaagcag	ttcgaaatac	attgagtttg	atgcattcct	120

gtggcatgta	tgactttctca	gggcagtttg	ctttccatgt	tggtcttcct	gcaaaatctg	180
gagttgctgg	gggcatttctt	ttagttgtcc	ccaatgttat	gggtatgatg	tgctggtytc	240
ctcctctgga	taagatgggc	aacagtgtta	agggaattca	cttttgtcac	gatcttgttt	300
ctctgtgtaa	tttccataac	tatgataatt	tgagacactt	tgcaaaaaaa	cttgatcctc	360
gaagagaagg	tggtgatcaa	aggcatttct	ttggaccatt	ggactatgaa	agtcctccaac	420
aagaacttgc	tttaaaagag	acagtatgga	aaaaagtgtc	acctgagtca	aatgaggaca	480
tctctacaac	tgtagtatat	agaatggaaa	gtctgggaga	gaaaagctaa	agaaatgggt	540
tctagtttca	gaatgtttct	tcatttaatc	tttcaaacat	ctttagcttt	tttttgcaag	600
ttataaatat	ttatttgagg	tattttttgt	tctcaatctt	gggtgctgga	gccataaagc	660
ttttttttcc	ttttaatctt	tgtataaagg	cagtagatta	agaagtgcac	ttgttggtct	720
ttaaaaagta	tttacaagta	cataaatttg	ctttattttt	aaaaatacaa	aaaggaaaaa	780
tttaaatttt	tttgatgta	attaaaatgt	taactatgtg	gtcagataat	cccattttac	840
aatagtaaca	gaaaattgta	attcttagtt	ctaaaaattca	caaattaaac	tcataagttt	900
tgttgcatct	tgttttttct	tttccatttt	taaaactaat	gtgatgtctt	tagtggcaat	960
agaaggtact	tctatgctaa	atacaaaact	aaaaaggcaa	aataatgaac	cccaaattat	1020
tttattttaa	atagcagtg	attataaaat	tagcttgtgt	ttacattttat	gccatttttg	1080
gtgatagatt	ggctttacat	tttaaaaaat	ttatttaaaa	atttatcaaa	tgcttttaaa	1140
tatgactcct	acttttttta	ttttgcaact	cctctgttct	gtcagagttg	ttatatacac	1200
gagtggtcta	tggtactaaa	acattccagc	caaagaattt	cagatgtgag	ataatgatgt	1260
ttcatcaata	aaaagctata	atgggttagtt	actcagaagg	agaaacagtg	agtgcttcca	1320
agtgaattgt	tcacctaaac	aattttattt	tcatattatc	cacataactt	tttctatgtt	1380
atattttaa	atgaatggca	aattttgggt	tttagctttt	acattttatt	atcttaattt	1440
tataaatgct	aatatttctt	ttgtgataag	ttatagcatc	tcataaagtt	tgttctattt	1500
gaagtttttt	agagtacttg	agaaatgaat	ttagtctgca	ggtagtaagt	atgctactaa	1560
aatacgttag	atctaaatcc	ttttatttgg	tataaaaaatg	caatattgag	aatcaaaact	1620
tggtttttaag	agaactatag	attctacaca	acctgatttc	aagtaattat	tcatagtatt	1680
tatagttgtc	ttggcaaagt	gattgtaaaa	ttctgtagga	cctattcaca	cttcttccct	1740
cttccatata	cttctctggt	tttccccata	gttcccctat	aatttcaagt	ttgttgaaac	1800
ctgttaattt	tagtggggga	ttagaagaaa	aacttggtgg	tttcttagca	tgatgggtgta	1860
tgtatgtggt	aatggaaaagt	ctgtaaaagt	aaatatagtg	tagcaaaaaa	gatttcactg	1920
agtatttttag	atactagtgc	aaataaagat	agaaaatctt	gatcataatg	tcttaagttt	1980
gggaactgtg	atattaagaa	aagaaattcc	cttctagagg	tgctggccaa	aaagcctttt	2040
gggttaactt	aagtattaaa	tttatatatt	taaataatta	tattttaagt	tgtagaggat	2100
tttcccaagg	attttatgct	tacttgaatg	ttctttgaat	gttcagatgc	atatacctaac	2160
tggaatgctt	tcaaggcctt	actgcatatt	tgtgttgcat	atttatgtta	gttgaccag	2220
ggccatttgt	agtttgggca	accgaatgcc	ttaattggaa	aaaaggcatt	gtggtttccc	2280
ctatgatcta	aattgttaca	ttttaccatt	tcatccgaa	gttggtttta	ctttatttaa	2340
tgaagattta	gttttcatat	cgtatacata	gctgtataga	tttcaaaatt	aggttggttaa	2400
tttggtgcac	ttactatttt	tgtgttggtg	atgctttaa	tgcatactta	aaaatgaagt	2460
actgttatct	aagctactgt	gtttagaaaa	tgttagaagt	gagcagaaat	ttttatagaa	2520
aagtataaac	ggaagaagag	ataagatact	gcgaataggc	cctcaaaact	aaaaaagaaa	2580
aaactttgcc	agttttaagg	acatattttg	attctttcag	tattcttaac	acctttttta	2640
acaaagttct	tgatagtacc	cactattatt	gggtttgttt	tatgccatta	ttgattcttg	2700
atattcaagc	atttacaatg	tagcatattt	gattttcttt	tttcttctct	tttttgcat	2760
cattaacatt	tcatttgaaa	tgcatattgt	tcttgaagta	ctttgttttt	agcataaatg	2820
ttgtgcattt	tatcttagtg	tttggatgaa	aacattttgt	ttgttttagct	ttcatttgct	2880
ttgtatattt	aataatgtac	ctttattttc	cagtatgcct	acattttgta	ttgcacaata	2940
aattttattt	aagctgaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	3000
aaaaaaaaaa	agggcggccg	c				3021

&lt;210&gt; 60

&lt;211&gt; 558

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens



<220>  
 <221> SITE  
 <222> (6)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (8)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (10)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (33)  
 <223> n equals a,t,g, or c

<400> 60	
acttcntnan ggggactttc aactggaaat tcnccctcac taatkggaaac aaaagctgga	60
gctccaccgc ggtggcggcc gctctagaac tagtggatcc cccgggctgc aggaattcgg	120
cacgagcctc cataggaacc cagtgactgg ggggtgacgc ctacaccccc agctatattgc	180
actctggtgt gtggtttgac tctgcttttc ttccggattg gccctgtggt cacagcctca	240
ggggggccagg ctggggggaac ctcacctggc ccgtactcct ggggggtttcc ctttgccatt	300
gggccccctg agggactgtg ggggctcaag ggtaatgccg gaggcccatg gccccagcga	360
ggggctgtgg ggcacctaga gttctcggtg tgtctccttc attcattggc ctctgctggg	420
gcctcctatg ggtgtcttac gtctgtccat ccatctgtcc gtggtcagaa gtggggtcag	480
tgtgtgagtg agagcaggag tatttatgaa aataaaacgt cgtttttcct ggaaaaaaaa	540
aaaaaaaaagg gcggccgc	558

<210> 61  
 <211> 28  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (28)  
 <223> Xaa equals stop translation

<400> 61  
 Met Ala Leu Ala Ala Ala Leu Arg Cys Leu Glu Trp Val Pro Ala Ser  
 1 5 10 15  
 Gly Glu Val Pro Ser Asn Arg Arg Ser His His Xaa  
 20 25

<210> 62  
 <211> 225  
 <212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (225)

<223> Xaa equals stop translation

<400> 62

Met Leu Arg Ala Pro Gly Cys Leu Leu Arg Thr Ser Val Ala Pro Ala  
1 5 10 15

Ala Ala Leu Ala Ala Leu Leu Ser Ser Leu Ala Arg Cys Ser Leu  
20 25 30

Leu Glu Pro Arg Asp Pro Val Ala Ser Ser Leu Ser Pro Tyr Phe Gly  
35 40 45

Thr Lys Thr Arg Tyr Glu Asp Val Asn Pro Val Leu Leu Ser Gly Pro  
50 55 60

Glu Ala Pro Trp Arg Asp Pro Glu Leu Leu Glu Gly Thr Cys Thr Pro  
65 70 75 80

Val Gln Leu Val Ala Leu Ile Arg His Gly Thr Arg Tyr Pro Thr Val  
85 90 95

Lys Gln Ile Arg Lys Leu Arg Gln Leu His Gly Leu Leu Gln Ala Arg  
100 105 110

Gly Ser Arg Asp Gly Gly Ala Ser Ser Thr Gly Ser Arg Asp Leu Gly  
115 120 125

Ala Ala Leu Ala Asp Trp Pro Leu Trp Tyr Ala Asp Trp Met Asp Gly  
130 135 140

Gln Leu Val Glu Lys Gly Arg Gln Asp Met Arg Gln Leu Ala Leu Arg  
145 150 155 160

Leu Ala Ser Leu Phe Pro Ala Leu Phe Ser Arg Glu Asn Tyr Gly Arg  
165 170 175

Cys Gly Ser Ser Pro Val Pro Ser Thr Ala Ala Trp Ile Ala Ala Pro  
180 185 190

Pro Ser Cys Arg Gly Cys Gly Ser Thr Thr Thr Leu Ala Cys Arg Arg  
195 200 205

Arg Thr Ser Gln Ile Trp Ser Leu Asp Leu Gln Gln Leu Met Ile Asn  
210 215 220

Xaa

225

<210> 63

<211> 19  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (19)  
<223> Xaa equals stop translation

<400> 63  
Leu Ala Thr Leu Leu Leu Arg Leu Leu Leu Ser Leu Gly Thr Gly Cys  
1 5 10 15

Gln Arg Xaa

<210> 64  
<211> 39  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (39)  
<223> Xaa equals stop translation

<400> 64  
Met Phe Gly Asn Ser Ser Cys Ser Thr Tyr Leu Leu Trp Val Ser Leu  
1 5 10 15

Phe Asn Phe Gly His Ser Ser Glu Cys Ile Met Ile Ser Cys Tyr Gly  
20 25 30

Phe Lys Phe Ala Phe Ser Xaa  
35

<210> 65  
<211> 67  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (67)  
<223> Xaa equals stop translation

<400> 65  
Met Cys Cys Pro Ser Leu Leu Lys Phe Tyr Phe Arg Phe Ser Ile Gly  
1 5 10 15

Tyr Leu Phe Cys Phe Leu Tyr Phe Phe Ser Leu Ser Leu Pro Pro Ser  
20 25 30

Arg Pro Pro Arg Pro Ile Pro Phe Leu Pro Leu Asp Phe His Pro Leu  
35 40 45

Gly Cys Leu Ala His Leu Tyr Ala Pro Ala Leu Gly Thr Gly Pro Asn  
50 55 60

Thr Trp Xaa  
65

<210> 66  
<211> 37  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (37)  
<223> Xaa equals stop translation

<400> 66  
Met Phe Cys His Cys Ile Val Cys Leu Leu Leu Val Leu Trp Ser Ser  
1 5 10 15

Leu Pro Phe Phe Ile Pro Ser Phe Leu Leu Leu Lys Val Ile Leu Ser  
20 25 30

Cys Gly Met Ile Xaa  
35

<210> 67  
<211> 38  
<212> PRT  
<213> Homo sapiens

<400> 67  
Met Asp Phe Thr Lys Leu Leu Thr Tyr Thr Phe Gly Phe Ala Val Phe  
1 5 10 15

Ile Val Leu Gly Lys Asn Cys Gly Phe Lys Asn Tyr Ser Leu Ile Lys  
20 25 30

Leu Leu Lys Lys Lys Lys  
35

<210> 68  
<211> 34  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (34)

<223> Xaa equals stop translation

<400> 68

Met Phe Ile Gly Asp Ser Ala Tyr Ile Phe Ile Thr Tyr Leu Leu Phe  
1 5 10 15

Trp Leu Leu Ser Asn Ile Leu Ser Phe Val Phe Ala Asn Ser Val His  
20 25 30

Glu Xaa

<210> 69

<211> 33

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (33)

<223> Xaa equals stop translation

<400> 69

Met Leu Lys Ile Leu Met Cys Lys Ser Pro Leu Ser Pro His Leu Phe  
1 5 10 15

Tyr Lys Leu Leu Trp Leu Glu Gly Phe Cys Phe Trp Leu Leu Ser Gly  
20 25 30

Xaa

<210> 70

<211> 59

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (59)

<223> Xaa equals stop translation

<400> 70

Met Pro Phe Cys Met Asn Ala Cys Glu Met Leu Leu Leu Leu Cys Met  
1 5 10 15

Ala Trp Leu Pro Trp Leu Ala Gly Ile Ser Ser Phe Val Val Phe Leu  
20 25 30

Ser Ser Leu Cys Ile Thr Val Ser Phe Val Phe Leu Ala Cys Lys Leu  
35 40 45

Leu Glu Asp Lys Gly Met Ser Glu Ser Ile Xaa

50

55

&lt;210&gt; 71

&lt;211&gt; 38

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (38)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 71

Met	Val	Trp	Ile	Cys	Val	Leu	Leu	Gln	Thr	Leu	Leu	Arg	His	Ile	Leu
1				5					10					15	

Arg	Ser	Met	Glu	Arg	Asn	Arg	Val	Asp	Asp	Lys	Val	Cys	Val	Val	Phe
			20					25					30		

Thr	Lys	Glu	Tyr	Ser	Xaa
					35

&lt;210&gt; 72

&lt;211&gt; 37

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (37)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 72

Met	Arg	Leu	Gly	Gly	Leu	Val	Phe	Thr	Met	His	Phe	Ser	Ala	Val	Ser
1				5					10					15	

Leu	Gly	Leu	Pro	Val	Leu	Arg	Gly	Thr	Phe	Pro	Val	Leu	Ala	Pro	Val
			20					25					30		

Val	Ile	Cys	Thr	Xaa
				35

&lt;210&gt; 73

&lt;211&gt; 38

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (38)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 73

Met Ala Asp Ala Thr Cys Thr Leu Leu Val Ile Phe Cys Val Met Gly  
1 5 10 15

Tyr Glu Met Val His Arg Lys Lys Pro Glu Lys Tyr Ala Lys Val Arg  
20 25 30

Phe Ile Leu Arg Val Xaa  
35

&lt;210&gt; 74

&lt;211&gt; 27

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (27)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 74

Met Asp Leu Val Glu Ala Phe Asn His Ser Arg Gly Pro Gln Val Met  
1 5 10 15

Leu Ile Ser Leu Leu Ala Gly Val Leu Val Xaa  
20 25

&lt;210&gt; 75

&lt;211&gt; 36

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (36)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 75

Met Trp Ser Arg Met Val Arg Ser Leu Trp Tyr Ile Met Phe Thr Trp  
1 5 10 15

Gln Gly Gly Ser Cys Val Leu Ser Gly Thr Gly Ser Leu Leu Ser Tyr  
20 25 30

Thr Arg Thr Xaa  
35

&lt;210&gt; 76

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

<220>  
 <221> SITE  
 <222> (12)  
 <223> Xaa equals stop translation  
  
 <400> 76  
 Met Trp Pro Trp Asp Met Val Phe Ser Trp Ser Xaa  
 1 5 10

<210> 77  
 <211> 52  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (51)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (52)  
 <223> Xaa equals stop translation

<400> 77  
 Met Thr Val Val Thr Ala Leu Leu Leu Ile Ile Leu Gln Thr Arg Asn  
 1 5 10 15  
 Leu Asn Ser Gly Gln Ile Ser Val Lys Asn Trp Gln Met Phe Phe Met  
 20 25 30  
 Arg Thr Leu Ile Met Asn Leu Ser Ala Ala Phe Gln Lys Val Arg Cys  
 35 40 45

Lys Met Xaa Xaa  
 50

<210> 78  
 <211> 6  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (6)  
 <223> Xaa equals stop translation

<400> 78  
 Met Gly His Thr Pro Xaa  
 1 5

<210> 79



<211> 35  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (35)  
 <223> Xaa equals stop translation

<400> 79  
 Met Leu Ser Gln Cys Leu Leu Gln Phe Val Val Trp Val Phe Phe Phe  
           1                  5                  10                  15  
 Leu Lys Pro His Asn Asn Phe Gly Lys Gln Cys Met Gly Arg Thr Cys  
                   20                  25                  30  
 Val Cys Xaa  
                   35

<210> 80  
 <211> 26  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (26)  
 <223> Xaa equals stop translation

<400> 80  
 Met Tyr Phe Cys Asp Thr Val Ile Met Phe Cys Ile Cys Leu Ile Leu  
           1                  5                  10                  15  
 Ala Asp Leu Gln Tyr Ala Ile Lys Val Xaa  
                   20                  25

<210> 81  
 <211> 71  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (71)  
 <223> Xaa equals stop translation

<400> 81  
 Met Pro Trp Cys Pro Cys Trp Thr Val Leu Thr Ser Lys Pro Phe Leu  
           1                  5                  10                  15  
 Ser Met Leu Pro Ala Cys Ser Ala Trp Pro Arg Ser Thr Phe Ser Ser  
                   20                  25                  30

Arg Thr Ser Val Trp Lys Ser Leu Arg Ser Pro Arg Leu Ser Trp Arg  
35 40 45  
Asn Thr Thr Arg Leu Gln Cys Phe Ser Pro Ser Asn Ser Cys Ser Gly  
50 55 60  
Met Ser Tyr Phe Ala Ser Xaa  
65 70

<210> 82  
<211> 46  
<212> PRT  
<213> Homo sapiens  
  
<220>  
<221> SITE  
<222> (46)  
<223> Xaa equals stop translation

<400> 82  
Met Gly Val Phe Asp Pro Thr Glu Ile His Asn Arg Gly Gln Leu Lys  
1 5 10 15  
Ser His Met Lys Glu Ala Met Ile Lys Leu Gly Phe His Leu Leu Cys  
20 25 30  
Phe Phe Met Tyr Leu Tyr Ser Gly Ser Asn Cys Pro Cys Xaa  
35 40 45

<210> 83  
<211> 30  
<212> PRT  
<213> Homo sapiens  
  
<220>  
<221> SITE  
<222> (30)  
<223> Xaa equals stop translation

<400> 83  
Met Val Leu Val Leu Leu Cys Val Gly Pro Leu Gly Thr Gln Ala Gly  
1 5 10 15  
Ala Asn Gly Ile Trp Ala Glu Leu Thr Glu Phe Leu Glu Xaa  
20 25 30

<210> 84  
<211> 59  
<212> PRT  
<213> Homo sapiens  
  
<220>

&lt;221&gt; SITE

&lt;222&gt; (59)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 84

Met Leu Leu Leu Val Ser Val Phe Ser Pro Val Leu Phe Ser Arg Ser  
1 5 10 15

Ser Thr Val Glu Met Asp Val Glu Pro Phe Cys Leu Val Leu Ser Ser  
20 25 30

Ala Phe Pro Glu Ile Thr Pro Pro Ile Ser Cys Leu Cys Leu Asn Met  
35 40 45

Phe Phe Ser Leu Leu Arg Ser Pro His Ser Xaa  
50 55

&lt;210&gt; 85

&lt;211&gt; 34

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (34)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 85

Met Val Cys Ala Cys Leu Leu Ser Leu Arg Leu Gly Leu Leu Thr Glu  
1 5 10 15

Cys Glu Tyr Lys Tyr Pro Tyr Leu Gly Glu Lys Tyr Ile Phe Lys Gly  
20 25 30

Trp Xaa

&lt;210&gt; 86

&lt;211&gt; 34

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (34)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 86

Met Phe Cys Ser Leu Leu Phe Ser Gln Tyr Val Gln Trp Leu Leu Ala  
1 5 10 15

Gln Asn Arg Gln Tyr Ser Leu Thr Glu Cys Tyr Trp Thr Leu Ser Val  
20 25 30

Tyr Xaa

&lt;210&gt; 87

&lt;211&gt; 291

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (291)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 87

Met Ala Val Thr Ala Gln Val Lys Ser Leu Thr Gln Lys Val Gln Ala  
 1 5 10 15

Gly Ala Tyr Pro Thr Glu Lys Gly Leu Ser Phe Leu Glu Val Lys Asp  
 20 25 30

Gln Leu Leu Leu Met Tyr Leu Met Asp Leu Thr His Leu Ile Leu Asp  
 35 40 45

Lys Ala Ser Gly Gly Ser Leu Gln Gly His Asp Ala Val Leu Arg Leu  
 50 55 60

Val Glu Ile Arg Thr Val Leu Glu Lys Leu Arg Pro Leu Asp Gln Lys  
 65 70 75 80

Leu Lys Tyr Gln Ile Asp Lys Leu Ile Lys Thr Ala Val Thr Gly Ser  
 85 90 95

Leu Ser Glu Asn Asp Pro Leu Arg Phe Lys Pro His Pro Ser Asn Met  
 100 105 110

Met Ser Lys Leu Ser Ser Glu Asp Glu Glu Glu Asp Glu Ala Glu Asp  
 115 120 125

Asp Gln Ser Glu Ala Ser Gly Lys Lys Ser Val Lys Gly Val Ser Lys  
 130 135 140

Lys Tyr Val Pro Pro Arg Leu Val Pro Val His Tyr Asp Glu Thr Glu  
 145 150 155 160

Ala Glu Arg Glu Lys Lys Arg Leu Glu Arg Ala Lys Arg Arg Ala Leu  
 165 170 175

Ser Ser Ser Val Ile Arg Glu Leu Lys Glu Gln Tyr Ser Asp Ala Pro  
 180 185 190

Glu Glu Ile Arg Asp Ala Arg His Pro His Val Thr Arg Gln Ser Gln  
 195 200 205

Glu Asp Gln His Arg Ile Asn Tyr Glu Glu Ser Met Met Val Arg Leu  
 210 215 220  
 Ser Val Ser Lys Arg Glu Lys Gly Arg Arg Lys Arg Ala Asn Val Met  
 225 230 235 240  
 Ser Ser Gln Leu His Ser Leu Thr His Phe Ser Asp Ile Ser Ala Leu  
 245 250 255  
 Thr Gly Gly Thr Val His Leu Asp Glu Asp Gln Asn Pro Ile Lys Lys  
 260 265 270  
 Arg Lys Lys Ile Pro Gln Lys Gly Arg Lys Lys Lys Gly Phe Arg Arg  
 275 280 285  
 Arg Arg Xaa  
 290

<210> 88  
 <211> 26  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (26)  
 <223> Xaa equals stop translation

<400> 88  
 Met Thr Arg Ser Leu Val Leu Arg Phe Lys Val Leu Leu Met Leu Gly  
 1 5 10 15

Leu Leu Ile Glu Val Ser Glu Glu Leu Xaa  
 20 25

<210> 89  
 <211> 74  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (74)  
 <223> Xaa equals stop translation

<400> 89  
 Met Pro Ser Leu Trp Asp Arg Phe Ser Ser Ser Ser Thr Phe Gln Leu  
 1 5 10 15

Thr Leu Val Leu Arg Leu Asp Ser Arg Leu Trp Pro Lys Ile Gln Gly  
 20 25 30

Leu Phe Ser Ser Ala Asn Ser Pro Phe Leu Pro Gly Phe Ser Gln Ser

35                      40                      45  
 Leu Thr Leu Ser Thr Gly Phe Arg Val Ile Lys Lys Lys Leu Tyr Ser  
     50                      55                      60  
 Ser Glu Gln Leu Leu Ile Glu Glu Cys Xaa  
     65                      70

<210> 90  
 <211> 44  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (28)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (33)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (44)  
 <223> Xaa equals stop translation

<400> 90  
 Asp Gln Phe Ser Thr Ala Val Arg His Arg Val Pro Ala Gly His Trp  
     1                      5                      10                      15  
 Gln Val Ala Gly Ser Thr Pro Thr Pro Cys Pro Xaa Asn Pro Asp Leu  
                     20                      25                      30

Xaa Pro Gly Lys Glu Arg Glu Gly Pro Val Ser Xaa  
     35                      40

<210> 91  
 <211> 34  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (34)  
 <223> Xaa equals stop translation

<400> 91  
 Met Ile Val Val Val Leu Trp Ile Asn Leu Cys Ser Trp Phe Cys Phe  
     1                      5                      10                      15  
 Val Ser Pro Leu Pro Lys Cys Ser Phe Gln Tyr Tyr Thr Arg Lys Arg

47

20

25

30

Ser Xaa

&lt;210&gt; 92

&lt;211&gt; 28

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (28)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 92

Met	Pro	Ile	Ser	Val	Ser	Ser	Phe	Cys	Ala	Ala	Val	Ile	Val	Gly	Leu
1				5					10					15	

Pro	Val	Ser	Phe	Glu	Leu	Trp	Ala	Leu	Pro	Gly	Xaa
	20						25				

&lt;210&gt; 93

&lt;211&gt; 145

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (145)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 93

Met	Asp	Val	Arg	Lys	Leu	Asp	Phe	Pro	Ser	Ala	Ser	Phe	Asp	Val	Val
1				5				10					15		

Leu	Glu	Lys	Gly	Thr	Leu	Asp	Ala	Leu	Leu	Ala	Gly	Glu	Arg	Asp	Pro
	20						25						30		

Trp	Thr	Val	Ser	Pro	Glu	Gly	Val	His	Thr	Val	Asp	Gln	Val	Leu	Ser
	35						40					45			

Glu	Val	Ser	Arg	Val	Leu	Val	Pro	Gly	Gly	Arg	Phe	Ile	Ser	Met	Thr
	50					55					60				

Ser	Ala	Ala	Pro	His	Phe	Arg	Thr	Arg	His	Tyr	Ala	Gln	Ala	Tyr	Tyr
65					70					75				80	

Gly	Trp	Ser	Leu	Arg	His	Ala	Thr	Tyr	Gly	Ser	Gly	Phe	His	Phe	His
			85						90					95	

Leu	Tyr	Leu	Met	His	Lys	Gly	Gly	Lys	Leu	Ser	Val	Ala	Gln	Leu	Ala
			100					105						110	

Leu Gly Ala Gln Ile Leu Ser Pro Pro Arg Thr Pro Thr Ser Pro Cys  
115 120 125

Phe Leu Gln Asp Ser Asp His Glu Asp Phe Leu Ser Ala Ile Gln Leu  
130 135 140

Xaa  
145

<210> 94  
<211> 16  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (16)  
<223> Xaa equals stop translation

<400> 94  
Met Leu His Phe Cys Phe Ile Phe Tyr Phe Ser Leu Leu Cys Phe Xaa  
1 5 10 15

<210> 95  
<211> 25  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (25)  
<223> Xaa equals stop translation

<400> 95  
Glu Lys Arg Arg Lys Lys Ala Arg Ser Thr Gly Asn Leu Gly Cys Gly  
1 5 10 15

Thr Met Ser Arg Arg Met Arg Thr Xaa  
20 25

<210> 96  
<211> 37  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (37)



<223> Xaa equals stop translation

<400> 96

Met Tyr Ile Asn Ser Met Phe Ile Phe Phe Ser Ile Leu Ser Asp Thr  
1 5 10 15

Val Leu Ala Ala Gly Leu Leu Lys Pro Ser Leu Val Val Ile Glu Ser  
20 25 30

Phe Pro Leu Leu Xaa  
35

<210> 97

<211> 26

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (26)

<223> Xaa equals stop translation

<400> 97

Met Gly Leu His Leu Thr Phe Leu Val Ile Leu Val Asp Gln Met Pro  
1 5 10 15

Leu Gly His Gln Ser Leu Leu Gln Asp Xaa  
20 25

<210> 98

<211> 30

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (30)

<223> Xaa equals stop translation

<400> 98

Met Trp Ala Gly Leu Gly Cys His Val Leu Ile Pro Leu Ser Phe Leu  
1 5 10 15

Lys Pro Trp Leu Gln Ala Ala Pro Ala Pro Gln Pro Ile Xaa  
20 25 30

<210> 99

<211> 106

<212> PRT

<213> Homo sapiens

<220>

&lt;221&gt; SITE

&lt;222&gt; (106)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 99

Met Leu Phe Ile Met Gly Tyr Ala Val Gly Trp Gly Pro Ile Thr Trp  
 1 5 10 15

Leu Leu Met Ser Glu Val Leu Pro Leu Arg Ala Arg Gly Val Ala Ser  
 20 25 30

Gly Leu Cys Val Leu Ala Ser Trp Leu Thr Ala Phe Val Leu Thr Lys  
 35 40 45

Ser Phe Leu Pro Val Val Ser Thr Phe Gly Leu Gln Val Pro Phe Phe  
 50 55 60

Phe Phe Ala Ala Ile Cys Leu Val Ser Leu Val Phe Thr Gly Cys Cys  
 65 70 75 80

Val Pro Glu Thr Lys Gly Arg Ser Leu Glu Gln Ile Glu Ser Phe Phe  
 85 90 95

Arg Thr Gly Arg Arg Ser Phe Leu Arg Xaa  
 100 105

&lt;210&gt; 100

&lt;211&gt; 51

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (51)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 100

Met Val Tyr Ile Tyr Tyr Leu Tyr Phe Leu Thr Phe Tyr Tyr Leu Leu  
 1 5 10 15

Asn Pro Leu His Gln Thr Thr Thr Tyr Gly Thr Ser Gln Gly Ser Ser  
 20 25 30

Leu Gly Ala Leu Phe Phe Lys Tyr Ser Val Leu Met Lys Asn Lys Phe  
 35 40 45

Asn Ile Xaa  
 50

&lt;210&gt; 101

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

<220>  
<221> SITE  
<222> (12)  
<223> Xaa equals stop translation

<400> 101  
Met Arg Leu Leu Val Leu Phe Cys Phe Ile Asn Xaa  
1 5 10

<210> 102  
<211> 31  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (31)  
<223> Xaa equals stop translation

<400> 102  
Met Trp His Met Ser Ile Ala Leu Ser Leu Pro Ser Cys Cys Val Leu  
1 5 10 15  
Leu Trp Thr Gly Arg Pro Gly Trp Asp Arg Leu Leu Phe Pro Xaa  
20 25 30

<210> 103  
<211> 39  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (39)  
<223> Xaa equals stop translation

<400> 103  
Met Leu Ser Gly Tyr Pro Leu Ser Phe Phe Leu Leu Thr Ile Cys Leu  
1 5 10 15  
Val Val Leu Thr Ala Arg Gly Thr Glu Gly Leu Cys Pro Gly Ile Trp  
20 25 30  
Arg Pro Ala Leu Phe Thr Xaa  
35

<210> 104  
<211> 20  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (20)  
<223> Xaa equals stop translation

<400> 104  
Met Leu Leu Phe Leu Leu Leu Leu Leu Ser Ser Leu Leu Ala Leu  
1 5 10 15

Asn Asp Cys Xaa  
20

<210> 105  
<211> 31  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (31)  
<223> Xaa equals stop translation

<400> 105  
Met Gly Ala Pro Thr Arg Lys Cys Ser Val Gln Trp Leu Ser Leu Ser  
1 5 10 15

Val Pro Phe Leu Ser Ala Gln Cys Ser Ala Trp Arg Ser Ile Xaa  
20 25 30

<210> 106  
<211> 26  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (26)  
<223> Xaa equals stop translation

<400> 106  
Met Met Thr Leu Gly Leu Ser Leu Phe Leu Phe Phe Cys Phe Val Gly  
1 5 10 15

Cys Glu Phe Glu Arg Phe Cys Asp Lys Xaa  
20 25

<210> 107  
<211> 41  
<212> PRT  
<213> Homo sapiens

<220>

<221> SITE  
<222> (41)  
<223> Xaa equals stop translation

<400> 107

Met Phe Trp Ile Pro Trp Val Leu Val Leu Cys Ser Ser Leu Pro Thr  
1 5 10 15

Cys Ala Gln Asp Ala Ala Leu Gly Ser Ser Thr His Gly Ser Phe Cys  
20 25 30

Trp Asp Gly Val Thr Tyr Gly Phe Xaa  
35 40

<210> 108  
<211> 10  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (10)  
<223> Xaa equals stop translation

<400> 108

Leu Lys Ile Leu Phe Leu Ile Glu Val Xaa  
1 5 10

<210> 109  
<211> 37  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (37)  
<223> Xaa equals stop translation

<400> 109

Met Leu Tyr Leu Asn Met Asn Gly Lys Phe Trp Phe Leu Ala Phe Thr  
1 5 10 15

Phe Tyr Tyr Leu Asn Phe Ile Asn Ala Asn Ile Ser Phe Val Ile Ser  
20 25 30

Tyr Ser Ile Ser Xaa  
35

<210> 110  
<211> 15  
<212> PRT  
<213> Homo sapiens

<220>  
 <221> SITE  
 <222> (15)  
 <223> Xaa equals stop translation  
  
 <400> 110  
 Met Pro Glu Ala His Gly Pro Ser Glu Gly Leu Trp Gly Thr Xaa  
   1                  5                  10                  15  
  
 <210> 111  
 <211> 312  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 111  
 Met Ile Arg Ile Ala Ala Leu Asn Ala Ser Ser Thr Ile Glu Asp Asp  
   1                  5                  10                  15  
 His Glu Gly Ser Phe Lys Ser His Lys Ile Gln Thr Lys Glu Ala Gln  
                   20                  25                  30  
 Glu Ala Glu Ala Phe Ala Leu Tyr His Lys Ala Leu Asp Leu Gln Lys  
                   35                  40                  45  
 His Asp Arg Phe Glu Glu Ser Ala Lys Ala Tyr His Glu Leu Leu Glu  
                   50                  55                  60  
 Ala Arg Leu Leu Arg Glu Ala Val Ser Ser Gly Asp Glu Lys Glu Gly  
   65                  70                  75                  80  
 Leu Lys His Pro Gly Leu Ile Leu Lys Tyr Ser Thr Tyr Lys Asn Leu  
                   85                  90                  95  
 Ala Gln Leu Ala Ala Gln Arg Glu Asp Leu Glu Thr Ala Met Glu Phe  
                   100                  105                  110  
 Tyr Leu Glu Ala Val Met Leu Asp Ser Thr Asp Val Asn Leu Trp Tyr  
                   115                  120                  125  
 Lys Ile Gly His Val Ala Leu Arg Leu Ile Arg Leu Pro Leu Ala Arg  
   130                  135                  140  
 His Ala Phe Glu Glu Gly Leu Arg Cys Asn Pro Asp His Trp Pro Cys  
  145                  150                  155                  160  
 Leu Asp Asn Leu Ile Thr Val Leu Tyr Thr Leu Ser Asp Tyr Thr Thr  
                   165                  170                  175  
 Cys Leu Tyr Phe Ile Cys Lys Ala Leu Glu Lys Asp Cys Arg Tyr Ser  
                   180                  185                  190  
 Lys Gly Leu Val Leu Lys Glu Lys Ile Phe Glu Glu Gln Pro Cys Leu  
   195                  200                  205

Arg Lys Asp Ser Leu Arg Met Phe Leu Lys Cys Asp Met Ser Val His  
 210 215 220

Glu Val Ser Val Asn Ala Ala Glu Thr Gln Ala Ile Val Asp Glu Ala  
 225 230 235 240

Leu Gly Leu Arg Lys Lys Arg Gln Ala Leu Ile Val Arg Glu Lys Glu  
 245 250 255

Pro Asp Leu Lys Leu Val Gln Pro Ile Pro Phe Phe Thr Trp Lys Cys  
 260 265 270

Leu Gly Glu Ser Leu Leu Ala Met Tyr Asn His Leu Thr Thr Cys Glu  
 275 280 285

Pro Pro Arg Pro Ser Leu Gly Lys Arg Ile Asp Leu Ser Asp Tyr Gln  
 290 295 300

Asp Pro Ser Gln Leu Leu Ala Pro  
 305 310

<210> 112

<211> 314

<212> PRT

<213> Homo sapiens

<400> 112

Met Ile Arg Ile Ala Ala Leu Asn Ala Ser Ser Thr Ile Glu Asp Asp  
 1 5 10 15

His Glu Gly Ser Phe Lys Ser His Lys Thr Gln Thr Lys Glu Ala Gln  
 20 25 30

Glu Ala Glu Ala Phe Ala Leu Tyr His Lys Ala Leu Asp Leu Gln Lys  
 35 40 45

His Asp Arg Phe Glu Glu Ser Ala Lys Ala Tyr His Glu Leu Leu Glu  
 50 55 60

Ala Ser Leu Leu Arg Glu Ala Val Ser Ser Gly Asp Glu Lys Glu Gly  
 65 70 75 80

Leu Lys His Pro Gly Leu Ile Leu Lys Tyr Ser Thr Tyr Lys Asn Leu  
 85 90 95

Ala Gln Leu Ala Ala Gln Arg Glu Asp Leu Glu Thr Ala Met Glu Phe  
 100 105 110

Tyr Leu Glu Ala Val Met Leu Asp Ser Thr Asp Val Asn Leu Trp Tyr  
 115 120 125

Lys Ile Gly His Val Ala Leu Arg Leu Ile Arg Ile Pro Leu Ala Arg  
 130 135 140

His Ala Phe Glu Glu Gly Leu Arg Cys Asn Pro Asp His Trp Pro Cys  
 145 150 155 160  
 Leu Asp Asn Leu Ile Thr Val Leu Tyr Thr Leu Ser Asp Tyr Thr Thr  
 165 170 175  
 Cys Leu Tyr Phe Ile Cys Lys Ala Leu Glu Lys Asp Cys Arg Tyr Ser  
 180 185 190  
 Lys Gly Leu Val Leu Lys Glu Lys Ile Phe Glu Glu Gln Pro Cys Leu  
 195 200 205  
 Arg Lys Asp Ser Leu Arg Met Phe Leu Lys Cys Asp Met Ser Ile His  
 210 215 220  
 Asp Val Ser Val Ser Ala Ala Glu Thr Gln Ala Ile Val Asp Glu Ala  
 225 230 235 240  
 Leu Gly Leu Arg Lys Lys Arg Gln Ala Leu Ile Val Arg Glu Lys Glu  
 245 250 255  
 Pro Asp Leu Lys Leu Val Gln Pro His Ser Phe Leu Ser Ser Pro Gly  
 260 265 270  
 Ser Ala Ser Glu Arg Ala Cys Trp Pro Cys Thr Ile Ile Ser Pro Pro  
 275 280 285  
 Val Ser Pro His Val Pro Ala Leu Ala Lys Gly Leu Ile Cys Arg Thr  
 290 295 300  
 Thr Arg Thr Pro Ala Ser Leu Leu Ser Pro  
 305 310

&lt;210&gt; 113

&lt;211&gt; 311

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 113

Leu Arg Leu Ile Thr Ser Ser Lys His Arg Cys Met Asp Ser Ser Ala  
 1 5 10 15  
 Ala Phe Leu Gln Gly Leu Trp Gln His Tyr His Pro Gly Leu Pro Pro  
 20 25 30  
 Pro Asp Val Ala Asp Met Glu Phe Gly Pro Pro Thr Val Asn Asp Lys  
 35 40 45  
 Leu Met Arg Phe Phe Asp His Cys Glu Lys Phe Leu Thr Glu Val Glu  
 50 55 60  
 Lys Asn Ala Thr Ala Leu Tyr His Val Glu Ala Phe Lys Thr Gly Pro  
 65 70 75 80



Glu Met Gln Asn Ile Leu Lys Lys Val Ala Ala Thr Leu Gln Val Pro  
                             85                            90                            95  
 Val Asn Asp Leu Asn Ala Asp Leu Ile Gln Val Ala Phe Phe Thr Cys  
                             100                            105                            110  
 Ser Phe Asp Leu Ala Ile Lys Gly Val Lys Ser Pro Trp Cys Asp Val  
                             115                            120                            125  
 Phe Asp Ile Asp Asp Ala Lys Val Leu Glu Tyr Leu Asn Asp Leu Lys  
                             130                            135                            140  
 Gln Tyr Trp Lys Arg Gly Tyr Gly Tyr Thr Ile Asn Ser Arg Ser Ser  
                             145                            150                            155                            160  
 Cys Thr Leu Phe Gln Asp Ile Phe Gln His Leu Asp Lys Ala Val Glu  
                             165                            170                            175  
 Gln Lys Gln Arg Ser Gln Pro Ile Ser Ser Pro Val Ile Leu Gln Phe  
                             180                            185                            190  
 Gly His Ala Glu Thr Leu Leu Pro Leu Leu Ser Leu Met Gly Tyr Phe  
                             195                            200                            205  
 Lys Asp Lys Glu Pro Leu Thr Ala Tyr Asn Tyr Lys Lys Gln Met His  
                             210                            215                            220  
 Arg Lys Phe Arg Ser Gly Leu Ile Val Pro Tyr Ala Ser Asn Leu Ile  
                             225                            230                            235                            240  
 Phe Val Leu Tyr His Cys Glu Asn Ala Lys Thr Pro Lys Glu Gln Phe  
                             245                            250                            255  
 Arg Val Gln Met Leu Leu Asn Glu Lys Val Leu Pro Leu Ala Tyr Ser  
                             260                            265                            270  
 Gln Glu Thr Val Ser Phe Tyr Glu Asp Leu Lys Asn His Tyr Lys Asp  
                             275                            280                            285  
 Ile Leu Gln Ser Cys Gln Thr Ser Glu Glu Cys Glu Leu Ala Arg Ala  
                             290                            295                            300  
 Asn Ser Thr Ser Asp Glu Leu  
                             305                            310

&lt;210&gt; 114

&lt;211&gt; 311

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (33)

Leu Arg Leu Ile Thr Ser Ser Lys His Arg Cys Met Asp Ser Ser Ala  
1 5 10 15

Ala Phe Leu Gln Gly Leu Trp Gln His Tyr His Pro Gly Leu Pro Pro  
20 25 30

Xaa Asp Val Ala Asp Met Glu Phe Gly Pro Pro Thr Val Asn Asp Lys  
35 40 45

Leu Met Arg Phe Phe Asp His Cys Glu Lys Phe Leu Thr Glu Val Glu  
50 55 60

Lys Asn Ala Thr Ala Leu Tyr His Val Glu Ala Phe Lys Thr Gly Pro  
65 70 75 80

Glu Met Gln Asn Ile Leu Lys Lys Val Ala Ala Thr Leu Gln Val Pro  
85 90 95

Val	Asn	Asp	Leu	Asn	Ala	Asp	Leu	Ile	Gln	Val	Ala	Phe	Phe	Thr	Cys
			100					105					110		

Ser Phe Asp Leu Ala Ile Lys Gly Val Lys Ser Pro Trp Cys Asp Val  
115 120 125

Phe Asp Ile Asp Asp Ala Lys Val Leu Glu Tyr Leu Asn Asp Leu Lys  
130 135 140

Gln Tyr Trp Lys Arg Gly Tyr Gly Tyr Thr Ile Asn Ser Arg Ser Ser  
145 150 155 160

Cys Thr Leu Phe Gln Asp Ile Phe Gln His Leu Asp Lys Ala Val Glu  
165 170 175

Gln Lys Gln Arg Ser Gln Pro Ile Ser Ser Pro Val Ile Leu Gln Phe  
180 185 190

Gly His Ala Glu Thr Leu Leu Pro Leu Leu Ser Leu Met Gly Tyr Phe  
195 200 205

Lys Asp Lys Glu Pro Leu Thr Ala Tyr Asn Tyr Lys Lys Gln Met His  
210 215 220

Arg Lys Phe Arg Ser Gly Leu Ile Val Pro Tyr Ala Ser Asn. Leu Ile  
225 230 235 240

Phe Val Leu Tyr His Cys Glu Asn Ala Lys Thr Pro Lys Glu Gln Phe  
245 250 255

Arg Val Gln Met Leu Leu Asn Glu Lys Val Leu Pro Leu Ala Tyr Ser  
260 265 270

Gln Glu Thr Val Ser Phe Tyr Glu Asp Leu Lys Asn His Tyr Lys Asp

275	280	285
Ile Leu Gln Ser Cys Gln Thr Ser Glu Glu Cys Glu Leu Ala Arg Ala		
290	295	300
Asn Ser Thr Ser Asp Glu Leu		
305	310	
<210> 115		
<211> 176		
<212> PRT		
<213> Homo sapiens		
<400> 115		
Met Leu Arg Ala Pro Gly Cys Leu Leu Arg Thr Ser Val Ala Pro Ala		
1	5	10
15		
Ala Ala Leu Ala Ala Ala Leu Leu Ser Ser Leu Ala Arg Cys Ser Leu		
20	25	30
Leu Glu Pro Arg Asp Pro Val Ala Ser Ser Leu Ser Pro Tyr Phe Gly		
35	40	45
Thr Lys Thr Arg Tyr Glu Asp Val Asn Pro Val Leu Leu Ser Gly Pro		
50	55	60
Glu Ala Pro Trp Arg Asp Pro Glu Leu Leu Glu Gly Thr Cys Thr Pro		
65	70	75
80		
Val Gln Leu Val Ala Leu Ile Arg His Gly Thr Arg Tyr Pro Thr Val		
85	90	95
Lys Gln Ile Arg Lys Leu Arg Gln Leu His Gly Leu Leu Gln Pro Arg		
100	105	110
Gly Ser Arg Asp Gly Gly Ala Ser Ser Thr Gly Ser Arg Asp Leu Gly		
115	120	125
Ala Ala Leu Arg Asp Trp Pro Leu Trp Tyr Ala Asp Trp Met Asp Gly		
130	135	140
Gln Leu Val Glu Lys Gly Arg Gln Asp Met Arg His Val Ala Leu Arg		
145	150	155
160		
Leu Ala Ser Leu Phe Pro Ala Leu Phe Ser Arg Glu Asn Tyr Gly Arg		
165	170	175

&lt;210&gt; 116

&lt;211&gt; 176

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 116

```

Met Leu Arg Ala Pro Gly Cys Leu Leu Arg Thr Ser Val Ala Pro Ala
 1              5              10              15

Ala Ala Leu Ala Ala Ala Leu Leu Ser Ser Leu Ala Arg Cys Ser Leu
      20              25              30

Leu Glu Pro Arg Asp Pro Val Ala Ser Ser Leu Ser Pro Tyr Phe Gly
      35              40              45

Thr Lys Thr Arg Tyr Glu Asp Val Asn Pro Val Leu Leu Ser Gly Pro
      50              55              60

Glu Ala Pro Trp Arg Asp Pro Glu Leu Leu Glu Gly Thr Cys Thr Pro
 65              70              75              80

Val Gln Leu Val Ala Leu Ile Arg His Gly Thr Arg Tyr Pro Thr Val
      85              90              95

Lys Gln Ile Arg Lys Leu Arg Gln Leu His Gly Leu Leu Gln Ala Arg
      100             105             110

Gly Ser Arg Asp Gly Gly Ala Ser Ser Thr Gly Ser Arg Asp Leu Gly
      115             120             125

Ala Ala Leu Ala Asp Trp Pro Leu Trp Tyr Ala Asp Trp Met Asp Gly
      130             135             140

Gln Leu Val Glu Lys Gly Arg Gln Asp Met Arg Gln Leu Ala Leu Arg
      145             150             155             160

Leu Ala Ser Leu Phe Pro Ala Leu Phe Ser Arg Glu Asn Tyr Gly Arg
      165             170             175

```

&lt;210&gt; 117

&lt;211&gt; 232

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 117

```

Met Pro Pro Arg Lys Lys Arg Arg Pro Ala Ser Gly Asp Asp Leu Ser
 1              5              10              15

Ala Lys Lys Ser Arg His Asp Ser Met Tyr Arg Lys Tyr Asp Ser Thr
      20              25              30

Arg Ile Lys Thr Glu Glu Glu Ala Phe Ser Ser Lys Arg Cys Leu Glu
      35              40              45

```

Trp Phe Tyr Glu Tyr Ala Gly Thr Asp Asp Val Val Gly Pro Glu Gly  
 50 55 60  
 Met Glu Lys Phe Cys Glu Asp Ile Gly Val Glu Pro Glu Asn Val Val  
 65 70 75 80  
 Met Leu Val Leu Ala Trp Lys Leu Asp Ala Gln Asn Met Gly Tyr Phe  
 85 90 95  
 Thr Leu Gln Glu Trp Leu Lys Gly Met Thr Ser Leu Gln Cys Asp Thr  
 100 105 110  
 Thr Glu Lys Leu Arg Asn Thr Leu Asp Tyr Leu Arg Ser Phe Leu Asn  
 115 120 125  
 Asp Ser Thr Asn Phe Lys Leu Ile Tyr Arg Tyr Ala Phe Asp Phe Ala  
 130 135 140  
 Arg Glu Lys Asp Gln Arg Ser Leu Asp Ile Asn Thr Ala Lys Cys Met  
 145 150 155 160  
 Leu Gly Leu Leu Leu Gly Lys Ile Trp Pro Leu Phe Pro Val Phe His  
 165 170 175  
 Gln Phe Leu Glu Gln Ser Lys Tyr Lys Val Ile Asn Lys Asp Gln Trp  
 180 185 190  
 Cys Asn Val Leu Glu Phe Ser Arg Thr Ile Asn Leu Asp Leu Ser Asn  
 195 200 205  
 Tyr Asp Glu Asp Gly Ala Trp Pro Val Leu Leu Asp Glu Phe Val Glu  
 210 215 220  
 Trp Tyr Lys Asp Lys Gln Met Ser  
 225 230

&lt;210&gt; 118

&lt;211&gt; 238

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (82)

&lt;223&gt; Xaa equals stop translation

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (96)

&lt;223&gt; Xaa equals stop translation

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (108)

<223> Xaa equals stop translation

<220>

<221> SITE

<222> (111)

<223> Xaa equals stop translation

<400> 118

Met	Pro	Val	Lys	Lys	Lys	Arg	Lys	Ser	Pro	Gly	Val	Ala	Ala	Ala	Val
1				5					10					15	
Ala	Glu	Asp	Gly	Gly	Leu	Lys	Lys	Cys	Lys	Ile	Ser	Ser	Tyr	Cys	Arg
			20					25					30		
Ser	Gln	Pro	Pro	Ala	Arg	Leu	Ile	Ser	Gly	Glu	Glu	His	Phe	Ser	Ser
		35					40					45			
Lys	Lys	Cys	Leu	Ala	Trp	Phe	Tyr	Glu	Tyr	Ala	Gly	Pro	Asp	Glu	Val
	50					55					60				
Val	Gly	Pro	Glu	Gly	Met	Glu	Lys	Phe	Cys	Glu	Asp	Ile	Gly	Val	Gly
65					70					75					80
Thr	Xaa	Lys	Tyr	Tyr	Tyr	Val	Ser	Phe	Ser	Val	Glu	Ile	Gly	Gly	Xaa
				85					90					95	
Asn	Met	Gly	Ile	Phe	Tyr	Gln	Gly	Arg	Met	Val	Xaa	Arg	Glu	Xaa	Leu
			100					105					110		
His	Tyr	Ser	Val	Thr	Ala	Gln	Lys	Ser	Tyr	Lys	Thr	Asn	Leu	Thr	Phe
		115					120					125			
Cys	Ala	Gln	Gln	Leu	Asn	Asp	Ile	Ser	Ser	Phe	Lys	Asn	Ile	Tyr	Arg
	130					135					140				
Tyr	Ala	Phe	Asp	Phe	Ala	Arg	Asp	Lys	Asp	Gln	Arg	Ser	Leu	Asp	Ile
145					150					155					160
Asp	Thr	Ala	Lys	Ser	Met	Leu	Ala	Leu	Leu	Leu	Gly	Arg	Thr	Trp	Pro
			165						170					175	
Leu	Phe	Ser	Val	Phe	Tyr	Gln	Tyr	Leu	Glu	Gln	Ser	Lys	Tyr	Arg	Val
			180					185					190		
Met	Asn	Lys	Asp	Gln	Trp	Tyr	Asn	Val	Leu	Glu	Phe	Ser	Arg	Thr	Val
		195					200					205			
His	Ala	Asp	Leu	Ser	Asn	Tyr	Asp	Glu	Asp	Gly	Ala	Trp	Pro	Val	Leu
	210					215					220				
Leu	Asp	Glu	Phe	Val	Glu	Trp	Gln	Lys	Val	Arg	Gln	Thr	Ser		
225					230					235					

<210> 119

<211> 51  
 <212> PRT  
 <213> Homo sapiens

<400> 119  
 Phe Glu Phe Leu Val Glu Thr Gly Phe Leu His Val Gly Gln Ala Gly  
 1 5 10 15  
 Leu Glu Leu Leu Thr Ser Gly Asp Leu Pro Ala Ser Ala Ser Gln Ser  
 20 25 30  
 Ala Arg Ile Thr Gly Val Ser His Arg Ala Arg Pro Glu Tyr Ser Tyr  
 35 40 45  
 Lys Leu Arg  
 50

<210> 120  
 <211> 50  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (5)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 120  
 Phe Ile Phe Leu Xaa Gln Met Glu Leu Cys His Ile Phe Gln Asp Gly  
 1 5 10 15  
 Leu Glu Leu Leu Thr Ser Arg Asp Gln Pro Thr Ser Ala Ser Gln Ser  
 20 25 30  
 Ala Gly Ile Thr Gly Met Gly His Arg Val Gln Pro Gly Ser Phe Ser  
 35 40 45  
 Ile Arg  
 50

<210> 121  
 <211> 72  
 <212> PRT  
 <213> Homo sapiens

<400> 121  
 Phe Phe Phe Glu Thr Gln Ser His Ser Val Thr Arg Leu Glu Cys Ser  
 1 5 10 15  
 Gly Thr Ile Ser Ala His Cys Asn Leu Cys Leu Pro Gly Ser Ser Asn  
 20 25 30  
 Ser Pro Ala Ser Ala Ser Arg Val Ala Gly Thr Ala Gly Thr Cys Arg

64

35 40 45

Arg Ala Gln Leu Ile Phe Val Phe Leu Ala Glu Met Gly Phe His His  
 50 55 60

Val Gly Arg Asp Gly Leu Asp Leu  
 65 70

<210> 122  
 <211> 72  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (4)  
 <223> Xaa equals stop translation

<220>  
 <221> SITE  
 <222> (14)  
 <223> Xaa equals stop translation

<400> 122

Tyr Ile Phe Xaa Thr Glu Ser Arg Phe Val Ala Arg Leu Xaa Cys Ser  
 1 5 10 15

Ser Met Ile Leu Ala His Cys Asn Leu Cys Leu Leu Gly Ser Ser Asn  
 20 25 30

Ser Pro Ala Ser Ala Ser Gln Val Ala Gly Thr Arg Gly Met Arg His  
 35 40 45

His Thr Gln Leu Ile Phe Val Leu Leu Val Glu Thr Gly Phe His His  
 50 55 60

Val Gly Gln Asp Gly Leu Asn Leu  
 65 70

<210> 123  
 <211> 16  
 <212> PRT  
 <213> Homo sapiens

<400> 123

Asn Leu Val Ile His Pro Pro Arg Ser Pro Lys Ala Leu Gly Leu Gln  
 1 5 10 15

<210> 124



&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 124

Asp Leu Met Ile Arg Leu Pro Arg Pro Pro Lys Met Leu Gly Leu Gln  
1 5 10 15

&lt;210&gt; 125

&lt;211&gt; 110

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 125

Glu Leu Arg Asp Ser Glu Pro Ser Ser Thr Val Ser Leu Asn Gly Thr  
1 5 10 15

Phe Phe Lys Met Glu Leu Phe Glu Gly Met Arg Glu Ser Thr Lys Ile  
20 25 30

Ser Ser Leu Leu Ala Glu Leu Glu Ala Ile Gln Arg Asn Ser Ala Ser  
35 40 45

Gln Lys Ser Val Ile Val Ser Gln Trp Thr Asn Met Leu Lys Val Val  
50 55 60

Ala Leu His Leu Lys Lys His Gly Leu Thr Tyr Ala Thr Ile Asp Gly  
65 70 75 80

Ser Val Asn Pro Lys Gln Arg Met Asp Leu Val Glu Ala Phe Asn His  
85 90 95

Ser Arg Gly Pro Gln Val Met Leu Ile Ser Leu Leu Ala Gly  
100 105 110

&lt;210&gt; 126

&lt;211&gt; 109

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 126

Glu Leu Val Asp Pro Pro Gly Cys Arg Asn Ser Ala Arg Gly Thr Phe  
1 5 10 15

Phe Lys Met Glu Leu Phe Glu Gly Met Arg Glu Ser Thr Lys Ile Ser  
20 25 30

Ser Leu Leu Ala Glu Leu Glu Ala Ile Gln Arg Asn Ser Ala Ser Gln  
35 40 45

Lys Ser Val Ile Val Ser Gln Trp Thr Asn Met Leu Lys Val Val Ala  
 50 55 60

Leu His Leu Lys Lys His Gly Leu Thr Tyr Ala Thr Ile Asp Gly Ser  
 65 70 75 80

Val Asn Pro Lys Gln Arg Met Asp Leu Val Glu Ala Phe Asn His Ser  
 85 90 95

Arg Gly Pro Gln Val Met Leu Ile Ser Leu Leu Ala Gly  
 100 105

<210> 127  
 <211> 164  
 <212> PRT  
 <213> Homo sapiens

<400> 127  
 Met Ile Val Ile Ser Val Glu Asp Pro Asp Met Asp Arg Phe Asp Tyr  
 1 5 10 15

Gly Glu Glu Ser Ser Met Ala Tyr Gly His Asp Tyr Ser Glu Asn Arg  
 20 25 30

Ser Leu Pro Val Thr Ile Pro Ser Tyr Asn Thr Val Gln Asp Ser Leu  
 35 40 45

Glu Arg Tyr Thr Val Phe Asn Ile His Met Ala Gly Arg Gln Leu Gly  
 50 55 60

Ser Arg Arg Tyr Ser Glu Phe Val Glu Leu His Leu Ala Leu Lys Lys  
 65 70 75 80

His Phe Tyr Asp Tyr Cys Phe Pro Gln Leu Pro Gly Lys Trp Pro Phe  
 85 90 95

Lys Leu Ser Glu Gln Gln Leu Asp Ser Arg Arg Arg Gly Leu Glu Gln  
 100 105 110

Tyr Leu Glu Lys Ile Cys Thr Ile Arg Val Ile Ala Glu Ser Glu Leu  
 115 120 125

Val Gln Lys Phe Leu Met Glu Cys Asp Pro Met Cys Glu Val Glu Ile  
 130 135 140

Arg Leu Met Leu Pro Asp Gly Ser Pro Ile Thr Ile Arg Thr Arg Arg  
 145 150 155 160

Ser Ile Thr Ser

<210> 128  
 <211> 168

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 128

Leu Thr Val Leu Ser Val Pro Pro His Glu Ala Asp Asn Leu Asp Pro  
 1 5 10 15

Ser Asp Asp Ser Leu Gly Gln Ser Phe Tyr Asp Tyr Thr Glu Lys Gln  
 20 25 30

Ala Val Pro Ile Ser Val Pro Arg Tyr Lys His Val Glu Gln Asn Gly  
 35 40 45

Glu Lys Phe Val Val Tyr Asn Val Tyr Met Ala Gly Arg Gln Leu Cys  
 50 55 60

Ser Lys Arg Tyr Arg Glu Phe Ala Ile Leu His Gln Asn Leu Lys Arg  
 65 70 75 80

Glu Phe Ala Asn Phe Thr Phe Pro Arg Leu Pro Gly Lys Trp Pro Phe  
 85 90 95

Ser Leu Ser Glu Gln Gln Leu Asp Ala Arg Arg Arg Gly Leu Glu Glu  
 100 105 110

Tyr Leu Glu Lys Val Cys Ser Ile Arg Val Ile Gly Glu Ser Asp Ile  
 115 120 125

Met Gln Glu Phe Leu Ser Glu Ser Asp Glu Asn Tyr Asn Gly Val Ser  
 130 135 140

Asp Val Glu Leu Arg Val Ala Leu Pro Asp Gly Thr Thr Val Thr Val  
 145 150 155 160

Arg Val Lys Lys Asn Ser Thr Thr  
 165

&lt;210&gt; 129

&lt;211&gt; 164

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 129

Arg Ala Arg Leu Ile Thr Ala Ala Glu Glu Ala Phe Thr His Ile Lys  
 1 5 10 15

Arg Ile His Asn Glu Pro Ala Pro Ala Leu Pro Leu Asp Pro Gln Glu  
 20 25 30

Ala Ala Ser Ala Val Phe Pro Ser Met Ala Arg Ala Leu Gln Lys Tyr  
 35 40 45

Leu Arg Val Thr Arg Gln Gln Pro Arg His Thr Phe Glu Ser Ile Leu  
 50 55 60

Lys His Leu Ala His Cys Leu Lys His Asp Leu Ser Pro Arg Ala Phe  
 65 70 75 80  
 Leu Glu Pro Tyr Leu Thr Glu Ser Pro Val Met Gln Ser Glu Lys Glu  
 85 90 95  
 Arg Arg Trp Val Gln Ser Trp Ser Leu Ile Cys Asp Glu Ile Val Ser  
 100 105 110  
 Arg Pro Ile Gly Asn Glu Cys Thr Phe Gln Leu Ile Gln Asn Asp Val  
 115 120 125  
 Ser Leu Met Val Thr Val His Lys Leu Pro His Phe Asn Leu Ala Glu  
 130 135 140  
 Glu Val Val Asp Pro Lys Ser Asn Lys Phe Val Leu Lys Leu Asn Ser  
 145 150 155 160  
 Glu Thr Ser Val

<210> 130  
 <211> 167  
 <212> PRT  
 <213> Homo sapiens

<400> 130  
 Lys Gln Arg Leu Val Val Ala Val Glu Glu Ala Phe Ile His Ile Gln  
 1 5 10 15  
 Arg Leu Gln Ala Glu Glu Gln Gln Lys Ala Pro Gly Glu Val Met Asp  
 20 25 30  
 Pro Arg Glu Ala Ala Gln Ala Ile Phe Pro Ser Met Ala Arg Ala Leu  
 35 40 45  
 Gln Lys Tyr Leu Arg Ile Thr Arg Gln Gln Asn Tyr His Ser Met Glu  
 50 55 60  
 Ser Ile Leu Gln His Leu Ala Phe Cys Ile Thr Asn Gly Met Thr Pro  
 65 70 75 80  
 Lys Ala Phe Leu Glu Arg Tyr Leu Ser Ala Gly Pro Thr Leu Gln Tyr  
 85 90 95  
 Asp Lys Asp Arg Trp Leu Ser Thr Gln Trp Arg Leu Val Ser Asp Glu  
 100 105 110  
 Ala Val Thr Asn Gly Leu Arg Asp Gly Ile Val Phe Val Leu Lys Cys  
 115 120 125  
 Leu Asp Phe Ser Leu Val Val Asn Val Lys Lys Ile Pro Phe Ile Ile  
 130 135 140

Leu Ser Glu Glu Phe Ile Asp Pro Lys Ser His Lys Phe Val Leu Arg  
 145 150 155 160

Leu Gln Ser Glu Thr Ser Val  
 165

<210> 131

<211> 95

<212> PRT

<213> Homo sapiens

<400> 131

Gln Phe Ile Leu Ser Gln Val Ala Leu Leu Glu Gln Val Asn Ala Leu  
 1 5 10 15

Val Pro Met Leu Asp Ser Ala His Ile Lys Ala Val Pro Glu His Ala  
 20 25 30

Ala Arg Leu Gln Arg Leu Ala Gln Ile His Ile Gln Gln Gln Asp Gln  
 35 40 45

Cys Val Glu Ile Thr Glu Glu Ser Lys Ala Leu Leu Glu Glu Tyr Asn  
 50 55 60

Lys Thr Thr Met Leu Leu Ser Lys Gln Phe Val Gln Trp Asp Glu Leu  
 65 70 75 80

Leu Cys Gln Leu Glu Ala Ala Thr Gln Val Lys Pro Ala Glu Glu  
 85 90 95

<210> 132

<211> 95

<212> PRT

<213> Homo sapiens

<400> 132

Gln Phe Ile Leu Ser Gln Val Ala Leu Leu Glu Gln Val Asn Ala Leu  
 1 5 10 15

Val Pro Met Leu Asp Ser Ala His Ile Lys Ala Val Pro Glu His Ala  
 20 25 30

Ala Arg Leu Gln Arg Leu Ala Gln Ile His Ile Gln Gln Gln Asp Gln  
 35 40 45

Cys Val Glu Ile Thr Glu Glu Ser Lys Ala Leu Leu Glu Glu Tyr Asn  
 50 55 60

Lys Thr Thr Met Leu Leu Ser Lys Gln Phe Val Gln Trp Asp Glu Leu  
 65 70 75 80

Leu Cys Gln Leu Glu Ala Ala Thr Gln Val Lys Pro Ala Glu Glu

70

85

90

95

&lt;210&gt; 133

&lt;211&gt; 50

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 133

Gly Gly Arg Cys Leu Gln Ser Gln Leu Leu Arg Arg Leu Arg Gln Glu  
1 5 10 15

Asn His Leu Asn Ser Gly Gly Arg Gly Cys Ser Glu Pro Lys Ser His  
20 25 30

Leu Cys Ile Pro Ala Trp Val Thr Glu Gly Asp Ser Val Ser Lys Gln  
35 40 45

Asn Lys  
50

&lt;210&gt; 134

&lt;211&gt; 50

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (6)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 134

Gly Gly Val Cys Leu Xaa Ser Gln Leu Leu Gly Arg Leu Arg Arg Glu  
1 5 10 15

Asn His Leu Asn Leu Gly Gly Gly Gly Cys Ser Glu Thr Arg Ser Arg  
20 25 30

His Cys Thr Pro Thr Trp Val Thr Gln Arg Asp Ser Val Ser Lys Lys  
35 40 45

Lys Arg  
50

&lt;210&gt; 135

&lt;211&gt; 33

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 135

His Leu Arg Ser Gly Val Gln Asp Tyr Pro Gly Gln His Gly Lys Ile  
1 5 10 15

Pro Ser Leu Leu Lys Ile Gln Glu Leu Ala Gly His Gly Gly Arg Cys  
                   20                  25                  30

Leu

<210> 136  
 <211> 28  
 <212> PRT  
 <213> Homo sapiens

<400> 136  
 His Leu Arg Ser Gly Val Asp Asp Gln Pro Gly Asn Thr Ala Arg Pro  
       1                  5                  10                  15

Arg Leu Tyr Lys His Ser Leu Gly Gly Trp Cys Met  
                   20                  25

<210> 137  
 <211> 101  
 <212> PRT  
 <213> Homo sapiens

<400> 137  
 Tyr Val Ala Pro Arg Ile Arg Ala Val Arg Tyr Glu Glu Glu Asp Glu  
       1                  5                  10                  15

Ala Pro Asn Lys Gln Gln Glu Lys Ala Lys Arg Arg Ala Met Gln Ser  
                   20                  25                  30

Ser Leu Ile Met Glu Leu Lys Asn Gln Tyr Ser Asp Ala Pro Glu Glu  
                   35                  40                  45

Ile Arg Glu Met Ser Glu Lys Lys Tyr Gln Tyr Asp Arg Glu Arg Glu  
                   50                  55                  60

Arg Tyr Glu Glu Asp Asn Phe Thr Arg Ile Arg Leu Asn Lys Asp Gln  
       65                  70                  75                  80

Lys Arg Arg Ser Glu Gln Leu Gly Arg Ser Glu Thr Leu Asp Asp Leu  
                   85                  90                  95

Leu Ser Phe Gly Asp  
                   100

<210> 138  
 <211> 107  
 <212> PRT  
 <213> Homo sapiens

<400> 138  
 Tyr Val Pro Pro Arg Leu Val Pro Val His Tyr Asp Glu Thr Glu Ala

72

1                    5                    10                    15  
 Glu Arg Glu Lys Lys Arg Leu Glu Arg Ala Lys Arg Arg Ala Leu Ser  
                   20                    25                    30  
 Ser Ser Val Ile Arg Glu Leu Lys Glu Gln Tyr Ser Asp Ala Pro Glu  
                   35                    40                    45  
 Glu Ile Arg Asp Ala Arg His Pro His Val Thr Arg Gln Ser Gln Glu  
                   50                    55                    60  
 Asp Gln His Arg Ile Asn Tyr Glu Glu Ser Met Met Val Arg Leu Ser  
                   65                    70                    75                    80  
 Val Ser Lys Arg Glu Lys Gly Arg Arg Lys Arg Ala Asn Val Met Ser  
                   85                    90                    95  
 Ser Gln Leu His Ser Leu Thr His Phe Ser Asp  
                   100                    105

<210> 139  
 <211> 90  
 <212> PRT  
 <213> Homo sapiens

<400> 139  
 Arg Asp Leu Lys Tyr Tyr Lys Val Met Pro Thr Phe His His Trp Arg  
   1                    5                    10                    15  
 Ala Gly Lys Gln Arg Asn Gly Leu Thr Phe Gln Thr Ala Ala Asp Ala  
                   20                    25                    30  
 Arg Ala Phe Asp Lys Gly Val Leu Arg Ala Tyr Asn Glu Leu Ile Asp  
                   35                    40                    45  
 Gly Leu Ala Lys Ser Asn Pro Thr Ile Ile Cys Pro Pro Leu Thr Lys  
                   50                    55                    60  
 Tyr Asp Ser Val Gly Glu Asp Asp Val Phe Met Thr Leu Asp Leu Pro  
                   65                    70                    75                    80  
 Val Glu Ser Glu Ser Leu Gln Lys Ile His  
                   85                    90

<210> 140  
 <211> 78  
 <212> PRT  
 <213> Homo sapiens

<400> 140  
 Lys Asp Leu Ile Tyr Asn Lys Val Thr Pro Thr Phe His His Trp Lys  
   1                    5                    10                    15



Ile Asp Asp Lys Lys Phe Gly Leu Thr Phe Gln Ser Pro Ala Asp Ala  
                   20                  25                  30

Arg Ala Phe Asp Arg Gly Ile Arg Arg Ala Ile Glu Asp Ile Ser Gln  
           35                  40                  45

Gly Cys Pro Glu Ser Lys Asn Glu Ala Glu Gly Ala Asp Asp Leu Gln  
           50                  55                  60

Ala Asn Glu Glu Asp Ser Ser Ser Ser Leu Val Lys Asp His  
       65                  70                  75

<210> 141

<211> 65

<212> PRT

<213> Homo sapiens

<400> 141

Asp Arg Ile Leu Val Leu Gly Cys Gly Asn Ser Ala Leu Ser Tyr Glu  
       1                  5                  10                  15

Leu Phe Leu Gly Gly Phe Pro Asp Val Thr Ser Val Asp Tyr Ser Ser  
           20                  25                  30

Val Val Val Ala Ala Met Arg Ala Arg Tyr Ala His Val Pro Thr Leu  
           35                  40                  45

Arg Trp Glu Thr Met Asp Val Arg Ala Leu Gly Phe Pro Ser Gly Ser  
       50                  55                  60

Phe  
       65

<210> 142

<211> 65

<212> PRT

<213> Homo sapiens

<400> 142

Asp Arg Ile Leu Val Leu Gly Cys Gly Asn Ser Ala Leu Ser Tyr Glu  
       1                  5                  10                  15

Leu Phe Leu Gly Gly Phe Pro Asn Val Thr Ser Val Asp Tyr Ser Ser  
           20                  25                  30

Val Val Val Ala Ala Met Gln Ala Arg Tyr Ala His Val Pro Gln Leu  
           35                  40                  45

Arg Trp Gly Asp His Gly Cys Ala Glu Ala Gly Leu Pro Gln Cys Phe  
       50                  55                  60

Phe  
       65

<210> 143  
 <211> 51  
 <212> PRT  
 <213> Homo sapiens

<400> 143  
 Glu Thr Met Asp Val Arg Ala Leu Gly Phe Pro Ser Gly Ser Phe Asp  
     1                    5                    10                    15  
 Val Val Leu Glu Lys Gly Thr Leu Asp Ala Leu Leu Thr Gly Glu Gln  
                     20                    25                    30  
 Asp Pro Trp Thr Val Ser Ser Glu Gly Val His Thr Val Asp Gln Val  
                     35                    40                    45  
 Leu Asn Glu  
             50

<210> 144  
 <211> 51  
 <212> PRT  
 <213> Homo sapiens

<400> 144  
 Glu Thr Met Asp Val Arg Lys Leu Asp Phe Pro Ser Ala Ser Phe Asp  
     1                    5                    10                    15  
 Val Val Leu Glu Lys Gly Thr Leu Asp Ala Leu Leu Ala Gly Glu Arg  
                     20                    25                    30  
 Asp Pro Trp Thr Val Ser Pro Glu Gly Val His Thr Val Asp Gln Val  
                     35                    40                    45  
 Leu Ser Glu  
             50

<210> 145  
 <211> 27  
 <212> PRT  
 <213> Homo sapiens

<400> 145  
 Arg Asp Gln Trp Ser Met Thr Pro Gln Thr Val Asn Ala Tyr Tyr Leu  
     1                    5                    10                    15  
 Pro Thr Lys Asn Glu Ile Val Phe Pro Ala Gly  
                     20                    25

<210> 146  
 <211> 29

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 146

Arg Asp Pro Trp Thr Val Ser Pro Glu Gly Val His Thr Val Asp Gln  
1 5 10 15

Val Leu Ser Glu Val Ser Arg Val Leu Val Pro Gly Gly  
20 25

&lt;210&gt; 147

&lt;211&gt; 86

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 147

Ala Ser Ser Ser Gly Lys Pro Gly Pro Thr Val Ile Lys Val Gln Asn  
1 5 10 15

Met Pro Phe Thr Val Ser Ile Asp Glu Ile Leu Asp Phe Phe Tyr Gly  
20 25 30

Tyr Gln Val Ile Pro Gly Ser Val Cys Leu Lys Tyr Asn Glu Lys Gly  
35 40 45

Met Pro Thr Gly Glu Ala Met Val Ala Phe Glu Ser Arg Asp Glu Ala  
50 55 60

Thr Ala Ala Val Ile Asp Leu Asn Asp Arg Pro Ile Gly Ser Arg Lys  
65 70 75 80

Val Lys Leu Val Leu Gly  
85

&lt;210&gt; 148

&lt;211&gt; 86

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 148

Ala Ser Ser Ser Gly Lys Pro Gly Pro Thr Val Ile Lys Val Gln Asn  
1 5 10 15

Met Pro Phe Thr Val Ser Ile Asp Glu Ile Leu Asp Phe Phe Tyr Gly  
20 25 30

Tyr Gln Val Ile Pro Gly Ser Val Cys Leu Lys Tyr Asn Glu Lys Gly  
35 40 45

Met Pro Thr Gly Glu Ala Met Val Ala Phe Glu Ser Arg Asp Glu Ala  
50 55 60

Thr Ala Ala Val Ile Asp Leu Asn Asp Arg Pro Ile Gly Ser Arg Lys

65                      70                      75                      80

Val Lys Leu Val Leu Gly

85

```
<210> 149
<211> 71
<212> PRT
<213> Homo sapiens
```

```

<400> 149
Val Tyr Leu Lys Gly Leu Pro Phe Glu Ala Glu Asn Lys His Val Ile
  1                               5                10                15

Asp Phe Phe Lys Lys Leu Asp Ile Val Glu Asp Ser Ile Tyr Ile Ala
  20                               25                30

Tyr Gly Pro Asn Gly Lys Ala Thr Gly Glu Gly Phe Val Glu Phe Arg
  35                               40                45

Asn Glu Ala Asp Tyr Lys Ala Leu Cys Arg His Lys Gln Tyr Met
  50                               55                60

Gly Asn Arg Phe Ile Gln Val
  65                70

```

```
<210> 150
<211> 72
<212> PRT
<213> Homo sapiens
```

```

<400> 150
Ile Lys Val Gln Asn Met Pro Phe Thr Val Ser Ile Asp Glu Ile Leu
  1                      5                      10                     15

Asp Phe Phe Tyr Gly Tyr Gln Val Ile Pro Gly Ser Val Cys Leu Lys
      20                      25                     30

Tyr Asn Glu Lys Gly Met Pro Thr Gly Glu Ala Met Val Ala Phe Glu
      35                      40                     45

Ser Arg Asp Glu Ala Thr Ala Ala Val Ile Asp Leu Asn Asp Arg Pro
  50                      55                     60

Ile Gly Ser Arg Lys Val Lys Leu
  65                      70

```

```
<210> 151
<211> 378
<212> PRT
<213> Homo sapiens
```

&lt;400&gt; 151

Leu Asn Asp Asp Glu Arg Val Ile Val Glu Thr Ala Ala Ala Phe Ala  
 1 5 10 15  
 Gly Lys Arg Leu Ala Pro His Ala Leu Glu Trp Asp Ala Ala Lys His  
 20 25 30  
 Phe Pro Val Asp Val Leu Arg Glu Ala Ala Glu Leu Gly Met Ala Ala  
 35 40 45  
 Ile Tyr Cys Arg Asp Asp Val Gly Gly Ser Gly Leu Arg Arg Leu Asp  
 50 55 60  
 Gly Val Arg Ile Phe Glu Gln Leu Ala Ile Ala Asp Pro Val Thr Ala  
 65 70 75 80  
 Ala Phe Leu Ser Ile His Asn Met Cys Ala Trp Met Ile Asp Ser Phe  
 85 90 95  
 Gly Thr Asp Glu Gln Arg Lys Asp Trp Ile Pro Arg Leu Ala Thr Met  
 100 105 110  
 Gly Val Ile Ala Ser Tyr Cys Leu Thr Glu Pro Gly Ala Gly Ser Asp  
 115 120 125  
 Ala Gly Ala Leu Ser Thr Arg Ala Val Arg His Gly Ser Gly Lys Gly  
 130 135 140  
 Gly Asp Tyr Val Leu Asp Gly Val Lys Gln Phe Ile Ser Gly Ala Ala  
 145 150 155 160  
 Ala Ser Asp Val Tyr Val Val Met Ala Arg Thr Gly Ala Glu Gly Pro  
 165 170 175  
 Arg Gly Val Ser Ala Phe Ile Val Glu Lys Gly Thr Pro Gly Leu Ser  
 180 185 190  
 Phe Gly Ala Pro Glu Ala Lys Met Gly Trp His Ala Gln Pro Thr Ala  
 195 200 205  
 Gln Val Val Leu Asp Gly Val Arg Val Pro Ala Glu Ala Met Leu Gly  
 210 215 220  
 Gly Ala Asp Gly Glu Gly Ala Gly Phe Gly Ile Ala Met Ser Gly Leu  
 225 230 235 240  
 Asn Gly Gly Arg Leu Asn Ile Ala Ala Cys Ser Leu Gly Gly Ala Gln  
 245 250 255  
 Ala Ala Phe Asp Lys Ala Gly Ala Tyr Val Arg Asp Arg Gln Ala Phe  
 260 265 270  
 Gly Gly Ser Leu Leu Asp Glu Pro Thr Val Arg Phe Thr Leu Ala Asp  
 275 280 285

Met Ala Thr Gly Leu Gln Thr Ser Arg Met Leu Leu Trp Arg Ala Ala  
290 295 300

Ser Ala Leu Asp Asp Asp Asp Ala Asp Lys Val Glu Leu Cys Ala Met  
305 310 315 320

Ala Lys Arg Tyr Val Thr Asp Thr Cys Phe Glu Val Ala Asp Gln Ala  
325 330 335

Leu Gln Leu His Gly Gly Tyr Gly Tyr Leu Arg Glu Tyr Gly Leu Glu  
340 345 350

Lys Ile Val Arg Asp Leu Arg Val His Arg Ile Leu Glu Gly Thr Asn  
355 360 365

Glu Ile Met Arg Leu Val Ile Gly Arg Ala  
370 375

<210> 152

<211> 371

<212> PRT

<213> Homo sapiens

<400> 152

Leu Asn Glu Glu Gln Lys Glu Phe Gln Lys Val Ala Phe Asp Phe Ala  
1 5 10 15

Ala Arg Glu Met Ala Pro Asn Met Ala Glu Trp Asp Gln Lys Glu Leu  
20 25 30

Phe Pro Val Asp Val Met Arg Lys Ala Ala Gln Leu Gly Phe Gly Gly  
35 40 45

Val Tyr Ile Gln Thr Asp Val Gly Gly Ser Gly Leu Ser Arg Leu Asp  
50 55 60

Thr Ser Val Ile Phe Glu Ala Leu Ala Thr Gly Cys Thr Ser Thr Thr  
65 70 75 80

Ala Tyr Ile Ser Ile His Asn Met Cys Ala Trp Met Ile Asp Ser Phe  
85 90 95

Gly Asn Glu Glu Gln Arg His Lys Phe Cys Pro Pro Leu Cys Thr Met  
100 105 110

Glu Lys Phe Ala Ser Tyr Cys Leu Thr Glu Pro Gly Ser Gly Ser Asp  
115 120 125

Ala Ala Ser Leu Leu Thr Ser Ala Lys Lys Gln Gly Asp His Tyr Ile  
130 135 140

Leu Asn Gly Ser Lys Ala Phe Ile Ser Gly Ala Gly Glu Ser Asp Ile  
145 150 155 160

Tyr Val Val Met Cys Arg Thr Gly Gly Pro Gly Pro Lys Gly Ile Ser  
 165 170 175  
 Cys Ile Val Val Glu Lys Gly Thr Pro Gly Leu Ser Phe Gly Lys Lys  
 180 185 190  
 Glu Lys Lys Val Gly Trp Asn Ser Gln Pro Thr Arg Ala Val Ile Phe  
 195 200 205  
 Glu Asp Cys Ala Val Pro Val Ala Asn Arg Ile Gly Ser Glu Gly Gln  
 210 215 220  
 Gly Phe Leu Ile Ala Val Arg Gly Leu Asn Gly Gly Arg Ile Asn Ile  
 225 230 235 240  
 Ala Ser Cys Ser Leu Gly Ala Ala His Ala Ser Val Ile Leu Thr Arg  
 245 250 255  
 Asp His Leu Asn Val Arg Lys Gln Phe Gly Glu Pro Leu Ala Ser Asn  
 260 265 270  
 Gln Tyr Leu Gln Phe Thr Leu Ala Asp Met Ala Thr Arg Leu Val Ala  
 275 280 285  
 Ala Arg Leu Met Val Arg Asn Ala Ala Val Ala Leu Gln Glu Glu Arg  
 290 295 300  
 Lys Asp Ala Val Ala Leu Cys Ser Met Ala Lys Leu Phe Ala Thr Asp  
 305 310 315 320  
 Glu Cys Phe Ala Ile Cys Asn Gln Ala Leu Gln Met His Gly Gly Tyr  
 325 330 335  
 Gly Tyr Leu Lys Asp Tyr Ala Val Gln Gln Tyr Val Arg Asp Ser Arg  
 340 345 350  
 Val His Gln Ile Leu Glu Gly Ser Asn Glu Val Met Arg Ile Leu Ile  
 355 360 365  
 Ser Arg Ser  
 370

&lt;210&gt; 153

&lt;211&gt; 91

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 153

Ala Pro Thr Gly Val Gln Trp His Asp Phe Gly Ser Leu Gln Pro Leu  
 1 5 10 15  
 Pro Pro Gly Phe Lys Arg Phe Ser Cys Leu Ser Leu Pro Arg Ser Trp  
 20 25 30

Val Ser His Arg Ala Arg Pro Glu Tyr Ser Tyr  
85 90

<213> Homo sapiens

Ser His Cys Ala Arg Pro Ala Leu Ala Phe  
85 90

<213> Homo sapiens

Phe Thr Asn Glu Gln Leu Asn Val Phe Leu Thr Asp His Thr Ala Pro  
50 55 60



Phe Val Asp Lys Val Phe Glu Ala Leu Thr Ser Lys Ser Tyr Met Pro  
 65 70 75 80

Ala Ser Thr Ala Pro Thr Ser Ala Ser Ala Thr Ala Pro Asp Leu Lys  
 85 90 95

Lys Glu Lys Ala Pro Ala Glu  
 100

<210> 156  
 <211> 109  
 <212> PRT  
 <213> Homo sapiens

<400> 156  
 Met Ile Ile Glu Asn Phe Glu Ala Leu Lys Ser Trp Leu Ser Lys Thr  
 1 5 10 15

Leu Glu Pro Ile Cys Asp Ala Asp Pro Ser Ala Leu Ala Lys Tyr Val  
 20 25 30

Leu Ala Leu Val Lys Lys Asp Lys Ser Glu Lys Glu Leu Lys Ala Leu  
 35 40 45

Cys Ile Asp Gln Leu Asp Val Phe Leu Gln Lys Glu Thr Gln Ile Phe  
 50 55 60

Val Glu Lys Leu Phe Asp Ala Val Asn Thr Lys Ser Tyr Leu Pro Pro  
 65 70 75 80

Pro Glu Gln Pro Ser Ser Gly Ser Leu Lys Val Glu Phe Phe Pro His  
 85 90 95

Gln Glu Lys Asp Ile Lys Lys Glu Glu Ile His Thr Glu  
 100 105

<210> 157  
 <211> 403  
 <212> PRT  
 <213> Homo sapiens

<400> 157  
 Arg Tyr Trp Gly Glu Ile Pro Ile Ser Ser Ser Gln Thr Asn Arg Ser  
 1 5 10 15

Ser Phe Asp Leu Leu Pro Arg Glu Phe Arg Leu Val Glu Val His Asp  
 20 25 30

Pro Pro Leu His Gln Pro Ser Ala Asn Lys Pro Lys Pro Pro Thr Met  
 35 40 45

Leu Asp Ile Pro Ser Glu Pro Cys Ser Leu Thr Ile His Thr Ile Gln

50	55	60
Leu Ile Gln His Asn Arg Arg Leu Arg Asn Leu Ile Ala Thr Ala Gln 65 70 75 80		
Ala Gln Asn Gln Gln Gln Thr Glu Gly Val Lys Thr Glu Glu Ser Glu 85 90 95		
Pro Leu Pro Ser Cys Pro Gly Ser Pro Pro Leu Pro Asp Asp Leu Leu 100 105 110		
Pro Leu Asp Cys Lys Asn Pro Asn Ala Pro Phe Gln Ile Arg His Ser 115 120 125		
Asp Pro Glu Ser Asp Phe Tyr Arg Gly Lys Gly Glu Pro Val Thr Glu 130 135 140		
Leu Ser Trp His Ser Cys Arg Gln Leu Leu Tyr Gln Ala Val Ala Thr 145 150 155 160		
Ile Leu Ala His Ala Gly Phe Asp Cys Ala Asn Glu Ser Val Leu Glu 165 170 175		
Thr Leu Thr Asp Val Ala His Glu Tyr Cys Leu Lys Phe Thr Lys Leu 180 185 190		
Leu Arg Phe Ala Val Asp Arg Glu Ala Arg Leu Gly Gln Thr Pro Phe 195 200 205		
Pro Asp Val Met Glu Gln Val Phe His Glu Val Gly Ile Gly Ser Val 210 215 220		
Leu Ser Leu Gln Lys Phe Trp Gln His Arg Ile Lys Asp Tyr His Ser 225 230 235 240		
Tyr Met Leu Gln Ile Ser Lys Gln Leu Ser Glu Glu Tyr Glu Arg Ile 245 250 255		
Val Asn Pro Glu Lys Ala Thr Glu Asp Ala Lys Pro Val Lys Ile Lys 260 265 270		
Glu Glu Pro Val Ser Asp Ile Thr Phe Pro Val Ser Glu Glu Leu Glu 275 280 285		
Ala Asp Leu Ala Ser Gly Asp Gln Ser Leu Pro Met Gly Val Leu Gly 290 295 300		
Ala Gln Ser Glu Arg Phe Pro Ser Asn Leu Glu Val Glu Ala Ser Pro 305 310 315 320		
Gln Ala Ser Ser Ala Glu Val Asn Ala Ser Pro Leu Trp Asn Leu Ala 325 330 335		
His Val Lys Met Glu Pro Gln Glu Ser Glu Glu Gly Asn Val Ser Gly 340 345 350		

His Gly Val Leu Gly Ser Asp Val Phe Glu Glu Pro Met Ser Gly Met  
 355 360 365

Ser Glu Ala Gly Ile Pro Gln Ser Pro Asp Asp Ser Asp Ser Ser Tyr  
 370 375 380

Gly Ser His Ser Thr Asp Ser Leu Met Gly Ser Ser Pro Val Phe Asn  
 385 390 395 400

Gln Arg Cys

<210> 158  
 <211> 404  
 <212> PRT  
 <213> Homo sapiens

<400> 158  
 Arg Val Arg Gly Glu Ile Pro Ile Ser Ser Ser Gln Thr Asn Arg Ser  
 1 5 10 15

Ser Phe Asp Leu Leu Pro Arg Glu Phe Arg Leu Val Glu Val His Asp  
 20 25 30

Pro Pro Leu His Gln Pro Ser Ala Asn Lys Pro Lys Pro Pro Thr Met  
 35 40 45

Leu Asp Ile Pro Ser Glu Pro Cys Ser Leu Thr Ile His Thr Ile Gln  
 50 55 60

Leu Ile Gln His Asn Arg Arg Leu Arg Asn Leu Ile Ala Thr Ala Gln  
 65 70 75 80

Ala Gln Asn Gln Gln Gln Thr Glu Gly Val Lys Thr Glu Glu Ser Glu  
 85 90 95

Pro Leu Pro Ser Cys Pro Gly Ser Pro Pro Leu Pro Asp Asp Leu Leu  
 100 105 110

Pro Leu Asp Cys Lys Asn Pro Asn Ala Pro Phe Gln Ile Arg His Ser  
 115 120 125

Asp Pro Glu Ser Asp Phe Tyr Arg Gly Lys Gly Glu Pro Val Thr Glu  
 130 135 140

Leu Ser Trp His Ser Cys Arg Gln Leu Leu Tyr Gln Ala Val Ala Thr  
 145 150 155 160

Ile Leu Ala His Ala Gly Phe Asp Cys Ala Asn Glu Ser Val Leu Glu  
 165 170 175

Thr Leu Thr Asp Val Ala His Glu Tyr Cys Leu Lys Phe Thr Lys Leu  
 180 185 190

Leu Arg Phe Ala Val Asp Arg Glu Ala Arg Leu Gly Gln Thr Pro Phe  
 195 200 205  
 Pro Leu Asn Gly Lys Glu Gln Gly Phe His Glu Val Gly Ile Gly Ser  
 210 215 220  
 Val Leu Ser Leu Gln Lys Phe Trp Gln His Arg Ile Lys Asp Tyr His  
 225 230 235 240  
 Ser Tyr Met Leu Gln Ile Ser Lys Gln Leu Ser Glu Glu Tyr Glu Arg  
 245 250 255  
 Ile Val Asn Pro Glu Lys Ala Thr Glu Asp Ala Lys Pro Val Lys Ile  
 260 265 270  
 Lys Glu Glu Pro Val Ser Asp Ile Thr Phe Pro Val Ser Glu Glu Leu  
 275 280 285  
 Glu Ala Asp Leu Ala Ser Gly Asp Gln Ser Leu Pro Met Gly Val Leu  
 290 295 300  
 Gly Ala Gln Ser Glu Arg Phe Pro Ser Asn Leu Glu Val Glu Ala Ser  
 305 310 315 320  
 Pro Gln Ala Ser Ser Ala Glu Val Asn Ala Ser Pro Leu Trp Asn Leu  
 325 330 335  
 Ala His Val Lys Met Glu Pro Gln Glu Ser Glu Glu Gly Asn Val Ser  
 340 345 350  
 Gly His Gly Val Leu Gly Ser Asp Val Phe Glu Glu Pro Ile Ser Gly  
 355 360 365  
 Met Ser Glu Ala Gly Ile Pro Gln Ser Pro Asp Asp Ser Asp Ser Ser  
 370 375 380  
 Tyr Gly Ser His Ser Thr Asp Ser Leu Met Gly Ser Ser Pro Val Phe  
 385 390 395 400  
 Asn Gln Arg Cys

&lt;210&gt; 159

&lt;211&gt; 72

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 159

Gln Ala Gly Arg Cys Gly Ser Arg Leu His Phe Gly Arg Pro Arg Arg  
 1 5 10 15

Ala Asp Tyr Leu Arg Ile Gly Val Pro Asp Gln Arg Gly Gln Arg Gly  
 20 25 30

Glu Ser Pro Ser Leu Leu Lys Asn Thr Lys Ile Ser Trp Ala Trp Trp  
                   35                  40                  45

Val Pro Val Ile Pro Ala Ile Arg Glu Gly Glu Ala Gly Glu Ser Leu  
           50                  55                  60

Glu Pro Gly Arg Gln Arg Leu Gln  
   65                  70

<210> 160  
 <211> 76  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (10)  
 <223> Xaa equals stop translation

<220>  
 <221> SITE  
 <222> (28)  
 <223> Xaa equals stop translation

<400> 160  
 Gln Ala Gly Arg Ser Gly Ser Arg Leu Xaa Ser Gln His Phe Gly Arg  
   1                  5                  10                  15

Pro Arg Gln Val Asp His Leu Arg Ser Gly Val Xaa Asp Gln Pro Gly  
           20                  25                  30

Gln His Gly Glu Thr Pro Ser Leu Leu Lys Asn Thr Lys Ile Ser Trp  
           35                  40                  45

Ala Trp Trp Arg Ala Pro Val Ile Leu Ala Thr Gln Glu Ala Glu Ala  
   50                  55                  60

Gly Glu Ser Leu Glu Pro Gly Arg Trp Trp Leu Gln  
   65                  70                  75

<210> 161  
 <211> 150  
 <212> PRT  
 <213> Homo sapiens

<400> 161  
 Gly Gln Ala Ala Arg Tyr Pro Trp Met Ala Phe Pro Arg Asn Ser Ile  
   1                  5                  10                  15

Met His Leu Asn His Thr Ala Asn Pro Thr Ser Asn Ser Asn Phe Leu  
           20                  25                  30

<213> Homo sapiens

<223> Xaa equals any of the naturally occurring L-amino acids

<223> Xaa equals any of the naturally occurring L-amino acids

Gly Gln Ala Ala Arg Tyr Pro Trp Met Ala Phe Pro Arg Asn Ser Ile  
1 5 10 15

Met His Leu Asn His Thr Ala Asn Pro Thr Ser Asn Ser Asn Phe Leu  
20 25 30

Asp Leu Asn Leu Pro Pro Gln His Asn Thr Gly Leu Gly Gly Ile Pro  
35 40 45

Val Ala Gly Ile Pro Ala Ser Ser Gly Asn Ser Leu Asp Ser Leu Gln  
50 55 60

Asp Asp Asn Pro Pro His Trp Leu Lys Ser Leu Gln Ala Leu Thr Glu  
65 70 75 80

```
<210> 163
<211> 198
<212> PRT
<213> Homo sapiens
```

<400> 163

Met 1	Lys	Leu	Tyr	Ser 5	Leu	Ser	Val	Leu	Tyr 10	Lys	Gly	Glu	Ala	Lys 15	Val
Val	Leu	Leu	Lys 20	Ala	Ala	Tyr	Asp 25	Val	Ser	Ser	Phe	Ser	Phe 30	Phe	Gln
Arg	Ser	Ser 35	Val	Gln	Glu	Phe	Met 40	Thr	Phe	Thr	Ser	Gln 45	Leu	Ile	Val
Glu 50	Arg	Ser	Ser	Lys	Gly	Thr 55	Arg	Ala	Ser	Val	Lys 60	Glu	Gln	Asp	Tyr
Leu 65	Cys	His	Val	Tyr	Val 70	Arg	Asn	Asp	Ser	Leu 75	Ala	Gly	Val	Val	Ile 80
Ala	Asp	Asn	Glu	Tyr 85	Pro	Ser	Arg	Val	Ala 90	Phe	Thr	Leu	Leu	Glu 95	Lys
Val	Leu	Asp 100	Glu	Phe	Ser	Lys	Gln 105	Val	Asp	Arg	Ile	Asp 110	Trp	Pro	Val
Gly	Ser 115	Pro	Ala	Thr	Ile	His	Tyr 120	Pro	Ala	Leu	Asp 125	Gly	His	Leu	Ser
Arg 130	Tyr	Gln	Asn	Pro	Arg	Glu 135	Ala	Asp	Pro	Met	Thr 140	Lys	Val	Gln	Ala
Glu 145	Leu	Asp	Glu	Thr	Lys 150	Ile	Ile	Leu	His	Asn 155	Thr	Met	Glu	Ser	Leu 160
Leu	Glu	Arg	Gly 165	Glu	Lys	Leu	Asp 170	Asp	Leu	Val	Ser 175	Lys	Ser	Glu	Val

Leu Gly Thr Gln Ser Lys Ala Phe Tyr Lys Thr Ala Arg Lys Gln Asn  
 180 185 190

Ser Cys Cys Ala Ile Met  
 195

<210> 164

<211> 198

<212> PRT

<213> Homo sapiens

<400> 164

Met Lys Leu Tyr Ser Leu Ser Val Leu Tyr Lys Gly Glu Ala Lys Val  
 1 5 10 15

Val Leu Leu Lys Ala Ala Tyr Asp Val Ser Ser Phe Ser Phe Phe Gln  
 20 25 30

Arg Ser Ser Val Gln Glu Phe Met Thr Phe Thr Ser Gln Leu Ile Val  
 35 40 45

Glu Arg Ser Ser Lys Gly Thr Arg Ala Ser Val Lys Glu Gln Asp Tyr  
 50 55 60

Leu Cys His Val Tyr Val Arg Asn Asp Ser Leu Ala Gly Val Val Ile  
 65 70 75 80

Ala Asp Asn Glu Tyr Pro Ser Arg Val Ala Phe Thr Leu Leu Glu Lys  
 85 90 95

Val Leu Asp Glu Phe Ser Lys Gln Val Asp Arg Ile Asp Trp Pro Val  
 100 105 110

Gly Ser Pro Ala Thr Ile His Tyr Pro Ala Leu Asp Gly His Leu Ser  
 115 120 125

Arg Tyr Gln Asn Pro Arg Glu Ala Asp Pro Met Thr Lys Val Gln Ala  
 130 135 140

Glu Leu Asp Glu Thr Lys Ile Ile Leu His Asn Thr Met Glu Ser Leu  
 145 150 155 160

Leu Glu Arg Gly Glu Lys Leu Asp Asp Leu Val Ser Lys Ser Glu Val  
 165 170 175

Leu Gly Thr Gln Ser Lys Ala Phe Tyr Lys Thr Ala Arg Lys Gln Asn  
 180 185 190

Ser Cys Cys Ala Ile Met  
 195

<210> 165



&lt;211&gt; 127

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 165

Cys Glu Ser Ala Ser Val Met Ala Ala Thr Leu Ala Asn Gly Gly Phe  
 1 5 10 15

Cys Pro Ile Thr Gly Glu Arg Val Leu Ser Pro Glu Ala Val Arg Asn  
 20 25 30

Thr Leu Ser Leu Met His Ser Cys Gly Met Tyr Asp Phe Ser Gly Gln  
 35 40 45

Phe Ala Phe His Val Gly Leu Pro Ala Lys Ser Gly Val Ala Gly Gly  
 50 55 60

Ile Leu Leu Val Val Pro Asn Val Met Gly Met Met Cys Trp Ser Pro  
 65 70 75 80

Pro Leu Asp Lys Met Gly Asn Ser Val Lys Gly Ile His Phe Cys His  
 85 90 95

Asp Leu Val Ser Leu Cys Asn Phe His Asn Tyr Asp Asn Leu Arg His  
 100 105 110

Phe Ala Lys Lys Leu Asp Pro Arg Arg Glu Gly Gly Asp Gln Arg  
 115 120 125

&lt;210&gt; 166

&lt;211&gt; 127

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (79)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 166

Cys Glu Ser Ala Ser Val Met Ala Ala Thr Leu Ala Asn Gly Gly Phe  
 1 5 10 15

Cys Pro Ile Thr Gly Glu Arg Val Leu Ser Pro Glu Ala Val Arg Asn  
 20 25 30

Thr Leu Ser Leu Met His Ser Cys Gly Met Tyr Asp Phe Ser Gly Gln  
 35 40 45

Phe Ala Phe His Val Gly Leu Pro Ala Lys Ser Gly Val Ala Gly Gly  
 50 55 60

Ile Leu Leu Val Val Pro Asn Val Met Gly Met Met Cys Trp Xaa Pro  
 65 70 75 80

Pro Leu Asp Lys Met Gly Asn Ser Val Lys Gly Ile His Phe Cys His  
85 90 95

Asp Leu Val Ser Leu Cys Asn Phe His Asn Tyr Asp Asn Leu Arg His  
100 105 110

Phe Ala Lys Lys Leu Asp Pro Arg Arg Glu Gly Gly Asp Gln Arg  
115 120 125

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/07505

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : C12N 15/12, 5/10; C12P 21/02; C07K 14/47

US CL : 435/69.1, 71.1, 320.1, 471, 252.3; 536/23.5, 24.3; 530/350

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 71.1, 320.1, 471, 252.3; 536/23.5, 24.3; 530/350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

West US Patent full, STN via medline, biosis, caplus, embase. Sequence search for SEQ ID NOs:11 and 61.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	LAI et al. Cain, a Novel Physiologic Protein Inhibitor of Calcineurin. Journal of Biological Chemistry. 17 July 1998, Vol. 273, No. 29, pages 1825-18331, especially see abstract, page middle of 4, page 7, last paragraph and page 11, 3rd paragraph. See sequence comparison 'A'.	1-3, 7-10, ----- 4-6, 21
X --- Y	EP 0 444 758 A1 (GIST-BROCADES N.V.) 04 September 1991 (04.09.1991), page 15, lines 15-25. Also see sequence comparison 'B'.	11, 14-16 ----- 12

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance		
*B* earlier document published on or after the international filing date	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed	*A*	document member of the same patent family

Date of the actual completion of the international search

31 MAY 2000

Date of mailing of the international search report

06 JUL 2000

 Name and mailing address of the ISA/US  
 Commissioner of Patents and Trademarks  
 Box PCT  
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

FOZIA HAMUD

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/07505

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-12, 14-16, 21

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/07505

### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-12, 14-16 and 21, drawn to an isolated nucleic acid molecule comprising the polynucleotide sequence set forth in SEQ ID NO:X (SEQ ID NO:X represents SEQ ID NO:11 to SEQ ID NO:60) encoding a polypeptide with the amino sequence set forth in SEQ ID NO:Y (SEQ ID NO Y represents SEQ ID NO:61 to SEQ ID NO:110), a recombinant vector, a host cell, a method of producing the encoded polypeptide, and the encoded polypeptide.

Group II, claim 13, drawn to an isolated antibody that selectively binds to the polypeptide with the amino sequence set forth in SEQ ID NO:Y.

Group III, claim 17, drawn to a method for preventing, treating or ameliorating a medical condition comprising administering the polypeptide with the amino sequence set forth in SEQ ID NO:Y.

Group IV, claim 17, drawn to a method for preventing, treating or ameliorating a medical condition comprising administering the polynucleotide with the sequence set forth in SEQ ID NO:X.

Group V, claim 18, drawn to a method for diagnosing a pathological condition by determining the presence or absence of a mutation in the polynucleotide of SEQ ID NO:X.

Group VI, claim 19, drawn to a method for diagnosing a pathological condition by determining the presence or amount of expression of the polypeptide of SEQ ID NO:Y.

Group VII, claims 20, 23, drawn to a method for identifying a binding partner to the polypeptide of SEQ ID NO:X.

Group VIII, claim 22 drawn to a method for identifying an activity in a biological assay for the polypeptide of SEQ ID NO:X.

The inventions listed as Groups I-VIII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Pursuant to 37 C.F.R. § 1.475 (d), the ISA/US considers that where multiple products and processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto. Accordingly, the main invention (Group I) comprises the first-recited product, the isolated nucleic acid molecule comprising the polynucleotide sequence set forth in SEQ ID NO:X (SEQ ID NO: 11-SEQ ID NO:60) encoding a polypeptide with the amino sequence set forth in SEQ ID NO:Y (SEQ ID NO:61-SEQ ID NO:110), a recombinant vector, a host cell, a method of producing the encoded polypeptide, and the encoded polypeptide. Further pursuant to 37 C.F.R. § 1.475 (d), the ISA/US considers that any feature which the subsequently recited products and methods share with the main invention does not constitute a special technical feature within the meaning of PCT Rule 13.2 and that each of such products and methods accordingly defines a separate invention.

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: SEQ ID NO:X corresponds to SEQ ID NOs: 11-60 and SEQ ID NO:Y corresponds to SEQ ID NOs:61-110, these nucleotide and amino acids sequences have different structural and functional features. Applicants elected SEQ ID NO:11 and SEQ ID NO:61 to be searched.